biologicalSystem	effect	efoId	ensemblId	pmid	ref	symptom	target	uberonCode	url
cardiovascular system	activation_general	HP_0001662	ENSG00000181072	""	HeCaToS	bradycardia	CHRM2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0001962	ENSG00000181072	""	HeCaToS	palpitations	CHRM2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0004269	ENSG00000181072	""	HeCaToS	dysrhythmia	CHRM2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000181072	""	HeCaToS	peripheral edema	CHRM2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0001649	ENSG00000181072	""	HeCaToS	tachycardia	CHRM2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000181072	""	HeCaToS	vagal effects (key role in control of heart rate and smooth muscle activity)	CHRM2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	EFO_0009836	ENSG00000133019	23197038	Bowes et al. (2012)	bronchoconstriction	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0002019	ENSG00000133019	23197038	Bowes et al. (2012)	constipation	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0000622	ENSG00000133019	23197038	Bowes et al. (2012)	blurred vision	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0011499	ENSG00000133019	23197038	Bowes et al. (2012)	pupil dilation	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0009869	ENSG00000133019	23197038	Bowes et al. (2012)	dry mouth	CHRM3	UBERON_0005409	""
gastrointestinal	activation_general	GO_0046878	ENSG00000133019	23197038	Bowes et al. (2012)	increased salivation	CHRM3	UBERON_0005409	""
gastrointestinal	activation_general	GO_0014831	ENSG00000133019	23197038	Bowes et al. (2012)	gastrointestinal smooth muscle constriction	CHRM3	UBERON_0005409	""
gastrointestinal	activation_general	GO_0014848	ENSG00000133019	23197038	Bowes et al. (2012)	urinary smooth muscle constriction	CHRM3	UBERON_0005409	""
pulmonary	activation_general	EFO_0009836	ENSG00000133019	23197038	Bowes et al. (2012)	bronchoconstriction	CHRM3	UBERON_0002048	""
pulmonary	inhibition_general	HP_0002019	ENSG00000133019	23197038	Bowes et al. (2012)	constipation	CHRM3	UBERON_0002048	""
pulmonary	inhibition_general	HP_0000622	ENSG00000133019	23197038	Bowes et al. (2012)	blurred vision	CHRM3	UBERON_0002048	""
pulmonary	inhibition_general	HP_0011499	ENSG00000133019	23197038	Bowes et al. (2012)	pupil dilation	CHRM3	UBERON_0002048	""
pulmonary	inhibition_general	EFO_0009869	ENSG00000133019	23197038	Bowes et al. (2012)	dry mouth	CHRM3	UBERON_0002048	""
pulmonary	activation_general	GO_0046878	ENSG00000133019	23197038	Bowes et al. (2012)	increased salivation	CHRM3	UBERON_0002048	""
pulmonary	activation_general	GO_0014831	ENSG00000133019	23197038	Bowes et al. (2012)	gastrointestinal smooth muscle constriction	CHRM3	UBERON_0002048	""
pulmonary	activation_general	GO_0014848	ENSG00000133019	23197038	Bowes et al. (2012)	urinary smooth muscle constriction	CHRM3	UBERON_0002048	""
cardiovascular system	activation_general	GO_0060087	ENSG00000184845	23197038	Bowes et al. (2012)	vascular relaxation	DRD1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_1000904	ENSG00000184845	23197038	Bowes et al. (2012)	dyskinesia	DRD1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001300	ENSG00000184845	23197038	Bowes et al. (2012)	parkinsonian symptoms (tremors)	DRD1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009848	ENSG00000184845	23197038	Bowes et al. (2012)	anti-emetic effects	DRD1	UBERON_0004535	""
cardiovascular system	inhibition_general	MONDO_0002050	ENSG00000184845	23197038	Bowes et al. (2012)	depression	DRD1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005230	ENSG00000184845	23197038	Bowes et al. (2012)	anxiety	DRD1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0004320	ENSG00000184845	23197038	Bowes et al. (2012)	suicidal intent	DRD1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0005251	ENSG00000184845	23197038	Bowes et al. (2012)	decreased blood pressure	DRD1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0002315	ENSG00000184845	23197038	Bowes et al. (2012)	headaches	DRD1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009847	ENSG00000184845	23197038	Bowes et al. (2012)	dizziness	DRD1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0002018	ENSG00000184845	23197038	Bowes et al. (2012)	nausea	DRD1	UBERON_0004535	""
cardiovascular system	activation_general	GO_0035812	ENSG00000184845	23197038	Bowes et al. (2012)	natriuresis	DRD1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0003890	ENSG00000184845	23197038	Bowes et al. (2012)	abuse potential	DRD1	UBERON_0004535	""
central nervous system	activation_general	GO_0060087	ENSG00000184845	23197038	Bowes et al. (2012)	vascular relaxation	DRD1	UBERON_0001017	""
central nervous system	inhibition_general	EFO_1000904	ENSG00000184845	23197038	Bowes et al. (2012)	dyskinesia	DRD1	UBERON_0001017	""
central nervous system	inhibition_general	HP_0001300	ENSG00000184845	23197038	Bowes et al. (2012)	parkinsonian symptoms (tremors)	DRD1	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0009848	ENSG00000184845	23197038	Bowes et al. (2012)	anti-emetic effects	DRD1	UBERON_0001017	""
central nervous system	inhibition_general	MONDO_0002050	ENSG00000184845	23197038	Bowes et al. (2012)	depression	DRD1	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0005230	ENSG00000184845	23197038	Bowes et al. (2012)	anxiety	DRD1	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0004320	ENSG00000184845	23197038	Bowes et al. (2012)	suicidal intent	DRD1	UBERON_0001017	""
central nervous system	activation_general	EFO_0005251	ENSG00000184845	23197038	Bowes et al. (2012)	decreased blood pressure	DRD1	UBERON_0001017	""
central nervous system	activation_general	HP_0002315	ENSG00000184845	23197038	Bowes et al. (2012)	headaches	DRD1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009847	ENSG00000184845	23197038	Bowes et al. (2012)	dizziness	DRD1	UBERON_0001017	""
central nervous system	activation_general	HP_0002018	ENSG00000184845	23197038	Bowes et al. (2012)	nausea	DRD1	UBERON_0001017	""
central nervous system	activation_general	GO_0035812	ENSG00000184845	23197038	Bowes et al. (2012)	natriuresis	DRD1	UBERON_0001017	""
central nervous system	activation_general	EFO_0003890	ENSG00000184845	23197038	Bowes et al. (2012)	abuse potential	DRD1	UBERON_0001017	""
nervous system	activation_acute	EFO_0009853	ENSG00000177098	28216264	Lynch et al. (2017)	convulsions	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000177098	28216264	Lynch et al. (2017)	decreased pain	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	NCIT_C74532	ENSG00000177098	28216264	Lynch et al. (2017)	agitation	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_1000712	ENSG00000177098	28216264	Lynch et al. (2017)	decreased sweating	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0011499	ENSG00000177098	28216264	Lynch et al. (2017)	increased pupil diameter	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000177098	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0031860	ENSG00000177098	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0005251	ENSG00000177098	28216264	Lynch et al. (2017)	decreased blood pressure	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	GO_0045822	ENSG00000177098	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_1001497	ENSG00000177098	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0006677	ENSG00000177098	28216264	Lynch et al. (2017)	increased QRS complex	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004269	ENSG00000177098	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009839	ENSG00000177098	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030897	ENSG00000177098	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0011037	ENSG00000177098	28216264	Lynch et al. (2017)	decreased urine excretion	SCN4B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001259	ENSG00000177098	28216264	Lynch et al. (2017)	coma	SCN4B	UBERON_0001016	""
cardiovascular	activation_acute	HP_0002094	ENSG00000177098	28216264	Lynch et al. (2017)	dyspnea	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000177098	28216264	Lynch et al. (2017)	decreased pain	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	NCIT_C74532	ENSG00000177098	28216264	Lynch et al. (2017)	agitation	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_1000712	ENSG00000177098	28216264	Lynch et al. (2017)	decreased sweating	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011499	ENSG00000177098	28216264	Lynch et al. (2017)	increased pupil diameter	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000177098	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0031860	ENSG00000177098	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000177098	28216264	Lynch et al. (2017)	decreased blood pressure	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0045822	ENSG00000177098	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_1001497	ENSG00000177098	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0006677	ENSG00000177098	28216264	Lynch et al. (2017)	increased QRS complex	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000177098	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009839	ENSG00000177098	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000177098	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011037	ENSG00000177098	28216264	Lynch et al. (2017)	decreased urine excretion	SCN4B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001259	ENSG00000177098	28216264	Lynch et al. (2017)	coma	SCN4B	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000177098	28216264	Lynch et al. (2017)	convulsions	SCN4B	UBERON_0004535	""
respiratory	activation_acute	HP_0002094	ENSG00000177098	28216264	Lynch et al. (2017)	dyspnea	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	GO_1904057	ENSG00000177098	28216264	Lynch et al. (2017)	decreased pain	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	NCIT_C74532	ENSG00000177098	28216264	Lynch et al. (2017)	agitation	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_1000712	ENSG00000177098	28216264	Lynch et al. (2017)	decreased sweating	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0011499	ENSG00000177098	28216264	Lynch et al. (2017)	increased pupil diameter	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009853	ENSG00000177098	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0031860	ENSG00000177098	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0005251	ENSG00000177098	28216264	Lynch et al. (2017)	decreased blood pressure	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	GO_0045822	ENSG00000177098	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_1001497	ENSG00000177098	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0006677	ENSG00000177098	28216264	Lynch et al. (2017)	increased QRS complex	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0004269	ENSG00000177098	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009839	ENSG00000177098	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0030897	ENSG00000177098	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0011037	ENSG00000177098	28216264	Lynch et al. (2017)	decreased urine excretion	SCN4B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0001259	ENSG00000177098	28216264	Lynch et al. (2017)	coma	SCN4B	UBERON_0001004	""
cardiovascular	activation_acute	GO_0040013	ENSG00000177098	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN4B	UBERON_0004535	""
nervous system	activation_acute	EFO_0004269	ENSG00000177098	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN4B	UBERON_0001016	""
nervous system	activation_acute	HP_0001649	ENSG00000177098	28216264	Lynch et al. (2017)	increased heart rate	SCN4B	UBERON_0001016	""
respiratory	activation_acute	HP_0001649	ENSG00000177098	28216264	Lynch et al. (2017)	increased heart rate	SCN4B	UBERON_0001004	""
nervous system	activation_acute	HP_0002094	ENSG00000177098	28216264	Lynch et al. (2017)	dyspnea	SCN4B	UBERON_0001016	""
respiratory	activation_acute	GO_0040013	ENSG00000177098	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN4B	UBERON_0001004	""
nervous system	activation_acute	GO_0040013	ENSG00000177098	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN4B	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0004269	ENSG00000177098	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN4B	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001649	ENSG00000177098	28216264	Lynch et al. (2017)	increased heart rate	SCN4B	UBERON_0004535	""
respiratory	activation_acute	EFO_0004269	ENSG00000177098	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN4B	UBERON_0001004	""
respiratory	activation_acute	EFO_0009853	ENSG00000177098	28216264	Lynch et al. (2017)	convulsions	SCN4B	UBERON_0001004	""
cardiovascular system	inhibition_general	""	ENSG00000112759	""	HeCaToS	peripheral and central vasodilation	SLC29A1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	GO_0090331	ENSG00000112759	""	HeCaToS	inhibition of platelet aggregation	SLC29A1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0009843	ENSG00000112759	""	HeCaToS	promotion of sleep	SLC29A1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0003913	ENSG00000112759	""	HeCaToS	angina pectoris	SLC29A1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0009847	ENSG00000112759	""	HeCaToS	dizziness	SLC29A1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000112759	""	HeCaToS	hypotension	SLC29A1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000112759	""	HeCaToS	rare (0.1%) serious side effects have been observed with the ENT1 inhibitor dipyridamole when given IV for 4 min: cardiac death, fatal and nonfatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction, and bronchospasm (from the drug label)	SLC29A1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
blood	activation_acute	HP_0003074	ENSG00000169252	28216264	Lynch et al. (2017)	increased blood glucose	ADRB2	UBERON_0000178	""
blood	inhibition_acute	HP_0032263	ENSG00000169252	28216264	Lynch et al. (2017)	increased blood pressure	ADRB2	UBERON_0000178	""
cardiovascular	activation_acute	EFO_0003144	ENSG00000169252	28216264	Lynch et al. (2017)	heart failure	ADRB2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000169252	28216264	Lynch et al. (2017)	increased blood pressure	ADRB2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002900	ENSG00000169252	28216264	Lynch et al. (2017)	decreased blood potassium	ADRB2	UBERON_0004535	""
blood	activation_acute	HP_0005184	ENSG00000169252	28216264	Lynch et al. (2017)	increased QTc interval	ADRB2	UBERON_0000178	""
blood	activation_acute	HP_0025428	ENSG00000169252	28216264	Lynch et al. (2017)	bronchospasm	ADRB2	UBERON_0000178	""
blood	activation_acute	HP_0001649	ENSG00000169252	28216264	Lynch et al. (2017)	increased heart rate	ADRB2	UBERON_0000178	""
cardiovascular	activation_acute	HP_0003074	ENSG00000169252	28216264	Lynch et al. (2017)	increased blood glucose	ADRB2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001649	ENSG00000169252	28216264	Lynch et al. (2017)	increased heart rate	ADRB2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0025428	ENSG00000169252	28216264	Lynch et al. (2017)	bronchospasm	ADRB2	UBERON_0004535	""
blood	activation_acute	EFO_0003144	ENSG00000169252	28216264	Lynch et al. (2017)	heart failure	ADRB2	UBERON_0000178	""
cardiovascular	activation_acute	HP_0005184	ENSG00000169252	28216264	Lynch et al. (2017)	increased QTc interval	ADRB2	UBERON_0004535	""
cardiovascular	activation_acute	GO_0045823	ENSG00000169252	28216264	Lynch et al. (2017)	increased cardiac contractility	ADRB2	UBERON_0004535	""
blood	activation_acute	GO_0045823	ENSG00000169252	28216264	Lynch et al. (2017)	increased cardiac contractility	ADRB2	UBERON_0000178	""
blood	activation_acute	HP_0002900	ENSG00000169252	28216264	Lynch et al. (2017)	decreased blood potassium	ADRB2	UBERON_0000178	""
cardiovascular system	activation_general	EFO_0005251	ENSG00000168398	""	Urban et al. (2012)	arteriolar dilation/hypotension	BDKRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000318	ENSG00000168398	""	Urban et al. (2012)	cardiomyopathy	BDKRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000537	ENSG00000168398	""	Urban et al. (2012)	hypertension	BDKRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0004269	ENSG00000168398	""	Urban et al. (2012)	arrhythmia	BDKRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0006939	ENSG00000168398	""	Urban et al. (2012)	smooth-muscle contraction	BDKRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0012735	ENSG00000168398	""	Urban et al. (2012)	cough	BDKRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0003843	ENSG00000168398	""	Urban et al. (2012)	nociception	BDKRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000168398	""	Urban et al. (2012)	angiogenesis	BDKRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000168398	""	Urban et al. (2012)	acute allergic inflammation	BDKRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
respiratory	activation_acute	GO_0090331	ENSG00000136160	28216264	Lynch et al. (2017)	decreased platelet aggregation	EDNRB	UBERON_0001004	""
respiratory	inhibition_acute	HP_0032263	ENSG00000136160	28216264	Lynch et al. (2017)	increased blood pressure	EDNRB	UBERON_0001004	""
respiratory	inhibition_developmental toxicity	EFO_0005269	ENSG00000136160	28216264	Lynch et al. (2017)	cardiovascular malformations	EDNRB	UBERON_0001004	""
respiratory	inhibition_developmental toxicity	HP_0000234	ENSG00000136160	28216264	Lynch et al. (2017)	craniofacial abnormalities	EDNRB	UBERON_0001004	""
respiratory	inhibition_acute	HP_0011037	ENSG00000136160	28216264	Lynch et al. (2017)	decreased urine excretion	EDNRB	UBERON_0001004	""
respiratory	inhibition_acute	GO_0120061	ENSG00000136160	28216264	Lynch et al. (2017)	decreased gastric emptying	EDNRB	UBERON_0001004	""
respiratory	inhibition_acute	HP_0030897	ENSG00000136160	28216264	Lynch et al. (2017)	decreased intestinal transit	EDNRB	UBERON_0001004	""
respiratory	inhibition_acute	GO_1904057	ENSG00000136160	28216264	Lynch et al. (2017)	decreased pain	EDNRB	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009836	ENSG00000136160	28216264	Lynch et al. (2017)	bronchoconstriction	EDNRB	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000136160	28216264	Lynch et al. (2017)	increased blood pressure	EDNRB	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	EFO_0005269	ENSG00000136160	28216264	Lynch et al. (2017)	cardiovascular malformations	EDNRB	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	HP_0000234	ENSG00000136160	28216264	Lynch et al. (2017)	craniofacial abnormalities	EDNRB	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011037	ENSG00000136160	28216264	Lynch et al. (2017)	decreased urine excretion	EDNRB	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0120061	ENSG00000136160	28216264	Lynch et al. (2017)	decreased gastric emptying	EDNRB	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000136160	28216264	Lynch et al. (2017)	decreased intestinal transit	EDNRB	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000136160	28216264	Lynch et al. (2017)	decreased pain	EDNRB	UBERON_0004535	""
renal	activation_acute	EFO_0003896	ENSG00000136160	28216264	Lynch et al. (2017)	left ventricular hypertrophy	EDNRB	UBERON_0001008	""
renal	inhibition_acute	HP_0032263	ENSG00000136160	28216264	Lynch et al. (2017)	increased blood pressure	EDNRB	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_0005269	ENSG00000136160	28216264	Lynch et al. (2017)	cardiovascular malformations	EDNRB	UBERON_0001008	""
renal	inhibition_developmental toxicity	HP_0000234	ENSG00000136160	28216264	Lynch et al. (2017)	craniofacial abnormalities	EDNRB	UBERON_0001008	""
renal	inhibition_acute	HP_0011037	ENSG00000136160	28216264	Lynch et al. (2017)	decreased urine excretion	EDNRB	UBERON_0001008	""
renal	inhibition_acute	GO_0120061	ENSG00000136160	28216264	Lynch et al. (2017)	decreased gastric emptying	EDNRB	UBERON_0001008	""
renal	inhibition_acute	HP_0030897	ENSG00000136160	28216264	Lynch et al. (2017)	decreased intestinal transit	EDNRB	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000136160	28216264	Lynch et al. (2017)	decreased pain	EDNRB	UBERON_0001008	""
renal	activation_acute	GO_0008283	ENSG00000136160	28216264	Lynch et al. (2017)	cell proliferation	EDNRB	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0001361	ENSG00000136160	28216264	Lynch et al. (2017)	pulmonary hypertension	EDNRB	UBERON_0004535	""
renal	activation_acute	HP_0031860	ENSG00000136160	28216264	Lynch et al. (2017)	increased then decreased heart rate	EDNRB	UBERON_0001008	""
blood	activation_acute	EFO_0003896	ENSG00000136160	28216264	Lynch et al. (2017)	left ventricular hypertrophy	EDNRB	UBERON_0000178	""
blood	inhibition_acute	HP_0032263	ENSG00000136160	28216264	Lynch et al. (2017)	increased blood pressure	EDNRB	UBERON_0000178	""
blood	inhibition_developmental toxicity	EFO_0005269	ENSG00000136160	28216264	Lynch et al. (2017)	cardiovascular malformations	EDNRB	UBERON_0000178	""
blood	inhibition_developmental toxicity	HP_0000234	ENSG00000136160	28216264	Lynch et al. (2017)	craniofacial abnormalities	EDNRB	UBERON_0000178	""
blood	inhibition_acute	HP_0011037	ENSG00000136160	28216264	Lynch et al. (2017)	decreased urine excretion	EDNRB	UBERON_0000178	""
blood	inhibition_acute	GO_0120061	ENSG00000136160	28216264	Lynch et al. (2017)	decreased gastric emptying	EDNRB	UBERON_0000178	""
blood	inhibition_acute	HP_0030897	ENSG00000136160	28216264	Lynch et al. (2017)	decreased intestinal transit	EDNRB	UBERON_0000178	""
blood	inhibition_acute	GO_1904057	ENSG00000136160	28216264	Lynch et al. (2017)	decreased pain	EDNRB	UBERON_0000178	""
blood	activation_acute	HP_0031860	ENSG00000136160	28216264	Lynch et al. (2017)	increased then decreased heart rate	EDNRB	UBERON_0000178	""
cardiovascular	activation_acute	EFO_0003896	ENSG00000136160	28216264	Lynch et al. (2017)	left ventricular hypertrophy	EDNRB	UBERON_0004535	""
respiratory	activation_acute	EFO_0003896	ENSG00000136160	28216264	Lynch et al. (2017)	left ventricular hypertrophy	EDNRB	UBERON_0001004	""
respiratory	activation_acute	EFO_0001361	ENSG00000136160	28216264	Lynch et al. (2017)	pulmonary hypertension	EDNRB	UBERON_0001004	""
blood	activation_acute	GO_0008283	ENSG00000136160	28216264	Lynch et al. (2017)	cell proliferation	EDNRB	UBERON_0000178	""
respiratory	activation_acute	EFO_0009833	ENSG00000136160	28216264	Lynch et al. (2017)	glomerular and tubulointerstitial structural injury	EDNRB	UBERON_0001004	""
respiratory	activation_acute	GO_0008283	ENSG00000136160	28216264	Lynch et al. (2017)	cell proliferation	EDNRB	UBERON_0001004	""
renal	activation_acute	GO_0090331	ENSG00000136160	28216264	Lynch et al. (2017)	decreased platelet aggregation	EDNRB	UBERON_0001008	""
renal	activation_acute	EFO_0001361	ENSG00000136160	28216264	Lynch et al. (2017)	pulmonary hypertension	EDNRB	UBERON_0001008	""
gastrointestinal	activation_acute	GO_0090331	ENSG00000136160	28216264	Lynch et al. (2017)	decreased platelet aggregation	EDNRB	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0032263	ENSG00000136160	28216264	Lynch et al. (2017)	increased blood pressure	EDNRB	UBERON_0005409	""
gastrointestinal	inhibition_developmental toxicity	EFO_0005269	ENSG00000136160	28216264	Lynch et al. (2017)	cardiovascular malformations	EDNRB	UBERON_0005409	""
gastrointestinal	inhibition_developmental toxicity	HP_0000234	ENSG00000136160	28216264	Lynch et al. (2017)	craniofacial abnormalities	EDNRB	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0011037	ENSG00000136160	28216264	Lynch et al. (2017)	decreased urine excretion	EDNRB	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0120061	ENSG00000136160	28216264	Lynch et al. (2017)	decreased gastric emptying	EDNRB	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0030897	ENSG00000136160	28216264	Lynch et al. (2017)	decreased intestinal transit	EDNRB	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1904057	ENSG00000136160	28216264	Lynch et al. (2017)	decreased pain	EDNRB	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0031860	ENSG00000136160	28216264	Lynch et al. (2017)	increased then decreased heart rate	EDNRB	UBERON_0005409	""
gastrointestinal	activation_acute	GO_0008283	ENSG00000136160	28216264	Lynch et al. (2017)	cell proliferation	EDNRB	UBERON_0005409	""
cardiovascular	activation_acute	GO_0090331	ENSG00000136160	28216264	Lynch et al. (2017)	decreased platelet aggregation	EDNRB	UBERON_0004535	""
blood	activation_acute	HP_0030972	ENSG00000136160	28216264	Lynch et al. (2017)	decreased then increased blood pressure	EDNRB	UBERON_0000178	""
renal	activation_acute	EFO_0009833	ENSG00000136160	28216264	Lynch et al. (2017)	glomerular and tubulointerstitial structural injury	EDNRB	UBERON_0001008	""
gastrointestinal	activation_acute	EFO_0003896	ENSG00000136160	28216264	Lynch et al. (2017)	left ventricular hypertrophy	EDNRB	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0009833	ENSG00000136160	28216264	Lynch et al. (2017)	glomerular and tubulointerstitial structural injury	EDNRB	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0030972	ENSG00000136160	28216264	Lynch et al. (2017)	decreased then increased blood pressure	EDNRB	UBERON_0005409	""
blood	activation_acute	EFO_0009836	ENSG00000136160	28216264	Lynch et al. (2017)	bronchoconstriction	EDNRB	UBERON_0000178	""
blood	activation_acute	EFO_0009833	ENSG00000136160	28216264	Lynch et al. (2017)	glomerular and tubulointerstitial structural injury	EDNRB	UBERON_0000178	""
cardiovascular	activation_acute	GO_0008283	ENSG00000136160	28216264	Lynch et al. (2017)	cell proliferation	EDNRB	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0001361	ENSG00000136160	28216264	Lynch et al. (2017)	pulmonary hypertension	EDNRB	UBERON_0005409	""
respiratory	activation_acute	EFO_0009836	ENSG00000136160	28216264	Lynch et al. (2017)	bronchoconstriction	EDNRB	UBERON_0001004	""
cardiovascular	activation_acute	HP_0031860	ENSG00000136160	28216264	Lynch et al. (2017)	increased then decreased heart rate	EDNRB	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0009833	ENSG00000136160	28216264	Lynch et al. (2017)	glomerular and tubulointerstitial structural injury	EDNRB	UBERON_0005409	""
renal	activation_acute	EFO_0009836	ENSG00000136160	28216264	Lynch et al. (2017)	bronchoconstriction	EDNRB	UBERON_0001008	""
respiratory	activation_acute	HP_0031860	ENSG00000136160	28216264	Lynch et al. (2017)	increased then decreased heart rate	EDNRB	UBERON_0001004	""
cardiovascular	activation_acute	HP_0030972	ENSG00000136160	28216264	Lynch et al. (2017)	decreased then increased blood pressure	EDNRB	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0009836	ENSG00000136160	28216264	Lynch et al. (2017)	bronchoconstriction	EDNRB	UBERON_0005409	""
renal	activation_acute	HP_0030972	ENSG00000136160	28216264	Lynch et al. (2017)	decreased then increased blood pressure	EDNRB	UBERON_0001008	""
blood	activation_acute	EFO_0001361	ENSG00000136160	28216264	Lynch et al. (2017)	pulmonary hypertension	EDNRB	UBERON_0000178	""
respiratory	activation_acute	HP_0030972	ENSG00000136160	28216264	Lynch et al. (2017)	decreased then increased blood pressure	EDNRB	UBERON_0001004	""
blood	activation_acute	GO_0090331	ENSG00000136160	28216264	Lynch et al. (2017)	decreased platelet aggregation	EDNRB	UBERON_0000178	""
cardiovascular system	inhibition_general	""	ENSG00000189221	""	HeCaToS	"hypertensive when combined with pressor amines such as tyramine present in cheese: inhibitors may induce severe hypertensive crisis (known as \"cheese reaction\")"	MAOA	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000189221	""	HeCaToS	centrally mediated side effects such as the serotonin syndrome, dizziness, blurred vision, weakness, and hypomania	MAOA	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
central nervous system	inhibition_general	""	ENSG00000189221	""	HeCaToS	"hypertensive when combined with pressor amines such as tyramine present in cheese: inhibitors may induce severe hypertensive crisis (known as \"cheese reaction\")"	MAOA	UBERON_0001017	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
central nervous system	inhibition_general	""	ENSG00000189221	""	HeCaToS	centrally mediated side effects such as the serotonin syndrome, dizziness, blurred vision, weakness, and hypomania	MAOA	UBERON_0001017	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_1001484	ENSG00000082556	""	Urban et al. (2012)	analgesia	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009868	ENSG00000082556	""	Urban et al. (2012)	sedation	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0005251	ENSG00000082556	""	Urban et al. (2012)	hypotension	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0001649	ENSG00000082556	""	Urban et al. (2012)	tachycardia	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0000103	ENSG00000082556	""	Urban et al. (2012)	diuresis	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009867	ENSG00000082556	""	Urban et al. (2012)	dysphoria	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009847	ENSG00000082556	""	Urban et al. (2012)	dizziness	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0003401	ENSG00000082556	""	Urban et al. (2012)	paresthesia	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000082556	""	Urban et al. (2012)	antipruritic effects	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000082556	""	Urban et al. (2012)	interaction with dopaminergic transmission and hallucination	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000082556	""	Urban et al. (2012)	psychotomimetic effects. In case of mixed (partial) agonist/antagonist analgesic drugs, psychotomimesis is undesirable and serves to limit abuse potential	OPRK1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_1001484	ENSG00000082556	""	Urban et al. (2012)	analgesia	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009868	ENSG00000082556	""	Urban et al. (2012)	sedation	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0005251	ENSG00000082556	""	Urban et al. (2012)	hypotension	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0001649	ENSG00000082556	""	Urban et al. (2012)	tachycardia	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0000103	ENSG00000082556	""	Urban et al. (2012)	diuresis	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009867	ENSG00000082556	""	Urban et al. (2012)	dysphoria	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009847	ENSG00000082556	""	Urban et al. (2012)	dizziness	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0003401	ENSG00000082556	""	Urban et al. (2012)	paresthesia	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000082556	""	Urban et al. (2012)	antipruritic effects	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000082556	""	Urban et al. (2012)	interaction with dopaminergic transmission and hallucination	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000082556	""	Urban et al. (2012)	psychotomimetic effects. In case of mixed (partial) agonist/antagonist analgesic drugs, psychotomimesis is undesirable and serves to limit abuse potential	OPRK1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000373	ENSG00000103546	""	HeCaToS	congestive heart failure	SLC6A2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0000537	ENSG00000103546	""	HeCaToS	hypertension (supine)	SLC6A2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0001649	ENSG00000103546	""	HeCaToS	tachycardia	SLC6A2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000103546	""	HeCaToS	may be useful for treatment of ADHD (atomoxetine) and depression	SLC6A2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
renal	activation_acute	GO_0035815	ENSG00000180772	28216264	Lynch et al. (2017)	increased urinary sodium excretion	AGTR2	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000180772	28216264	Lynch et al. (2017)	decreased pain	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_0000480	ENSG00000180772	28216264	Lynch et al. (2017)	death	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_0007401	ENSG00000180772	28216264	Lynch et al. (2017)	oligoamnios	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_1002048	ENSG00000180772	28216264	Lynch et al. (2017)	renal failure	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_0005251	ENSG00000180772	28216264	Lynch et al. (2017)	decreased blood pressure	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	HP_0002089	ENSG00000180772	28216264	Lynch et al. (2017)	pulmonary hypoplasia	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_1000644	ENSG00000180772	28216264	Lynch et al. (2017)	respiratory distress syndrome	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	HP_0001643	ENSG00000180772	28216264	Lynch et al. (2017)	persistent patent ductus arteriosus	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	HP_0010539	ENSG00000180772	28216264	Lynch et al. (2017)	hypocalvaria	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	MONDO_0019054	ENSG00000180772	28216264	Lynch et al. (2017)	limb defects	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_0000495	ENSG00000180772	28216264	Lynch et al. (2017)	intrauterine growth retardation	AGTR2	UBERON_0001008	""
renal	inhibition_developmental toxicity	MONDO_0016054	ENSG00000180772	28216264	Lynch et al. (2017)	cerebral complications	AGTR2	UBERON_0001008	""
renal	activation_acute	HP_0000103	ENSG00000180772	28216264	Lynch et al. (2017)	increased urine excretion	AGTR2	UBERON_0001008	""
cardiovascular system	activation_general	EFO_0005251	ENSG00000168398	""	HeCaToS	arteriolar dilation/hypotension	BDKRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0000318	ENSG00000168398	""	HeCaToS	cardiomyopathy	BDKRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0000537	ENSG00000168398	""	HeCaToS	hypertension	BDKRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0004269	ENSG00000168398	""	HeCaToS	arrhythmia	BDKRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0006939	ENSG00000168398	""	HeCaToS	smooth-muscle contraction	BDKRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0012735	ENSG00000168398	""	HeCaToS	cough	BDKRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0003843	ENSG00000168398	""	HeCaToS	nociception	BDKRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000168398	""	HeCaToS	angiogenesis	BDKRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000168398	""	HeCaToS	acute allergic inflammation	BDKRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular	activation_acute	EFO_0003843	ENSG00000116032	28216264	Lynch et al. (2017)	pain	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000116032	28216264	Lynch et al. (2017)	decreased pain	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000735	ENSG00000116032	28216264	Lynch et al. (2017)	impaired social interactions	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000733	ENSG00000116032	28216264	Lynch et al. (2017)	stereotypy	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_chronic	EFO_0005407	ENSG00000116032	28216264	Lynch et al. (2017)	psychosis	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0002180	ENSG00000116032	28216264	Lynch et al. (2017)	neurodegeneration	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040017	ENSG00000116032	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000437	ENSG00000116032	28216264	Lynch et al. (2017)	ataxia	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000116032	28216264	Lynch et al. (2017)	dizziness	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0001072	ENSG00000116032	28216264	Lynch et al. (2017)	decreased memory	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005407	ENSG00000116032	28216264	Lynch et al. (2017)	psychosis	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000116032	28216264	Lynch et al. (2017)	decreased convulsions	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003890	ENSG00000116032	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000116032	28216264	Lynch et al. (2017)	neurotoxicity	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000116032	28216264	Lynch et al. (2017)	increased blood pressure	GRIN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000116032	28216264	Lynch et al. (2017)	increased heart rate	GRIN3B	UBERON_0004535	""
central nervous system	activation_acute	HP_0032263	ENSG00000116032	28216264	Lynch et al. (2017)	increased blood pressure	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1904057	ENSG00000116032	28216264	Lynch et al. (2017)	decreased pain	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000735	ENSG00000116032	28216264	Lynch et al. (2017)	impaired social interactions	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000733	ENSG00000116032	28216264	Lynch et al. (2017)	stereotypy	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_chronic	EFO_0005407	ENSG00000116032	28216264	Lynch et al. (2017)	psychosis	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0002180	ENSG00000116032	28216264	Lynch et al. (2017)	neurodegeneration	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0040017	ENSG00000116032	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	MONDO_0000437	ENSG00000116032	28216264	Lynch et al. (2017)	ataxia	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009847	ENSG00000116032	28216264	Lynch et al. (2017)	dizziness	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0001072	ENSG00000116032	28216264	Lynch et al. (2017)	decreased memory	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005407	ENSG00000116032	28216264	Lynch et al. (2017)	psychosis	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000116032	28216264	Lynch et al. (2017)	decreased convulsions	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003890	ENSG00000116032	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000116032	28216264	Lynch et al. (2017)	neurotoxicity	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0032263	ENSG00000116032	28216264	Lynch et al. (2017)	increased blood pressure	GRIN3B	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001649	ENSG00000116032	28216264	Lynch et al. (2017)	increased heart rate	GRIN3B	UBERON_0001017	""
cardiovascular	activation_acute	HP_0031860	ENSG00000116032	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN3B	UBERON_0004535	""
central nervous system	activation_acute	EFO_0003843	ENSG00000116032	28216264	Lynch et al. (2017)	pain	GRIN3B	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000116032	28216264	Lynch et al. (2017)	convulsions	GRIN3B	UBERON_0004535	""
central nervous system	activation_acute	HP_0031860	ENSG00000116032	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN3B	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009853	ENSG00000116032	28216264	Lynch et al. (2017)	convulsions	GRIN3B	UBERON_0001017	""
cardiovascular	activation_acute	HP_0032263	ENSG00000116032	28216264	Lynch et al. (2017)	increased blood pressure	GRIN3B	UBERON_0004535	""
cardiovascular	activation_acute	HP_0000737	ENSG00000180720	28216264	Lynch et al. (2017)	irritability	CHRM4	UBERON_0004535	""
nervous system	activation_acute	EFO_0005251	ENSG00000180720	28216264	Lynch et al. (2017)	decreased blood pressure	CHRM4	UBERON_0001016	""
nervous system	activation_acute	EFO_0009852	ENSG00000180720	28216264	Lynch et al. (2017)	exhaustion	CHRM4	UBERON_0001016	""
nervous system	activation_acute	Orphanet_98578	ENSG00000180720	28216264	Lynch et al. (2017)	ptosis	CHRM4	UBERON_0001016	""
nervous system	activation_acute	EFO_0009845	ENSG00000180720	28216264	Lynch et al. (2017)	catalepsy	CHRM4	UBERON_0001016	""
nervous system	activation_acute	HP_0000632	ENSG00000180720	28216264	Lynch et al. (2017)	lacrimation	CHRM4	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000180720	28216264	Lynch et al. (2017)	decreased blood pressure	CHRM4	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009845	ENSG00000180720	28216264	Lynch et al. (2017)	catalepsy	CHRM4	UBERON_0004535	""
nervous system	activation_acute	""	ENSG00000180720	28216264	Lynch et al. (2017)	frothing	CHRM4	UBERON_0001016	""
cardiovascular	activation_acute	Orphanet_98578	ENSG00000180720	28216264	Lynch et al. (2017)	ptosis	CHRM4	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001662	ENSG00000180720	28216264	Lynch et al. (2017)	decreased heart rate	CHRM4	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000180720	28216264	Lynch et al. (2017)	frothing	CHRM4	UBERON_0004535	""
cardiovascular	activation_acute	HP_0000616	ENSG00000180720	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM4	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009846	ENSG00000180720	28216264	Lynch et al. (2017)	muscle cramps	CHRM4	UBERON_0004535	""
cardiovascular	activation_acute	HP_0000622	ENSG00000180720	28216264	Lynch et al. (2017)	blurred vision	CHRM4	UBERON_0004535	""
nervous system	activation_acute	HP_0001662	ENSG00000180720	28216264	Lynch et al. (2017)	decreased heart rate	CHRM4	UBERON_0001016	""
nervous system	activation_acute	HP_0000616	ENSG00000180720	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM4	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000975	ENSG00000180720	28216264	Lynch et al. (2017)	sweating	CHRM4	UBERON_0004535	""
nervous system	activation_acute	HP_0000622	ENSG00000180720	28216264	Lynch et al. (2017)	blurred vision	CHRM4	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009852	ENSG00000180720	28216264	Lynch et al. (2017)	exhaustion	CHRM4	UBERON_0004535	""
nervous system	activation_acute	HP_0000737	ENSG00000180720	28216264	Lynch et al. (2017)	irritability	CHRM4	UBERON_0001016	""
nervous system	activation_acute	HP_0000975	ENSG00000180720	28216264	Lynch et al. (2017)	sweating	CHRM4	UBERON_0001016	""
cardiovascular	activation_acute	GO_0046878	ENSG00000180720	28216264	Lynch et al. (2017)	increased salivation	CHRM4	UBERON_0004535	""
nervous system	activation_acute	EFO_0009846	ENSG00000180720	28216264	Lynch et al. (2017)	muscle cramps	CHRM4	UBERON_0001016	""
nervous system	activation_acute	GO_0046878	ENSG00000180720	28216264	Lynch et al. (2017)	increased salivation	CHRM4	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000632	ENSG00000180720	28216264	Lynch et al. (2017)	lacrimation	CHRM4	UBERON_0004535	""
cardiovascular system	inhibition_general	""	ENSG00000180210	""	HeCaToS	thrombin-deficient mice were found to be prone to fatal hemorrhagic events	F2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
blood	activation_acute	HP_0011499	ENSG00000102468	28216264	Lynch et al. (2017)	increased pupil diameter	HTR2A	UBERON_0000178	""
blood	inhibition_acute	GO_0090331	ENSG00000102468	28216264	Lynch et al. (2017)	decreased platelet aggregation	HTR2A	UBERON_0000178	""
blood	inhibition_acute	HP_0002045	ENSG00000102468	28216264	Lynch et al. (2017)	decreased body temperature	HTR2A	UBERON_0000178	""
blood	inhibition_acute	GO_1904057	ENSG00000102468	28216264	Lynch et al. (2017)	decreased pain	HTR2A	UBERON_0000178	""
blood	inhibition_acute	GO_0050728	ENSG00000102468	28216264	Lynch et al. (2017)	decreased inflammation	HTR2A	UBERON_0000178	""
blood	inhibition_acute	EFO_0008568	ENSG00000102468	28216264	Lynch et al. (2017)	increased sleep	HTR2A	UBERON_0000178	""
cardiovascular	activation_acute	HP_0000733	ENSG00000102468	28216264	Lynch et al. (2017)	stereotypy	HTR2A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0090331	ENSG00000102468	28216264	Lynch et al. (2017)	decreased platelet aggregation	HTR2A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002045	ENSG00000102468	28216264	Lynch et al. (2017)	decreased body temperature	HTR2A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000102468	28216264	Lynch et al. (2017)	decreased pain	HTR2A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0050728	ENSG00000102468	28216264	Lynch et al. (2017)	decreased inflammation	HTR2A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000102468	28216264	Lynch et al. (2017)	increased sleep	HTR2A	UBERON_0004535	""
cardiovascular	activation_acute	HP_0011499	ENSG00000102468	28216264	Lynch et al. (2017)	increased pupil diameter	HTR2A	UBERON_0004535	""
blood	activation_acute	HP_0001649	ENSG00000102468	28216264	Lynch et al. (2017)	increased heart rate	HTR2A	UBERON_0000178	""
blood	activation_acute	""	ENSG00000102468	28216264	Lynch et al. (2017)	hypervigilance	HTR2A	UBERON_0000178	""
cardiovascular	activation_acute	GO_1904058	ENSG00000102468	28216264	Lynch et al. (2017)	increased pain	HTR2A	UBERON_0004535	""
cardiovascular	activation_acute	HP_0000975	ENSG00000102468	28216264	Lynch et al. (2017)	sweating	HTR2A	UBERON_0004535	""
nervous system	activation_acute	NCIT_C74532	ENSG00000102468	28216264	Lynch et al. (2017)	agitation	HTR2A	UBERON_0001016	""
nervous system	inhibition_acute	GO_0090331	ENSG00000102468	28216264	Lynch et al. (2017)	decreased platelet aggregation	HTR2A	UBERON_0001016	""
nervous system	inhibition_acute	HP_0002045	ENSG00000102468	28216264	Lynch et al. (2017)	decreased body temperature	HTR2A	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000102468	28216264	Lynch et al. (2017)	decreased pain	HTR2A	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050728	ENSG00000102468	28216264	Lynch et al. (2017)	decreased inflammation	HTR2A	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0008568	ENSG00000102468	28216264	Lynch et al. (2017)	increased sleep	HTR2A	UBERON_0001016	""
nervous system	activation_acute	GO_0070527	ENSG00000102468	28216264	Lynch et al. (2017)	platelet aggregation	HTR2A	UBERON_0001016	""
blood	activation_acute	GO_0070527	ENSG00000102468	28216264	Lynch et al. (2017)	platelet aggregation	HTR2A	UBERON_0000178	""
cardiovascular	activation_acute	HP_0001945	ENSG00000102468	28216264	Lynch et al. (2017)	increased body temperature	HTR2A	UBERON_0004535	""
nervous system	activation_acute	HP_0011499	ENSG00000102468	28216264	Lynch et al. (2017)	increased pupil diameter	HTR2A	UBERON_0001016	""
cardiovascular	activation_acute	""	ENSG00000102468	28216264	Lynch et al. (2017)	hypervigilance	HTR2A	UBERON_0004535	""
blood	activation_acute	EFO_0001072	ENSG00000102468	28216264	Lynch et al. (2017)	decreased memory	HTR2A	UBERON_0000178	""
blood	activation_acute	HP_0001347	ENSG00000102468	28216264	Lynch et al. (2017)	hyperreflexia	HTR2A	UBERON_0000178	""
nervous system	activation_acute	HP_0000733	ENSG00000102468	28216264	Lynch et al. (2017)	stereotypy	HTR2A	UBERON_0001016	""
blood	activation_acute	HP_0001336	ENSG00000102468	28216264	Lynch et al. (2017)	myoclonus	HTR2A	UBERON_0000178	""
nervous system	activation_acute	EFO_0005407	ENSG00000102468	28216264	Lynch et al. (2017)	psychosis	HTR2A	UBERON_0001016	""
blood	activation_acute	GO_1904058	ENSG00000102468	28216264	Lynch et al. (2017)	increased pain	HTR2A	UBERON_0000178	""
cardiovascular	activation_acute	HP_0001347	ENSG00000102468	28216264	Lynch et al. (2017)	hyperreflexia	HTR2A	UBERON_0004535	""
nervous system	activation_acute	HP_0001336	ENSG00000102468	28216264	Lynch et al. (2017)	myoclonus	HTR2A	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000102468	28216264	Lynch et al. (2017)	decreased memory	HTR2A	UBERON_0004535	""
nervous system	activation_acute	EFO_0003890	ENSG00000102468	28216264	Lynch et al. (2017)	drug abuse/dependence	HTR2A	UBERON_0001016	""
nervous system	activation_acute	HP_0000975	ENSG00000102468	28216264	Lynch et al. (2017)	sweating	HTR2A	UBERON_0001016	""
blood	activation_acute	HP_0001945	ENSG00000102468	28216264	Lynch et al. (2017)	increased body temperature	HTR2A	UBERON_0000178	""
blood	activation_acute	EFO_0005407	ENSG00000102468	28216264	Lynch et al. (2017)	psychosis	HTR2A	UBERON_0000178	""
nervous system	activation_acute	HP_0032263	ENSG00000102468	28216264	Lynch et al. (2017)	increased blood pressure	HTR2A	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000738	ENSG00000102468	28216264	Lynch et al. (2017)	hallucinations	HTR2A	UBERON_0004535	""
nervous system	activation_acute	HP_0001347	ENSG00000102468	28216264	Lynch et al. (2017)	hyperreflexia	HTR2A	UBERON_0001016	""
cardiovascular	activation_acute	GO_0070527	ENSG00000102468	28216264	Lynch et al. (2017)	platelet aggregation	HTR2A	UBERON_0004535	""
nervous system	activation_acute	GO_1904058	ENSG00000102468	28216264	Lynch et al. (2017)	increased pain	HTR2A	UBERON_0001016	""
cardiovascular	activation_acute	HP_0001649	ENSG00000102468	28216264	Lynch et al. (2017)	increased heart rate	HTR2A	UBERON_0004535	""
blood	activation_acute	HP_0000975	ENSG00000102468	28216264	Lynch et al. (2017)	sweating	HTR2A	UBERON_0000178	""
cardiovascular	activation_acute	HP_0001336	ENSG00000102468	28216264	Lynch et al. (2017)	myoclonus	HTR2A	UBERON_0004535	""
nervous system	activation_acute	HP_0001649	ENSG00000102468	28216264	Lynch et al. (2017)	increased heart rate	HTR2A	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0005407	ENSG00000102468	28216264	Lynch et al. (2017)	psychosis	HTR2A	UBERON_0004535	""
blood	activation_acute	EFO_0003890	ENSG00000102468	28216264	Lynch et al. (2017)	drug abuse/dependence	HTR2A	UBERON_0000178	""
blood	activation_acute	HP_0000738	ENSG00000102468	28216264	Lynch et al. (2017)	hallucinations	HTR2A	UBERON_0000178	""
nervous system	activation_acute	HP_0001945	ENSG00000102468	28216264	Lynch et al. (2017)	increased body temperature	HTR2A	UBERON_0001016	""
nervous system	activation_acute	""	ENSG00000102468	28216264	Lynch et al. (2017)	hypervigilance	HTR2A	UBERON_0001016	""
nervous system	activation_acute	HP_0000738	ENSG00000102468	28216264	Lynch et al. (2017)	hallucinations	HTR2A	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000102468	28216264	Lynch et al. (2017)	drug abuse/dependence	HTR2A	UBERON_0004535	""
cardiovascular	activation_acute	HP_0032263	ENSG00000102468	28216264	Lynch et al. (2017)	increased blood pressure	HTR2A	UBERON_0004535	""
blood	activation_acute	HP_0000733	ENSG00000102468	28216264	Lynch et al. (2017)	stereotypy	HTR2A	UBERON_0000178	""
blood	activation_acute	HP_0032263	ENSG00000102468	28216264	Lynch et al. (2017)	increased blood pressure	HTR2A	UBERON_0000178	""
nervous system	activation_acute	EFO_0001072	ENSG00000102468	28216264	Lynch et al. (2017)	decreased memory	HTR2A	UBERON_0001016	""
blood	activation_acute	NCIT_C74532	ENSG00000102468	28216264	Lynch et al. (2017)	agitation	HTR2A	UBERON_0000178	""
cardiovascular	activation_acute	NCIT_C74532	ENSG00000102468	28216264	Lynch et al. (2017)	agitation	HTR2A	UBERON_0004535	""
nervous system	activation_general	EFO_1001484	ENSG00000116329	""	HeCaToS	analgesia	OPRD1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	""	ENSG00000116329	""	HeCaToS	selective d-opioid receptor antagonists but not mu antagonist increase blood pressure, cardiac output, contractibility, and bloodflow to the heart, kidneys, gastrointestinal tract and skeletal muscle in conscious dog with right heart failure	OPRD1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009867	ENSG00000116329	""	HeCaToS	dysphoria	OPRD1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_1000902	ENSG00000116329	""	HeCaToS	psychomimetic effects	OPRD1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0000319	ENSG00000116329	""	HeCaToS	cardiovascular effects	OPRD1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009853	ENSG00000116329	""	HeCaToS	convulsion	OPRD1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009853	ENSG00000116329	""	HeCaToS	many d agonists may cause seizures and convulsions at high doses, although not all d agonists produce this effect	OPRD1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000116329	""	HeCaToS	all the subtype selective opiate receptor agonists have effects on the heart	OPRD1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009842	ENSG00000116329	""	HeCaToS	respiratory depression may be associated with opioid treatment	OPRD1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_1001484	ENSG00000116329	""	HeCaToS	analgesia	OPRD1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000116329	""	HeCaToS	selective d-opioid receptor antagonists but not mu antagonist increase blood pressure, cardiac output, contractibility, and bloodflow to the heart, kidneys, gastrointestinal tract and skeletal muscle in conscious dog with right heart failure	OPRD1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009867	ENSG00000116329	""	HeCaToS	dysphoria	OPRD1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_1000902	ENSG00000116329	""	HeCaToS	psychomimetic effects	OPRD1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0000319	ENSG00000116329	""	HeCaToS	cardiovascular effects	OPRD1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009853	ENSG00000116329	""	HeCaToS	convulsion	OPRD1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009853	ENSG00000116329	""	HeCaToS	many d agonists may cause seizures and convulsions at high doses, although not all d agonists produce this effect	OPRD1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000116329	""	HeCaToS	all the subtype selective opiate receptor agonists have effects on the heart	OPRD1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009842	ENSG00000116329	""	HeCaToS	respiratory depression may be associated with opioid treatment	OPRD1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
pulmonary	activation_general	HP_0001649	ENSG00000169252	23197038	Bowes et al. (2012)	increased heart rate	ADRB2	UBERON_0002048	""
pulmonary	inhibition_general	EFO_0005251	ENSG00000169252	23197038	Bowes et al. (2012)	decreased blood pressure	ADRB2	UBERON_0002048	""
pulmonary	activation_general	EFO_0009837	ENSG00000169252	23197038	Bowes et al. (2012)	bronchodilation	ADRB2	UBERON_0002048	""
pulmonary	activation_general	""	ENSG00000169252	23197038	Bowes et al. (2012)	peripheral vasodilation	ADRB2	UBERON_0002048	""
pulmonary	activation_general	HP_0001337	ENSG00000169252	23197038	Bowes et al. (2012)	skeletal muscle tremor	ADRB2	UBERON_0002048	""
pulmonary	activation_general	GO_0070094	ENSG00000169252	23197038	Bowes et al. (2012)	increased glycogenolysis and glucagon release	ADRB2	UBERON_0002048	""
cardiovascular system	activation_general	HP_0001649	ENSG00000169252	23197038	Bowes et al. (2012)	increased heart rate	ADRB2	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000169252	23197038	Bowes et al. (2012)	decreased blood pressure	ADRB2	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009837	ENSG00000169252	23197038	Bowes et al. (2012)	bronchodilation	ADRB2	UBERON_0004535	""
cardiovascular system	activation_general	""	ENSG00000169252	23197038	Bowes et al. (2012)	peripheral vasodilation	ADRB2	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001337	ENSG00000169252	23197038	Bowes et al. (2012)	skeletal muscle tremor	ADRB2	UBERON_0004535	""
cardiovascular system	activation_general	GO_0070094	ENSG00000169252	23197038	Bowes et al. (2012)	increased glycogenolysis and glucagon release	ADRB2	UBERON_0004535	""
cardiovascular system	activation_general	""	ENSG00000142208	""	HeCaToS	may be cardioprotective	AKT1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0003074	ENSG00000142208	""	HeCaToS	hyperglycemia	AKT1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000142208	""	HeCaToS	apoptototic cell death in cancer cells	AKT1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0001685	ENSG00000166148	""	HeCaToS	myocardial fibrosis	AVPR1A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0002503	ENSG00000166148	""	HeCaToS	hypertrophy	AVPR1A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000166148	""	HeCaToS	vasoconstriction	AVPR1A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0003144	ENSG00000166148	""	HeCaToS	heart failure	AVPR1A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_acute	EFO_0003843	ENSG00000115353	28216264	Lynch et al. (2017)	pain	TACR1	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000115353	28216264	Lynch et al. (2017)	decreased pain	TACR1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050728	ENSG00000115353	28216264	Lynch et al. (2017)	decreased inflammation	TACR1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0040013	ENSG00000115353	28216264	Lynch et al. (2017)	decreased locomotor activity	TACR1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009874	ENSG00000115353	28216264	Lynch et al. (2017)	decreased anxiety	TACR1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0032277	ENSG00000115353	28216264	Lynch et al. (2017)	decreased gonadotrophic hormones	TACR1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000029	ENSG00000115353	28216264	Lynch et al. (2017)	testicular degeneration	TACR1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000823	ENSG00000115353	28216264	Lynch et al. (2017)	delayed/absent sexual maturity	TACR1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0002017	ENSG00000115353	28216264	Lynch et al. (2017)	vomiting	TACR1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1904057	ENSG00000115353	28216264	Lynch et al. (2017)	decreased pain	TACR1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0050728	ENSG00000115353	28216264	Lynch et al. (2017)	decreased inflammation	TACR1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0040013	ENSG00000115353	28216264	Lynch et al. (2017)	decreased locomotor activity	TACR1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009874	ENSG00000115353	28216264	Lynch et al. (2017)	decreased anxiety	TACR1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0032277	ENSG00000115353	28216264	Lynch et al. (2017)	decreased gonadotrophic hormones	TACR1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000029	ENSG00000115353	28216264	Lynch et al. (2017)	testicular degeneration	TACR1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000823	ENSG00000115353	28216264	Lynch et al. (2017)	delayed/absent sexual maturity	TACR1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0005251	ENSG00000115353	28216264	Lynch et al. (2017)	decreased blood pressure	TACR1	UBERON_0005409	""
nervous system	activation_acute	GO_0006954	ENSG00000115353	28216264	Lynch et al. (2017)	inflammation	TACR1	UBERON_0001016	""
immune	activation_acute	HP_0410204	ENSG00000115353	28216264	Lynch et al. (2017)	increased intestinal transit	TACR1	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000115353	28216264	Lynch et al. (2017)	decreased pain	TACR1	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000115353	28216264	Lynch et al. (2017)	decreased inflammation	TACR1	UBERON_0002405	""
immune	inhibition_acute	GO_0040013	ENSG00000115353	28216264	Lynch et al. (2017)	decreased locomotor activity	TACR1	UBERON_0002405	""
immune	inhibition_acute	EFO_0009874	ENSG00000115353	28216264	Lynch et al. (2017)	decreased anxiety	TACR1	UBERON_0002405	""
immune	inhibition_acute	GO_0032277	ENSG00000115353	28216264	Lynch et al. (2017)	decreased gonadotrophic hormones	TACR1	UBERON_0002405	""
immune	inhibition_acute	HP_0000029	ENSG00000115353	28216264	Lynch et al. (2017)	testicular degeneration	TACR1	UBERON_0002405	""
immune	inhibition_acute	HP_0000823	ENSG00000115353	28216264	Lynch et al. (2017)	delayed/absent sexual maturity	TACR1	UBERON_0002405	""
gonad	activation_acute	GO_0006954	ENSG00000115353	28216264	Lynch et al. (2017)	inflammation	TACR1	UBERON_0000991	""
gonad	inhibition_acute	GO_1904057	ENSG00000115353	28216264	Lynch et al. (2017)	decreased pain	TACR1	UBERON_0000991	""
gonad	inhibition_acute	GO_0050728	ENSG00000115353	28216264	Lynch et al. (2017)	decreased inflammation	TACR1	UBERON_0000991	""
gonad	inhibition_acute	GO_0040013	ENSG00000115353	28216264	Lynch et al. (2017)	decreased locomotor activity	TACR1	UBERON_0000991	""
gonad	inhibition_acute	EFO_0009874	ENSG00000115353	28216264	Lynch et al. (2017)	decreased anxiety	TACR1	UBERON_0000991	""
gonad	inhibition_acute	GO_0032277	ENSG00000115353	28216264	Lynch et al. (2017)	decreased gonadotrophic hormones	TACR1	UBERON_0000991	""
gonad	inhibition_acute	HP_0000029	ENSG00000115353	28216264	Lynch et al. (2017)	testicular degeneration	TACR1	UBERON_0000991	""
gonad	inhibition_acute	HP_0000823	ENSG00000115353	28216264	Lynch et al. (2017)	delayed/absent sexual maturity	TACR1	UBERON_0000991	""
nervous system	activation_acute	EFO_0005251	ENSG00000115353	28216264	Lynch et al. (2017)	decreased blood pressure	TACR1	UBERON_0001016	""
nervous system	activation_acute	HP_0410204	ENSG00000115353	28216264	Lynch et al. (2017)	increased intestinal transit	TACR1	UBERON_0001016	""
nervous system	activation_acute	GO_0120061	ENSG00000115353	28216264	Lynch et al. (2017)	decreased gastric emptying	TACR1	UBERON_0001016	""
gastrointestinal	activation_acute	GO_0006954	ENSG00000115353	28216264	Lynch et al. (2017)	inflammation	TACR1	UBERON_0005409	""
immune	activation_acute	EFO_0009836	ENSG00000115353	28216264	Lynch et al. (2017)	bronchoconstriction	TACR1	UBERON_0002405	""
nervous system	activation_acute	EFO_0009836	ENSG00000115353	28216264	Lynch et al. (2017)	bronchoconstriction	TACR1	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_0003843	ENSG00000115353	28216264	Lynch et al. (2017)	pain	TACR1	UBERON_0005409	""
gonad	activation_acute	EFO_0009836	ENSG00000115353	28216264	Lynch et al. (2017)	bronchoconstriction	TACR1	UBERON_0000991	""
gastrointestinal	activation_acute	GO_0120061	ENSG00000115353	28216264	Lynch et al. (2017)	decreased gastric emptying	TACR1	UBERON_0005409	""
gonad	activation_acute	HP_0410204	ENSG00000115353	28216264	Lynch et al. (2017)	increased intestinal transit	TACR1	UBERON_0000991	""
gonad	activation_acute	HP_0002017	ENSG00000115353	28216264	Lynch et al. (2017)	vomiting	TACR1	UBERON_0000991	""
immune	activation_acute	GO_0006954	ENSG00000115353	28216264	Lynch et al. (2017)	inflammation	TACR1	UBERON_0002405	""
gastrointestinal	activation_acute	HP_0410204	ENSG00000115353	28216264	Lynch et al. (2017)	increased intestinal transit	TACR1	UBERON_0005409	""
gonad	activation_acute	EFO_0005251	ENSG00000115353	28216264	Lynch et al. (2017)	decreased blood pressure	TACR1	UBERON_0000991	""
gonad	activation_acute	EFO_0003843	ENSG00000115353	28216264	Lynch et al. (2017)	pain	TACR1	UBERON_0000991	""
immune	activation_acute	GO_0120061	ENSG00000115353	28216264	Lynch et al. (2017)	decreased gastric emptying	TACR1	UBERON_0002405	""
immune	activation_acute	EFO_0003843	ENSG00000115353	28216264	Lynch et al. (2017)	pain	TACR1	UBERON_0002405	""
immune	activation_acute	HP_0002017	ENSG00000115353	28216264	Lynch et al. (2017)	vomiting	TACR1	UBERON_0002405	""
gastrointestinal	activation_acute	EFO_0009836	ENSG00000115353	28216264	Lynch et al. (2017)	bronchoconstriction	TACR1	UBERON_0005409	""
gonad	activation_acute	GO_0120061	ENSG00000115353	28216264	Lynch et al. (2017)	decreased gastric emptying	TACR1	UBERON_0000991	""
immune	activation_acute	EFO_0005251	ENSG00000115353	28216264	Lynch et al. (2017)	decreased blood pressure	TACR1	UBERON_0002405	""
nervous system	activation_acute	HP_0002017	ENSG00000115353	28216264	Lynch et al. (2017)	vomiting	TACR1	UBERON_0001016	""
gastrointestinal	activation_general	GO_0006939	ENSG00000120907	""	HeCaToS	smooth-muscle contraction (prostate in particular, effects on the lower urinary tract)	ADRA1A	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	EFO_0005252	ENSG00000120907	""	HeCaToS	orthostatic hypotension	ADRA1A	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	""	ENSG00000120907	""	HeCaToS	other bloodpressure- related adverse effects	ADRA1A	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	EFO_0004714	ENSG00000120907	""	HeCaToS	impact on various aspects of sexual function	ADRA1A	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	GO_0045823	ENSG00000120907	""	HeCaToS	cardiac positive ionotropy	ADRA1A	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	EFO_0004269	ENSG00000120907	""	HeCaToS	arrhythmia	ADRA1A	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0006939	ENSG00000120907	""	HeCaToS	smooth-muscle contraction (prostate in particular, effects on the lower urinary tract)	ADRA1A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0005252	ENSG00000120907	""	HeCaToS	orthostatic hypotension	ADRA1A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000120907	""	HeCaToS	other bloodpressure- related adverse effects	ADRA1A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0004714	ENSG00000120907	""	HeCaToS	impact on various aspects of sexual function	ADRA1A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0045823	ENSG00000120907	""	HeCaToS	cardiac positive ionotropy	ADRA1A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0004269	ENSG00000120907	""	HeCaToS	arrhythmia	ADRA1A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	GO_0060454	ENSG00000113749	23197038	Bowes et al. (2012)	increased gastric acid secretion	HRH2	UBERON_0005409	""
gastrointestinal	inhibition_general	GO_0060455	ENSG00000113749	23197038	Bowes et al. (2012)	decreased gastric acid secretion	HRH2	UBERON_0005409	""
gastrointestinal	activation_general	HP_0002017	ENSG00000113749	23197038	Bowes et al. (2012)	emesis	HRH2	UBERON_0005409	""
gastrointestinal	activation_general	GO_0045823	ENSG00000113749	23197038	Bowes et al. (2012)	positive inotropy	HRH2	UBERON_0005409	""
cardiovascular system	activation_general	GO_0060454	ENSG00000113749	23197038	Bowes et al. (2012)	increased gastric acid secretion	HRH2	UBERON_0004535	""
cardiovascular system	inhibition_general	GO_0060455	ENSG00000113749	23197038	Bowes et al. (2012)	decreased gastric acid secretion	HRH2	UBERON_0004535	""
cardiovascular system	activation_general	HP_0002017	ENSG00000113749	23197038	Bowes et al. (2012)	emesis	HRH2	UBERON_0004535	""
cardiovascular system	activation_general	GO_0045823	ENSG00000113749	23197038	Bowes et al. (2012)	positive inotropy	HRH2	UBERON_0004535	""
immune	inhibition_general	GO_0050728	ENSG00000113448	23197038	Bowes et al. (2012)	anti-inflammatory activities	PDE4D	UBERON_0002405	""
immune	inhibition_general	GO_0036276	ENSG00000113448	23197038	Bowes et al. (2012)	antidepressant-like activities	PDE4D	UBERON_0002405	""
immune	inhibition_general	HP_0002017	ENSG00000113448	23197038	Bowes et al. (2012)	emesis	PDE4D	UBERON_0002405	""
immune	inhibition_general	EFO_0006803	ENSG00000113448	23197038	Bowes et al. (2012)	vasculitis	PDE4D	UBERON_0002405	""
immune	inhibition_general	EFO_0009011	ENSG00000113448	23197038	Bowes et al. (2012)	arteritis	PDE4D	UBERON_0002405	""
immune	inhibition_general	EFO_0009875	ENSG00000113448	23197038	Bowes et al. (2012)	possible thymus atrophy	PDE4D	UBERON_0002405	""
central nervous system	inhibition_general	GO_0050728	ENSG00000113448	23197038	Bowes et al. (2012)	anti-inflammatory activities	PDE4D	UBERON_0001017	""
central nervous system	inhibition_general	GO_0036276	ENSG00000113448	23197038	Bowes et al. (2012)	antidepressant-like activities	PDE4D	UBERON_0001017	""
central nervous system	inhibition_general	HP_0002017	ENSG00000113448	23197038	Bowes et al. (2012)	emesis	PDE4D	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0006803	ENSG00000113448	23197038	Bowes et al. (2012)	vasculitis	PDE4D	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0009011	ENSG00000113448	23197038	Bowes et al. (2012)	arteritis	PDE4D	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0009875	ENSG00000113448	23197038	Bowes et al. (2012)	possible thymus atrophy	PDE4D	UBERON_0001017	""
nervous system	activation_acute	HP_0001324	ENSG00000142319	28216264	Lynch et al. (2017)	decreased motor strength	SLC6A3	UBERON_0001016	""
nervous system	inhibition_acute	GO_0040017	ENSG00000142319	28216264	Lynch et al. (2017)	increased locomotor activity	SLC6A3	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000733	ENSG00000142319	28216264	Lynch et al. (2017)	stereotypy	SLC6A3	UBERON_0001016	""
nervous system	inhibition_acute	""	ENSG00000142319	28216264	Lynch et al. (2017)	psychostimulation	SLC6A3	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0003890	ENSG00000142319	28216264	Lynch et al. (2017)	drug abuse/dependence	SLC6A3	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000142319	28216264	Lynch et al. (2017)	convulsions	SLC6A3	UBERON_0001016	""
nervous system	inhibition_acute	MONDO_0002050	ENSG00000142319	28216264	Lynch et al. (2017)	depression	SLC6A3	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001300	ENSG00000142319	28216264	Lynch et al. (2017)	parkinsonism	SLC6A3	UBERON_0001016	""
nervous system	inhibition_acute	EFO_1000904	ENSG00000142319	28216264	Lynch et al. (2017)	dyskinesia	SLC6A3	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001332	ENSG00000142319	28216264	Lynch et al. (2017)	dystonia	SLC6A3	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0003894	ENSG00000142319	28216264	Lynch et al. (2017)	acne	SLC6A3	UBERON_0001016	""
nervous system	activation_acute	HP_0002275	ENSG00000142319	28216264	Lynch et al. (2017)	decreased motor coordination	SLC6A3	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000069431	28216264	Lynch et al. (2017)	decreased convulsions	ABCC9	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000069431	28216264	Lynch et al. (2017)	decreased heart rate	ABCC9	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000069431	28216264	Lynch et al. (2017)	atrioventricular block	ABCC9	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000842	ENSG00000069431	28216264	Lynch et al. (2017)	increased blood insulin	ABCC9	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001943	ENSG00000069431	28216264	Lynch et al. (2017)	decreased blood glucose	ABCC9	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000069431	28216264	Lynch et al. (2017)	increased urine excretion	ABCC9	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000069431	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ABCC9	UBERON_0004535	""
cardiovascular	activation_acute	HP_0031860	ENSG00000069431	28216264	Lynch et al. (2017)	abnormal pulse	ABCC9	UBERON_0004535	""
renal	activation_acute	EFO_0009853	ENSG00000069431	28216264	Lynch et al. (2017)	decreased convulsions	ABCC9	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000069431	28216264	Lynch et al. (2017)	decreased heart rate	ABCC9	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000069431	28216264	Lynch et al. (2017)	atrioventricular block	ABCC9	UBERON_0001008	""
renal	inhibition_acute	HP_0000842	ENSG00000069431	28216264	Lynch et al. (2017)	increased blood insulin	ABCC9	UBERON_0001008	""
renal	inhibition_acute	HP_0001943	ENSG00000069431	28216264	Lynch et al. (2017)	decreased blood glucose	ABCC9	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000069431	28216264	Lynch et al. (2017)	increased urine excretion	ABCC9	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000069431	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ABCC9	UBERON_0001008	""
renal	activation_acute	HP_0011015	ENSG00000069431	28216264	Lynch et al. (2017)	increased/decreased blood glucose	ABCC9	UBERON_0001008	""
pancreas	activation_acute	HP_0040216	ENSG00000069431	28216264	Lynch et al. (2017)	decreased blood insulin	ABCC9	UBERON_0001264	""
pancreas	inhibition_acute	HP_0001662	ENSG00000069431	28216264	Lynch et al. (2017)	decreased heart rate	ABCC9	UBERON_0001264	""
pancreas	inhibition_acute	MONDO_0000465	ENSG00000069431	28216264	Lynch et al. (2017)	atrioventricular block	ABCC9	UBERON_0001264	""
pancreas	inhibition_acute	HP_0000842	ENSG00000069431	28216264	Lynch et al. (2017)	increased blood insulin	ABCC9	UBERON_0001264	""
pancreas	inhibition_acute	HP_0001943	ENSG00000069431	28216264	Lynch et al. (2017)	decreased blood glucose	ABCC9	UBERON_0001264	""
pancreas	inhibition_acute	HP_0000103	ENSG00000069431	28216264	Lynch et al. (2017)	increased urine excretion	ABCC9	UBERON_0001264	""
pancreas	inhibition_acute	GO_0035815	ENSG00000069431	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ABCC9	UBERON_0001264	""
cardiovascular	activation_acute	EFO_0004269	ENSG00000069431	28216264	Lynch et al. (2017)	cardiac arrhythmia	ABCC9	UBERON_0004535	""
renal	activation_acute	""	ENSG00000069431	28216264	Lynch et al. (2017)	cardiac lesions	ABCC9	UBERON_0001008	""
cardiovascular	activation_acute	""	ENSG00000069431	28216264	Lynch et al. (2017)	cardiac lesions	ABCC9	UBERON_0004535	""
renal	activation_acute	EFO_0005251	ENSG00000069431	28216264	Lynch et al. (2017)	decreased blood pressure	ABCC9	UBERON_0001008	""
renal	activation_acute	HP_0040216	ENSG00000069431	28216264	Lynch et al. (2017)	decreased blood insulin	ABCC9	UBERON_0001008	""
cardiovascular	activation_acute	HP_0001649	ENSG00000069431	28216264	Lynch et al. (2017)	increased heart rate	ABCC9	UBERON_0004535	""
pancreas	activation_acute	""	ENSG00000069431	28216264	Lynch et al. (2017)	cardiac lesions	ABCC9	UBERON_0001264	""
pancreas	activation_acute	EFO_0009853	ENSG00000069431	28216264	Lynch et al. (2017)	decreased convulsions	ABCC9	UBERON_0001264	""
pancreas	activation_acute	HP_0011015	ENSG00000069431	28216264	Lynch et al. (2017)	increased/decreased blood glucose	ABCC9	UBERON_0001264	""
renal	activation_acute	EFO_0004269	ENSG00000069431	28216264	Lynch et al. (2017)	cardiac arrhythmia	ABCC9	UBERON_0001008	""
cardiovascular	activation_acute	HP_0011015	ENSG00000069431	28216264	Lynch et al. (2017)	increased/decreased blood glucose	ABCC9	UBERON_0004535	""
renal	activation_acute	HP_0031860	ENSG00000069431	28216264	Lynch et al. (2017)	abnormal pulse	ABCC9	UBERON_0001008	""
cardiovascular	activation_acute	HP_0040216	ENSG00000069431	28216264	Lynch et al. (2017)	decreased blood insulin	ABCC9	UBERON_0004535	""
renal	activation_acute	HP_0001649	ENSG00000069431	28216264	Lynch et al. (2017)	increased heart rate	ABCC9	UBERON_0001008	""
pancreas	activation_acute	HP_0001649	ENSG00000069431	28216264	Lynch et al. (2017)	increased heart rate	ABCC9	UBERON_0001264	""
pancreas	activation_acute	HP_0031860	ENSG00000069431	28216264	Lynch et al. (2017)	abnormal pulse	ABCC9	UBERON_0001264	""
pancreas	activation_acute	EFO_0005251	ENSG00000069431	28216264	Lynch et al. (2017)	decreased blood pressure	ABCC9	UBERON_0001264	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000069431	28216264	Lynch et al. (2017)	decreased blood pressure	ABCC9	UBERON_0004535	""
pancreas	activation_acute	EFO_0004269	ENSG00000069431	28216264	Lynch et al. (2017)	cardiac arrhythmia	ABCC9	UBERON_0001264	""
cardiovascular system	activation_general	EFO_0009868	ENSG00000150594	""	HeCaToS	sedation	ADRA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0030895	ENSG00000150594	""	HeCaToS	may induce gastrointestinal prokinetic effects	ADRA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_1001484	ENSG00000150594	""	HeCaToS	analgesia	ADRA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000150594	""	HeCaToS	anesthetic-sparing effect	ADRA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0005251	ENSG00000150594	""	HeCaToS	central hypotension (reduction of blood pressure and heart rate)	ADRA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0002045	ENSG00000150594	""	HeCaToS	hypothermia	ADRA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0003074	ENSG00000150594	""	HeCaToS	hyperglycemia	ADRA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0001072	ENSG00000150594	""	HeCaToS	memory impairment	ADRA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0004566	ENSG00000150594	""	HeCaToS	weight gain	ADRA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009868	ENSG00000150594	""	HeCaToS	sedation	ADRA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0030895	ENSG00000150594	""	HeCaToS	may induce gastrointestinal prokinetic effects	ADRA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_1001484	ENSG00000150594	""	HeCaToS	analgesia	ADRA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000150594	""	HeCaToS	anesthetic-sparing effect	ADRA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0005251	ENSG00000150594	""	HeCaToS	central hypotension (reduction of blood pressure and heart rate)	ADRA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0002045	ENSG00000150594	""	HeCaToS	hypothermia	ADRA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0003074	ENSG00000150594	""	HeCaToS	hyperglycemia	ADRA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0001072	ENSG00000150594	""	HeCaToS	memory impairment	ADRA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0004566	ENSG00000150594	""	HeCaToS	weight gain	ADRA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
central nervous system	activation_general	EFO_1001484	ENSG00000116329	23197038	Bowes et al. (2012)	analgesia	OPRD1	UBERON_0001017	""
central nervous system	inhibition_general	HP_0032263	ENSG00000116329	23197038	Bowes et al. (2012)	increased blood pressure	OPRD1	UBERON_0001017	""
central nervous system	inhibition_general	GO_0045823	ENSG00000116329	23197038	Bowes et al. (2012)	increased cardiac contractility	OPRD1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009867	ENSG00000116329	23197038	Bowes et al. (2012)	dysphoria	OPRD1	UBERON_0001017	""
central nervous system	activation_general	EFO_1000902	ENSG00000116329	23197038	Bowes et al. (2012)	psychomimetic effects	OPRD1	UBERON_0001017	""
central nervous system	activation_general	EFO_0000319	ENSG00000116329	23197038	Bowes et al. (2012)	cardiovascular effects	OPRD1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009853	ENSG00000116329	23197038	Bowes et al. (2012)	convulsion	OPRD1	UBERON_0001017	""
cardiovascular system	activation_general	EFO_1001484	ENSG00000116329	23197038	Bowes et al. (2012)	analgesia	OPRD1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0032263	ENSG00000116329	23197038	Bowes et al. (2012)	increased blood pressure	OPRD1	UBERON_0004535	""
cardiovascular system	inhibition_general	GO_0045823	ENSG00000116329	23197038	Bowes et al. (2012)	increased cardiac contractility	OPRD1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009867	ENSG00000116329	23197038	Bowes et al. (2012)	dysphoria	OPRD1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_1000902	ENSG00000116329	23197038	Bowes et al. (2012)	psychomimetic effects	OPRD1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0000319	ENSG00000116329	23197038	Bowes et al. (2012)	cardiovascular effects	OPRD1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009853	ENSG00000116329	23197038	Bowes et al. (2012)	convulsion	OPRD1	UBERON_0004535	""
gastrointestinal	activation_general	""	ENSG00000151067	""	HeCaToS	increased mortality of heart failure patients	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	EFO_0005251	ENSG00000151067	""	HeCaToS	hypotension	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	""	ENSG00000151067	""	HeCaToS	reflex tachycardia	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	EFO_0004269	ENSG00000151067	""	HeCaToS	arrhythmia	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	EFO_0009847	ENSG00000151067	""	HeCaToS	dizziness	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	HP_0002315	ENSG00000151067	""	HeCaToS	headache	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	HP_0031284	ENSG00000151067	""	HeCaToS	redness in the face	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	""	ENSG00000151067	""	HeCaToS	fluid buildup in the legs	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	HP_0031860	ENSG00000151067	""	HeCaToS	effect on heart rate	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	HP_0002019	ENSG00000151067	""	HeCaToS	constipation	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	HP_0001250	ENSG00000151067	""	HeCaToS	induction of seizures	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	""	ENSG00000151067	""	HeCaToS	increases in peripheral vascular resistance	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	HP_0032263	ENSG00000151067	""	HeCaToS	increased systolic blood pressure	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	EFO_0004269	ENSG00000151067	""	HeCaToS	arrhythmia	CACNA1C	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000151067	""	HeCaToS	increased mortality of heart failure patients	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000151067	""	HeCaToS	hypotension	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000151067	""	HeCaToS	reflex tachycardia	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0004269	ENSG00000151067	""	HeCaToS	arrhythmia	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0009847	ENSG00000151067	""	HeCaToS	dizziness	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0002315	ENSG00000151067	""	HeCaToS	headache	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0031284	ENSG00000151067	""	HeCaToS	redness in the face	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000151067	""	HeCaToS	fluid buildup in the legs	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0031860	ENSG00000151067	""	HeCaToS	effect on heart rate	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0002019	ENSG00000151067	""	HeCaToS	constipation	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0001250	ENSG00000151067	""	HeCaToS	induction of seizures	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000151067	""	HeCaToS	increases in peripheral vascular resistance	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0032263	ENSG00000151067	""	HeCaToS	increased systolic blood pressure	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0004269	ENSG00000151067	""	HeCaToS	arrhythmia	CACNA1C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000151067	""	HeCaToS	increased mortality of heart failure patients	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0005251	ENSG00000151067	""	HeCaToS	hypotension	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	""	ENSG00000151067	""	HeCaToS	reflex tachycardia	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0004269	ENSG00000151067	""	HeCaToS	arrhythmia	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0009847	ENSG00000151067	""	HeCaToS	dizziness	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0002315	ENSG00000151067	""	HeCaToS	headache	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0031284	ENSG00000151067	""	HeCaToS	redness in the face	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	""	ENSG00000151067	""	HeCaToS	fluid buildup in the legs	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0031860	ENSG00000151067	""	HeCaToS	effect on heart rate	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0002019	ENSG00000151067	""	HeCaToS	constipation	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0001250	ENSG00000151067	""	HeCaToS	induction of seizures	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000151067	""	HeCaToS	increases in peripheral vascular resistance	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0032263	ENSG00000151067	""	HeCaToS	increased systolic blood pressure	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0004269	ENSG00000151067	""	HeCaToS	arrhythmia	CACNA1C	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0060454	ENSG00000113749	""	HeCaToS	stimulation of gastric acid secretion	HRH2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	GO_0060455	ENSG00000113749	""	HeCaToS	reduction of gastric acid secretion	HRH2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0045823	ENSG00000113749	""	HeCaToS	positive inotropic effect on the human ventricle	HRH2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0002017	ENSG00000113749	""	HeCaToS	emesis	HRH2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	GO_0060454	ENSG00000113749	""	HeCaToS	stimulation of gastric acid secretion	HRH2	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	GO_0060455	ENSG00000113749	""	HeCaToS	reduction of gastric acid secretion	HRH2	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	GO_0045823	ENSG00000113749	""	HeCaToS	positive inotropic effect on the human ventricle	HRH2	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	HP_0002017	ENSG00000113749	""	HeCaToS	emesis	HRH2	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
central nervous system	activation_acute	GO_0040017	ENSG00000116329	28216264	Lynch et al. (2017)	increased locomotor activity	OPRD1	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1904058	ENSG00000116329	28216264	Lynch et al. (2017)	increased pain	OPRD1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005230	ENSG00000116329	28216264	Lynch et al. (2017)	increased anxiety	OPRD1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009853	ENSG00000116329	28216264	Lynch et al. (2017)	convulsions	OPRD1	UBERON_0001017	""
central nervous system	activation_acute	HP_0030897	ENSG00000116329	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	OPRD1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009842	ENSG00000116329	28216264	Lynch et al. (2017)	respiratory depression	OPRD1	UBERON_0001017	""
central nervous system	activation_acute	GO_1904057	ENSG00000116329	28216264	Lynch et al. (2017)	decreased pain	OPRD1	UBERON_0001017	""
central nervous system	activation_acute	HP_0031844	ENSG00000116329	28216264	Lynch et al. (2017)	euphoria	OPRD1	UBERON_0001017	""
central nervous system	activation_acute	HP_0002045	ENSG00000116329	28216264	Lynch et al. (2017)	decreased body temperature	OPRD1	UBERON_0001017	""
cardiovascular system	activation_general	GO_0045823	ENSG00000043591	""	HeCaToS	may stimulate cardiac muscle (increase heart rate and force of contraction)	ADRB1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0000319	ENSG00000043591	""	HeCaToS	may stress cardiovascular performance	ADRB1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0001662	ENSG00000043591	""	HeCaToS	bradycardia	ADRB1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0060087	ENSG00000043591	""	HeCaToS	may contribute to the relaxation of blood vessels	ADRB1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_acute	EFO_1000014	ENSG00000181072	28216264	Lynch et al. (2017)	acidosis	CHRM2	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001649	ENSG00000181072	28216264	Lynch et al. (2017)	increased heart rate	CHRM2	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009836	ENSG00000181072	28216264	Lynch et al. (2017)	bronchoconstriction	CHRM2	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001337	ENSG00000181072	28216264	Lynch et al. (2017)	tremors	CHRM2	UBERON_0001016	""
cardiovascular	activation_acute	HP_0012735	ENSG00000181072	28216264	Lynch et al. (2017)	cough	CHRM2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000181072	28216264	Lynch et al. (2017)	increased heart rate	CHRM2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009836	ENSG00000181072	28216264	Lynch et al. (2017)	bronchoconstriction	CHRM2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001337	ENSG00000181072	28216264	Lynch et al. (2017)	tremors	CHRM2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0000622	ENSG00000181072	28216264	Lynch et al. (2017)	blurred vision	CHRM2	UBERON_0004535	""
respiratory	activation_acute	HP_0000737	ENSG00000181072	28216264	Lynch et al. (2017)	irritability	CHRM2	UBERON_0001004	""
respiratory	inhibition_acute	HP_0001649	ENSG00000181072	28216264	Lynch et al. (2017)	increased heart rate	CHRM2	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009836	ENSG00000181072	28216264	Lynch et al. (2017)	bronchoconstriction	CHRM2	UBERON_0001004	""
respiratory	inhibition_acute	HP_0001337	ENSG00000181072	28216264	Lynch et al. (2017)	tremors	CHRM2	UBERON_0001004	""
nervous system	activation_acute	HP_0031860	ENSG00000181072	28216264	Lynch et al. (2017)	decreased/increased heart rate	CHRM2	UBERON_0001016	""
nervous system	activation_acute	EFO_0009852	ENSG00000181072	28216264	Lynch et al. (2017)	exhaustion	CHRM2	UBERON_0001016	""
nervous system	activation_acute	HP_0000632	ENSG00000181072	28216264	Lynch et al. (2017)	lacrimation	CHRM2	UBERON_0001016	""
nervous system	activation_acute	HP_0030972	ENSG00000181072	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM2	UBERON_0001016	""
cardiovascular	activation_acute	HP_0040223	ENSG00000181072	28216264	Lynch et al. (2017)	pulmonary hemorrhage	CHRM2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0005165	ENSG00000181072	28216264	Lynch et al. (2017)	decreased PR interval	CHRM2	UBERON_0004535	""
nervous system	activation_acute	EFO_0009866	ENSG00000181072	28216264	Lynch et al. (2017)	pulmonary congestion	CHRM2	UBERON_0001016	""
cardiovascular	activation_acute	HP_0031860	ENSG00000181072	28216264	Lynch et al. (2017)	decreased/increased heart rate	CHRM2	UBERON_0004535	""
respiratory	activation_acute	Orphanet_98578	ENSG00000181072	28216264	Lynch et al. (2017)	ptosis	CHRM2	UBERON_0001004	""
respiratory	activation_acute	HP_0000622	ENSG00000181072	28216264	Lynch et al. (2017)	blurred vision	CHRM2	UBERON_0001004	""
respiratory	activation_acute	HP_0040223	ENSG00000181072	28216264	Lynch et al. (2017)	pulmonary hemorrhage	CHRM2	UBERON_0001004	""
nervous system	activation_acute	""	ENSG00000181072	28216264	Lynch et al. (2017)	frothing	CHRM2	UBERON_0001016	""
respiratory	activation_acute	""	ENSG00000181072	28216264	Lynch et al. (2017)	frothing	CHRM2	UBERON_0001004	""
nervous system	activation_acute	GO_0046878	ENSG00000181072	28216264	Lynch et al. (2017)	increased salivation	CHRM2	UBERON_0001016	""
cardiovascular	activation_acute	EFO_1000014	ENSG00000181072	28216264	Lynch et al. (2017)	acidosis	CHRM2	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000181072	28216264	Lynch et al. (2017)	bronchorrhea	CHRM2	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009866	ENSG00000181072	28216264	Lynch et al. (2017)	pulmonary congestion	CHRM2	UBERON_0004535	""
respiratory	activation_acute	EFO_1000014	ENSG00000181072	28216264	Lynch et al. (2017)	acidosis	CHRM2	UBERON_0001004	""
respiratory	activation_acute	HP_0030972	ENSG00000181072	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM2	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009852	ENSG00000181072	28216264	Lynch et al. (2017)	exhaustion	CHRM2	UBERON_0004535	""
respiratory	activation_acute	HP_0000616	ENSG00000181072	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM2	UBERON_0001004	""
nervous system	activation_acute	HP_0000616	ENSG00000181072	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM2	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000737	ENSG00000181072	28216264	Lynch et al. (2017)	irritability	CHRM2	UBERON_0004535	""
respiratory	activation_acute	HP_0012735	ENSG00000181072	28216264	Lynch et al. (2017)	cough	CHRM2	UBERON_0001004	""
cardiovascular	activation_acute	HP_0001945	ENSG00000181072	28216264	Lynch et al. (2017)	increased body temperature	CHRM2	UBERON_0004535	""
respiratory	activation_acute	""	ENSG00000181072	28216264	Lynch et al. (2017)	bronchorrhea	CHRM2	UBERON_0001004	""
respiratory	activation_acute	EFO_0009852	ENSG00000181072	28216264	Lynch et al. (2017)	exhaustion	CHRM2	UBERON_0001004	""
respiratory	activation_acute	HP_0001945	ENSG00000181072	28216264	Lynch et al. (2017)	increased body temperature	CHRM2	UBERON_0001004	""
respiratory	activation_acute	EFO_0009866	ENSG00000181072	28216264	Lynch et al. (2017)	pulmonary congestion	CHRM2	UBERON_0001004	""
cardiovascular	activation_acute	HP_0025428	ENSG00000181072	28216264	Lynch et al. (2017)	bronchospasm	CHRM2	UBERON_0004535	""
nervous system	activation_acute	HP_0001945	ENSG00000181072	28216264	Lynch et al. (2017)	increased body temperature	CHRM2	UBERON_0001016	""
nervous system	activation_acute	HP_0000975	ENSG00000181072	28216264	Lynch et al. (2017)	sweating	CHRM2	UBERON_0001016	""
nervous system	activation_acute	HP_0012735	ENSG00000181072	28216264	Lynch et al. (2017)	cough	CHRM2	UBERON_0001016	""
nervous system	activation_acute	""	ENSG00000181072	28216264	Lynch et al. (2017)	bronchorrhea	CHRM2	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000975	ENSG00000181072	28216264	Lynch et al. (2017)	sweating	CHRM2	UBERON_0004535	""
respiratory	activation_acute	GO_0046878	ENSG00000181072	28216264	Lynch et al. (2017)	increased salivation	CHRM2	UBERON_0001004	""
respiratory	activation_acute	HP_0000975	ENSG00000181072	28216264	Lynch et al. (2017)	sweating	CHRM2	UBERON_0001004	""
nervous system	activation_acute	HP_0005165	ENSG00000181072	28216264	Lynch et al. (2017)	decreased PR interval	CHRM2	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000632	ENSG00000181072	28216264	Lynch et al. (2017)	lacrimation	CHRM2	UBERON_0004535	""
respiratory	activation_acute	HP_0000632	ENSG00000181072	28216264	Lynch et al. (2017)	lacrimation	CHRM2	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009846	ENSG00000181072	28216264	Lynch et al. (2017)	muscle cramps	CHRM2	UBERON_0004535	""
nervous system	activation_acute	HP_0040223	ENSG00000181072	28216264	Lynch et al. (2017)	pulmonary hemorrhage	CHRM2	UBERON_0001016	""
cardiovascular	activation_acute	Orphanet_98578	ENSG00000181072	28216264	Lynch et al. (2017)	ptosis	CHRM2	UBERON_0004535	""
nervous system	activation_acute	EFO_0009846	ENSG00000181072	28216264	Lynch et al. (2017)	muscle cramps	CHRM2	UBERON_0001016	""
cardiovascular	activation_acute	GO_0046878	ENSG00000181072	28216264	Lynch et al. (2017)	increased salivation	CHRM2	UBERON_0004535	""
nervous system	activation_acute	HP_0000737	ENSG00000181072	28216264	Lynch et al. (2017)	irritability	CHRM2	UBERON_0001016	""
nervous system	activation_acute	Orphanet_98578	ENSG00000181072	28216264	Lynch et al. (2017)	ptosis	CHRM2	UBERON_0001016	""
respiratory	activation_acute	EFO_0009846	ENSG00000181072	28216264	Lynch et al. (2017)	muscle cramps	CHRM2	UBERON_0001004	""
respiratory	activation_acute	HP_0025428	ENSG00000181072	28216264	Lynch et al. (2017)	bronchospasm	CHRM2	UBERON_0001004	""
respiratory	activation_acute	HP_0005165	ENSG00000181072	28216264	Lynch et al. (2017)	decreased PR interval	CHRM2	UBERON_0001004	""
nervous system	activation_acute	EFO_0009841	ENSG00000181072	28216264	Lynch et al. (2017)	decreased/increased respiratory rate	CHRM2	UBERON_0001016	""
nervous system	activation_acute	HP_0025428	ENSG00000181072	28216264	Lynch et al. (2017)	bronchospasm	CHRM2	UBERON_0001016	""
respiratory	activation_acute	EFO_0009841	ENSG00000181072	28216264	Lynch et al. (2017)	decreased/increased respiratory rate	CHRM2	UBERON_0001004	""
respiratory	activation_acute	HP_0031860	ENSG00000181072	28216264	Lynch et al. (2017)	decreased/increased heart rate	CHRM2	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009841	ENSG00000181072	28216264	Lynch et al. (2017)	decreased/increased respiratory rate	CHRM2	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000181072	28216264	Lynch et al. (2017)	frothing	CHRM2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0030972	ENSG00000181072	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0000616	ENSG00000181072	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM2	UBERON_0004535	""
nervous system	activation_acute	HP_0000622	ENSG00000181072	28216264	Lynch et al. (2017)	blurred vision	CHRM2	UBERON_0001016	""
cardiovascular system	inhibition_chronic	""	ENSG00000152270	""	HeCaToS	increased mortality in heart failure patients	PDE3B	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0004308	ENSG00000152270	""	HeCaToS	could induce ventricular arrhythmias in ~10% of patients	PDE3B	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0001649	ENSG00000152270	""	HeCaToS	tachycardia	PDE3B	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000152270	""	HeCaToS	hypotension	PDE3B	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_chronic	HP_0001873	ENSG00000152270	""	HeCaToS	thrombocytopenia	PDE3B	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
respiratory	activation_acute	EFO_0009853	ENSG00000166257	28216264	Lynch et al. (2017)	convulsions	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	GO_1904057	ENSG00000166257	28216264	Lynch et al. (2017)	decreased pain	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	NCIT_C74532	ENSG00000166257	28216264	Lynch et al. (2017)	agitation	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_1000712	ENSG00000166257	28216264	Lynch et al. (2017)	decreased sweating	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0011499	ENSG00000166257	28216264	Lynch et al. (2017)	increased pupil diameter	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009853	ENSG00000166257	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0031860	ENSG00000166257	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0005251	ENSG00000166257	28216264	Lynch et al. (2017)	decreased blood pressure	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	GO_0045822	ENSG00000166257	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_1001497	ENSG00000166257	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0006677	ENSG00000166257	28216264	Lynch et al. (2017)	increased QRS complex	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0004269	ENSG00000166257	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009839	ENSG00000166257	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0030897	ENSG00000166257	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0011037	ENSG00000166257	28216264	Lynch et al. (2017)	decreased urine excretion	SCN3B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0001259	ENSG00000166257	28216264	Lynch et al. (2017)	coma	SCN3B	UBERON_0001004	""
nervous system	activation_acute	HP_0001649	ENSG00000166257	28216264	Lynch et al. (2017)	increased heart rate	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000166257	28216264	Lynch et al. (2017)	decreased pain	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	NCIT_C74532	ENSG00000166257	28216264	Lynch et al. (2017)	agitation	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_1000712	ENSG00000166257	28216264	Lynch et al. (2017)	decreased sweating	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0011499	ENSG00000166257	28216264	Lynch et al. (2017)	increased pupil diameter	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000166257	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0031860	ENSG00000166257	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0005251	ENSG00000166257	28216264	Lynch et al. (2017)	decreased blood pressure	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	GO_0045822	ENSG00000166257	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_1001497	ENSG00000166257	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0006677	ENSG00000166257	28216264	Lynch et al. (2017)	increased QRS complex	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004269	ENSG00000166257	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009839	ENSG00000166257	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030897	ENSG00000166257	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0011037	ENSG00000166257	28216264	Lynch et al. (2017)	decreased urine excretion	SCN3B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001259	ENSG00000166257	28216264	Lynch et al. (2017)	coma	SCN3B	UBERON_0001016	""
respiratory	activation_acute	HP_0001649	ENSG00000166257	28216264	Lynch et al. (2017)	increased heart rate	SCN3B	UBERON_0001004	""
cardiovascular	activation_acute	HP_0001649	ENSG00000166257	28216264	Lynch et al. (2017)	increased heart rate	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000166257	28216264	Lynch et al. (2017)	decreased pain	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	NCIT_C74532	ENSG00000166257	28216264	Lynch et al. (2017)	agitation	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_1000712	ENSG00000166257	28216264	Lynch et al. (2017)	decreased sweating	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011499	ENSG00000166257	28216264	Lynch et al. (2017)	increased pupil diameter	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000166257	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0031860	ENSG00000166257	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000166257	28216264	Lynch et al. (2017)	decreased blood pressure	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0045822	ENSG00000166257	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_1001497	ENSG00000166257	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0006677	ENSG00000166257	28216264	Lynch et al. (2017)	increased QRS complex	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000166257	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009839	ENSG00000166257	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000166257	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011037	ENSG00000166257	28216264	Lynch et al. (2017)	decreased urine excretion	SCN3B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001259	ENSG00000166257	28216264	Lynch et al. (2017)	coma	SCN3B	UBERON_0004535	""
nervous system	activation_acute	HP_0002094	ENSG00000166257	28216264	Lynch et al. (2017)	dyspnea	SCN3B	UBERON_0001016	""
cardiovascular	activation_acute	GO_0040013	ENSG00000166257	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN3B	UBERON_0004535	""
respiratory	activation_acute	GO_0040013	ENSG00000166257	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN3B	UBERON_0001004	""
nervous system	activation_acute	EFO_0009853	ENSG00000166257	28216264	Lynch et al. (2017)	convulsions	SCN3B	UBERON_0001016	""
nervous system	activation_acute	GO_0040013	ENSG00000166257	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN3B	UBERON_0001016	""
respiratory	activation_acute	HP_0002094	ENSG00000166257	28216264	Lynch et al. (2017)	dyspnea	SCN3B	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000166257	28216264	Lynch et al. (2017)	convulsions	SCN3B	UBERON_0004535	""
nervous system	activation_acute	EFO_0004269	ENSG00000166257	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN3B	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0004269	ENSG00000166257	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN3B	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002094	ENSG00000166257	28216264	Lynch et al. (2017)	dyspnea	SCN3B	UBERON_0004535	""
respiratory	activation_acute	EFO_0004269	ENSG00000166257	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN3B	UBERON_0001004	""
nervous system	activation_general	EFO_1001484	ENSG00000116329	""	Urban et al. (2012)	analgesia	OPRD1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	""	ENSG00000116329	""	Urban et al. (2012)	selective d-opioid receptor antagonists but not mu antagonist increase blood pressure, cardiac output, contractibility, and bloodflow to the heart, kidneys, gastrointestinal tract and skeletal muscle in conscious dog with right heart failure	OPRD1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009867	ENSG00000116329	""	Urban et al. (2012)	dysphoria	OPRD1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_1000902	ENSG00000116329	""	Urban et al. (2012)	psychomimetic effects	OPRD1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0000319	ENSG00000116329	""	Urban et al. (2012)	cardiovascular effects	OPRD1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009853	ENSG00000116329	""	Urban et al. (2012)	convulsion	OPRD1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009853	ENSG00000116329	""	Urban et al. (2012)	many d agonists may cause seizures and convulsions at high doses, although not all d agonists produce this effect	OPRD1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000116329	""	Urban et al. (2012)	all the subtype selective opiate receptor agonists have effects on the heart	OPRD1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009842	ENSG00000116329	""	Urban et al. (2012)	respiratory depression may be associated with opioid treatment	OPRD1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_1001484	ENSG00000116329	""	Urban et al. (2012)	analgesia	OPRD1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000116329	""	Urban et al. (2012)	selective d-opioid receptor antagonists but not mu antagonist increase blood pressure, cardiac output, contractibility, and bloodflow to the heart, kidneys, gastrointestinal tract and skeletal muscle in conscious dog with right heart failure	OPRD1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009867	ENSG00000116329	""	Urban et al. (2012)	dysphoria	OPRD1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_1000902	ENSG00000116329	""	Urban et al. (2012)	psychomimetic effects	OPRD1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0000319	ENSG00000116329	""	Urban et al. (2012)	cardiovascular effects	OPRD1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009853	ENSG00000116329	""	Urban et al. (2012)	convulsion	OPRD1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009853	ENSG00000116329	""	Urban et al. (2012)	many d agonists may cause seizures and convulsions at high doses, although not all d agonists produce this effect	OPRD1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000116329	""	Urban et al. (2012)	all the subtype selective opiate receptor agonists have effects on the heart	OPRD1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009842	ENSG00000116329	""	Urban et al. (2012)	respiratory depression may be associated with opioid treatment	OPRD1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular	activation_acute	GO_0070527	ENSG00000169403	28216264	Lynch et al. (2017)	platelet aggregation	PTAFR	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0050728	ENSG00000169403	28216264	Lynch et al. (2017)	decreased inflammation	PTAFR	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000169403	28216264	Lynch et al. (2017)	decreased pain	PTAFR	UBERON_0004535	""
blood	activation_acute	EFO_0005251	ENSG00000169403	28216264	Lynch et al. (2017)	decreased blood pressure	PTAFR	UBERON_0000178	""
blood	inhibition_acute	GO_0050728	ENSG00000169403	28216264	Lynch et al. (2017)	decreased inflammation	PTAFR	UBERON_0000178	""
blood	inhibition_acute	GO_1904057	ENSG00000169403	28216264	Lynch et al. (2017)	decreased pain	PTAFR	UBERON_0000178	""
blood	activation_acute	GO_0070527	ENSG00000169403	28216264	Lynch et al. (2017)	platelet aggregation	PTAFR	UBERON_0000178	""
respiratory	activation_acute	EFO_0005251	ENSG00000169403	28216264	Lynch et al. (2017)	decreased blood pressure	PTAFR	UBERON_0001004	""
respiratory	inhibition_acute	GO_0050728	ENSG00000169403	28216264	Lynch et al. (2017)	decreased inflammation	PTAFR	UBERON_0001004	""
respiratory	inhibition_acute	GO_1904057	ENSG00000169403	28216264	Lynch et al. (2017)	decreased pain	PTAFR	UBERON_0001004	""
respiratory	activation_acute	GO_0045822	ENSG00000169403	28216264	Lynch et al. (2017)	decreased cardiac contractility	PTAFR	UBERON_0001004	""
renal	activation_acute	GO_0006954	ENSG00000169403	28216264	Lynch et al. (2017)	inflammation	PTAFR	UBERON_0001008	""
renal	inhibition_acute	GO_0050728	ENSG00000169403	28216264	Lynch et al. (2017)	decreased inflammation	PTAFR	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000169403	28216264	Lynch et al. (2017)	decreased pain	PTAFR	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0003843	ENSG00000169403	28216264	Lynch et al. (2017)	pain	PTAFR	UBERON_0004535	""
respiratory	activation_acute	GO_0006954	ENSG00000169403	28216264	Lynch et al. (2017)	inflammation	PTAFR	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000169403	28216264	Lynch et al. (2017)	decreased blood pressure	PTAFR	UBERON_0004535	""
cardiovascular	activation_acute	GO_0035814	ENSG00000169403	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PTAFR	UBERON_0004535	""
renal	activation_acute	HP_0001662	ENSG00000169403	28216264	Lynch et al. (2017)	decreased heart rate	PTAFR	UBERON_0001008	""
renal	activation_acute	GO_0045822	ENSG00000169403	28216264	Lynch et al. (2017)	decreased cardiac contractility	PTAFR	UBERON_0001008	""
renal	activation_acute	HP_0011037	ENSG00000169403	28216264	Lynch et al. (2017)	decreased urine excretion	PTAFR	UBERON_0001008	""
immune	activation_acute	GO_0045822	ENSG00000169403	28216264	Lynch et al. (2017)	decreased cardiac contractility	PTAFR	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000169403	28216264	Lynch et al. (2017)	decreased inflammation	PTAFR	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000169403	28216264	Lynch et al. (2017)	decreased pain	PTAFR	UBERON_0002405	""
renal	activation_acute	EFO_0003843	ENSG00000169403	28216264	Lynch et al. (2017)	pain	PTAFR	UBERON_0001008	""
immune	activation_acute	GO_0035814	ENSG00000169403	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PTAFR	UBERON_0002405	""
cardiovascular	activation_acute	HP_0011037	ENSG00000169403	28216264	Lynch et al. (2017)	decreased urine excretion	PTAFR	UBERON_0004535	""
immune	activation_acute	HP_0011037	ENSG00000169403	28216264	Lynch et al. (2017)	decreased urine excretion	PTAFR	UBERON_0002405	""
cardiovascular	activation_acute	GO_0045822	ENSG00000169403	28216264	Lynch et al. (2017)	decreased cardiac contractility	PTAFR	UBERON_0004535	""
respiratory	activation_acute	GO_0070527	ENSG00000169403	28216264	Lynch et al. (2017)	platelet aggregation	PTAFR	UBERON_0001004	""
immune	activation_acute	EFO_0005414	ENSG00000169403	28216264	Lynch et al. (2017)	increased airway responsiveness to antigens	PTAFR	UBERON_0002405	""
respiratory	activation_acute	HP_0011037	ENSG00000169403	28216264	Lynch et al. (2017)	decreased urine excretion	PTAFR	UBERON_0001004	""
blood	activation_acute	HP_0011037	ENSG00000169403	28216264	Lynch et al. (2017)	decreased urine excretion	PTAFR	UBERON_0000178	""
immune	activation_acute	EFO_0003843	ENSG00000169403	28216264	Lynch et al. (2017)	pain	PTAFR	UBERON_0002405	""
respiratory	activation_acute	GO_0035814	ENSG00000169403	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PTAFR	UBERON_0001004	""
blood	activation_acute	EFO_0005414	ENSG00000169403	28216264	Lynch et al. (2017)	increased airway responsiveness to antigens	PTAFR	UBERON_0000178	""
cardiovascular	activation_acute	GO_0006954	ENSG00000169403	28216264	Lynch et al. (2017)	inflammation	PTAFR	UBERON_0004535	""
blood	activation_acute	EFO_0009836	ENSG00000169403	28216264	Lynch et al. (2017)	bronchoconstriction	PTAFR	UBERON_0000178	""
blood	activation_acute	HP_0001662	ENSG00000169403	28216264	Lynch et al. (2017)	decreased heart rate	PTAFR	UBERON_0000178	""
renal	activation_acute	EFO_0005414	ENSG00000169403	28216264	Lynch et al. (2017)	increased airway responsiveness to antigens	PTAFR	UBERON_0001008	""
renal	activation_acute	EFO_0009836	ENSG00000169403	28216264	Lynch et al. (2017)	bronchoconstriction	PTAFR	UBERON_0001008	""
respiratory	activation_acute	EFO_0005414	ENSG00000169403	28216264	Lynch et al. (2017)	increased airway responsiveness to antigens	PTAFR	UBERON_0001004	""
respiratory	activation_acute	EFO_0009836	ENSG00000169403	28216264	Lynch et al. (2017)	bronchoconstriction	PTAFR	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009836	ENSG00000169403	28216264	Lynch et al. (2017)	bronchoconstriction	PTAFR	UBERON_0004535	""
immune	activation_acute	GO_0006954	ENSG00000169403	28216264	Lynch et al. (2017)	inflammation	PTAFR	UBERON_0002405	""
blood	activation_acute	GO_0045822	ENSG00000169403	28216264	Lynch et al. (2017)	decreased cardiac contractility	PTAFR	UBERON_0000178	""
renal	activation_acute	GO_0070527	ENSG00000169403	28216264	Lynch et al. (2017)	platelet aggregation	PTAFR	UBERON_0001008	""
blood	activation_acute	GO_0035814	ENSG00000169403	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PTAFR	UBERON_0000178	""
renal	activation_acute	EFO_0005251	ENSG00000169403	28216264	Lynch et al. (2017)	decreased blood pressure	PTAFR	UBERON_0001008	""
immune	activation_acute	HP_0001662	ENSG00000169403	28216264	Lynch et al. (2017)	decreased heart rate	PTAFR	UBERON_0002405	""
respiratory	activation_acute	EFO_0003843	ENSG00000169403	28216264	Lynch et al. (2017)	pain	PTAFR	UBERON_0001004	""
blood	activation_acute	EFO_0003843	ENSG00000169403	28216264	Lynch et al. (2017)	pain	PTAFR	UBERON_0000178	""
cardiovascular	activation_acute	HP_0001662	ENSG00000169403	28216264	Lynch et al. (2017)	decreased heart rate	PTAFR	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0005414	ENSG00000169403	28216264	Lynch et al. (2017)	increased airway responsiveness to antigens	PTAFR	UBERON_0004535	""
respiratory	activation_acute	HP_0001662	ENSG00000169403	28216264	Lynch et al. (2017)	decreased heart rate	PTAFR	UBERON_0001004	""
immune	activation_acute	EFO_0005251	ENSG00000169403	28216264	Lynch et al. (2017)	decreased blood pressure	PTAFR	UBERON_0002405	""
immune	activation_acute	GO_0070527	ENSG00000169403	28216264	Lynch et al. (2017)	platelet aggregation	PTAFR	UBERON_0002405	""
renal	activation_acute	GO_0035814	ENSG00000169403	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PTAFR	UBERON_0001008	""
blood	activation_acute	GO_0006954	ENSG00000169403	28216264	Lynch et al. (2017)	inflammation	PTAFR	UBERON_0000178	""
immune	activation_acute	EFO_0009836	ENSG00000169403	28216264	Lynch et al. (2017)	bronchoconstriction	PTAFR	UBERON_0002405	""
nervous system	activation_acute	EFO_0004874	ENSG00000147955	28216264	Lynch et al. (2017)	increased memory	SIGMAR1	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000147955	28216264	Lynch et al. (2017)	decreased pain	SIGMAR1	UBERON_0001016	""
nervous system	activation_acute	EFO_0003890	ENSG00000147955	28216264	Lynch et al. (2017)	drug abuse/dependence	SIGMAR1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009874	ENSG00000147955	28216264	Lynch et al. (2017)	decreased anxiety	SIGMAR1	UBERON_0001016	""
nervous system	activation_acute	HP_0000738	ENSG00000147955	28216264	Lynch et al. (2017)	hallucinations	SIGMAR1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009853	ENSG00000147955	28216264	Lynch et al. (2017)	decreased convulsions	SIGMAR1	UBERON_0001016	""
central nervous system	activation_general	EFO_0009874	ENSG00000022355	23197038	Bowes et al. (2012)	anxiolysis	GABRA1	UBERON_0001017	""
central nervous system	inhibition_general	HP_0001250	ENSG00000022355	23197038	Bowes et al. (2012)	seizure (when used as a BZD antidote)	GABRA1	UBERON_0001017	""
central nervous system	activation_general	""	ENSG00000022355	23197038	Bowes et al. (2012)	muscle relaxation	GABRA1	UBERON_0001017	""
central nervous system	activation_general	MONDO_0000437	ENSG00000022355	23197038	Bowes et al. (2012)	ataxia	GABRA1	UBERON_0001017	""
central nervous system	activation_general	GO_0036277	ENSG00000022355	23197038	Bowes et al. (2012)	anticonvulsant	GABRA1	UBERON_0001017	""
central nervous system	activation_general	EFO_0003890	ENSG00000022355	23197038	Bowes et al. (2012)	abuse potential	GABRA1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009868	ENSG00000022355	23197038	Bowes et al. (2012)	sedation	GABRA1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009847	ENSG00000022355	23197038	Bowes et al. (2012)	dizziness	GABRA1	UBERON_0001017	""
central nervous system	activation_general	MONDO_0002050	ENSG00000022355	23197038	Bowes et al. (2012)	depression	GABRA1	UBERON_0001017	""
central nervous system	activation_general	EFO_1001454	ENSG00000022355	23197038	Bowes et al. (2012)	anterograde amnesia	GABRA1	UBERON_0001017	""
pulmonary	activation_general	""	ENSG00000135914	23197038	Bowes et al. (2012)	potential cardiac valvulopathy	HTR2B	UBERON_0002048	""
pulmonary	inhibition_developmental toxicity	EFO_0005269	ENSG00000135914	23197038	Bowes et al. (2012)	possible cardiac effects, especially during embryonic development	HTR2B	UBERON_0002048	""
pulmonary	activation_general	EFO_0001361	ENSG00000135914	23197038	Bowes et al. (2012)	pulmonary hypertension	HTR2B	UBERON_0002048	""
development	activation_general	""	ENSG00000135914	23197038	Bowes et al. (2012)	potential cardiac valvulopathy	HTR2B	""	""
development	inhibition_developmental toxicity	EFO_0005269	ENSG00000135914	23197038	Bowes et al. (2012)	possible cardiac effects, especially during embryonic development	HTR2B	""	""
development	activation_general	EFO_0001361	ENSG00000135914	23197038	Bowes et al. (2012)	pulmonary hypertension	HTR2B	""	""
cardiovascular system	activation_general	""	ENSG00000135914	23197038	Bowes et al. (2012)	potential cardiac valvulopathy	HTR2B	UBERON_0004535	""
cardiovascular system	inhibition_developmental toxicity	EFO_0005269	ENSG00000135914	23197038	Bowes et al. (2012)	possible cardiac effects, especially during embryonic development	HTR2B	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0001361	ENSG00000135914	23197038	Bowes et al. (2012)	pulmonary hypertension	HTR2B	UBERON_0004535	""
cardiovascular system	inhibition_general	MONDO_0002442	ENSG00000183873	""	HeCaToS	long QT	SCN5A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0004269	ENSG00000183873	""	HeCaToS	arrhythmias	SCN5A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0005307	ENSG00000183873	""	HeCaToS	TdP	SCN5A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	MONDO_0020575	ENSG00000183873	""	HeCaToS	polymorphic ventricular tachycardia	SCN5A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular	inhibition_acute	GO_0045823	ENSG00000105409	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1A3	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000105409	28216264	Lynch et al. (2017)	decreased heart rate	ATP1A3	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000105409	28216264	Lynch et al. (2017)	atrioventricular block	ATP1A3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000105409	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1A3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004287	ENSG00000105409	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1A3	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000105409	28216264	Lynch et al. (2017)	increased urine excretion	ATP1A3	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000105409	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1A3	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002017	ENSG00000105409	28216264	Lynch et al. (2017)	vomiting	ATP1A3	UBERON_0004535	""
renal	inhibition_acute	GO_0045823	ENSG00000105409	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1A3	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000105409	28216264	Lynch et al. (2017)	decreased heart rate	ATP1A3	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000105409	28216264	Lynch et al. (2017)	atrioventricular block	ATP1A3	UBERON_0001008	""
renal	inhibition_acute	EFO_0004269	ENSG00000105409	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1A3	UBERON_0001008	""
renal	inhibition_acute	EFO_0004287	ENSG00000105409	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1A3	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000105409	28216264	Lynch et al. (2017)	increased urine excretion	ATP1A3	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000105409	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1A3	UBERON_0001008	""
renal	inhibition_acute	HP_0002017	ENSG00000105409	28216264	Lynch et al. (2017)	vomiting	ATP1A3	UBERON_0001008	""
cardiovascular system	activation_general	EFO_0009874	ENSG00000164128	""	HeCaToS	anxiolytic effects	NPY1R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000164128	""	HeCaToS	vasodilation (especially venous)	NPY1R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0005230	ENSG00000164128	""	HeCaToS	increase in anxiety-related effects	NPY1R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000164128	""	HeCaToS	vasoconstriction (vasodilation in subcutaneous arteries)	NPY1R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009829	ENSG00000164128	""	HeCaToS	smooth-muscle cell growth leading to atherosclerosis, restenosis, stroke	NPY1R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0100738	ENSG00000164128	""	HeCaToS	may result in stimulation of feeding behavior	NPY1R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009874	ENSG00000164128	""	HeCaToS	anxiolytic effects	NPY1R	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	""	ENSG00000164128	""	HeCaToS	vasodilation (especially venous)	NPY1R	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0005230	ENSG00000164128	""	HeCaToS	increase in anxiety-related effects	NPY1R	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000164128	""	HeCaToS	vasoconstriction (vasodilation in subcutaneous arteries)	NPY1R	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009829	ENSG00000164128	""	HeCaToS	smooth-muscle cell growth leading to atherosclerosis, restenosis, stroke	NPY1R	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0100738	ENSG00000164128	""	HeCaToS	may result in stimulation of feeding behavior	NPY1R	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	HP_0032263	ENSG00000168539	""	HeCaToS	increased blood pressure	CHRM1	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	HP_0100543	ENSG00000168539	""	HeCaToS	disruption of cognitive functions such as learning and memory	CHRM1	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	HP_0001649	ENSG00000168539	""	HeCaToS	increased heart rate	CHRM1	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	""	ENSG00000168539	""	HeCaToS	increased sympathetic outflow	CHRM1	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	HP_0012719	ENSG00000168539	""	HeCaToS	gastrointestinal side effects	CHRM1	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	GO_0042752	ENSG00000168539	""	HeCaToS	may be involved in the regulation of circadian rhythm	CHRM1	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0032263	ENSG00000168539	""	HeCaToS	increased blood pressure	CHRM1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0100543	ENSG00000168539	""	HeCaToS	disruption of cognitive functions such as learning and memory	CHRM1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0001649	ENSG00000168539	""	HeCaToS	increased heart rate	CHRM1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000168539	""	HeCaToS	increased sympathetic outflow	CHRM1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0012719	ENSG00000168539	""	HeCaToS	gastrointestinal side effects	CHRM1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	GO_0042752	ENSG00000168539	""	HeCaToS	may be involved in the regulation of circadian rhythm	CHRM1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0032263	ENSG00000168539	""	HeCaToS	increased blood pressure	CHRM1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0100543	ENSG00000168539	""	HeCaToS	disruption of cognitive functions such as learning and memory	CHRM1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0001649	ENSG00000168539	""	HeCaToS	increased heart rate	CHRM1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000168539	""	HeCaToS	increased sympathetic outflow	CHRM1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0012719	ENSG00000168539	""	HeCaToS	gastrointestinal side effects	CHRM1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0042752	ENSG00000168539	""	HeCaToS	may be involved in the regulation of circadian rhythm	CHRM1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0000275	ENSG00000180509	23197038	Bowes et al. (2012)	atrial fibrillation	KCNE1	UBERON_0004535	""
cardiovascular system	inhibition_general	MONDO_0002442	ENSG00000180509	23197038	Bowes et al. (2012)	long QT syndrome	KCNE1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0004238	ENSG00000180509	23197038	Bowes et al. (2012)	potential hearing impairment	KCNE1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0001063	ENSG00000180509	23197038	Bowes et al. (2012)	deafness	KCNE1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0012719	ENSG00000180509	23197038	Bowes et al. (2012)	gastrointestinal symptoms	KCNE1	UBERON_0004535	""
central nervous system	activation_general	""	ENSG00000184160	""	HeCaToS	involved in many processes such as the startle reflex, stress response, and locomotion	ADRA2C	UBERON_0001017	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
central nervous system	activation_general	""	ENSG00000184160	""	HeCaToS	venous contraction (contraction of human saphenous vein)	ADRA2C	UBERON_0001017	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
central nervous system	activation_general	EFO_0000537	ENSG00000184160	""	HeCaToS	hypertension	ADRA2C	UBERON_0001017	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
central nervous system	activation_general	EFO_1001375	ENSG00000184160	""	HeCaToS	cardiac ischemia	ADRA2C	UBERON_0001017	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000184160	""	HeCaToS	involved in many processes such as the startle reflex, stress response, and locomotion	ADRA2C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000184160	""	HeCaToS	venous contraction (contraction of human saphenous vein)	ADRA2C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0000537	ENSG00000184160	""	HeCaToS	hypertension	ADRA2C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_1001375	ENSG00000184160	""	HeCaToS	cardiac ischemia	ADRA2C	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0000275	ENSG00000053918	23197038	Bowes et al. (2012)	atrial fibrillation	KCNQ1	UBERON_0004535	""
cardiovascular system	inhibition_general	MONDO_0002442	ENSG00000053918	23197038	Bowes et al. (2012)	long QT syndrome	KCNQ1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0004238	ENSG00000053918	23197038	Bowes et al. (2012)	potential hearing impairment	KCNQ1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0001063	ENSG00000053918	23197038	Bowes et al. (2012)	deafness	KCNQ1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0012719	ENSG00000053918	23197038	Bowes et al. (2012)	gastrointestinal symptoms	KCNQ1	UBERON_0004535	""
nervous system	activation_acute	HP_0011499	ENSG00000150594	28216264	Lynch et al. (2017)	increased pupil diameter	ADRA2A	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001649	ENSG00000150594	28216264	Lynch et al. (2017)	increased heart rate	ADRA2A	UBERON_0001016	""
nervous system	inhibition_acute	HP_0410204	ENSG00000150594	28216264	Lynch et al. (2017)	increased gastrointestinal transit	ADRA2A	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000150594	28216264	Lynch et al. (2017)	increased convulsions	ADRA2A	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000842	ENSG00000150594	28216264	Lynch et al. (2017)	increased blood insulin	ADRA2A	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000150594	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA2A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000150594	28216264	Lynch et al. (2017)	increased heart rate	ADRA2A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0410204	ENSG00000150594	28216264	Lynch et al. (2017)	increased gastrointestinal transit	ADRA2A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000150594	28216264	Lynch et al. (2017)	increased convulsions	ADRA2A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000842	ENSG00000150594	28216264	Lynch et al. (2017)	increased blood insulin	ADRA2A	UBERON_0004535	""
pancreas	activation_acute	HP_0040216	ENSG00000150594	28216264	Lynch et al. (2017)	decreased blood insulin	ADRA2A	UBERON_0001264	""
pancreas	inhibition_acute	HP_0001649	ENSG00000150594	28216264	Lynch et al. (2017)	increased heart rate	ADRA2A	UBERON_0001264	""
pancreas	inhibition_acute	HP_0410204	ENSG00000150594	28216264	Lynch et al. (2017)	increased gastrointestinal transit	ADRA2A	UBERON_0001264	""
pancreas	inhibition_acute	EFO_0009853	ENSG00000150594	28216264	Lynch et al. (2017)	increased convulsions	ADRA2A	UBERON_0001264	""
pancreas	inhibition_acute	HP_0000842	ENSG00000150594	28216264	Lynch et al. (2017)	increased blood insulin	ADRA2A	UBERON_0001264	""
nervous system	activation_acute	GO_0120061	ENSG00000150594	28216264	Lynch et al. (2017)	decreased gastric emptying	ADRA2A	UBERON_0001016	""
pancreas	activation_acute	EFO_0001072	ENSG00000150594	28216264	Lynch et al. (2017)	decreased memory	ADRA2A	UBERON_0001264	""
nervous system	activation_acute	HP_0040216	ENSG00000150594	28216264	Lynch et al. (2017)	decreased blood insulin	ADRA2A	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0001662	ENSG00000150594	28216264	Lynch et al. (2017)	decreased heart rate	ADRA2A	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0001649	ENSG00000150594	28216264	Lynch et al. (2017)	increased heart rate	ADRA2A	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0410204	ENSG00000150594	28216264	Lynch et al. (2017)	increased gastrointestinal transit	ADRA2A	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009853	ENSG00000150594	28216264	Lynch et al. (2017)	increased convulsions	ADRA2A	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000842	ENSG00000150594	28216264	Lynch et al. (2017)	increased blood insulin	ADRA2A	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009868	ENSG00000150594	28216264	Lynch et al. (2017)	sedation	ADRA2A	UBERON_0005409	""
cardiovascular	activation_acute	HP_0040216	ENSG00000150594	28216264	Lynch et al. (2017)	decreased blood insulin	ADRA2A	UBERON_0004535	""
gastrointestinal	activation_acute	GO_0120061	ENSG00000150594	28216264	Lynch et al. (2017)	decreased gastric emptying	ADRA2A	UBERON_0005409	""
cardiovascular	activation_acute	GO_1904057	ENSG00000150594	28216264	Lynch et al. (2017)	decreased pain	ADRA2A	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009868	ENSG00000150594	28216264	Lynch et al. (2017)	sedation	ADRA2A	UBERON_0004535	""
pancreas	activation_acute	GO_0120061	ENSG00000150594	28216264	Lynch et al. (2017)	decreased gastric emptying	ADRA2A	UBERON_0001264	""
nervous system	activation_acute	EFO_0001072	ENSG00000150594	28216264	Lynch et al. (2017)	decreased memory	ADRA2A	UBERON_0001016	""
nervous system	activation_acute	EFO_0005251	ENSG00000150594	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA2A	UBERON_0001016	""
pancreas	activation_acute	GO_1904057	ENSG00000150594	28216264	Lynch et al. (2017)	decreased pain	ADRA2A	UBERON_0001264	""
nervous system	activation_acute	HP_0002045	ENSG00000150594	28216264	Lynch et al. (2017)	decreased body temperature	ADRA2A	UBERON_0001016	""
gastrointestinal	activation_acute	GO_1904057	ENSG00000150594	28216264	Lynch et al. (2017)	decreased pain	ADRA2A	UBERON_0005409	""
pancreas	activation_acute	HP_0011499	ENSG00000150594	28216264	Lynch et al. (2017)	increased pupil diameter	ADRA2A	UBERON_0001264	""
cardiovascular	activation_acute	HP_0001662	ENSG00000150594	28216264	Lynch et al. (2017)	decreased heart rate	ADRA2A	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0040216	ENSG00000150594	28216264	Lynch et al. (2017)	decreased blood insulin	ADRA2A	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0002045	ENSG00000150594	28216264	Lynch et al. (2017)	decreased body temperature	ADRA2A	UBERON_0005409	""
pancreas	activation_acute	EFO_0009868	ENSG00000150594	28216264	Lynch et al. (2017)	sedation	ADRA2A	UBERON_0001264	""
pancreas	activation_acute	EFO_0005251	ENSG00000150594	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA2A	UBERON_0001264	""
gastrointestinal	activation_acute	EFO_0005251	ENSG00000150594	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA2A	UBERON_0005409	""
nervous system	activation_acute	EFO_0009868	ENSG00000150594	28216264	Lynch et al. (2017)	sedation	ADRA2A	UBERON_0001016	""
cardiovascular	activation_acute	GO_0120061	ENSG00000150594	28216264	Lynch et al. (2017)	decreased gastric emptying	ADRA2A	UBERON_0004535	""
cardiovascular	activation_acute	HP_0011499	ENSG00000150594	28216264	Lynch et al. (2017)	increased pupil diameter	ADRA2A	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0001072	ENSG00000150594	28216264	Lynch et al. (2017)	decreased memory	ADRA2A	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000150594	28216264	Lynch et al. (2017)	decreased memory	ADRA2A	UBERON_0004535	""
nervous system	activation_acute	HP_0001662	ENSG00000150594	28216264	Lynch et al. (2017)	decreased heart rate	ADRA2A	UBERON_0001016	""
pancreas	activation_acute	HP_0002045	ENSG00000150594	28216264	Lynch et al. (2017)	decreased body temperature	ADRA2A	UBERON_0001264	""
pancreas	activation_acute	HP_0001662	ENSG00000150594	28216264	Lynch et al. (2017)	decreased heart rate	ADRA2A	UBERON_0001264	""
cardiovascular	activation_acute	HP_0002045	ENSG00000150594	28216264	Lynch et al. (2017)	decreased body temperature	ADRA2A	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0011499	ENSG00000150594	28216264	Lynch et al. (2017)	increased pupil diameter	ADRA2A	UBERON_0005409	""
nervous system	activation_acute	GO_1904057	ENSG00000150594	28216264	Lynch et al. (2017)	decreased pain	ADRA2A	UBERON_0001016	""
cardiovascular system	activation_general	""	ENSG00000169252	""	HeCaToS	may relax smooth muscle	ADRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0001662	ENSG00000169252	""	HeCaToS	bradycardia	ADRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0000319	ENSG00000169252	""	HeCaToS	may stress cardiovascular performance (b blockers)	ADRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0045823	ENSG00000169252	""	HeCaToS	may contribute to cardiac contractility (bronchodilatation, cardiac arrest)	ADRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0001252	ENSG00000169252	""	HeCaToS	hypotonia	ADRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000169252	""	HeCaToS	vasodilatation of the vascular beds of skeletal muscle	ADRB2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
renal	activation_acute	GO_1904058	ENSG00000109991	28216264	Lynch et al. (2017)	increased pain	P2RX3	UBERON_0001008	""
renal	activation_chronic	HP_0002180	ENSG00000109991	28216264	Lynch et al. (2017)	neurodegeneration	P2RX3	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000109991	28216264	Lynch et al. (2017)	decreased pain	P2RX3	UBERON_0001008	""
renal	inhibition_acute	GO_0050728	ENSG00000109991	28216264	Lynch et al. (2017)	decreased inflammation	P2RX3	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000109991	28216264	Lynch et al. (2017)	decreased convulsions	P2RX3	UBERON_0001008	""
nervous system	activation_acute	HP_0000103	ENSG00000109991	28216264	Lynch et al. (2017)	increased urine excretion	P2RX3	UBERON_0001016	""
nervous system	activation_chronic	HP_0002180	ENSG00000109991	28216264	Lynch et al. (2017)	neurodegeneration	P2RX3	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000109991	28216264	Lynch et al. (2017)	decreased pain	P2RX3	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050728	ENSG00000109991	28216264	Lynch et al. (2017)	decreased inflammation	P2RX3	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000109991	28216264	Lynch et al. (2017)	decreased convulsions	P2RX3	UBERON_0001016	""
immune	activation_acute	GO_1904058	ENSG00000109991	28216264	Lynch et al. (2017)	increased pain	P2RX3	UBERON_0002405	""
immune	activation_chronic	HP_0002180	ENSG00000109991	28216264	Lynch et al. (2017)	neurodegeneration	P2RX3	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000109991	28216264	Lynch et al. (2017)	decreased pain	P2RX3	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000109991	28216264	Lynch et al. (2017)	decreased inflammation	P2RX3	UBERON_0002405	""
immune	inhibition_acute	EFO_0009853	ENSG00000109991	28216264	Lynch et al. (2017)	decreased convulsions	P2RX3	UBERON_0002405	""
renal	activation_acute	HP_0000103	ENSG00000109991	28216264	Lynch et al. (2017)	increased urine excretion	P2RX3	UBERON_0001008	""
nervous system	activation_acute	EFO_0009473	ENSG00000109991	28216264	Lynch et al. (2017)	hemolysis	P2RX3	UBERON_0001016	""
immune	activation_acute	HP_0000103	ENSG00000109991	28216264	Lynch et al. (2017)	increased urine excretion	P2RX3	UBERON_0002405	""
nervous system	activation_acute	GO_1904058	ENSG00000109991	28216264	Lynch et al. (2017)	increased pain	P2RX3	UBERON_0001016	""
immune	activation_acute	EFO_0009473	ENSG00000109991	28216264	Lynch et al. (2017)	hemolysis	P2RX3	UBERON_0002405	""
nervous system	activation_acute	GO_0035815	ENSG00000109991	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX3	UBERON_0001016	""
renal	activation_acute	GO_0035815	ENSG00000109991	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX3	UBERON_0001008	""
immune	activation_acute	GO_0035815	ENSG00000109991	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX3	UBERON_0002405	""
renal	activation_acute	EFO_0009473	ENSG00000109991	28216264	Lynch et al. (2017)	hemolysis	P2RX3	UBERON_0001008	""
cardiovascular system	activation_general	""	ENSG00000006638	""	Urban et al. (2012)	vasoconstriction	TBXA2R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	GO_0090331	ENSG00000006638	""	Urban et al. (2012)	could cause bleeding by inhibiting platelet aggregation	TBXA2R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009836	ENSG00000006638	""	Urban et al. (2012)	bronchoconstriction	TBXA2R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0070527	ENSG00000006638	""	Urban et al. (2012)	platelet aggregation	TBXA2R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_1001375	ENSG00000006638	""	Urban et al. (2012)	myocardial ischemia	TBXA2R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0003144	ENSG00000006638	""	Urban et al. (2012)	heart failure	TBXA2R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	GO_0050728	ENSG00000073756	""	HeCaToS	antiinflammatory	PTGS2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	GO_0045839	ENSG00000073756	""	HeCaToS	inhibits some mitogenic actions	PTGS2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0000319	ENSG00000073756	""	HeCaToS	increased risk of adverse cardiovascular events (heart failure, clotting)	PTGS2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000073756	""	HeCaToS	increased risk of wound infections	PTGS2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0004755	ENSG00000073756	""	HeCaToS	supraventricular tachycardia	PTGS2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000073756	""	HeCaToS	hypotension	PTGS2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0000612	ENSG00000073756	""	HeCaToS	myocardial infarction	PTGS2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000073756	""	HeCaToS	cerebrovascular events have been reported	PTGS2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
endocrine	activation_general	EFO_0001663	ENSG00000169083	23197038	Bowes et al. (2012)	increased prostate carcinoma	AR	UBERON_0000949	""
endocrine	inhibition_general	EFO_0000279	ENSG00000169083	23197038	Bowes et al. (2012)	decreased spermatogenesis	AR	UBERON_0000949	""
endocrine	inhibition_general	EFO_0004234	ENSG00000169083	23197038	Bowes et al. (2012)	impotence	AR	UBERON_0000949	""
endocrine	inhibition_general	HP_0000771	ENSG00000169083	23197038	Bowes et al. (2012)	gynecomastia	AR	UBERON_0000949	""
endocrine	inhibition_general	EFO_1001366	ENSG00000169083	23197038	Bowes et al. (2012)	mastodynia	AR	UBERON_0000949	""
endocrine	inhibition_general	EFO_0000305	ENSG00000169083	23197038	Bowes et al. (2012)	increased breast carcinoma	AR	UBERON_0000949	""
endocrine	activation_general	EFO_0009373	ENSG00000169083	23197038	Bowes et al. (2012)	oedema	AR	UBERON_0000949	""
endocrine	activation_general	EFO_0009850	ENSG00000169083	23197038	Bowes et al. (2012)	androgenicity females	AR	UBERON_0000949	""
endocrine	activation_general	HP_0003720	ENSG00000169083	23197038	Bowes et al. (2012)	increased muscle mass	AR	UBERON_0000949	""
endocrine	activation_general	EFO_0003015	ENSG00000169083	23197038	Bowes et al. (2012)	increased hostility	AR	UBERON_0000949	""
endocrine	activation_general	EFO_0003877	ENSG00000169083	23197038	Bowes et al. (2012)	sleep apnoea	AR	UBERON_0000949	""
endocrine	activation_general	EFO_0001421	ENSG00000169083	23197038	Bowes et al. (2012)	liver complications	AR	UBERON_0000949	""
cardiovascular system	activation_general	EFO_0000275	ENSG00000053918	""	HeCaToS	atrial fibrillation	KCNQ1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	MONDO_0002442	ENSG00000053918	""	HeCaToS	long QT syndrome	KCNQ1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0004238	ENSG00000053918	""	HeCaToS	hearing impairment	KCNQ1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0001063	ENSG00000053918	""	HeCaToS	deafness	KCNQ1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0012719	ENSG00000053918	""	HeCaToS	gastrointestinal symptoms	KCNQ1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009868	ENSG00000150594	""	Urban et al. (2012)	sedation	ADRA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0030895	ENSG00000150594	""	Urban et al. (2012)	may induce gastrointestinal prokinetic effects	ADRA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_1001484	ENSG00000150594	""	Urban et al. (2012)	analgesia	ADRA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000150594	""	Urban et al. (2012)	anesthetic-sparing effect	ADRA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0005251	ENSG00000150594	""	Urban et al. (2012)	central hypotension (reduction of blood pressure and heart rate)	ADRA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0002045	ENSG00000150594	""	Urban et al. (2012)	hypothermia	ADRA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0003074	ENSG00000150594	""	Urban et al. (2012)	hyperglycemia	ADRA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0001072	ENSG00000150594	""	Urban et al. (2012)	memory impairment	ADRA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0004566	ENSG00000150594	""	Urban et al. (2012)	weight gain	ADRA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009868	ENSG00000150594	""	Urban et al. (2012)	sedation	ADRA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0030895	ENSG00000150594	""	Urban et al. (2012)	may induce gastrointestinal prokinetic effects	ADRA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_1001484	ENSG00000150594	""	Urban et al. (2012)	analgesia	ADRA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000150594	""	Urban et al. (2012)	anesthetic-sparing effect	ADRA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0005251	ENSG00000150594	""	Urban et al. (2012)	central hypotension (reduction of blood pressure and heart rate)	ADRA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0002045	ENSG00000150594	""	Urban et al. (2012)	hypothermia	ADRA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0003074	ENSG00000150594	""	Urban et al. (2012)	hyperglycemia	ADRA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0001072	ENSG00000150594	""	Urban et al. (2012)	memory impairment	ADRA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0004566	ENSG00000150594	""	Urban et al. (2012)	weight gain	ADRA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
cardiovascular	activation_acute	GO_1904057	ENSG00000145863	28216264	Lynch et al. (2017)	decreased pain	GABRA6	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000145863	28216264	Lynch et al. (2017)	convulsions	GABRA6	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000145863	28216264	Lynch et al. (2017)	decreased sleep	GABRA6	UBERON_0004535	""
central nervous system	activation_acute	EFO_0008568	ENSG00000145863	28216264	Lynch et al. (2017)	increased sleep	GABRA6	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000145863	28216264	Lynch et al. (2017)	convulsions	GABRA6	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000145863	28216264	Lynch et al. (2017)	decreased sleep	GABRA6	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009840	ENSG00000145863	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA6	UBERON_0001017	""
cardiovascular	activation_acute	GO_0045822	ENSG00000145863	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA6	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009872	ENSG00000145863	28216264	Lynch et al. (2017)	increased cardiac output	GABRA6	UBERON_0001017	""
central nervous system	activation_acute	GO_0045822	ENSG00000145863	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA6	UBERON_0001017	""
cardiovascular	activation_acute	HP_0002045	ENSG00000145863	28216264	Lynch et al. (2017)	decreased body temperature	GABRA6	UBERON_0004535	""
central nervous system	activation_acute	HP_0002045	ENSG00000145863	28216264	Lynch et al. (2017)	decreased body temperature	GABRA6	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000145863	28216264	Lynch et al. (2017)	decreased anxiety	GABRA6	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000145863	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA6	UBERON_0004535	""
central nervous system	activation_acute	GO_1904057	ENSG00000145863	28216264	Lynch et al. (2017)	decreased pain	GABRA6	UBERON_0001017	""
central nervous system	activation_acute	EFO_0005251	ENSG00000145863	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA6	UBERON_0001017	""
cardiovascular	activation_acute	GO_0040013	ENSG00000145863	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA6	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000145863	28216264	Lynch et al. (2017)	decreased convulsions	GABRA6	UBERON_0001017	""
cardiovascular	activation_acute	HP_0100738	ENSG00000145863	28216264	Lynch et al. (2017)	increased eating	GABRA6	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000145863	28216264	Lynch et al. (2017)	muscle relaxation	GABRA6	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000145863	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA6	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0008568	ENSG00000145863	28216264	Lynch et al. (2017)	increased sleep	GABRA6	UBERON_0004535	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000145863	28216264	Lynch et al. (2017)	ataxia	GABRA6	UBERON_0001017	""
central nervous system	activation_acute	EFO_0003890	ENSG00000145863	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA6	UBERON_0001017	""
central nervous system	activation_acute	""	ENSG00000145863	28216264	Lynch et al. (2017)	muscle relaxation	GABRA6	UBERON_0001017	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000145863	28216264	Lynch et al. (2017)	ataxia	GABRA6	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000145863	28216264	Lynch et al. (2017)	decreased memory	GABRA6	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000145863	28216264	Lynch et al. (2017)	decreased convulsions	GABRA6	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009874	ENSG00000145863	28216264	Lynch et al. (2017)	decreased anxiety	GABRA6	UBERON_0001017	""
central nervous system	activation_acute	EFO_0001072	ENSG00000145863	28216264	Lynch et al. (2017)	decreased memory	GABRA6	UBERON_0001017	""
central nervous system	activation_acute	GO_0040013	ENSG00000145863	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA6	UBERON_0001017	""
central nervous system	activation_acute	HP_0100738	ENSG00000145863	28216264	Lynch et al. (2017)	increased eating	GABRA6	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009872	ENSG00000145863	28216264	Lynch et al. (2017)	increased cardiac output	GABRA6	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000145863	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA6	UBERON_0004535	""
endocrine	activation_general	""	ENSG00000121853	""	HeCaToS	energy homeostasis	GHSR	UBERON_0000949	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
endocrine	inhibition_general	EFO_0000319	ENSG00000121853	""	HeCaToS	cardiovascular effects (might cause reduced rates of left ventricular contraction and relaxation, hypertension, tachycardia)	GHSR	UBERON_0000949	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
endocrine	inhibition_general	HP_0002579	ENSG00000121853	""	HeCaToS	might reduce gastric motility	GHSR	UBERON_0000949	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
endocrine	activation_general	GO_0030252	ENSG00000121853	""	HeCaToS	growth hormone release	GHSR	UBERON_0000949	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
endocrine	activation_general	HP_0003154	ENSG00000121853	""	HeCaToS	adrenocorticotropic hormone release	GHSR	UBERON_0000949	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
endocrine	activation_general	GO_0043400	ENSG00000121853	""	HeCaToS	cortisol release	GHSR	UBERON_0000949	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
endocrine	activation_general	HP_0100738	ENSG00000121853	""	HeCaToS	appetite stimulation	GHSR	UBERON_0000949	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
endocrine	activation_general	HP_0003074	ENSG00000121853	""	HeCaToS	hyperglycemia	GHSR	UBERON_0000949	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
endocrine	activation_general	HP_0040216	ENSG00000121853	""	HeCaToS	reduced insulin secretion	GHSR	UBERON_0000949	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
endocrine	activation_general	EFO_0005251	ENSG00000121853	""	HeCaToS	hypotension	GHSR	UBERON_0000949	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000121853	""	HeCaToS	energy homeostasis	GHSR	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0000319	ENSG00000121853	""	HeCaToS	cardiovascular effects (might cause reduced rates of left ventricular contraction and relaxation, hypertension, tachycardia)	GHSR	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0002579	ENSG00000121853	""	HeCaToS	might reduce gastric motility	GHSR	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0030252	ENSG00000121853	""	HeCaToS	growth hormone release	GHSR	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0003154	ENSG00000121853	""	HeCaToS	adrenocorticotropic hormone release	GHSR	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0043400	ENSG00000121853	""	HeCaToS	cortisol release	GHSR	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0100738	ENSG00000121853	""	HeCaToS	appetite stimulation	GHSR	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0003074	ENSG00000121853	""	HeCaToS	hyperglycemia	GHSR	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0040216	ENSG00000121853	""	HeCaToS	reduced insulin secretion	GHSR	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0005251	ENSG00000121853	""	HeCaToS	hypotension	GHSR	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_acute	HP_0002104	ENSG00000087085	28216264	Lynch et al. (2017)	apnea	ACHE	UBERON_0001016	""
nervous system	inhibition_chronic	HP_0100543	ENSG00000087085	28216264	Lynch et al. (2017)	cognitive deficit	ACHE	UBERON_0001016	""
nervous system	inhibition_chronic	EFO_0004247	ENSG00000087085	28216264	Lynch et al. (2017)	mood change	ACHE	UBERON_0001016	""
nervous system	inhibition_chronic	HP_0012332	ENSG00000087085	28216264	Lynch et al. (2017)	autonomic dysfunction	ACHE	UBERON_0001016	""
nervous system	inhibition_chronic	EFO_0003100	ENSG00000087085	28216264	Lynch et al. (2017)	peripheral neuropathy	ACHE	UBERON_0001016	""
nervous system	inhibition_chronic	MONDO_0044967	ENSG00000087085	28216264	Lynch et al. (2017)	tingling/weakness in limbs	ACHE	UBERON_0001016	""
nervous system	inhibition_chronic	HP_0009027	ENSG00000087085	28216264	Lynch et al. (2017)	foot drop	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009836	ENSG00000087085	28216264	Lynch et al. (2017)	bronchoconstriction	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009835	ENSG00000087085	28216264	Lynch et al. (2017)	increased bronchial secretions	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	""	ENSG00000087085	28216264	Lynch et al. (2017)	muscle relaxation	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	MONDO_0000437	ENSG00000087085	28216264	Lynch et al. (2017)	ataxia	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	GO_0046878	ENSG00000087085	28216264	Lynch et al. (2017)	increased salivation	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000632	ENSG00000087085	28216264	Lynch et al. (2017)	lacrimation	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000616	ENSG00000087085	28216264	Lynch et al. (2017)	decreased pupil diameter	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000622	ENSG00000087085	28216264	Lynch et al. (2017)	blurred vision	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000103	ENSG00000087085	28216264	Lynch et al. (2017)	increased urine excretion	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	GO_2000294	ENSG00000087085	28216264	Lynch et al. (2017)	increased defecation	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	HP_0002014	ENSG00000087085	28216264	Lynch et al. (2017)	diarrhea	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	HP_0002017	ENSG00000087085	28216264	Lynch et al. (2017)	vomiting	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030972	ENSG00000087085	28216264	Lynch et al. (2017)	increased then decreased blood pressure	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	HP_0031860	ENSG00000087085	28216264	Lynch et al. (2017)	increased then decreased heart rate	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000087085	28216264	Lynch et al. (2017)	convulsions	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001259	ENSG00000087085	28216264	Lynch et al. (2017)	coma	ACHE	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0000480	ENSG00000087085	28216264	Lynch et al. (2017)	death	ACHE	UBERON_0001016	""
cardiovascular	inhibition_acute	HP_0002104	ENSG00000087085	28216264	Lynch et al. (2017)	apnea	ACHE	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0100543	ENSG00000087085	28216264	Lynch et al. (2017)	cognitive deficit	ACHE	UBERON_0004535	""
cardiovascular	inhibition_chronic	EFO_0004247	ENSG00000087085	28216264	Lynch et al. (2017)	mood change	ACHE	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0012332	ENSG00000087085	28216264	Lynch et al. (2017)	autonomic dysfunction	ACHE	UBERON_0004535	""
cardiovascular	inhibition_chronic	EFO_0003100	ENSG00000087085	28216264	Lynch et al. (2017)	peripheral neuropathy	ACHE	UBERON_0004535	""
cardiovascular	inhibition_chronic	MONDO_0044967	ENSG00000087085	28216264	Lynch et al. (2017)	tingling/weakness in limbs	ACHE	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0009027	ENSG00000087085	28216264	Lynch et al. (2017)	foot drop	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009836	ENSG00000087085	28216264	Lynch et al. (2017)	bronchoconstriction	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009835	ENSG00000087085	28216264	Lynch et al. (2017)	increased bronchial secretions	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	""	ENSG00000087085	28216264	Lynch et al. (2017)	muscle relaxation	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000437	ENSG00000087085	28216264	Lynch et al. (2017)	ataxia	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0046878	ENSG00000087085	28216264	Lynch et al. (2017)	increased salivation	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000632	ENSG00000087085	28216264	Lynch et al. (2017)	lacrimation	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000616	ENSG00000087085	28216264	Lynch et al. (2017)	decreased pupil diameter	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000622	ENSG00000087085	28216264	Lynch et al. (2017)	blurred vision	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000087085	28216264	Lynch et al. (2017)	increased urine excretion	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_2000294	ENSG00000087085	28216264	Lynch et al. (2017)	increased defecation	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002014	ENSG00000087085	28216264	Lynch et al. (2017)	diarrhea	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002017	ENSG00000087085	28216264	Lynch et al. (2017)	vomiting	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030972	ENSG00000087085	28216264	Lynch et al. (2017)	increased then decreased blood pressure	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0031860	ENSG00000087085	28216264	Lynch et al. (2017)	increased then decreased heart rate	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000087085	28216264	Lynch et al. (2017)	convulsions	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001259	ENSG00000087085	28216264	Lynch et al. (2017)	coma	ACHE	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0000480	ENSG00000087085	28216264	Lynch et al. (2017)	death	ACHE	UBERON_0004535	""
gastrointestinal	inhibition_acute	HP_0002104	ENSG00000087085	28216264	Lynch et al. (2017)	apnea	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_chronic	HP_0100543	ENSG00000087085	28216264	Lynch et al. (2017)	cognitive deficit	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_chronic	EFO_0004247	ENSG00000087085	28216264	Lynch et al. (2017)	mood change	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_chronic	HP_0012332	ENSG00000087085	28216264	Lynch et al. (2017)	autonomic dysfunction	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_chronic	EFO_0003100	ENSG00000087085	28216264	Lynch et al. (2017)	peripheral neuropathy	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_chronic	MONDO_0044967	ENSG00000087085	28216264	Lynch et al. (2017)	tingling/weakness in limbs	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_chronic	HP_0009027	ENSG00000087085	28216264	Lynch et al. (2017)	foot drop	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009836	ENSG00000087085	28216264	Lynch et al. (2017)	bronchoconstriction	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009835	ENSG00000087085	28216264	Lynch et al. (2017)	increased bronchial secretions	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	""	ENSG00000087085	28216264	Lynch et al. (2017)	muscle relaxation	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	MONDO_0000437	ENSG00000087085	28216264	Lynch et al. (2017)	ataxia	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0046878	ENSG00000087085	28216264	Lynch et al. (2017)	increased salivation	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000632	ENSG00000087085	28216264	Lynch et al. (2017)	lacrimation	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000616	ENSG00000087085	28216264	Lynch et al. (2017)	decreased pupil diameter	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000622	ENSG00000087085	28216264	Lynch et al. (2017)	blurred vision	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000103	ENSG00000087085	28216264	Lynch et al. (2017)	increased urine excretion	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_2000294	ENSG00000087085	28216264	Lynch et al. (2017)	increased defecation	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0002014	ENSG00000087085	28216264	Lynch et al. (2017)	diarrhea	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0002017	ENSG00000087085	28216264	Lynch et al. (2017)	vomiting	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0030972	ENSG00000087085	28216264	Lynch et al. (2017)	increased then decreased blood pressure	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0031860	ENSG00000087085	28216264	Lynch et al. (2017)	increased then decreased heart rate	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009853	ENSG00000087085	28216264	Lynch et al. (2017)	convulsions	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0001259	ENSG00000087085	28216264	Lynch et al. (2017)	coma	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0000480	ENSG00000087085	28216264	Lynch et al. (2017)	death	ACHE	UBERON_0005409	""
respiratory	inhibition_acute	HP_0002104	ENSG00000087085	28216264	Lynch et al. (2017)	apnea	ACHE	UBERON_0001004	""
respiratory	inhibition_chronic	HP_0100543	ENSG00000087085	28216264	Lynch et al. (2017)	cognitive deficit	ACHE	UBERON_0001004	""
respiratory	inhibition_chronic	EFO_0004247	ENSG00000087085	28216264	Lynch et al. (2017)	mood change	ACHE	UBERON_0001004	""
respiratory	inhibition_chronic	HP_0012332	ENSG00000087085	28216264	Lynch et al. (2017)	autonomic dysfunction	ACHE	UBERON_0001004	""
respiratory	inhibition_chronic	EFO_0003100	ENSG00000087085	28216264	Lynch et al. (2017)	peripheral neuropathy	ACHE	UBERON_0001004	""
respiratory	inhibition_chronic	MONDO_0044967	ENSG00000087085	28216264	Lynch et al. (2017)	tingling/weakness in limbs	ACHE	UBERON_0001004	""
respiratory	inhibition_chronic	HP_0009027	ENSG00000087085	28216264	Lynch et al. (2017)	foot drop	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009836	ENSG00000087085	28216264	Lynch et al. (2017)	bronchoconstriction	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009835	ENSG00000087085	28216264	Lynch et al. (2017)	increased bronchial secretions	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	""	ENSG00000087085	28216264	Lynch et al. (2017)	muscle relaxation	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	MONDO_0000437	ENSG00000087085	28216264	Lynch et al. (2017)	ataxia	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	GO_0046878	ENSG00000087085	28216264	Lynch et al. (2017)	increased salivation	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	HP_0000632	ENSG00000087085	28216264	Lynch et al. (2017)	lacrimation	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	HP_0000616	ENSG00000087085	28216264	Lynch et al. (2017)	decreased pupil diameter	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	HP_0000622	ENSG00000087085	28216264	Lynch et al. (2017)	blurred vision	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	HP_0000103	ENSG00000087085	28216264	Lynch et al. (2017)	increased urine excretion	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	GO_2000294	ENSG00000087085	28216264	Lynch et al. (2017)	increased defecation	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	HP_0002014	ENSG00000087085	28216264	Lynch et al. (2017)	diarrhea	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	HP_0002017	ENSG00000087085	28216264	Lynch et al. (2017)	vomiting	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	HP_0030972	ENSG00000087085	28216264	Lynch et al. (2017)	increased then decreased blood pressure	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	HP_0031860	ENSG00000087085	28216264	Lynch et al. (2017)	increased then decreased heart rate	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009853	ENSG00000087085	28216264	Lynch et al. (2017)	convulsions	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	HP_0001259	ENSG00000087085	28216264	Lynch et al. (2017)	coma	ACHE	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0000480	ENSG00000087085	28216264	Lynch et al. (2017)	death	ACHE	UBERON_0001004	""
endocrine	activation_general	""	ENSG00000121853	""	Urban et al. (2012)	energy homeostasis	GHSR	UBERON_0000949	https://doi.org/10.1002/9781118098141.ch2
endocrine	inhibition_general	EFO_0000319	ENSG00000121853	""	Urban et al. (2012)	cardiovascular effects (might cause reduced rates of left ventricular contraction and relaxation, hypertension, tachycardia)	GHSR	UBERON_0000949	https://doi.org/10.1002/9781118098141.ch2
endocrine	inhibition_general	HP_0002579	ENSG00000121853	""	Urban et al. (2012)	might reduce gastric motility	GHSR	UBERON_0000949	https://doi.org/10.1002/9781118098141.ch2
endocrine	activation_general	GO_0030252	ENSG00000121853	""	Urban et al. (2012)	growth hormone release	GHSR	UBERON_0000949	https://doi.org/10.1002/9781118098141.ch2
endocrine	activation_general	HP_0003154	ENSG00000121853	""	Urban et al. (2012)	adrenocorticotropic hormone release	GHSR	UBERON_0000949	https://doi.org/10.1002/9781118098141.ch2
endocrine	activation_general	GO_0043400	ENSG00000121853	""	Urban et al. (2012)	cortisol release	GHSR	UBERON_0000949	https://doi.org/10.1002/9781118098141.ch2
endocrine	activation_general	HP_0100738	ENSG00000121853	""	Urban et al. (2012)	appetite stimulation	GHSR	UBERON_0000949	https://doi.org/10.1002/9781118098141.ch2
endocrine	activation_general	HP_0003074	ENSG00000121853	""	Urban et al. (2012)	hyperglycemia	GHSR	UBERON_0000949	https://doi.org/10.1002/9781118098141.ch2
endocrine	activation_general	HP_0040216	ENSG00000121853	""	Urban et al. (2012)	reduced insulin secretion	GHSR	UBERON_0000949	https://doi.org/10.1002/9781118098141.ch2
endocrine	activation_general	EFO_0005251	ENSG00000121853	""	Urban et al. (2012)	hypotension	GHSR	UBERON_0000949	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000121853	""	Urban et al. (2012)	energy homeostasis	GHSR	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000319	ENSG00000121853	""	Urban et al. (2012)	cardiovascular effects (might cause reduced rates of left ventricular contraction and relaxation, hypertension, tachycardia)	GHSR	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0002579	ENSG00000121853	""	Urban et al. (2012)	might reduce gastric motility	GHSR	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0030252	ENSG00000121853	""	Urban et al. (2012)	growth hormone release	GHSR	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0003154	ENSG00000121853	""	Urban et al. (2012)	adrenocorticotropic hormone release	GHSR	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0043400	ENSG00000121853	""	Urban et al. (2012)	cortisol release	GHSR	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0100738	ENSG00000121853	""	Urban et al. (2012)	appetite stimulation	GHSR	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0003074	ENSG00000121853	""	Urban et al. (2012)	hyperglycemia	GHSR	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0040216	ENSG00000121853	""	Urban et al. (2012)	reduced insulin secretion	GHSR	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0005251	ENSG00000121853	""	Urban et al. (2012)	hypotension	GHSR	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_chronic	""	ENSG00000172572	""	Urban et al. (2012)	increased mortality in heart failure patients	PDE3A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0004308	ENSG00000172572	""	Urban et al. (2012)	could induce ventricular arrhythmias in ~10% of patients	PDE3A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0001649	ENSG00000172572	""	Urban et al. (2012)	tachycardia	PDE3A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000172572	""	Urban et al. (2012)	hypotension	PDE3A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_chronic	HP_0001873	ENSG00000172572	""	Urban et al. (2012)	thrombocytopenia	PDE3A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_1001484	ENSG00000082556	""	HeCaToS	analgesia	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009868	ENSG00000082556	""	HeCaToS	sedation	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0005251	ENSG00000082556	""	HeCaToS	hypotension	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0001649	ENSG00000082556	""	HeCaToS	tachycardia	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0000103	ENSG00000082556	""	HeCaToS	diuresis	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009867	ENSG00000082556	""	HeCaToS	dysphoria	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009847	ENSG00000082556	""	HeCaToS	dizziness	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0003401	ENSG00000082556	""	HeCaToS	paresthesia	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000082556	""	HeCaToS	antipruritic effects	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000082556	""	HeCaToS	interaction with dopaminergic transmission and hallucination	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000082556	""	HeCaToS	psychotomimetic effects. In case of mixed (partial) agonist/antagonist analgesic drugs, psychotomimesis is undesirable and serves to limit abuse potential	OPRK1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_1001484	ENSG00000082556	""	HeCaToS	analgesia	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009868	ENSG00000082556	""	HeCaToS	sedation	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0005251	ENSG00000082556	""	HeCaToS	hypotension	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0001649	ENSG00000082556	""	HeCaToS	tachycardia	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0000103	ENSG00000082556	""	HeCaToS	diuresis	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009867	ENSG00000082556	""	HeCaToS	dysphoria	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009847	ENSG00000082556	""	HeCaToS	dizziness	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0003401	ENSG00000082556	""	HeCaToS	paresthesia	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000082556	""	HeCaToS	antipruritic effects	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000082556	""	HeCaToS	interaction with dopaminergic transmission and hallucination	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000082556	""	HeCaToS	psychotomimetic effects. In case of mixed (partial) agonist/antagonist analgesic drugs, psychotomimesis is undesirable and serves to limit abuse potential	OPRK1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000144891	""	HeCaToS	vasocontriction	AGTR1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000144891	""	HeCaToS	antihypertensive and cardioprotective agent	AGTR1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000144891	""	HeCaToS	hypotension	AGTR1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0009869	ENSG00000144891	""	HeCaToS	dry mouth	AGTR1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0001959	ENSG00000144891	""	HeCaToS	excessive thirst	AGTR1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0009847	ENSG00000144891	""	HeCaToS	dizziness	AGTR1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0031860	ENSG00000144891	""	HeCaToS	slow or irregular heartbeat	AGTR1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0045823	ENSG00000144891	""	HeCaToS	positive inotropy	AGTR1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0008283	ENSG00000144891	""	HeCaToS	cell proliferation and migration	AGTR1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
respiratory	activation_acute	HP_0002014	ENSG00000133019	28216264	Lynch et al. (2017)	diarrhea	CHRM3	UBERON_0001004	""
respiratory	inhibition_acute	GO_0120061	ENSG00000133019	28216264	Lynch et al. (2017)	decreased gastric emptying	CHRM3	UBERON_0001004	""
respiratory	inhibition_acute	HP_0030897	ENSG00000133019	28216264	Lynch et al. (2017)	decreased intestinal transit	CHRM3	UBERON_0001004	""
respiratory	inhibition_acute	HP_0002019	ENSG00000133019	28216264	Lynch et al. (2017)	constipation	CHRM3	UBERON_0001004	""
respiratory	inhibition_acute	GO_1905747	ENSG00000133019	28216264	Lynch et al. (2017)	decreased salivation	CHRM3	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009869	ENSG00000133019	28216264	Lynch et al. (2017)	dry mouth	CHRM3	UBERON_0001004	""
respiratory	inhibition_acute	HP_0011499	ENSG00000133019	28216264	Lynch et al. (2017)	increased pupil diameter	CHRM3	UBERON_0001004	""
respiratory	inhibition_acute	HP_0000622	ENSG00000133019	28216264	Lynch et al. (2017)	blurred vision	CHRM3	UBERON_0001004	""
gastrointestinal	activation_acute	HP_0000622	ENSG00000133019	28216264	Lynch et al. (2017)	blurred vision	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0120061	ENSG00000133019	28216264	Lynch et al. (2017)	decreased gastric emptying	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0030897	ENSG00000133019	28216264	Lynch et al. (2017)	decreased intestinal transit	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0002019	ENSG00000133019	28216264	Lynch et al. (2017)	constipation	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1905747	ENSG00000133019	28216264	Lynch et al. (2017)	decreased salivation	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009869	ENSG00000133019	28216264	Lynch et al. (2017)	dry mouth	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0011499	ENSG00000133019	28216264	Lynch et al. (2017)	increased pupil diameter	CHRM3	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000622	ENSG00000133019	28216264	Lynch et al. (2017)	blurred vision	CHRM3	UBERON_0005409	""
liver	activation_acute	EFO_1000014	ENSG00000133019	28216264	Lynch et al. (2017)	acidosis	CHRM3	UBERON_0002107	""
liver	inhibition_acute	GO_0120061	ENSG00000133019	28216264	Lynch et al. (2017)	decreased gastric emptying	CHRM3	UBERON_0002107	""
liver	inhibition_acute	HP_0030897	ENSG00000133019	28216264	Lynch et al. (2017)	decreased intestinal transit	CHRM3	UBERON_0002107	""
liver	inhibition_acute	HP_0002019	ENSG00000133019	28216264	Lynch et al. (2017)	constipation	CHRM3	UBERON_0002107	""
liver	inhibition_acute	GO_1905747	ENSG00000133019	28216264	Lynch et al. (2017)	decreased salivation	CHRM3	UBERON_0002107	""
liver	inhibition_acute	EFO_0009869	ENSG00000133019	28216264	Lynch et al. (2017)	dry mouth	CHRM3	UBERON_0002107	""
liver	inhibition_acute	HP_0011499	ENSG00000133019	28216264	Lynch et al. (2017)	increased pupil diameter	CHRM3	UBERON_0002107	""
liver	inhibition_acute	HP_0000622	ENSG00000133019	28216264	Lynch et al. (2017)	blurred vision	CHRM3	UBERON_0002107	""
cardiovascular	activation_acute	HP_0030972	ENSG00000133019	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM3	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0120061	ENSG00000133019	28216264	Lynch et al. (2017)	decreased gastric emptying	CHRM3	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000133019	28216264	Lynch et al. (2017)	decreased intestinal transit	CHRM3	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002019	ENSG00000133019	28216264	Lynch et al. (2017)	constipation	CHRM3	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1905747	ENSG00000133019	28216264	Lynch et al. (2017)	decreased salivation	CHRM3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009869	ENSG00000133019	28216264	Lynch et al. (2017)	dry mouth	CHRM3	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011499	ENSG00000133019	28216264	Lynch et al. (2017)	increased pupil diameter	CHRM3	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000622	ENSG00000133019	28216264	Lynch et al. (2017)	blurred vision	CHRM3	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001399	ENSG00000133019	28216264	Lynch et al. (2017)	liver failure	CHRM3	UBERON_0004535	""
liver	activation_acute	EFO_0009836	ENSG00000133019	28216264	Lynch et al. (2017)	bronchoconstriction	CHRM3	UBERON_0002107	""
nervous system	activation_acute	HP_0001945	ENSG00000133019	28216264	Lynch et al. (2017)	increased body temperature	CHRM3	UBERON_0001016	""
nervous system	inhibition_acute	GO_0120061	ENSG00000133019	28216264	Lynch et al. (2017)	decreased gastric emptying	CHRM3	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030897	ENSG00000133019	28216264	Lynch et al. (2017)	decreased intestinal transit	CHRM3	UBERON_0001016	""
nervous system	inhibition_acute	HP_0002019	ENSG00000133019	28216264	Lynch et al. (2017)	constipation	CHRM3	UBERON_0001016	""
nervous system	inhibition_acute	GO_1905747	ENSG00000133019	28216264	Lynch et al. (2017)	decreased salivation	CHRM3	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009869	ENSG00000133019	28216264	Lynch et al. (2017)	dry mouth	CHRM3	UBERON_0001016	""
nervous system	inhibition_acute	HP_0011499	ENSG00000133019	28216264	Lynch et al. (2017)	increased pupil diameter	CHRM3	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000622	ENSG00000133019	28216264	Lynch et al. (2017)	blurred vision	CHRM3	UBERON_0001016	""
nervous system	activation_acute	HP_0002014	ENSG00000133019	28216264	Lynch et al. (2017)	diarrhea	CHRM3	UBERON_0001016	""
respiratory	activation_acute	EFO_0009836	ENSG00000133019	28216264	Lynch et al. (2017)	bronchoconstriction	CHRM3	UBERON_0001004	""
cardiovascular	activation_acute	Orphanet_98578	ENSG00000133019	28216264	Lynch et al. (2017)	ptosis	CHRM3	UBERON_0004535	""
liver	activation_acute	HP_0000622	ENSG00000133019	28216264	Lynch et al. (2017)	blurred vision	CHRM3	UBERON_0002107	""
gastrointestinal	activation_acute	Orphanet_98578	ENSG00000133019	28216264	Lynch et al. (2017)	ptosis	CHRM3	UBERON_0005409	""
gastrointestinal	activation_acute	""	ENSG00000133019	28216264	Lynch et al. (2017)	frothing	CHRM3	UBERON_0005409	""
cardiovascular	activation_acute	GO_2000428	ENSG00000133019	28216264	Lynch et al. (2017)	neutrophil collection within the sinusoids	CHRM3	UBERON_0004535	""
respiratory	activation_acute	HP_0000975	ENSG00000133019	28216264	Lynch et al. (2017)	sweating	CHRM3	UBERON_0001004	""
respiratory	activation_acute	HP_0012735	ENSG00000133019	28216264	Lynch et al. (2017)	cough	CHRM3	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009846	ENSG00000133019	28216264	Lynch et al. (2017)	muscle cramps	CHRM3	UBERON_0004535	""
liver	activation_acute	HP_0032155	ENSG00000133019	28216264	Lynch et al. (2017)	abdominal cramps	CHRM3	UBERON_0002107	""
liver	activation_acute	EFO_0009846	ENSG00000133019	28216264	Lynch et al. (2017)	muscle cramps	CHRM3	UBERON_0002107	""
respiratory	activation_acute	EFO_1000014	ENSG00000133019	28216264	Lynch et al. (2017)	acidosis	CHRM3	UBERON_0001004	""
cardiovascular	activation_acute	HP_0032155	ENSG00000133019	28216264	Lynch et al. (2017)	abdominal cramps	CHRM3	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000133019	28216264	Lynch et al. (2017)	frothing	CHRM3	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0032155	ENSG00000133019	28216264	Lynch et al. (2017)	abdominal cramps	CHRM3	UBERON_0005409	""
nervous system	activation_acute	EFO_0009840	ENSG00000133019	28216264	Lynch et al. (2017)	increased respiratory rate	CHRM3	UBERON_0001016	""
nervous system	activation_acute	HP_0000622	ENSG00000133019	28216264	Lynch et al. (2017)	blurred vision	CHRM3	UBERON_0001016	""
liver	activation_acute	HP_0002014	ENSG00000133019	28216264	Lynch et al. (2017)	diarrhea	CHRM3	UBERON_0002107	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000133019	28216264	Lynch et al. (2017)	increased respiratory rate	CHRM3	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0030972	ENSG00000133019	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM3	UBERON_0005409	""
liver	activation_acute	HP_0001945	ENSG00000133019	28216264	Lynch et al. (2017)	increased body temperature	CHRM3	UBERON_0002107	""
liver	activation_acute	EFO_0009840	ENSG00000133019	28216264	Lynch et al. (2017)	increased respiratory rate	CHRM3	UBERON_0002107	""
nervous system	activation_acute	EFO_0001421	ENSG00000133019	28216264	Lynch et al. (2017)	centrilobular liver congestion	CHRM3	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_0001421	ENSG00000133019	28216264	Lynch et al. (2017)	centrilobular liver congestion	CHRM3	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009836	ENSG00000133019	28216264	Lynch et al. (2017)	bronchoconstriction	CHRM3	UBERON_0005409	""
liver	activation_acute	HP_0000737	ENSG00000133019	28216264	Lynch et al. (2017)	irritability	CHRM3	UBERON_0002107	""
nervous system	activation_acute	HP_0012735	ENSG00000133019	28216264	Lynch et al. (2017)	cough	CHRM3	UBERON_0001016	""
respiratory	activation_acute	Orphanet_98578	ENSG00000133019	28216264	Lynch et al. (2017)	ptosis	CHRM3	UBERON_0001004	""
gastrointestinal	activation_acute	HP_0025428	ENSG00000133019	28216264	Lynch et al. (2017)	bronchospasm	CHRM3	UBERON_0005409	""
respiratory	activation_acute	EFO_0009840	ENSG00000133019	28216264	Lynch et al. (2017)	increased respiratory rate	CHRM3	UBERON_0001004	""
cardiovascular	activation_acute	HP_0000632	ENSG00000133019	28216264	Lynch et al. (2017)	lacrimation	CHRM3	UBERON_0004535	""
liver	activation_acute	HP_0000632	ENSG00000133019	28216264	Lynch et al. (2017)	lacrimation	CHRM3	UBERON_0002107	""
respiratory	activation_acute	HP_0031860	ENSG00000133019	28216264	Lynch et al. (2017)	increased/decreased heart rate	CHRM3	UBERON_0001004	""
gastrointestinal	activation_acute	HP_0012735	ENSG00000133019	28216264	Lynch et al. (2017)	cough	CHRM3	UBERON_0005409	""
liver	activation_acute	HP_0012735	ENSG00000133019	28216264	Lynch et al. (2017)	cough	CHRM3	UBERON_0002107	""
liver	activation_acute	Orphanet_98578	ENSG00000133019	28216264	Lynch et al. (2017)	ptosis	CHRM3	UBERON_0002107	""
respiratory	activation_acute	HP_0000632	ENSG00000133019	28216264	Lynch et al. (2017)	lacrimation	CHRM3	UBERON_0001004	""
cardiovascular	activation_acute	HP_0000737	ENSG00000133019	28216264	Lynch et al. (2017)	irritability	CHRM3	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0002014	ENSG00000133019	28216264	Lynch et al. (2017)	diarrhea	CHRM3	UBERON_0005409	""
liver	activation_acute	HP_0000975	ENSG00000133019	28216264	Lynch et al. (2017)	sweating	CHRM3	UBERON_0002107	""
nervous system	activation_acute	EFO_0009637	ENSG00000133019	28216264	Lynch et al. (2017)	pleural effusions	CHRM3	UBERON_0001016	""
respiratory	activation_acute	HP_0025428	ENSG00000133019	28216264	Lynch et al. (2017)	bronchospasm	CHRM3	UBERON_0001004	""
respiratory	activation_acute	""	ENSG00000133019	28216264	Lynch et al. (2017)	frothing	CHRM3	UBERON_0001004	""
liver	activation_acute	EFO_0009852	ENSG00000133019	28216264	Lynch et al. (2017)	exhaustion	CHRM3	UBERON_0002107	""
cardiovascular	activation_acute	GO_0046878	ENSG00000133019	28216264	Lynch et al. (2017)	increased salivation	CHRM3	UBERON_0004535	""
liver	activation_acute	GO_0046878	ENSG00000133019	28216264	Lynch et al. (2017)	increased salivation	CHRM3	UBERON_0002107	""
liver	activation_acute	HP_0031860	ENSG00000133019	28216264	Lynch et al. (2017)	increased/decreased heart rate	CHRM3	UBERON_0002107	""
gastrointestinal	activation_acute	HP_0001399	ENSG00000133019	28216264	Lynch et al. (2017)	liver failure	CHRM3	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009852	ENSG00000133019	28216264	Lynch et al. (2017)	exhaustion	CHRM3	UBERON_0005409	""
nervous system	activation_acute	HP_0031860	ENSG00000133019	28216264	Lynch et al. (2017)	increased/decreased heart rate	CHRM3	UBERON_0001016	""
respiratory	activation_acute	EFO_0001421	ENSG00000133019	28216264	Lynch et al. (2017)	centrilobular liver congestion	CHRM3	UBERON_0001004	""
liver	activation_acute	HP_0030972	ENSG00000133019	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM3	UBERON_0002107	""
liver	activation_acute	""	ENSG00000133019	28216264	Lynch et al. (2017)	frothing	CHRM3	UBERON_0002107	""
respiratory	activation_acute	HP_0000622	ENSG00000133019	28216264	Lynch et al. (2017)	blurred vision	CHRM3	UBERON_0001004	""
cardiovascular	activation_acute	EFO_1000014	ENSG00000133019	28216264	Lynch et al. (2017)	acidosis	CHRM3	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_1000014	ENSG00000133019	28216264	Lynch et al. (2017)	acidosis	CHRM3	UBERON_0005409	""
nervous system	activation_acute	Orphanet_98578	ENSG00000133019	28216264	Lynch et al. (2017)	ptosis	CHRM3	UBERON_0001016	""
nervous system	activation_acute	HP_0032155	ENSG00000133019	28216264	Lynch et al. (2017)	abdominal cramps	CHRM3	UBERON_0001016	""
nervous system	activation_acute	""	ENSG00000133019	28216264	Lynch et al. (2017)	bronchorrhea	CHRM3	UBERON_0001016	""
nervous system	activation_acute	GO_2000428	ENSG00000133019	28216264	Lynch et al. (2017)	neutrophil collection within the sinusoids	CHRM3	UBERON_0001016	""
respiratory	activation_acute	EFO_0009637	ENSG00000133019	28216264	Lynch et al. (2017)	pleural effusions	CHRM3	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0001421	ENSG00000133019	28216264	Lynch et al. (2017)	centrilobular liver congestion	CHRM3	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0000632	ENSG00000133019	28216264	Lynch et al. (2017)	lacrimation	CHRM3	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0009836	ENSG00000133019	28216264	Lynch et al. (2017)	bronchoconstriction	CHRM3	UBERON_0004535	""
liver	activation_acute	HP_0001399	ENSG00000133019	28216264	Lynch et al. (2017)	liver failure	CHRM3	UBERON_0002107	""
respiratory	activation_acute	""	ENSG00000133019	28216264	Lynch et al. (2017)	bronchorrhea	CHRM3	UBERON_0001004	""
gastrointestinal	activation_acute	EFO_0009846	ENSG00000133019	28216264	Lynch et al. (2017)	muscle cramps	CHRM3	UBERON_0005409	""
respiratory	activation_acute	EFO_0009852	ENSG00000133019	28216264	Lynch et al. (2017)	exhaustion	CHRM3	UBERON_0001004	""
nervous system	activation_acute	HP_0000632	ENSG00000133019	28216264	Lynch et al. (2017)	lacrimation	CHRM3	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_0009840	ENSG00000133019	28216264	Lynch et al. (2017)	increased respiratory rate	CHRM3	UBERON_0005409	""
gastrointestinal	activation_acute	GO_0046878	ENSG00000133019	28216264	Lynch et al. (2017)	increased salivation	CHRM3	UBERON_0005409	""
liver	activation_acute	EFO_0009637	ENSG00000133019	28216264	Lynch et al. (2017)	pleural effusions	CHRM3	UBERON_0002107	""
gastrointestinal	activation_acute	HP_0000737	ENSG00000133019	28216264	Lynch et al. (2017)	irritability	CHRM3	UBERON_0005409	""
gastrointestinal	activation_acute	GO_2000428	ENSG00000133019	28216264	Lynch et al. (2017)	neutrophil collection within the sinusoids	CHRM3	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0031860	ENSG00000133019	28216264	Lynch et al. (2017)	increased/decreased heart rate	CHRM3	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0001945	ENSG00000133019	28216264	Lynch et al. (2017)	increased body temperature	CHRM3	UBERON_0005409	""
nervous system	activation_acute	EFO_0009846	ENSG00000133019	28216264	Lynch et al. (2017)	muscle cramps	CHRM3	UBERON_0001016	""
cardiovascular	activation_acute	HP_0001945	ENSG00000133019	28216264	Lynch et al. (2017)	increased body temperature	CHRM3	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0000975	ENSG00000133019	28216264	Lynch et al. (2017)	sweating	CHRM3	UBERON_0005409	""
nervous system	activation_acute	EFO_0009836	ENSG00000133019	28216264	Lynch et al. (2017)	bronchoconstriction	CHRM3	UBERON_0001016	""
respiratory	activation_acute	GO_0046878	ENSG00000133019	28216264	Lynch et al. (2017)	increased salivation	CHRM3	UBERON_0001004	""
cardiovascular	activation_acute	""	ENSG00000133019	28216264	Lynch et al. (2017)	bronchorrhea	CHRM3	UBERON_0004535	""
nervous system	activation_acute	HP_0000616	ENSG00000133019	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM3	UBERON_0001016	""
nervous system	activation_acute	HP_0000975	ENSG00000133019	28216264	Lynch et al. (2017)	sweating	CHRM3	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000622	ENSG00000133019	28216264	Lynch et al. (2017)	blurred vision	CHRM3	UBERON_0004535	""
cardiovascular	activation_acute	HP_0000616	ENSG00000133019	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM3	UBERON_0004535	""
liver	activation_acute	HP_0000616	ENSG00000133019	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM3	UBERON_0002107	""
liver	activation_acute	EFO_0001421	ENSG00000133019	28216264	Lynch et al. (2017)	centrilobular liver congestion	CHRM3	UBERON_0002107	""
respiratory	activation_acute	HP_0001945	ENSG00000133019	28216264	Lynch et al. (2017)	increased body temperature	CHRM3	UBERON_0001004	""
nervous system	activation_acute	""	ENSG00000133019	28216264	Lynch et al. (2017)	frothing	CHRM3	UBERON_0001016	""
nervous system	activation_acute	HP_0001399	ENSG00000133019	28216264	Lynch et al. (2017)	liver failure	CHRM3	UBERON_0001016	""
nervous system	activation_acute	HP_0030972	ENSG00000133019	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM3	UBERON_0001016	""
cardiovascular	activation_acute	HP_0031860	ENSG00000133019	28216264	Lynch et al. (2017)	increased/decreased heart rate	CHRM3	UBERON_0004535	""
cardiovascular	activation_acute	HP_0025428	ENSG00000133019	28216264	Lynch et al. (2017)	bronchospasm	CHRM3	UBERON_0004535	""
liver	activation_acute	GO_2000428	ENSG00000133019	28216264	Lynch et al. (2017)	neutrophil collection within the sinusoids	CHRM3	UBERON_0002107	""
nervous system	activation_acute	EFO_1000014	ENSG00000133019	28216264	Lynch et al. (2017)	acidosis	CHRM3	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0000616	ENSG00000133019	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM3	UBERON_0005409	""
liver	activation_acute	HP_0025428	ENSG00000133019	28216264	Lynch et al. (2017)	bronchospasm	CHRM3	UBERON_0002107	""
gastrointestinal	activation_acute	EFO_0009637	ENSG00000133019	28216264	Lynch et al. (2017)	pleural effusions	CHRM3	UBERON_0005409	""
nervous system	activation_acute	HP_0000737	ENSG00000133019	28216264	Lynch et al. (2017)	irritability	CHRM3	UBERON_0001016	""
respiratory	activation_acute	HP_0000616	ENSG00000133019	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM3	UBERON_0001004	""
respiratory	activation_acute	HP_0030972	ENSG00000133019	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM3	UBERON_0001004	""
respiratory	activation_acute	HP_0032155	ENSG00000133019	28216264	Lynch et al. (2017)	abdominal cramps	CHRM3	UBERON_0001004	""
respiratory	activation_acute	EFO_0009846	ENSG00000133019	28216264	Lynch et al. (2017)	muscle cramps	CHRM3	UBERON_0001004	""
respiratory	activation_acute	GO_2000428	ENSG00000133019	28216264	Lynch et al. (2017)	neutrophil collection within the sinusoids	CHRM3	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009637	ENSG00000133019	28216264	Lynch et al. (2017)	pleural effusions	CHRM3	UBERON_0004535	""
nervous system	activation_acute	GO_0046878	ENSG00000133019	28216264	Lynch et al. (2017)	increased salivation	CHRM3	UBERON_0001016	""
cardiovascular	activation_acute	HP_0012735	ENSG00000133019	28216264	Lynch et al. (2017)	cough	CHRM3	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002014	ENSG00000133019	28216264	Lynch et al. (2017)	diarrhea	CHRM3	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009852	ENSG00000133019	28216264	Lynch et al. (2017)	exhaustion	CHRM3	UBERON_0004535	""
nervous system	activation_acute	HP_0025428	ENSG00000133019	28216264	Lynch et al. (2017)	bronchospasm	CHRM3	UBERON_0001016	""
respiratory	activation_acute	HP_0001399	ENSG00000133019	28216264	Lynch et al. (2017)	liver failure	CHRM3	UBERON_0001004	""
nervous system	activation_acute	EFO_0009852	ENSG00000133019	28216264	Lynch et al. (2017)	exhaustion	CHRM3	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000975	ENSG00000133019	28216264	Lynch et al. (2017)	sweating	CHRM3	UBERON_0004535	""
gastrointestinal	activation_acute	""	ENSG00000133019	28216264	Lynch et al. (2017)	bronchorrhea	CHRM3	UBERON_0005409	""
liver	activation_acute	""	ENSG00000133019	28216264	Lynch et al. (2017)	bronchorrhea	CHRM3	UBERON_0002107	""
respiratory	activation_acute	HP_0000737	ENSG00000133019	28216264	Lynch et al. (2017)	irritability	CHRM3	UBERON_0001004	""
Immune	activation_general	GO_0042110	ENSG00000182866	23197038	Bowes et al. (2012)	T cell activation	LCK	""	""
Immune	inhibition_general	""	ENSG00000182866	23197038	Bowes et al. (2012)	T cell inhibition	LCK	""	""
Immune	inhibition_general	HP_0002721	ENSG00000182866	23197038	Bowes et al. (2012)	SCID-like immunodeficiency	LCK	""	""
immune	activation_acute	GO_0090331	ENSG00000132170	28216264	Lynch et al. (2017)	decreased platelet aggregation	PPARG	UBERON_0002405	""
immune	inhibition_acute	GO_0050729	ENSG00000132170	28216264	Lynch et al. (2017)	increased inflammation	PPARG	UBERON_0002405	""
cardiovascular	activation_acute	HP_0001943	ENSG00000132170	28216264	Lynch et al. (2017)	decreased blood glucose	PPARG	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0050729	ENSG00000132170	28216264	Lynch et al. (2017)	increased inflammation	PPARG	UBERON_0004535	""
immune	activation_acute	EFO_0003144	ENSG00000132170	28216264	Lynch et al. (2017)	heart failure	PPARG	UBERON_0002405	""
renal	activation_acute	EFO_0009871	ENSG00000132170	28216264	Lynch et al. (2017)	increased heart weight	PPARG	UBERON_0001008	""
renal	inhibition_acute	GO_0050729	ENSG00000132170	28216264	Lynch et al. (2017)	increased inflammation	PPARG	UBERON_0001008	""
cardiovascular	activation_acute	HP_0011105	ENSG00000132170	28216264	Lynch et al. (2017)	increased plasma volume	PPARG	UBERON_0004535	""
renal	activation_acute	GO_0035814	ENSG00000132170	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PPARG	UBERON_0001008	""
immune	activation_acute	HP_0011105	ENSG00000132170	28216264	Lynch et al. (2017)	increased plasma volume	PPARG	UBERON_0002405	""
renal	activation_acute	GO_0050728	ENSG00000132170	28216264	Lynch et al. (2017)	decreased inflammation	PPARG	UBERON_0001008	""
immune	activation_acute	GO_0003092	ENSG00000132170	28216264	Lynch et al. (2017)	increased water retention	PPARG	UBERON_0002405	""
renal	activation_acute	EFO_0004566	ENSG00000132170	28216264	Lynch et al. (2017)	increased body weight	PPARG	UBERON_0001008	""
renal	activation_acute	GO_0090331	ENSG00000132170	28216264	Lynch et al. (2017)	decreased platelet aggregation	PPARG	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0004566	ENSG00000132170	28216264	Lynch et al. (2017)	increased body weight	PPARG	UBERON_0004535	""
renal	activation_acute	HP_0011105	ENSG00000132170	28216264	Lynch et al. (2017)	increased plasma volume	PPARG	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0003144	ENSG00000132170	28216264	Lynch et al. (2017)	heart failure	PPARG	UBERON_0004535	""
immune	activation_acute	GO_0035814	ENSG00000132170	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PPARG	UBERON_0002405	""
renal	activation_acute	EFO_0003144	ENSG00000132170	28216264	Lynch et al. (2017)	heart failure	PPARG	UBERON_0001008	""
cardiovascular	activation_acute	GO_0003092	ENSG00000132170	28216264	Lynch et al. (2017)	increased water retention	PPARG	UBERON_0004535	""
renal	activation_acute	HP_0011037	ENSG00000132170	28216264	Lynch et al. (2017)	decreased urine excretion	PPARG	UBERON_0001008	""
cardiovascular	activation_acute	HP_0011037	ENSG00000132170	28216264	Lynch et al. (2017)	decreased urine excretion	PPARG	UBERON_0004535	""
immune	activation_acute	EFO_0009871	ENSG00000132170	28216264	Lynch et al. (2017)	increased heart weight	PPARG	UBERON_0002405	""
immune	activation_acute	HP_0001943	ENSG00000132170	28216264	Lynch et al. (2017)	decreased blood glucose	PPARG	UBERON_0002405	""
cardiovascular	activation_acute	GO_0090331	ENSG00000132170	28216264	Lynch et al. (2017)	decreased platelet aggregation	PPARG	UBERON_0004535	""
renal	activation_acute	GO_0003092	ENSG00000132170	28216264	Lynch et al. (2017)	increased water retention	PPARG	UBERON_0001008	""
renal	activation_acute	HP_0001943	ENSG00000132170	28216264	Lynch et al. (2017)	decreased blood glucose	PPARG	UBERON_0001008	""
cardiovascular	activation_acute	GO_0050728	ENSG00000132170	28216264	Lynch et al. (2017)	decreased inflammation	PPARG	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009871	ENSG00000132170	28216264	Lynch et al. (2017)	increased heart weight	PPARG	UBERON_0004535	""
immune	activation_acute	GO_0050728	ENSG00000132170	28216264	Lynch et al. (2017)	decreased inflammation	PPARG	UBERON_0002405	""
immune	activation_acute	EFO_0004566	ENSG00000132170	28216264	Lynch et al. (2017)	increased body weight	PPARG	UBERON_0002405	""
cardiovascular	activation_acute	GO_0035814	ENSG00000132170	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PPARG	UBERON_0004535	""
immune	activation_acute	HP_0011037	ENSG00000132170	28216264	Lynch et al. (2017)	decreased urine excretion	PPARG	UBERON_0002405	""
central nervous system	inhibition_general	HP_0001649	ENSG00000103546	23197038	Bowes et al. (2012)	increased heart rate	SLC6A2	UBERON_0001017	""
central nervous system	inhibition_general	HP_0032263	ENSG00000103546	23197038	Bowes et al. (2012)	increased blood pressure	SLC6A2	UBERON_0001017	""
central nervous system	inhibition_general	GO_0040017	ENSG00000103546	23197038	Bowes et al. (2012)	increased locomotor activity	SLC6A2	UBERON_0001017	""
central nervous system	inhibition_general	HP_0002019	ENSG00000103546	23197038	Bowes et al. (2012)	constipation	SLC6A2	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0003890	ENSG00000103546	23197038	Bowes et al. (2012)	abuse potential	SLC6A2	UBERON_0001017	""
cardiovascular system	inhibition_general	HP_0001649	ENSG00000103546	23197038	Bowes et al. (2012)	increased heart rate	SLC6A2	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0032263	ENSG00000103546	23197038	Bowes et al. (2012)	increased blood pressure	SLC6A2	UBERON_0004535	""
cardiovascular system	inhibition_general	GO_0040017	ENSG00000103546	23197038	Bowes et al. (2012)	increased locomotor activity	SLC6A2	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0002019	ENSG00000103546	23197038	Bowes et al. (2012)	constipation	SLC6A2	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0003890	ENSG00000103546	23197038	Bowes et al. (2012)	abuse potential	SLC6A2	UBERON_0004535	""
peripheral nervous system	activation_acute	GO_0050727	ENSG00000170425	28216264	Lynch et al. (2017)	increased/decreased inflammation	ADORA2B	UBERON_0000010	""
peripheral nervous system	inhibition_acute	GO_0050727	ENSG00000170425	28216264	Lynch et al. (2017)	increased/decreased inflammation	ADORA2B	UBERON_0000010	""
peripheral nervous system	inhibition_acute	GO_1904057	ENSG00000170425	28216264	Lynch et al. (2017)	decreased pain	ADORA2B	UBERON_0000010	""
immune	activation_acute	GO_0050727	ENSG00000170425	28216264	Lynch et al. (2017)	increased/decreased inflammation	ADORA2B	UBERON_0002405	""
immune	inhibition_acute	GO_0050727	ENSG00000170425	28216264	Lynch et al. (2017)	increased/decreased inflammation	ADORA2B	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000170425	28216264	Lynch et al. (2017)	decreased pain	ADORA2B	UBERON_0002405	""
gastrointestinal	activation_general	GO_0006939	ENSG00000120907	""	Urban et al. (2012)	smooth-muscle contraction (prostate in particular, effects on the lower urinary tract)	ADRA1A	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	EFO_0005252	ENSG00000120907	""	Urban et al. (2012)	orthostatic hypotension	ADRA1A	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	""	ENSG00000120907	""	Urban et al. (2012)	other bloodpressure- related adverse effects	ADRA1A	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	EFO_0004714	ENSG00000120907	""	Urban et al. (2012)	impact on various aspects of sexual function	ADRA1A	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	GO_0045823	ENSG00000120907	""	Urban et al. (2012)	cardiac positive ionotropy	ADRA1A	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	EFO_0004269	ENSG00000120907	""	Urban et al. (2012)	arrhythmia	ADRA1A	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0006939	ENSG00000120907	""	Urban et al. (2012)	smooth-muscle contraction (prostate in particular, effects on the lower urinary tract)	ADRA1A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0005252	ENSG00000120907	""	Urban et al. (2012)	orthostatic hypotension	ADRA1A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000120907	""	Urban et al. (2012)	other bloodpressure- related adverse effects	ADRA1A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0004714	ENSG00000120907	""	Urban et al. (2012)	impact on various aspects of sexual function	ADRA1A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0045823	ENSG00000120907	""	Urban et al. (2012)	cardiac positive ionotropy	ADRA1A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0004269	ENSG00000120907	""	Urban et al. (2012)	arrhythmia	ADRA1A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000138435	""	HeCaToS	modulation of neurotransmitters (e.g. dopaminergic, serotoninergic, glutamatergic) with effects on cognitive and motor function. They exhibit analgesic activity (epibatidine) and may stimulate autonomic cardiovascular, respiratory, and gastrointestinal function (palpitation/nausea)	CHRNA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000138435	""	HeCaToS	muscle relaxant	CHRNA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000138435	""	HeCaToS	antihypertensive agent	CHRNA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	activation_general	""	ENSG00000138435	""	HeCaToS	modulation of neurotransmitters (e.g. dopaminergic, serotoninergic, glutamatergic) with effects on cognitive and motor function. They exhibit analgesic activity (epibatidine) and may stimulate autonomic cardiovascular, respiratory, and gastrointestinal function (palpitation/nausea)	CHRNA1	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	""	ENSG00000138435	""	HeCaToS	muscle relaxant	CHRNA1	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	""	ENSG00000138435	""	HeCaToS	antihypertensive agent	CHRNA1	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
respiratory	activation_general	""	ENSG00000138435	""	HeCaToS	modulation of neurotransmitters (e.g. dopaminergic, serotoninergic, glutamatergic) with effects on cognitive and motor function. They exhibit analgesic activity (epibatidine) and may stimulate autonomic cardiovascular, respiratory, and gastrointestinal function (palpitation/nausea)	CHRNA1	UBERON_0001004	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
respiratory	inhibition_general	""	ENSG00000138435	""	HeCaToS	muscle relaxant	CHRNA1	UBERON_0001004	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
respiratory	inhibition_general	""	ENSG00000138435	""	HeCaToS	antihypertensive agent	CHRNA1	UBERON_0001004	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000138435	""	HeCaToS	modulation of neurotransmitters (e.g. dopaminergic, serotoninergic, glutamatergic) with effects on cognitive and motor function. They exhibit analgesic activity (epibatidine) and may stimulate autonomic cardiovascular, respiratory, and gastrointestinal function (palpitation/nausea)	CHRNA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	""	ENSG00000138435	""	HeCaToS	muscle relaxant	CHRNA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	""	ENSG00000138435	""	HeCaToS	antihypertensive agent	CHRNA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular	activation_acute	MONDO_0000437	ENSG00000104783	28216264	Lynch et al. (2017)	ataxia	KCNN4	UBERON_0004535	""
cardiovascular	inhibition_acute	""	ENSG00000104783	28216264	Lynch et al. (2017)	increased atrial refractory period	KCNN4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000104783	28216264	Lynch et al. (2017)	convulsions	KCNN4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000104783	28216264	Lynch et al. (2017)	neurotoxicity	KCNN4	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000104783	28216264	Lynch et al. (2017)	decreased convulsions	KCNN4	UBERON_0001017	""
central nervous system	inhibition_acute	""	ENSG00000104783	28216264	Lynch et al. (2017)	increased atrial refractory period	KCNN4	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000104783	28216264	Lynch et al. (2017)	convulsions	KCNN4	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000104783	28216264	Lynch et al. (2017)	neurotoxicity	KCNN4	UBERON_0001017	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000104783	28216264	Lynch et al. (2017)	ataxia	KCNN4	UBERON_0001017	""
central nervous system	activation_acute	GO_0040013	ENSG00000104783	28216264	Lynch et al. (2017)	decreased locomotor activity	KCNN4	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000104783	28216264	Lynch et al. (2017)	decreased convulsions	KCNN4	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000104783	28216264	Lynch et al. (2017)	decreased locomotor activity	KCNN4	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0004698	ENSG00000108576	""	HeCaToS	insomnia	SLC6A4	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0005230	ENSG00000108576	""	HeCaToS	anxiety	SLC6A4	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0002017	ENSG00000108576	""	HeCaToS	nausea and vomiting	SLC6A4	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0004714	ENSG00000108576	""	HeCaToS	sexual dysfunction	SLC6A4	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0032155	ENSG00000108576	""	HeCaToS	gastrointestinal cramps	SLC6A4	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0002014	ENSG00000108576	""	HeCaToS	diarrhea	SLC6A4	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0002315	ENSG00000108576	""	HeCaToS	headache	SLC6A4	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0009551	ENSG00000108576	""	HeCaToS	valvular heart disease	SLC6A4	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	MONDO_0001999	ENSG00000108576	""	HeCaToS	primary pulmonary hypertension	SLC6A4	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0004698	ENSG00000108576	""	HeCaToS	insomnia	SLC6A4	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0005230	ENSG00000108576	""	HeCaToS	anxiety	SLC6A4	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0002017	ENSG00000108576	""	HeCaToS	nausea and vomiting	SLC6A4	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0004714	ENSG00000108576	""	HeCaToS	sexual dysfunction	SLC6A4	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0032155	ENSG00000108576	""	HeCaToS	gastrointestinal cramps	SLC6A4	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0002014	ENSG00000108576	""	HeCaToS	diarrhea	SLC6A4	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0002315	ENSG00000108576	""	HeCaToS	headache	SLC6A4	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0009551	ENSG00000108576	""	HeCaToS	valvular heart disease	SLC6A4	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	MONDO_0001999	ENSG00000108576	""	HeCaToS	primary pulmonary hypertension	SLC6A4	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	EFO_0004698	ENSG00000108576	""	HeCaToS	insomnia	SLC6A4	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	EFO_0005230	ENSG00000108576	""	HeCaToS	anxiety	SLC6A4	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	HP_0002017	ENSG00000108576	""	HeCaToS	nausea and vomiting	SLC6A4	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	EFO_0004714	ENSG00000108576	""	HeCaToS	sexual dysfunction	SLC6A4	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	HP_0032155	ENSG00000108576	""	HeCaToS	gastrointestinal cramps	SLC6A4	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	HP_0002014	ENSG00000108576	""	HeCaToS	diarrhea	SLC6A4	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	HP_0002315	ENSG00000108576	""	HeCaToS	headache	SLC6A4	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	EFO_0009551	ENSG00000108576	""	HeCaToS	valvular heart disease	SLC6A4	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
gastrointestinal	inhibition_general	MONDO_0001999	ENSG00000108576	""	HeCaToS	primary pulmonary hypertension	SLC6A4	UBERON_0005409	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000151617	""	HeCaToS	vasoconstriction	EDNRA	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_developmental toxicity	EFO_0009880	ENSG00000151617	""	HeCaToS	teratogenicity	EDNRA	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009836	ENSG00000151617	""	HeCaToS	bronchoconstriction	EDNRA	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0035932	ENSG00000151617	""	HeCaToS	aldosterone secretion	EDNRA	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0033687	ENSG00000151617	""	HeCaToS	osteoblast proliferation	EDNRA	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
central nervous system	activation_general	EFO_0005407	ENSG00000176884	23197038	Bowes et al. (2012)	psychosis (schizophrenia-like)	GRIN1	UBERON_0001017	""
central nervous system	activation_general	HP_0000738	ENSG00000176884	23197038	Bowes et al. (2012)	hallucinations	GRIN1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009267	ENSG00000176884	23197038	Bowes et al. (2012)	delirium and disoriented behaviour	GRIN1	UBERON_0001017	""
central nervous system	activation_general	HP_0001250	ENSG00000176884	23197038	Bowes et al. (2012)	seizures	GRIN1	UBERON_0001017	""
central nervous system	activation_general	EFO_0005595	ENSG00000176884	23197038	Bowes et al. (2012)	neurotoxicity	GRIN1	UBERON_0001017	""
immune	activation_general	GO_0050777	ENSG00000282608	""	HeCaToS	immunosuppression	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
immune	inhibition_general	EFO_1001375	ENSG00000282608	""	HeCaToS	myocardial ischemia (inferred by author)	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
immune	inhibition_general	GO_0050729	ENSG00000282608	""	HeCaToS	proinflammatory effects (inferred by author)	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
immune	inhibition_general	EFO_0000537	ENSG00000282608	""	HeCaToS	hypertension (inferred by author)	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
immune	inhibition_general	""	ENSG00000282608	""	HeCaToS	interference with the regulation of cell growth (inferred by author)	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
immune	activation_general	EFO_0005251	ENSG00000282608	""	HeCaToS	hypotension	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
immune	activation_general	""	ENSG00000282608	""	HeCaToS	antiischaemic (cardioprotective)	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
immune	activation_general	""	ENSG00000282608	""	HeCaToS	proischemic (cerebral)	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
immune	activation_general	EFO_0009426	ENSG00000282608	""	HeCaToS	cell necrosis	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
immune	activation_general	GO_0008283	ENSG00000282608	""	HeCaToS	cell proliferation	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
immune	activation_general	""	ENSG00000282608	""	HeCaToS	angiogenesis	ADORA3	UBERON_0002405	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0050777	ENSG00000282608	""	HeCaToS	immunosuppression	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_1001375	ENSG00000282608	""	HeCaToS	myocardial ischemia (inferred by author)	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	GO_0050729	ENSG00000282608	""	HeCaToS	proinflammatory effects (inferred by author)	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0000537	ENSG00000282608	""	HeCaToS	hypertension (inferred by author)	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000282608	""	HeCaToS	interference with the regulation of cell growth (inferred by author)	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0005251	ENSG00000282608	""	HeCaToS	hypotension	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000282608	""	HeCaToS	antiischaemic (cardioprotective)	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000282608	""	HeCaToS	proischemic (cerebral)	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009426	ENSG00000282608	""	HeCaToS	cell necrosis	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0008283	ENSG00000282608	""	HeCaToS	cell proliferation	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000282608	""	HeCaToS	angiogenesis	ADORA3	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_chronic	""	ENSG00000172572	""	HeCaToS	increased mortality in heart failure patients	PDE3A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0004308	ENSG00000172572	""	HeCaToS	could induce ventricular arrhythmias in ~10% of patients	PDE3A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0001649	ENSG00000172572	""	HeCaToS	tachycardia	PDE3A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000172572	""	HeCaToS	hypotension	PDE3A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_chronic	HP_0001873	ENSG00000172572	""	HeCaToS	thrombocytopenia	PDE3A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000112759	""	Urban et al. (2012)	peripheral and central vasodilation	SLC29A1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	GO_0090331	ENSG00000112759	""	Urban et al. (2012)	inhibition of platelet aggregation	SLC29A1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0009843	ENSG00000112759	""	Urban et al. (2012)	promotion of sleep	SLC29A1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0003913	ENSG00000112759	""	Urban et al. (2012)	angina pectoris	SLC29A1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0009847	ENSG00000112759	""	Urban et al. (2012)	dizziness	SLC29A1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000112759	""	Urban et al. (2012)	hypotension	SLC29A1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000112759	""	Urban et al. (2012)	rare (0.1%) serious side effects have been observed with the ENT1 inhibitor dipyridamole when given IV for 4 min: cardiac death, fatal and nonfatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction, and bronchospasm (from the drug label)	SLC29A1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000006638	""	HeCaToS	vasoconstriction	TBXA2R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	GO_0090331	ENSG00000006638	""	HeCaToS	could cause bleeding by inhibiting platelet aggregation	TBXA2R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009836	ENSG00000006638	""	HeCaToS	bronchoconstriction	TBXA2R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0070527	ENSG00000006638	""	HeCaToS	platelet aggregation	TBXA2R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_1001375	ENSG00000006638	""	HeCaToS	myocardial ischemia	TBXA2R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0003144	ENSG00000006638	""	HeCaToS	heart failure	TBXA2R	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
Immune	inhibition_general	GO_0050729	ENSG00000188822	23197038	Bowes et al. (2012)	increased inflammation	CNR2	""	""
Immune	inhibition_general	EFO_0009877	ENSG00000188822	23197038	Bowes et al. (2012)	decreased bone mass	CNR2	""	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000186297	28216264	Lynch et al. (2017)	decreased memory	GABRA5	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000186297	28216264	Lynch et al. (2017)	convulsions	GABRA5	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000186297	28216264	Lynch et al. (2017)	decreased sleep	GABRA5	UBERON_0004535	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000186297	28216264	Lynch et al. (2017)	ataxia	GABRA5	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000186297	28216264	Lynch et al. (2017)	convulsions	GABRA5	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000186297	28216264	Lynch et al. (2017)	decreased sleep	GABRA5	UBERON_0001017	""
cardiovascular	activation_acute	HP_0002045	ENSG00000186297	28216264	Lynch et al. (2017)	decreased body temperature	GABRA5	UBERON_0004535	""
central nervous system	activation_acute	GO_0040013	ENSG00000186297	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA5	UBERON_0001017	""
cardiovascular	activation_acute	""	ENSG00000186297	28216264	Lynch et al. (2017)	muscle relaxation	GABRA5	UBERON_0004535	""
central nervous system	activation_acute	EFO_0005251	ENSG00000186297	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA5	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000186297	28216264	Lynch et al. (2017)	decreased convulsions	GABRA5	UBERON_0004535	""
central nervous system	activation_acute	EFO_0008568	ENSG00000186297	28216264	Lynch et al. (2017)	increased sleep	GABRA5	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009840	ENSG00000186297	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA5	UBERON_0001017	""
central nervous system	activation_acute	EFO_0003890	ENSG00000186297	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA5	UBERON_0001017	""
cardiovascular	activation_acute	GO_0045822	ENSG00000186297	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA5	UBERON_0004535	""
central nervous system	activation_acute	GO_1904057	ENSG00000186297	28216264	Lynch et al. (2017)	decreased pain	GABRA5	UBERON_0001017	""
central nervous system	activation_acute	GO_0045822	ENSG00000186297	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA5	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000186297	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA5	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009874	ENSG00000186297	28216264	Lynch et al. (2017)	decreased anxiety	GABRA5	UBERON_0001017	""
cardiovascular	activation_acute	GO_0040013	ENSG00000186297	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA5	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0008568	ENSG00000186297	28216264	Lynch et al. (2017)	increased sleep	GABRA5	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000186297	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA5	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009872	ENSG00000186297	28216264	Lynch et al. (2017)	increased cardiac output	GABRA5	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000186297	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA5	UBERON_0004535	""
central nervous system	activation_acute	EFO_0001072	ENSG00000186297	28216264	Lynch et al. (2017)	decreased memory	GABRA5	UBERON_0001017	""
central nervous system	activation_acute	HP_0002045	ENSG00000186297	28216264	Lynch et al. (2017)	decreased body temperature	GABRA5	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009872	ENSG00000186297	28216264	Lynch et al. (2017)	increased cardiac output	GABRA5	UBERON_0004535	""
central nervous system	activation_acute	""	ENSG00000186297	28216264	Lynch et al. (2017)	muscle relaxation	GABRA5	UBERON_0001017	""
cardiovascular	activation_acute	GO_1904057	ENSG00000186297	28216264	Lynch et al. (2017)	decreased pain	GABRA5	UBERON_0004535	""
central nervous system	activation_acute	HP_0100738	ENSG00000186297	28216264	Lynch et al. (2017)	increased eating	GABRA5	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009853	ENSG00000186297	28216264	Lynch et al. (2017)	decreased convulsions	GABRA5	UBERON_0001017	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000186297	28216264	Lynch et al. (2017)	ataxia	GABRA5	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000186297	28216264	Lynch et al. (2017)	decreased anxiety	GABRA5	UBERON_0004535	""
cardiovascular	activation_acute	HP_0100738	ENSG00000186297	28216264	Lynch et al. (2017)	increased eating	GABRA5	UBERON_0004535	""
cardiovascular system	activation_general	""	ENSG00000135914	""	HeCaToS	cardiac valvulopathy	HTR2B	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_developmental toxicity	EFO_0000318	ENSG00000135914	""	HeCaToS	possible effect on cardiac development leading to cardiomyopathy (based on knockout mouse data)	HTR2B	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0000537	ENSG00000135914	""	HeCaToS	hypertension	HTR2B	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000135914	""	HeCaToS	withdrawal of pergolide products	HTR2B	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000189221	""	Urban et al. (2012)	"hypertensive when combined with pressor amines such as tyramine present in cheese: inhibitors may induce severe hypertensive crisis (known as \"cheese reaction\")"	MAOA	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000189221	""	Urban et al. (2012)	centrally mediated side effects such as the serotonin syndrome, dizziness, blurred vision, weakness, and hypomania	MAOA	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
central nervous system	inhibition_general	""	ENSG00000189221	""	Urban et al. (2012)	"hypertensive when combined with pressor amines such as tyramine present in cheese: inhibitors may induce severe hypertensive crisis (known as \"cheese reaction\")"	MAOA	UBERON_0001017	https://doi.org/10.1002/9781118098141.ch2
central nervous system	inhibition_general	""	ENSG00000189221	""	Urban et al. (2012)	centrally mediated side effects such as the serotonin syndrome, dizziness, blurred vision, weakness, and hypomania	MAOA	UBERON_0001017	https://doi.org/10.1002/9781118098141.ch2
liver	activation_acute	""	ENSG00000168539	28216264	Lynch et al. (2017)	frothing	CHRM1	UBERON_0002107	""
liver	inhibition_acute	GO_0040017	ENSG00000168539	28216264	Lynch et al. (2017)	increased locomotor activity	CHRM1	UBERON_0002107	""
liver	inhibition_acute	EFO_0009853	ENSG00000168539	28216264	Lynch et al. (2017)	decreased convulsions	CHRM1	UBERON_0002107	""
liver	inhibition_acute	EFO_0001072	ENSG00000168539	28216264	Lynch et al. (2017)	decreased memory	CHRM1	UBERON_0002107	""
liver	inhibition_acute	HP_0100543	ENSG00000168539	28216264	Lynch et al. (2017)	decreased cognitive function	CHRM1	UBERON_0002107	""
liver	inhibition_acute	HP_0000622	ENSG00000168539	28216264	Lynch et al. (2017)	blurred vision	CHRM1	UBERON_0002107	""
liver	inhibition_acute	HP_0001649	ENSG00000168539	28216264	Lynch et al. (2017)	increased heart rate	CHRM1	UBERON_0002107	""
liver	inhibition_acute	GO_0060455	ENSG00000168539	28216264	Lynch et al. (2017)	decreased gastric acid secretion	CHRM1	UBERON_0002107	""
liver	activation_acute	GO_0046878	ENSG00000168539	28216264	Lynch et al. (2017)	increased salivation	CHRM1	UBERON_0002107	""
liver	activation_acute	GO_2000428	ENSG00000168539	28216264	Lynch et al. (2017)	neutrophil collection within the sinusoids	CHRM1	UBERON_0002107	""
gastrointestinal	activation_acute	HP_0002017	ENSG00000168539	28216264	Lynch et al. (2017)	vomiting	CHRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0040017	ENSG00000168539	28216264	Lynch et al. (2017)	increased locomotor activity	CHRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009853	ENSG00000168539	28216264	Lynch et al. (2017)	decreased convulsions	CHRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0001072	ENSG00000168539	28216264	Lynch et al. (2017)	decreased memory	CHRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0100543	ENSG00000168539	28216264	Lynch et al. (2017)	decreased cognitive function	CHRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000622	ENSG00000168539	28216264	Lynch et al. (2017)	blurred vision	CHRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0001649	ENSG00000168539	28216264	Lynch et al. (2017)	increased heart rate	CHRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0060455	ENSG00000168539	28216264	Lynch et al. (2017)	decreased gastric acid secretion	CHRM1	UBERON_0005409	""
respiratory	activation_acute	""	ENSG00000168539	28216264	Lynch et al. (2017)	bronchorrhea	CHRM1	UBERON_0001004	""
respiratory	inhibition_acute	GO_0040017	ENSG00000168539	28216264	Lynch et al. (2017)	increased locomotor activity	CHRM1	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009853	ENSG00000168539	28216264	Lynch et al. (2017)	decreased convulsions	CHRM1	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0001072	ENSG00000168539	28216264	Lynch et al. (2017)	decreased memory	CHRM1	UBERON_0001004	""
respiratory	inhibition_acute	HP_0100543	ENSG00000168539	28216264	Lynch et al. (2017)	decreased cognitive function	CHRM1	UBERON_0001004	""
respiratory	inhibition_acute	HP_0000622	ENSG00000168539	28216264	Lynch et al. (2017)	blurred vision	CHRM1	UBERON_0001004	""
respiratory	inhibition_acute	HP_0001649	ENSG00000168539	28216264	Lynch et al. (2017)	increased heart rate	CHRM1	UBERON_0001004	""
respiratory	inhibition_acute	GO_0060455	ENSG00000168539	28216264	Lynch et al. (2017)	decreased gastric acid secretion	CHRM1	UBERON_0001004	""
liver	activation_acute	EFO_1000014	ENSG00000168539	28216264	Lynch et al. (2017)	acidosis	CHRM1	UBERON_0002107	""
respiratory	activation_acute	HP_0030972	ENSG00000168539	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM1	UBERON_0001004	""
cardiovascular	activation_acute	HP_0012735	ENSG00000168539	28216264	Lynch et al. (2017)	cough	CHRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040017	ENSG00000168539	28216264	Lynch et al. (2017)	increased locomotor activity	CHRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000168539	28216264	Lynch et al. (2017)	decreased convulsions	CHRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0001072	ENSG00000168539	28216264	Lynch et al. (2017)	decreased memory	CHRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0100543	ENSG00000168539	28216264	Lynch et al. (2017)	decreased cognitive function	CHRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000622	ENSG00000168539	28216264	Lynch et al. (2017)	blurred vision	CHRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000168539	28216264	Lynch et al. (2017)	increased heart rate	CHRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0060455	ENSG00000168539	28216264	Lynch et al. (2017)	decreased gastric acid secretion	CHRM1	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0001945	ENSG00000168539	28216264	Lynch et al. (2017)	increased body temperature	CHRM1	UBERON_0005409	""
respiratory	activation_acute	EFO_0009852	ENSG00000168539	28216264	Lynch et al. (2017)	exhaustion	CHRM1	UBERON_0001004	""
cardiovascular	activation_acute	HP_0000975	ENSG00000168539	28216264	Lynch et al. (2017)	sweating	CHRM1	UBERON_0004535	""
nervous system	activation_acute	HP_0000737	ENSG00000168539	28216264	Lynch et al. (2017)	irritability	CHRM1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0040017	ENSG00000168539	28216264	Lynch et al. (2017)	increased locomotor activity	CHRM1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000168539	28216264	Lynch et al. (2017)	decreased convulsions	CHRM1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0001072	ENSG00000168539	28216264	Lynch et al. (2017)	decreased memory	CHRM1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0100543	ENSG00000168539	28216264	Lynch et al. (2017)	decreased cognitive function	CHRM1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000622	ENSG00000168539	28216264	Lynch et al. (2017)	blurred vision	CHRM1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001649	ENSG00000168539	28216264	Lynch et al. (2017)	increased heart rate	CHRM1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0060455	ENSG00000168539	28216264	Lynch et al. (2017)	decreased gastric acid secretion	CHRM1	UBERON_0001016	""
nervous system	activation_acute	""	ENSG00000168539	28216264	Lynch et al. (2017)	bronchorrhea	CHRM1	UBERON_0001016	""
cardiovascular	activation_acute	GO_2000428	ENSG00000168539	28216264	Lynch et al. (2017)	neutrophil collection within the sinusoids	CHRM1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000168539	28216264	Lynch et al. (2017)	increased convulsions	CHRM1	UBERON_0004535	""
nervous system	activation_acute	EFO_0004874	ENSG00000168539	28216264	Lynch et al. (2017)	increased memory	CHRM1	UBERON_0001016	""
liver	activation_acute	HP_0032155	ENSG00000168539	28216264	Lynch et al. (2017)	abdominal cramps	CHRM1	UBERON_0002107	""
gastrointestinal	activation_acute	""	ENSG00000168539	28216264	Lynch et al. (2017)	frothing	CHRM1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0001421	ENSG00000168539	28216264	Lynch et al. (2017)	centrilobular liver congestion	CHRM1	UBERON_0005409	""
cardiovascular	activation_acute	""	ENSG00000168539	28216264	Lynch et al. (2017)	bronchorrhea	CHRM1	UBERON_0004535	""
respiratory	activation_acute	HP_0012735	ENSG00000168539	28216264	Lynch et al. (2017)	cough	CHRM1	UBERON_0001004	""
liver	activation_acute	HP_0031860	ENSG00000168539	28216264	Lynch et al. (2017)	increased/decreased heart rate	CHRM1	UBERON_0002107	""
gastrointestinal	activation_acute	HP_0000737	ENSG00000168539	28216264	Lynch et al. (2017)	irritability	CHRM1	UBERON_0005409	""
cardiovascular	activation_acute	Orphanet_98578	ENSG00000168539	28216264	Lynch et al. (2017)	ptosis	CHRM1	UBERON_0004535	""
liver	activation_acute	EFO_0009852	ENSG00000168539	28216264	Lynch et al. (2017)	exhaustion	CHRM1	UBERON_0002107	""
respiratory	activation_acute	HP_0025428	ENSG00000168539	28216264	Lynch et al. (2017)	bronchospasm	CHRM1	UBERON_0001004	""
cardiovascular	activation_acute	HP_0000737	ENSG00000168539	28216264	Lynch et al. (2017)	irritability	CHRM1	UBERON_0004535	""
nervous system	activation_acute	EFO_0009846	ENSG00000168539	28216264	Lynch et al. (2017)	muscle cramps	CHRM1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0001399	ENSG00000168539	28216264	Lynch et al. (2017)	liver failure	CHRM1	UBERON_0004535	""
respiratory	activation_acute	HP_0000632	ENSG00000168539	28216264	Lynch et al. (2017)	lacrimation	CHRM1	UBERON_0001004	""
cardiovascular	activation_acute	HP_0000632	ENSG00000168539	28216264	Lynch et al. (2017)	lacrimation	CHRM1	UBERON_0004535	""
gastrointestinal	activation_acute	Orphanet_98578	ENSG00000168539	28216264	Lynch et al. (2017)	ptosis	CHRM1	UBERON_0005409	""
liver	activation_acute	HP_0000975	ENSG00000168539	28216264	Lynch et al. (2017)	sweating	CHRM1	UBERON_0002107	""
gastrointestinal	activation_acute	HP_0032155	ENSG00000168539	28216264	Lynch et al. (2017)	abdominal cramps	CHRM1	UBERON_0005409	""
liver	activation_acute	HP_0001945	ENSG00000168539	28216264	Lynch et al. (2017)	increased body temperature	CHRM1	UBERON_0002107	""
liver	activation_acute	HP_0030972	ENSG00000168539	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM1	UBERON_0002107	""
gastrointestinal	activation_acute	GO_0040013	ENSG00000168539	28216264	Lynch et al. (2017)	decreased locomotor activity	CHRM1	UBERON_0005409	""
respiratory	activation_acute	GO_0046878	ENSG00000168539	28216264	Lynch et al. (2017)	increased salivation	CHRM1	UBERON_0001004	""
gastrointestinal	activation_acute	EFO_0009840	ENSG00000168539	28216264	Lynch et al. (2017)	increased respiratory rate	CHRM1	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0004874	ENSG00000168539	28216264	Lynch et al. (2017)	increased memory	CHRM1	UBERON_0004535	""
respiratory	activation_acute	EFO_0001421	ENSG00000168539	28216264	Lynch et al. (2017)	centrilobular liver congestion	CHRM1	UBERON_0001004	""
respiratory	activation_acute	HP_0031860	ENSG00000168539	28216264	Lynch et al. (2017)	increased/decreased heart rate	CHRM1	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009846	ENSG00000168539	28216264	Lynch et al. (2017)	muscle cramps	CHRM1	UBERON_0004535	""
respiratory	activation_acute	HP_0001945	ENSG00000168539	28216264	Lynch et al. (2017)	increased body temperature	CHRM1	UBERON_0001004	""
gastrointestinal	activation_acute	HP_0030972	ENSG00000168539	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM1	UBERON_0005409	""
liver	activation_acute	HP_0001399	ENSG00000168539	28216264	Lynch et al. (2017)	liver failure	CHRM1	UBERON_0002107	""
nervous system	activation_acute	HP_0031860	ENSG00000168539	28216264	Lynch et al. (2017)	increased/decreased heart rate	CHRM1	UBERON_0001016	""
nervous system	activation_acute	HP_0030972	ENSG00000168539	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM1	UBERON_0001016	""
respiratory	activation_acute	HP_0001399	ENSG00000168539	28216264	Lynch et al. (2017)	liver failure	CHRM1	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0001421	ENSG00000168539	28216264	Lynch et al. (2017)	centrilobular liver congestion	CHRM1	UBERON_0004535	""
liver	activation_acute	HP_0025428	ENSG00000168539	28216264	Lynch et al. (2017)	bronchospasm	CHRM1	UBERON_0002107	""
nervous system	activation_acute	HP_0000975	ENSG00000168539	28216264	Lynch et al. (2017)	sweating	CHRM1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009853	ENSG00000168539	28216264	Lynch et al. (2017)	increased convulsions	CHRM1	UBERON_0001016	""
respiratory	activation_acute	Orphanet_98578	ENSG00000168539	28216264	Lynch et al. (2017)	ptosis	CHRM1	UBERON_0001004	""
cardiovascular	activation_acute	EFO_1000014	ENSG00000168539	28216264	Lynch et al. (2017)	acidosis	CHRM1	UBERON_0004535	""
liver	activation_acute	EFO_0001421	ENSG00000168539	28216264	Lynch et al. (2017)	centrilobular liver congestion	CHRM1	UBERON_0002107	""
respiratory	activation_acute	EFO_0009840	ENSG00000168539	28216264	Lynch et al. (2017)	increased respiratory rate	CHRM1	UBERON_0001004	""
liver	activation_acute	GO_0040013	ENSG00000168539	28216264	Lynch et al. (2017)	decreased locomotor activity	CHRM1	UBERON_0002107	""
nervous system	activation_acute	EFO_0009840	ENSG00000168539	28216264	Lynch et al. (2017)	increased respiratory rate	CHRM1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0025428	ENSG00000168539	28216264	Lynch et al. (2017)	bronchospasm	CHRM1	UBERON_0005409	""
cardiovascular	activation_acute	GO_0046878	ENSG00000168539	28216264	Lynch et al. (2017)	increased salivation	CHRM1	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000168539	28216264	Lynch et al. (2017)	frothing	CHRM1	UBERON_0004535	""
liver	activation_acute	HP_0000737	ENSG00000168539	28216264	Lynch et al. (2017)	irritability	CHRM1	UBERON_0002107	""
liver	activation_acute	HP_0000622	ENSG00000168539	28216264	Lynch et al. (2017)	blurred vision	CHRM1	UBERON_0002107	""
cardiovascular	activation_acute	HP_0032155	ENSG00000168539	28216264	Lynch et al. (2017)	abdominal cramps	CHRM1	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0004874	ENSG00000168539	28216264	Lynch et al. (2017)	increased memory	CHRM1	UBERON_0005409	""
cardiovascular	activation_acute	HP_0000622	ENSG00000168539	28216264	Lynch et al. (2017)	blurred vision	CHRM1	UBERON_0004535	""
liver	activation_acute	HP_0002017	ENSG00000168539	28216264	Lynch et al. (2017)	vomiting	CHRM1	UBERON_0002107	""
liver	activation_acute	EFO_0009846	ENSG00000168539	28216264	Lynch et al. (2017)	muscle cramps	CHRM1	UBERON_0002107	""
gastrointestinal	activation_acute	""	ENSG00000168539	28216264	Lynch et al. (2017)	bronchorrhea	CHRM1	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0000616	ENSG00000168539	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM1	UBERON_0005409	""
nervous system	activation_acute	HP_0000622	ENSG00000168539	28216264	Lynch et al. (2017)	blurred vision	CHRM1	UBERON_0001016	""
respiratory	activation_acute	EFO_0009853	ENSG00000168539	28216264	Lynch et al. (2017)	increased convulsions	CHRM1	UBERON_0001004	""
nervous system	activation_acute	HP_0032155	ENSG00000168539	28216264	Lynch et al. (2017)	abdominal cramps	CHRM1	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_1000014	ENSG00000168539	28216264	Lynch et al. (2017)	acidosis	CHRM1	UBERON_0005409	""
nervous system	activation_acute	""	ENSG00000168539	28216264	Lynch et al. (2017)	frothing	CHRM1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009852	ENSG00000168539	28216264	Lynch et al. (2017)	exhaustion	CHRM1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0030972	ENSG00000168539	28216264	Lynch et al. (2017)	increased/decreased blood pressure	CHRM1	UBERON_0004535	""
respiratory	activation_acute	EFO_0004874	ENSG00000168539	28216264	Lynch et al. (2017)	increased memory	CHRM1	UBERON_0001004	""
cardiovascular	activation_acute	HP_0025428	ENSG00000168539	28216264	Lynch et al. (2017)	bronchospasm	CHRM1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000168539	28216264	Lynch et al. (2017)	increased respiratory rate	CHRM1	UBERON_0004535	""
nervous system	activation_acute	HP_0002017	ENSG00000168539	28216264	Lynch et al. (2017)	vomiting	CHRM1	UBERON_0001016	""
liver	activation_acute	Orphanet_98578	ENSG00000168539	28216264	Lynch et al. (2017)	ptosis	CHRM1	UBERON_0002107	""
nervous system	activation_acute	HP_0000616	ENSG00000168539	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0002017	ENSG00000168539	28216264	Lynch et al. (2017)	vomiting	CHRM1	UBERON_0004535	""
nervous system	activation_acute	HP_0001945	ENSG00000168539	28216264	Lynch et al. (2017)	increased body temperature	CHRM1	UBERON_0001016	""
respiratory	activation_acute	EFO_0009846	ENSG00000168539	28216264	Lynch et al. (2017)	muscle cramps	CHRM1	UBERON_0001004	""
nervous system	activation_acute	GO_0040013	ENSG00000168539	28216264	Lynch et al. (2017)	decreased locomotor activity	CHRM1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0031860	ENSG00000168539	28216264	Lynch et al. (2017)	increased/decreased heart rate	CHRM1	UBERON_0004535	""
respiratory	activation_acute	EFO_1000014	ENSG00000168539	28216264	Lynch et al. (2017)	acidosis	CHRM1	UBERON_0001004	""
respiratory	activation_acute	HP_0000737	ENSG00000168539	28216264	Lynch et al. (2017)	irritability	CHRM1	UBERON_0001004	""
nervous system	activation_acute	Orphanet_98578	ENSG00000168539	28216264	Lynch et al. (2017)	ptosis	CHRM1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0031860	ENSG00000168539	28216264	Lynch et al. (2017)	increased/decreased heart rate	CHRM1	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0000632	ENSG00000168539	28216264	Lynch et al. (2017)	lacrimation	CHRM1	UBERON_0005409	""
nervous system	activation_acute	EFO_1000014	ENSG00000168539	28216264	Lynch et al. (2017)	acidosis	CHRM1	UBERON_0001016	""
respiratory	activation_acute	HP_0000616	ENSG00000168539	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM1	UBERON_0001004	""
gastrointestinal	activation_acute	HP_0000975	ENSG00000168539	28216264	Lynch et al. (2017)	sweating	CHRM1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009846	ENSG00000168539	28216264	Lynch et al. (2017)	muscle cramps	CHRM1	UBERON_0005409	""
nervous system	activation_acute	GO_0046878	ENSG00000168539	28216264	Lynch et al. (2017)	increased salivation	CHRM1	UBERON_0001016	""
liver	activation_acute	EFO_0009840	ENSG00000168539	28216264	Lynch et al. (2017)	increased respiratory rate	CHRM1	UBERON_0002107	""
cardiovascular	activation_acute	HP_0000616	ENSG00000168539	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM1	UBERON_0004535	""
respiratory	activation_acute	HP_0000622	ENSG00000168539	28216264	Lynch et al. (2017)	blurred vision	CHRM1	UBERON_0001004	""
liver	activation_acute	HP_0000616	ENSG00000168539	28216264	Lynch et al. (2017)	decreased pupil diameter	CHRM1	UBERON_0002107	""
respiratory	activation_acute	GO_2000428	ENSG00000168539	28216264	Lynch et al. (2017)	neutrophil collection within the sinusoids	CHRM1	UBERON_0001004	""
liver	activation_acute	HP_0012735	ENSG00000168539	28216264	Lynch et al. (2017)	cough	CHRM1	UBERON_0002107	""
gastrointestinal	activation_acute	HP_0012735	ENSG00000168539	28216264	Lynch et al. (2017)	cough	CHRM1	UBERON_0005409	""
nervous system	activation_acute	HP_0000632	ENSG00000168539	28216264	Lynch et al. (2017)	lacrimation	CHRM1	UBERON_0001016	""
gastrointestinal	activation_acute	GO_0046878	ENSG00000168539	28216264	Lynch et al. (2017)	increased salivation	CHRM1	UBERON_0005409	""
liver	activation_acute	EFO_0004874	ENSG00000168539	28216264	Lynch et al. (2017)	increased memory	CHRM1	UBERON_0002107	""
respiratory	activation_acute	HP_0002017	ENSG00000168539	28216264	Lynch et al. (2017)	vomiting	CHRM1	UBERON_0001004	""
nervous system	activation_acute	EFO_0001421	ENSG00000168539	28216264	Lynch et al. (2017)	centrilobular liver congestion	CHRM1	UBERON_0001016	""
respiratory	activation_acute	""	ENSG00000168539	28216264	Lynch et al. (2017)	frothing	CHRM1	UBERON_0001004	""
respiratory	activation_acute	HP_0000975	ENSG00000168539	28216264	Lynch et al. (2017)	sweating	CHRM1	UBERON_0001004	""
respiratory	activation_acute	GO_0040013	ENSG00000168539	28216264	Lynch et al. (2017)	decreased locomotor activity	CHRM1	UBERON_0001004	""
gastrointestinal	activation_acute	EFO_0009853	ENSG00000168539	28216264	Lynch et al. (2017)	increased convulsions	CHRM1	UBERON_0005409	""
liver	activation_acute	HP_0000632	ENSG00000168539	28216264	Lynch et al. (2017)	lacrimation	CHRM1	UBERON_0002107	""
cardiovascular	activation_acute	EFO_0009852	ENSG00000168539	28216264	Lynch et al. (2017)	exhaustion	CHRM1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001945	ENSG00000168539	28216264	Lynch et al. (2017)	increased body temperature	CHRM1	UBERON_0004535	""
gastrointestinal	activation_acute	GO_0060454	ENSG00000168539	28216264	Lynch et al. (2017)	increased gastric acid secretion	CHRM1	UBERON_0005409	""
nervous system	activation_acute	HP_0025428	ENSG00000168539	28216264	Lynch et al. (2017)	bronchospasm	CHRM1	UBERON_0001016	""
gastrointestinal	activation_acute	GO_2000428	ENSG00000168539	28216264	Lynch et al. (2017)	neutrophil collection within the sinusoids	CHRM1	UBERON_0005409	""
liver	activation_acute	EFO_0009853	ENSG00000168539	28216264	Lynch et al. (2017)	increased convulsions	CHRM1	UBERON_0002107	""
liver	activation_acute	""	ENSG00000168539	28216264	Lynch et al. (2017)	bronchorrhea	CHRM1	UBERON_0002107	""
nervous system	activation_acute	GO_0060454	ENSG00000168539	28216264	Lynch et al. (2017)	increased gastric acid secretion	CHRM1	UBERON_0001016	""
respiratory	activation_acute	GO_0060454	ENSG00000168539	28216264	Lynch et al. (2017)	increased gastric acid secretion	CHRM1	UBERON_0001004	""
nervous system	activation_acute	HP_0012735	ENSG00000168539	28216264	Lynch et al. (2017)	cough	CHRM1	UBERON_0001016	""
nervous system	activation_acute	HP_0001399	ENSG00000168539	28216264	Lynch et al. (2017)	liver failure	CHRM1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0000622	ENSG00000168539	28216264	Lynch et al. (2017)	blurred vision	CHRM1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009852	ENSG00000168539	28216264	Lynch et al. (2017)	exhaustion	CHRM1	UBERON_0005409	""
respiratory	activation_acute	HP_0032155	ENSG00000168539	28216264	Lynch et al. (2017)	abdominal cramps	CHRM1	UBERON_0001004	""
cardiovascular	activation_acute	GO_0060454	ENSG00000168539	28216264	Lynch et al. (2017)	increased gastric acid secretion	CHRM1	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000168539	28216264	Lynch et al. (2017)	decreased locomotor activity	CHRM1	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0001399	ENSG00000168539	28216264	Lynch et al. (2017)	liver failure	CHRM1	UBERON_0005409	""
nervous system	activation_acute	GO_2000428	ENSG00000168539	28216264	Lynch et al. (2017)	neutrophil collection within the sinusoids	CHRM1	UBERON_0001016	""
liver	activation_acute	GO_0060454	ENSG00000168539	28216264	Lynch et al. (2017)	increased gastric acid secretion	CHRM1	UBERON_0002107	""
nervous system	inhibition_acute	HP_0032263	ENSG00000103546	28216264	Lynch et al. (2017)	increased blood pressure	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001649	ENSG00000103546	28216264	Lynch et al. (2017)	increased heart rate	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	HP_0005184	ENSG00000103546	28216264	Lynch et al. (2017)	increased QTc interval	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009872	ENSG00000103546	28216264	Lynch et al. (2017)	increased cardiac output	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0005252	ENSG00000103546	28216264	Lynch et al. (2017)	orthostatic hypotension	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0002503	ENSG00000103546	28216264	Lynch et al. (2017)	ventricular hypertrophy	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	HP_0100738	ENSG00000103546	28216264	Lynch et al. (2017)	decreased eating	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	HP_0002019	ENSG00000103546	28216264	Lynch et al. (2017)	constipation	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	GO_1905747	ENSG00000103546	28216264	Lynch et al. (2017)	decreased salivation	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000019	ENSG00000103546	28216264	Lynch et al. (2017)	urinary hesitancy	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000103546	28216264	Lynch et al. (2017)	decreased pain	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	GO_0040013	ENSG00000103546	28216264	Lynch et al. (2017)	decreased locomotor activity	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0008568	ENSG00000103546	28216264	Lynch et al. (2017)	decreased sleep	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000975	ENSG00000103546	28216264	Lynch et al. (2017)	sweating	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030211	ENSG00000103546	28216264	Lynch et al. (2017)	decreased pupillary reflex	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000622	ENSG00000103546	28216264	Lynch et al. (2017)	blurred vision	SLC6A2	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0003890	ENSG00000103546	28216264	Lynch et al. (2017)	drug abuse/dependence	SLC6A2	UBERON_0001016	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000103546	28216264	Lynch et al. (2017)	increased blood pressure	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000103546	28216264	Lynch et al. (2017)	increased heart rate	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0005184	ENSG00000103546	28216264	Lynch et al. (2017)	increased QTc interval	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009872	ENSG00000103546	28216264	Lynch et al. (2017)	increased cardiac output	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005252	ENSG00000103546	28216264	Lynch et al. (2017)	orthostatic hypotension	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0002503	ENSG00000103546	28216264	Lynch et al. (2017)	ventricular hypertrophy	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0100738	ENSG00000103546	28216264	Lynch et al. (2017)	decreased eating	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002019	ENSG00000103546	28216264	Lynch et al. (2017)	constipation	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1905747	ENSG00000103546	28216264	Lynch et al. (2017)	decreased salivation	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000019	ENSG00000103546	28216264	Lynch et al. (2017)	urinary hesitancy	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000103546	28216264	Lynch et al. (2017)	decreased pain	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040013	ENSG00000103546	28216264	Lynch et al. (2017)	decreased locomotor activity	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000103546	28216264	Lynch et al. (2017)	decreased sleep	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000975	ENSG00000103546	28216264	Lynch et al. (2017)	sweating	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030211	ENSG00000103546	28216264	Lynch et al. (2017)	decreased pupillary reflex	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000622	ENSG00000103546	28216264	Lynch et al. (2017)	blurred vision	SLC6A2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003890	ENSG00000103546	28216264	Lynch et al. (2017)	drug abuse/dependence	SLC6A2	UBERON_0004535	""
cardiovascular system	activation_general	""	ENSG00000163485	""	HeCaToS	cardioprotection	ADORA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000163485	""	HeCaToS	vasodilation	ADORA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	HP_0000103	ENSG00000163485	""	HeCaToS	diuresis	ADORA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	GO_0035812	ENSG00000163485	""	HeCaToS	natriuresis	ADORA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0001662	ENSG00000163485	""	HeCaToS	bradycardia	ADORA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000163485	""	HeCaToS	vasoconstriction	ADORA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009836	ENSG00000163485	""	HeCaToS	bronchoconstriction	ADORA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009843	ENSG00000163485	""	HeCaToS	induction of sleep	ADORA1	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000163485	""	HeCaToS	cardioprotection	ADORA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	""	ENSG00000163485	""	HeCaToS	vasodilation	ADORA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	HP_0000103	ENSG00000163485	""	HeCaToS	diuresis	ADORA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	GO_0035812	ENSG00000163485	""	HeCaToS	natriuresis	ADORA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	HP_0001662	ENSG00000163485	""	HeCaToS	bradycardia	ADORA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000163485	""	HeCaToS	vasoconstriction	ADORA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009836	ENSG00000163485	""	HeCaToS	bronchoconstriction	ADORA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009843	ENSG00000163485	""	HeCaToS	induction of sleep	ADORA1	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
renal	activation_general	""	ENSG00000163485	""	HeCaToS	cardioprotection	ADORA1	UBERON_0001008	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
renal	inhibition_general	""	ENSG00000163485	""	HeCaToS	vasodilation	ADORA1	UBERON_0001008	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
renal	inhibition_general	HP_0000103	ENSG00000163485	""	HeCaToS	diuresis	ADORA1	UBERON_0001008	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
renal	inhibition_general	GO_0035812	ENSG00000163485	""	HeCaToS	natriuresis	ADORA1	UBERON_0001008	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
renal	activation_general	HP_0001662	ENSG00000163485	""	HeCaToS	bradycardia	ADORA1	UBERON_0001008	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
renal	activation_general	""	ENSG00000163485	""	HeCaToS	vasoconstriction	ADORA1	UBERON_0001008	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
renal	activation_general	EFO_0009836	ENSG00000163485	""	HeCaToS	bronchoconstriction	ADORA1	UBERON_0001008	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
renal	activation_general	EFO_0009843	ENSG00000163485	""	HeCaToS	induction of sleep	ADORA1	UBERON_0001008	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
Pharmaco-kinetics	inhibition_acute	EFO_0009878	ENSG00000189221	28216264	Lynch et al. (2017)	drug-drug interactions	MAOA	""	""
Pharmaco-kinetics	inhibition_acute	EFO_0009874	ENSG00000189221	28216264	Lynch et al. (2017)	decreased anxiety	MAOA	""	""
Pharmaco-kinetics	inhibition_acute	EFO_0003015	ENSG00000189221	28216264	Lynch et al. (2017)	decreased aggression	MAOA	""	""
Pharmaco-kinetics	inhibition_acute	EFO_0009847	ENSG00000189221	28216264	Lynch et al. (2017)	dizziness	MAOA	""	""
Pharmaco-kinetics	inhibition_acute	HP_0002018	ENSG00000189221	28216264	Lynch et al. (2017)	nausea	MAOA	""	""
Pharmaco-kinetics	inhibition_acute	EFO_0008568	ENSG00000189221	28216264	Lynch et al. (2017)	sleep disturbances	MAOA	""	""
Pharmaco-kinetics	inhibition_acute	HP_0012378	ENSG00000189221	28216264	Lynch et al. (2017)	fatigue	MAOA	""	""
Pharmaco-kinetics	inhibition_acute	HP_0001324	ENSG00000189221	28216264	Lynch et al. (2017)	weakness	MAOA	""	""
Pharmaco-kinetics	inhibition_acute	HP_0001337	ENSG00000189221	28216264	Lynch et al. (2017)	tremors	MAOA	""	""
central nervous system	inhibition_acute	EFO_0009878	ENSG00000189221	28216264	Lynch et al. (2017)	drug-drug interactions	MAOA	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009874	ENSG00000189221	28216264	Lynch et al. (2017)	decreased anxiety	MAOA	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003015	ENSG00000189221	28216264	Lynch et al. (2017)	decreased aggression	MAOA	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009847	ENSG00000189221	28216264	Lynch et al. (2017)	dizziness	MAOA	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0002018	ENSG00000189221	28216264	Lynch et al. (2017)	nausea	MAOA	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000189221	28216264	Lynch et al. (2017)	sleep disturbances	MAOA	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0012378	ENSG00000189221	28216264	Lynch et al. (2017)	fatigue	MAOA	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001324	ENSG00000189221	28216264	Lynch et al. (2017)	weakness	MAOA	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001337	ENSG00000189221	28216264	Lynch et al. (2017)	tremors	MAOA	UBERON_0001017	""
pancreas	activation_acute	GO_0060455	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric acid secretion	OPRM1	UBERON_0001264	""
pancreas	inhibition_acute	EFO_0003843	ENSG00000112038	28216264	Lynch et al. (2017)	pain	OPRM1	UBERON_0001264	""
pancreas	inhibition_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased convulsions	OPRM1	UBERON_0001264	""
pancreas	inhibition_acute	HP_0001649	ENSG00000112038	28216264	Lynch et al. (2017)	increased heart rate	OPRM1	UBERON_0001264	""
pancreas	inhibition_acute	HP_0032263	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood pressure	OPRM1	UBERON_0001264	""
pancreas	inhibition_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0001264	""
pancreas	inhibition_acute	HP_0410204	ENSG00000112038	28216264	Lynch et al. (2017)	increased gastrointestinal transit	OPRM1	UBERON_0001264	""
pancreas	inhibition_acute	EFO_0008533	ENSG00000112038	28216264	Lynch et al. (2017)	dyspepsia	OPRM1	UBERON_0001264	""
pancreas	inhibition_acute	EFO_0009669	ENSG00000112038	28216264	Lynch et al. (2017)	gas	OPRM1	UBERON_0001264	""
pancreas	activation_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased convulsions	OPRM1	UBERON_0001264	""
respiratory	activation_acute	HP_0004370	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased body temperature	OPRM1	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0003843	ENSG00000112038	28216264	Lynch et al. (2017)	pain	OPRM1	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased convulsions	OPRM1	UBERON_0001004	""
respiratory	inhibition_acute	HP_0001649	ENSG00000112038	28216264	Lynch et al. (2017)	increased heart rate	OPRM1	UBERON_0001004	""
respiratory	inhibition_acute	HP_0032263	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood pressure	OPRM1	UBERON_0001004	""
respiratory	inhibition_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0001004	""
respiratory	inhibition_acute	HP_0410204	ENSG00000112038	28216264	Lynch et al. (2017)	increased gastrointestinal transit	OPRM1	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0008533	ENSG00000112038	28216264	Lynch et al. (2017)	dyspepsia	OPRM1	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009669	ENSG00000112038	28216264	Lynch et al. (2017)	gas	OPRM1	UBERON_0001004	""
gastrointestinal	activation_acute	GO_0060455	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric acid secretion	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0003843	ENSG00000112038	28216264	Lynch et al. (2017)	pain	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased convulsions	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0001649	ENSG00000112038	28216264	Lynch et al. (2017)	increased heart rate	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0032263	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood pressure	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0410204	ENSG00000112038	28216264	Lynch et al. (2017)	increased gastrointestinal transit	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0008533	ENSG00000112038	28216264	Lynch et al. (2017)	dyspepsia	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009669	ENSG00000112038	28216264	Lynch et al. (2017)	gas	OPRM1	UBERON_0005409	""
respiratory	activation_acute	HP_0001662	ENSG00000112038	28216264	Lynch et al. (2017)	decreased heart rate	OPRM1	UBERON_0001004	""
respiratory	activation_acute	HP_0003074	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood glucose	OPRM1	UBERON_0001004	""
respiratory	activation_acute	GO_0060455	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric acid secretion	OPRM1	UBERON_0001004	""
nervous system	activation_acute	EFO_0003890	ENSG00000112038	28216264	Lynch et al. (2017)	drug abuse/dependence	OPRM1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0003843	ENSG00000112038	28216264	Lynch et al. (2017)	pain	OPRM1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased convulsions	OPRM1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001649	ENSG00000112038	28216264	Lynch et al. (2017)	increased heart rate	OPRM1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0032263	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood pressure	OPRM1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0410204	ENSG00000112038	28216264	Lynch et al. (2017)	increased gastrointestinal transit	OPRM1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0008533	ENSG00000112038	28216264	Lynch et al. (2017)	dyspepsia	OPRM1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009669	ENSG00000112038	28216264	Lynch et al. (2017)	gas	OPRM1	UBERON_0001016	""
nervous system	activation_acute	HP_0004370	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased body temperature	OPRM1	UBERON_0001016	""
pancreas	activation_acute	EFO_0009872	ENSG00000112038	28216264	Lynch et al. (2017)	decreased cardiac output	OPRM1	UBERON_0001264	""
gastrointestinal	activation_acute	""	ENSG00000112038	28216264	Lynch et al. (2017)	scratching	OPRM1	UBERON_0005409	""
renal	activation_acute	HP_0000842	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood insulin	OPRM1	UBERON_0001008	""
renal	inhibition_acute	EFO_0003843	ENSG00000112038	28216264	Lynch et al. (2017)	pain	OPRM1	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased convulsions	OPRM1	UBERON_0001008	""
renal	inhibition_acute	HP_0001649	ENSG00000112038	28216264	Lynch et al. (2017)	increased heart rate	OPRM1	UBERON_0001008	""
renal	inhibition_acute	HP_0032263	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood pressure	OPRM1	UBERON_0001008	""
renal	inhibition_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0001008	""
renal	inhibition_acute	HP_0410204	ENSG00000112038	28216264	Lynch et al. (2017)	increased gastrointestinal transit	OPRM1	UBERON_0001008	""
renal	inhibition_acute	EFO_0008533	ENSG00000112038	28216264	Lynch et al. (2017)	dyspepsia	OPRM1	UBERON_0001008	""
renal	inhibition_acute	EFO_0009669	ENSG00000112038	28216264	Lynch et al. (2017)	gas	OPRM1	UBERON_0001008	""
renal	activation_acute	GO_0060455	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric acid secretion	OPRM1	UBERON_0001008	""
nervous system	activation_acute	HP_0001662	ENSG00000112038	28216264	Lynch et al. (2017)	decreased heart rate	OPRM1	UBERON_0001016	""
respiratory	activation_acute	HP_0007686	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased pupil diameter	OPRM1	UBERON_0001004	""
renal	activation_acute	HP_0030972	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased blood pressure	OPRM1	UBERON_0001008	""
renal	activation_acute	EFO_0009872	ENSG00000112038	28216264	Lynch et al. (2017)	decreased cardiac output	OPRM1	UBERON_0001008	""
respiratory	activation_acute	HP_0030972	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased blood pressure	OPRM1	UBERON_0001004	""
nervous system	activation_acute	EFO_0009839	ENSG00000112038	28216264	Lynch et al. (2017)	decreased respiratory rate	OPRM1	UBERON_0001016	""
respiratory	activation_acute	HP_0030897	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	OPRM1	UBERON_0001004	""
gastrointestinal	activation_acute	HP_0001662	ENSG00000112038	28216264	Lynch et al. (2017)	decreased heart rate	OPRM1	UBERON_0005409	""
renal	activation_acute	GO_1904057	ENSG00000112038	28216264	Lynch et al. (2017)	decreased pain	OPRM1	UBERON_0001008	""
pancreas	activation_acute	HP_0001662	ENSG00000112038	28216264	Lynch et al. (2017)	decreased heart rate	OPRM1	UBERON_0001264	""
nervous system	activation_acute	GO_1904057	ENSG00000112038	28216264	Lynch et al. (2017)	decreased pain	OPRM1	UBERON_0001016	""
respiratory	activation_acute	GO_1904057	ENSG00000112038	28216264	Lynch et al. (2017)	decreased pain	OPRM1	UBERON_0001004	""
renal	activation_acute	HP_0000103	ENSG00000112038	28216264	Lynch et al. (2017)	increased urine excretion	OPRM1	UBERON_0001008	""
gastrointestinal	activation_acute	EFO_0004874	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased memory	OPRM1	UBERON_0005409	""
cardiovascular	activation_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003843	ENSG00000112038	28216264	Lynch et al. (2017)	pain	OPRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased convulsions	OPRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000112038	28216264	Lynch et al. (2017)	increased heart rate	OPRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood pressure	OPRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0410204	ENSG00000112038	28216264	Lynch et al. (2017)	increased gastrointestinal transit	OPRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008533	ENSG00000112038	28216264	Lynch et al. (2017)	dyspepsia	OPRM1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009669	ENSG00000112038	28216264	Lynch et al. (2017)	gas	OPRM1	UBERON_0004535	""
pancreas	activation_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0001264	""
renal	activation_acute	""	ENSG00000112038	28216264	Lynch et al. (2017)	scratching	OPRM1	UBERON_0001008	""
renal	activation_acute	HP_0007686	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased pupil diameter	OPRM1	UBERON_0001008	""
cardiovascular	activation_acute	HP_0030972	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased blood pressure	OPRM1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0030897	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	OPRM1	UBERON_0004535	""
respiratory	activation_acute	EFO_0009839	ENSG00000112038	28216264	Lynch et al. (2017)	decreased respiratory rate	OPRM1	UBERON_0001004	""
respiratory	activation_acute	HP_0000103	ENSG00000112038	28216264	Lynch et al. (2017)	increased urine excretion	OPRM1	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009839	ENSG00000112038	28216264	Lynch et al. (2017)	decreased respiratory rate	OPRM1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000112038	28216264	Lynch et al. (2017)	decreased anxiety	OPRM1	UBERON_0004535	""
nervous system	activation_acute	HP_0030972	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased blood pressure	OPRM1	UBERON_0001016	""
renal	activation_acute	GO_0035815	ENSG00000112038	28216264	Lynch et al. (2017)	increased urinary sodium excretion	OPRM1	UBERON_0001008	""
pancreas	activation_acute	HP_0007686	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased pupil diameter	OPRM1	UBERON_0001264	""
gastrointestinal	activation_acute	EFO_0009872	ENSG00000112038	28216264	Lynch et al. (2017)	decreased cardiac output	OPRM1	UBERON_0005409	""
pancreas	activation_acute	HP_0030972	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased blood pressure	OPRM1	UBERON_0001264	""
cardiovascular	activation_acute	EFO_0004874	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased memory	OPRM1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0004370	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased body temperature	OPRM1	UBERON_0004535	""
pancreas	activation_acute	EFO_0009874	ENSG00000112038	28216264	Lynch et al. (2017)	decreased anxiety	OPRM1	UBERON_0001264	""
gastrointestinal	activation_acute	HP_0030897	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	OPRM1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009868	ENSG00000112038	28216264	Lynch et al. (2017)	sedation	OPRM1	UBERON_0005409	""
respiratory	activation_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0001004	""
gastrointestinal	activation_acute	GO_1904057	ENSG00000112038	28216264	Lynch et al. (2017)	decreased pain	OPRM1	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000112038	28216264	Lynch et al. (2017)	drug abuse/dependence	OPRM1	UBERON_0004535	""
renal	activation_acute	HP_0001662	ENSG00000112038	28216264	Lynch et al. (2017)	decreased heart rate	OPRM1	UBERON_0001008	""
gastrointestinal	activation_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0003890	ENSG00000112038	28216264	Lynch et al. (2017)	drug abuse/dependence	OPRM1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009874	ENSG00000112038	28216264	Lynch et al. (2017)	decreased anxiety	OPRM1	UBERON_0005409	""
nervous system	activation_acute	EFO_0009874	ENSG00000112038	28216264	Lynch et al. (2017)	decreased anxiety	OPRM1	UBERON_0001016	""
pancreas	activation_acute	EFO_0003890	ENSG00000112038	28216264	Lynch et al. (2017)	drug abuse/dependence	OPRM1	UBERON_0001264	""
cardiovascular	activation_acute	""	ENSG00000112038	28216264	Lynch et al. (2017)	scratching	OPRM1	UBERON_0004535	""
nervous system	activation_acute	GO_0035815	ENSG00000112038	28216264	Lynch et al. (2017)	increased urinary sodium excretion	OPRM1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0000103	ENSG00000112038	28216264	Lynch et al. (2017)	increased urine excretion	OPRM1	UBERON_0005409	""
nervous system	activation_acute	HP_0030897	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	OPRM1	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_0009839	ENSG00000112038	28216264	Lynch et al. (2017)	decreased respiratory rate	OPRM1	UBERON_0005409	""
pancreas	activation_acute	EFO_0004874	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased memory	OPRM1	UBERON_0001264	""
respiratory	activation_acute	EFO_0009868	ENSG00000112038	28216264	Lynch et al. (2017)	sedation	OPRM1	UBERON_0001004	""
pancreas	activation_acute	HP_0030897	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	OPRM1	UBERON_0001264	""
nervous system	activation_acute	HP_0007686	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased pupil diameter	OPRM1	UBERON_0001016	""
renal	activation_acute	HP_0004370	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased body temperature	OPRM1	UBERON_0001008	""
renal	activation_acute	EFO_0009839	ENSG00000112038	28216264	Lynch et al. (2017)	decreased respiratory rate	OPRM1	UBERON_0001008	""
pancreas	activation_acute	EFO_0009868	ENSG00000112038	28216264	Lynch et al. (2017)	sedation	OPRM1	UBERON_0001264	""
gastrointestinal	activation_acute	HP_0030972	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased blood pressure	OPRM1	UBERON_0005409	""
cardiovascular	activation_acute	HP_0000103	ENSG00000112038	28216264	Lynch et al. (2017)	increased urine excretion	OPRM1	UBERON_0004535	""
nervous system	activation_acute	""	ENSG00000112038	28216264	Lynch et al. (2017)	scratching	OPRM1	UBERON_0001016	""
renal	activation_acute	HP_0003074	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood glucose	OPRM1	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0009868	ENSG00000112038	28216264	Lynch et al. (2017)	sedation	OPRM1	UBERON_0004535	""
nervous system	activation_acute	HP_0003074	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood glucose	OPRM1	UBERON_0001016	""
cardiovascular	activation_acute	GO_1904057	ENSG00000112038	28216264	Lynch et al. (2017)	decreased pain	OPRM1	UBERON_0004535	""
respiratory	activation_acute	EFO_0004874	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased memory	OPRM1	UBERON_0001004	""
cardiovascular	activation_acute	GO_0035815	ENSG00000112038	28216264	Lynch et al. (2017)	increased urinary sodium excretion	OPRM1	UBERON_0004535	""
pancreas	activation_acute	HP_0000103	ENSG00000112038	28216264	Lynch et al. (2017)	increased urine excretion	OPRM1	UBERON_0001264	""
respiratory	activation_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased convulsions	OPRM1	UBERON_0001004	""
cardiovascular	activation_acute	HP_0001662	ENSG00000112038	28216264	Lynch et al. (2017)	decreased heart rate	OPRM1	UBERON_0004535	""
renal	activation_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0001008	""
cardiovascular	activation_acute	HP_0000842	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood insulin	OPRM1	UBERON_0004535	""
nervous system	activation_acute	GO_0060455	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric acid secretion	OPRM1	UBERON_0001016	""
respiratory	activation_acute	EFO_0003890	ENSG00000112038	28216264	Lynch et al. (2017)	drug abuse/dependence	OPRM1	UBERON_0001004	""
pancreas	activation_acute	GO_0035815	ENSG00000112038	28216264	Lynch et al. (2017)	increased urinary sodium excretion	OPRM1	UBERON_0001264	""
renal	activation_acute	HP_0030897	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	OPRM1	UBERON_0001008	""
gastrointestinal	activation_acute	HP_0003074	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood glucose	OPRM1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased convulsions	OPRM1	UBERON_0005409	""
respiratory	activation_acute	GO_0035815	ENSG00000112038	28216264	Lynch et al. (2017)	increased urinary sodium excretion	OPRM1	UBERON_0001004	""
nervous system	activation_acute	EFO_0009872	ENSG00000112038	28216264	Lynch et al. (2017)	decreased cardiac output	OPRM1	UBERON_0001016	""
renal	activation_acute	EFO_0009874	ENSG00000112038	28216264	Lynch et al. (2017)	decreased anxiety	OPRM1	UBERON_0001008	""
gastrointestinal	activation_acute	GO_0035815	ENSG00000112038	28216264	Lynch et al. (2017)	increased urinary sodium excretion	OPRM1	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased convulsions	OPRM1	UBERON_0004535	""
nervous system	activation_acute	HP_0000103	ENSG00000112038	28216264	Lynch et al. (2017)	increased urine excretion	OPRM1	UBERON_0001016	""
renal	activation_acute	EFO_0004874	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased memory	OPRM1	UBERON_0001008	""
nervous system	activation_acute	EFO_0004874	ENSG00000112038	28216264	Lynch et al. (2017)	increased/decreased memory	OPRM1	UBERON_0001016	""
nervous system	activation_acute	HP_0000842	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood insulin	OPRM1	UBERON_0001016	""
cardiovascular	activation_acute	GO_0060455	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric acid secretion	OPRM1	UBERON_0004535	""
pancreas	activation_acute	""	ENSG00000112038	28216264	Lynch et al. (2017)	scratching	OPRM1	UBERON_0001264	""
nervous system	activation_acute	GO_0120061	ENSG00000112038	28216264	Lynch et al. (2017)	decreased gastric emptying	OPRM1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0000842	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood insulin	OPRM1	UBERON_0005409	""
respiratory	activation_acute	""	ENSG00000112038	28216264	Lynch et al. (2017)	scratching	OPRM1	UBERON_0001004	""
cardiovascular	activation_acute	HP_0007686	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased pupil diameter	OPRM1	UBERON_0004535	""
respiratory	activation_acute	HP_0000842	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood insulin	OPRM1	UBERON_0001004	""
nervous system	activation_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased convulsions	OPRM1	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009872	ENSG00000112038	28216264	Lynch et al. (2017)	decreased cardiac output	OPRM1	UBERON_0004535	""
pancreas	activation_acute	EFO_0009839	ENSG00000112038	28216264	Lynch et al. (2017)	decreased respiratory rate	OPRM1	UBERON_0001264	""
renal	activation_acute	EFO_0009853	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased convulsions	OPRM1	UBERON_0001008	""
respiratory	activation_acute	EFO_0009872	ENSG00000112038	28216264	Lynch et al. (2017)	decreased cardiac output	OPRM1	UBERON_0001004	""
pancreas	activation_acute	HP_0004370	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased body temperature	OPRM1	UBERON_0001264	""
gastrointestinal	activation_acute	HP_0007686	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased pupil diameter	OPRM1	UBERON_0005409	""
pancreas	activation_acute	HP_0003074	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood glucose	OPRM1	UBERON_0001264	""
nervous system	activation_acute	EFO_0009868	ENSG00000112038	28216264	Lynch et al. (2017)	sedation	OPRM1	UBERON_0001016	""
renal	activation_acute	EFO_0003890	ENSG00000112038	28216264	Lynch et al. (2017)	drug abuse/dependence	OPRM1	UBERON_0001008	""
gastrointestinal	activation_acute	HP_0004370	ENSG00000112038	28216264	Lynch et al. (2017)	decreased/increased body temperature	OPRM1	UBERON_0005409	""
pancreas	activation_acute	HP_0000842	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood insulin	OPRM1	UBERON_0001264	""
cardiovascular	activation_acute	HP_0003074	ENSG00000112038	28216264	Lynch et al. (2017)	increased blood glucose	OPRM1	UBERON_0004535	""
renal	activation_acute	EFO_0009868	ENSG00000112038	28216264	Lynch et al. (2017)	sedation	OPRM1	UBERON_0001008	""
pancreas	activation_acute	GO_1904057	ENSG00000112038	28216264	Lynch et al. (2017)	decreased pain	OPRM1	UBERON_0001264	""
respiratory	activation_acute	EFO_0009874	ENSG00000112038	28216264	Lynch et al. (2017)	decreased anxiety	OPRM1	UBERON_0001004	""
nervous system	activation_general	GO_0090331	ENSG00000128271	""	HeCaToS	inhibition of platelet aggregation	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	GO_1901731	ENSG00000128271	""	HeCaToS	increased platelet aggregation	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0000537	ENSG00000128271	""	HeCaToS	hypertension	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	NCIT_C74532	ENSG00000128271	""	HeCaToS	nervousness (tremors, agitation)	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0009849	ENSG00000128271	""	HeCaToS	arousal	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	EFO_0004698	ENSG00000128271	""	HeCaToS	insomnia	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	inhibition_general	""	ENSG00000128271	""	HeCaToS	cerebral and coronary vasodilation (in microvessels only)	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	GO_0050728	ENSG00000128271	""	HeCaToS	antiinflammation	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000128271	""	HeCaToS	neuroprotective effects	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	""	ENSG00000128271	""	HeCaToS	coronary vasodilation	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0005251	ENSG00000128271	""	HeCaToS	decreased blood pressure	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	GO_1900135	ENSG00000128271	""	HeCaToS	increased plasma renin activity	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
nervous system	activation_general	EFO_0009843	ENSG00000128271	""	HeCaToS	sleep induction	ADORA2A	UBERON_0001016	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0090331	ENSG00000128271	""	HeCaToS	inhibition of platelet aggregation	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	GO_1901731	ENSG00000128271	""	HeCaToS	increased platelet aggregation	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0000537	ENSG00000128271	""	HeCaToS	hypertension	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	NCIT_C74532	ENSG00000128271	""	HeCaToS	nervousness (tremors, agitation)	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0009849	ENSG00000128271	""	HeCaToS	arousal	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	EFO_0004698	ENSG00000128271	""	HeCaToS	insomnia	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	inhibition_general	""	ENSG00000128271	""	HeCaToS	cerebral and coronary vasodilation (in microvessels only)	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_0050728	ENSG00000128271	""	HeCaToS	antiinflammation	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000128271	""	HeCaToS	neuroprotective effects	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	""	ENSG00000128271	""	HeCaToS	coronary vasodilation	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0005251	ENSG00000128271	""	HeCaToS	decreased blood pressure	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	GO_1900135	ENSG00000128271	""	HeCaToS	increased plasma renin activity	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0009843	ENSG00000128271	""	HeCaToS	sleep induction	ADORA2A	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	EFO_0000275	ENSG00000053918	""	Urban et al. (2012)	atrial fibrillation	KCNQ1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	MONDO_0002442	ENSG00000053918	""	Urban et al. (2012)	long QT syndrome	KCNQ1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0004238	ENSG00000053918	""	Urban et al. (2012)	hearing impairment	KCNQ1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0001063	ENSG00000053918	""	Urban et al. (2012)	deafness	KCNQ1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0012719	ENSG00000053918	""	Urban et al. (2012)	gastrointestinal symptoms	KCNQ1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
urogenital	activation_acute	HP_0000130	ENSG00000125384	28216264	Lynch et al. (2017)	decreased uterine motility	PTGER2	UBERON_0004122	""
urogenital	inhibition_acute	GO_0050727	ENSG00000125384	28216264	Lynch et al. (2017)	decreased/increased inflammation	PTGER2	UBERON_0004122	""
immune	activation_acute	GO_0050727	ENSG00000125384	28216264	Lynch et al. (2017)	increased/decreased inflammation	PTGER2	UBERON_0002405	""
immune	inhibition_acute	GO_0050727	ENSG00000125384	28216264	Lynch et al. (2017)	decreased/increased inflammation	PTGER2	UBERON_0002405	""
immune	activation_acute	HP_0000130	ENSG00000125384	28216264	Lynch et al. (2017)	decreased uterine motility	PTGER2	UBERON_0002405	""
urogenital	activation_acute	GO_0050727	ENSG00000125384	28216264	Lynch et al. (2017)	increased/decreased inflammation	PTGER2	UBERON_0004122	""
renal	activation_acute	EFO_0004269	ENSG00000163485	28216264	Lynch et al. (2017)	cardiac arrhythmia	ADORA1	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000163485	28216264	Lynch et al. (2017)	convulsions	ADORA1	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000163485	28216264	Lynch et al. (2017)	increased urine excretion	ADORA1	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000163485	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ADORA1	UBERON_0001008	""
nervous system	activation_acute	EFO_0004269	ENSG00000163485	28216264	Lynch et al. (2017)	cardiac arrhythmia	ADORA1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000163485	28216264	Lynch et al. (2017)	convulsions	ADORA1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0000103	ENSG00000163485	28216264	Lynch et al. (2017)	increased urine excretion	ADORA1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0035815	ENSG00000163485	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ADORA1	UBERON_0001016	""
renal	activation_acute	MONDO_0000465	ENSG00000163485	28216264	Lynch et al. (2017)	atrioventricular block	ADORA1	UBERON_0001008	""
nervous system	activation_acute	MONDO_0000465	ENSG00000163485	28216264	Lynch et al. (2017)	atrioventricular block	ADORA1	UBERON_0001016	""
renal	activation_acute	EFO_0003144	ENSG00000163485	28216264	Lynch et al. (2017)	heart failure	ADORA1	UBERON_0001008	""
renal	activation_acute	EFO_0005251	ENSG00000163485	28216264	Lynch et al. (2017)	decreased blood pressure	ADORA1	UBERON_0001008	""
renal	activation_acute	EFO_0000480	ENSG00000163485	28216264	Lynch et al. (2017)	death	ADORA1	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000163485	28216264	Lynch et al. (2017)	decreased blood pressure	ADORA1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000163485	28216264	Lynch et al. (2017)	convulsions	ADORA1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000163485	28216264	Lynch et al. (2017)	increased urine excretion	ADORA1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000163485	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ADORA1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003144	ENSG00000163485	28216264	Lynch et al. (2017)	heart failure	ADORA1	UBERON_0004535	""
nervous system	activation_acute	GO_1904057	ENSG00000163485	28216264	Lynch et al. (2017)	decreased pain	ADORA1	UBERON_0001016	""
nervous system	activation_acute	EFO_0000480	ENSG00000163485	28216264	Lynch et al. (2017)	death	ADORA1	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0000480	ENSG00000163485	28216264	Lynch et al. (2017)	death	ADORA1	UBERON_0004535	""
nervous system	activation_acute	HP_0001662	ENSG00000163485	28216264	Lynch et al. (2017)	decreased heart rate	ADORA1	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0004269	ENSG00000163485	28216264	Lynch et al. (2017)	cardiac arrhythmia	ADORA1	UBERON_0004535	""
renal	activation_acute	GO_1904057	ENSG00000163485	28216264	Lynch et al. (2017)	decreased pain	ADORA1	UBERON_0001008	""
nervous system	activation_acute	EFO_0005251	ENSG00000163485	28216264	Lynch et al. (2017)	decreased blood pressure	ADORA1	UBERON_0001016	""
nervous system	activation_acute	EFO_0003144	ENSG00000163485	28216264	Lynch et al. (2017)	heart failure	ADORA1	UBERON_0001016	""
cardiovascular	activation_acute	MONDO_0000465	ENSG00000163485	28216264	Lynch et al. (2017)	atrioventricular block	ADORA1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001662	ENSG00000163485	28216264	Lynch et al. (2017)	decreased heart rate	ADORA1	UBERON_0004535	""
cardiovascular	activation_acute	GO_1904057	ENSG00000163485	28216264	Lynch et al. (2017)	decreased pain	ADORA1	UBERON_0004535	""
renal	activation_acute	HP_0001662	ENSG00000163485	28216264	Lynch et al. (2017)	decreased heart rate	ADORA1	UBERON_0001008	""
cardiovascular system	activation_general	GO_0090331	ENSG00000128271	""	Urban et al. (2012)	inhibition of platelet aggregation	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	GO_1901731	ENSG00000128271	""	Urban et al. (2012)	increased platelet aggregation	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000537	ENSG00000128271	""	Urban et al. (2012)	hypertension	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	NCIT_C74532	ENSG00000128271	""	Urban et al. (2012)	nervousness (tremors, agitation)	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0009849	ENSG00000128271	""	Urban et al. (2012)	arousal	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0004698	ENSG00000128271	""	Urban et al. (2012)	insomnia	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000128271	""	Urban et al. (2012)	cerebral and coronary vasodilation (in microvessels only)	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0050728	ENSG00000128271	""	Urban et al. (2012)	antiinflammation	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000128271	""	Urban et al. (2012)	neuroprotective effects	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000128271	""	Urban et al. (2012)	coronary vasodilation	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0005251	ENSG00000128271	""	Urban et al. (2012)	decreased blood pressure	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_1900135	ENSG00000128271	""	Urban et al. (2012)	increased plasma renin activity	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009843	ENSG00000128271	""	Urban et al. (2012)	sleep induction	ADORA2A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	GO_0090331	ENSG00000128271	""	Urban et al. (2012)	inhibition of platelet aggregation	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	GO_1901731	ENSG00000128271	""	Urban et al. (2012)	increased platelet aggregation	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0000537	ENSG00000128271	""	Urban et al. (2012)	hypertension	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	NCIT_C74532	ENSG00000128271	""	Urban et al. (2012)	nervousness (tremors, agitation)	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0009849	ENSG00000128271	""	Urban et al. (2012)	arousal	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0004698	ENSG00000128271	""	Urban et al. (2012)	insomnia	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	""	ENSG00000128271	""	Urban et al. (2012)	cerebral and coronary vasodilation (in microvessels only)	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	GO_0050728	ENSG00000128271	""	Urban et al. (2012)	antiinflammation	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000128271	""	Urban et al. (2012)	neuroprotective effects	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000128271	""	Urban et al. (2012)	coronary vasodilation	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0005251	ENSG00000128271	""	Urban et al. (2012)	decreased blood pressure	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	GO_1900135	ENSG00000128271	""	Urban et al. (2012)	increased plasma renin activity	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009843	ENSG00000128271	""	Urban et al. (2012)	sleep induction	ADORA2A	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	MONDO_0002442	ENSG00000183873	""	Urban et al. (2012)	long QT	SCN5A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0004269	ENSG00000183873	""	Urban et al. (2012)	arrhythmias	SCN5A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0005307	ENSG00000183873	""	Urban et al. (2012)	TdP	SCN5A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	MONDO_0020575	ENSG00000183873	""	Urban et al. (2012)	polymorphic ventricular tachycardia	SCN5A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
central nervous system	activation_acute	EFO_0009874	ENSG00000169083	28216264	Lynch et al. (2017)	decreased anxiety	AR	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0004566	ENSG00000169083	28216264	Lynch et al. (2017)	increased body weight	AR	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0002614	ENSG00000169083	28216264	Lynch et al. (2017)	insulin resistance	AR	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0004211	ENSG00000169083	28216264	Lynch et al. (2017)	increased triglycerides	AR	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0031217	ENSG00000169083	28216264	Lynch et al. (2017)	hot flashes	AR	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0004714	ENSG00000169083	28216264	Lynch et al. (2017)	sexual dysfunction	AR	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0002653	ENSG00000169083	28216264	Lynch et al. (2017)	bone pain	AR	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003882	ENSG00000169083	28216264	Lynch et al. (2017)	osteoporosis	AR	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009870	ENSG00000169083	28216264	Lynch et al. (2017)	bone metastasis	AR	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0004272	ENSG00000169083	28216264	Lynch et al. (2017)	anemia	AR	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0001072	ENSG00000169083	28216264	Lynch et al. (2017)	decreased memory	AR	UBERON_0001017	""
central nervous system	inhibition_acute	NCIT_C117245	ENSG00000169083	28216264	Lynch et al. (2017)	decreased attention	AR	UBERON_0001017	""
central nervous system	inhibition_acute	MONDO_0002050	ENSG00000169083	28216264	Lynch et al. (2017)	depression	AR	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0000612	ENSG00000169083	28216264	Lynch et al. (2017)	heart attack	AR	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0000480	ENSG00000169083	28216264	Lynch et al. (2017)	death	AR	UBERON_0001017	""
central nervous system	activation_acute	EFO_0003890	ENSG00000169083	28216264	Lynch et al. (2017)	drug abuse/dependence	AR	UBERON_0001017	""
endocrine	activation_acute	EFO_0003890	ENSG00000169083	28216264	Lynch et al. (2017)	drug abuse/dependence	AR	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0004566	ENSG00000169083	28216264	Lynch et al. (2017)	increased body weight	AR	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0002614	ENSG00000169083	28216264	Lynch et al. (2017)	insulin resistance	AR	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0004211	ENSG00000169083	28216264	Lynch et al. (2017)	increased triglycerides	AR	UBERON_0000949	""
endocrine	inhibition_acute	HP_0031217	ENSG00000169083	28216264	Lynch et al. (2017)	hot flashes	AR	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0004714	ENSG00000169083	28216264	Lynch et al. (2017)	sexual dysfunction	AR	UBERON_0000949	""
endocrine	inhibition_acute	HP_0002653	ENSG00000169083	28216264	Lynch et al. (2017)	bone pain	AR	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0003882	ENSG00000169083	28216264	Lynch et al. (2017)	osteoporosis	AR	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0009870	ENSG00000169083	28216264	Lynch et al. (2017)	bone metastasis	AR	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0004272	ENSG00000169083	28216264	Lynch et al. (2017)	anemia	AR	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0001072	ENSG00000169083	28216264	Lynch et al. (2017)	decreased memory	AR	UBERON_0000949	""
endocrine	inhibition_acute	NCIT_C117245	ENSG00000169083	28216264	Lynch et al. (2017)	decreased attention	AR	UBERON_0000949	""
endocrine	inhibition_acute	MONDO_0002050	ENSG00000169083	28216264	Lynch et al. (2017)	depression	AR	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0000612	ENSG00000169083	28216264	Lynch et al. (2017)	heart attack	AR	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0000480	ENSG00000169083	28216264	Lynch et al. (2017)	death	AR	UBERON_0000949	""
endocrine	activation_acute	EFO_0009874	ENSG00000169083	28216264	Lynch et al. (2017)	decreased anxiety	AR	UBERON_0000949	""
cardiovascular system	activation_general	HP_0032263	ENSG00000151617	23197038	Bowes et al. (2012)	increased blood pressure	EDNRA	UBERON_0004535	""
cardiovascular system	inhibition_developmental toxicity	EFO_0009880	ENSG00000151617	23197038	Bowes et al. (2012)	teratogenicity	EDNRA	UBERON_0004535	""
cardiovascular system	activation_general	GO_0035932	ENSG00000151617	23197038	Bowes et al. (2012)	aldosterone secretion	EDNRA	UBERON_0004535	""
cardiovascular system	activation_general	GO_0033687	ENSG00000151617	23197038	Bowes et al. (2012)	osteoblast proliferation	EDNRA	UBERON_0004535	""
development	activation_general	HP_0032263	ENSG00000151617	23197038	Bowes et al. (2012)	increased blood pressure	EDNRA	""	""
development	inhibition_developmental toxicity	EFO_0009880	ENSG00000151617	23197038	Bowes et al. (2012)	teratogenicity	EDNRA	""	""
development	activation_general	GO_0035932	ENSG00000151617	23197038	Bowes et al. (2012)	aldosterone secretion	EDNRA	""	""
development	activation_general	GO_0033687	ENSG00000151617	23197038	Bowes et al. (2012)	osteoblast proliferation	EDNRA	""	""
cardiovascular system	activation_general	GO_0006939	ENSG00000102468	23197038	Bowes et al. (2012)	smooth muscle contraction	HTR2A	UBERON_0004535	""
cardiovascular system	activation_general	GO_0070527	ENSG00000102468	23197038	Bowes et al. (2012)	platelet aggregation	HTR2A	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0001072	ENSG00000102468	23197038	Bowes et al. (2012)	potential memory impairments	HTR2A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0000738	ENSG00000102468	23197038	Bowes et al. (2012)	hallucinations	HTR2A	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0000692	ENSG00000102468	23197038	Bowes et al. (2012)	schizophrenia	HTR2A	UBERON_0004535	""
cardiovascular system	activation_general	EFO_1001842	ENSG00000102468	23197038	Bowes et al. (2012)	serotonin syndrome	HTR2A	UBERON_0004535	""
central nervous system	activation_general	GO_0006939	ENSG00000102468	23197038	Bowes et al. (2012)	smooth muscle contraction	HTR2A	UBERON_0001017	""
central nervous system	activation_general	GO_0070527	ENSG00000102468	23197038	Bowes et al. (2012)	platelet aggregation	HTR2A	UBERON_0001017	""
central nervous system	activation_general	EFO_0001072	ENSG00000102468	23197038	Bowes et al. (2012)	potential memory impairments	HTR2A	UBERON_0001017	""
central nervous system	activation_general	HP_0000738	ENSG00000102468	23197038	Bowes et al. (2012)	hallucinations	HTR2A	UBERON_0001017	""
central nervous system	activation_general	EFO_0000692	ENSG00000102468	23197038	Bowes et al. (2012)	schizophrenia	HTR2A	UBERON_0001017	""
central nervous system	activation_general	EFO_1001842	ENSG00000102468	23197038	Bowes et al. (2012)	serotonin syndrome	HTR2A	UBERON_0001017	""
cardiovascular system	activation_general	EFO_0009868	ENSG00000112038	23197038	Bowes et al. (2012)	sedation	OPRM1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0030895	ENSG00000112038	23197038	Bowes et al. (2012)	increased gastrointestinal motility	OPRM1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0008533	ENSG00000112038	23197038	Bowes et al. (2012)	dyspepsia	OPRM1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009669	ENSG00000112038	23197038	Bowes et al. (2012)	flatulence	OPRM1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0002579	ENSG00000112038	23197038	Bowes et al. (2012)	decreased gastrointestinal motility	OPRM1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0000616	ENSG00000112038	23197038	Bowes et al. (2012)	pupil constriction	OPRM1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0003890	ENSG00000112038	23197038	Bowes et al. (2012)	abuse liability	OPRM1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009842	ENSG00000112038	23197038	Bowes et al. (2012)	respiratory depression	OPRM1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0000616	ENSG00000112038	23197038	Bowes et al. (2012)	miosis	OPRM1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0002045	ENSG00000112038	23197038	Bowes et al. (2012)	hypothermia	OPRM1	UBERON_0004535	""
gastrointestinal	activation_general	EFO_0009868	ENSG00000112038	23197038	Bowes et al. (2012)	sedation	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0030895	ENSG00000112038	23197038	Bowes et al. (2012)	increased gastrointestinal motility	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0008533	ENSG00000112038	23197038	Bowes et al. (2012)	dyspepsia	OPRM1	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0009669	ENSG00000112038	23197038	Bowes et al. (2012)	flatulence	OPRM1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0002579	ENSG00000112038	23197038	Bowes et al. (2012)	decreased gastrointestinal motility	OPRM1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0000616	ENSG00000112038	23197038	Bowes et al. (2012)	pupil constriction	OPRM1	UBERON_0005409	""
gastrointestinal	activation_general	EFO_0003890	ENSG00000112038	23197038	Bowes et al. (2012)	abuse liability	OPRM1	UBERON_0005409	""
gastrointestinal	activation_general	EFO_0009842	ENSG00000112038	23197038	Bowes et al. (2012)	respiratory depression	OPRM1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0000616	ENSG00000112038	23197038	Bowes et al. (2012)	miosis	OPRM1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0002045	ENSG00000112038	23197038	Bowes et al. (2012)	hypothermia	OPRM1	UBERON_0005409	""
central nervous system	activation_general	EFO_0009868	ENSG00000112038	23197038	Bowes et al. (2012)	sedation	OPRM1	UBERON_0001017	""
central nervous system	inhibition_general	HP_0030895	ENSG00000112038	23197038	Bowes et al. (2012)	increased gastrointestinal motility	OPRM1	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0008533	ENSG00000112038	23197038	Bowes et al. (2012)	dyspepsia	OPRM1	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0009669	ENSG00000112038	23197038	Bowes et al. (2012)	flatulence	OPRM1	UBERON_0001017	""
central nervous system	activation_general	HP_0002579	ENSG00000112038	23197038	Bowes et al. (2012)	decreased gastrointestinal motility	OPRM1	UBERON_0001017	""
central nervous system	activation_general	HP_0000616	ENSG00000112038	23197038	Bowes et al. (2012)	pupil constriction	OPRM1	UBERON_0001017	""
central nervous system	activation_general	EFO_0003890	ENSG00000112038	23197038	Bowes et al. (2012)	abuse liability	OPRM1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009842	ENSG00000112038	23197038	Bowes et al. (2012)	respiratory depression	OPRM1	UBERON_0001017	""
central nervous system	activation_general	HP_0000616	ENSG00000112038	23197038	Bowes et al. (2012)	miosis	OPRM1	UBERON_0001017	""
central nervous system	activation_general	HP_0002045	ENSG00000112038	23197038	Bowes et al. (2012)	hypothermia	OPRM1	UBERON_0001017	""
renal	inhibition_acute	GO_0045823	ENSG00000143153	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1B1	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000143153	28216264	Lynch et al. (2017)	decreased heart rate	ATP1B1	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000143153	28216264	Lynch et al. (2017)	atrioventricular block	ATP1B1	UBERON_0001008	""
renal	inhibition_acute	EFO_0004269	ENSG00000143153	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1B1	UBERON_0001008	""
renal	inhibition_acute	EFO_0004287	ENSG00000143153	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1B1	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000143153	28216264	Lynch et al. (2017)	increased urine excretion	ATP1B1	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000143153	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1B1	UBERON_0001008	""
renal	inhibition_acute	HP_0002017	ENSG00000143153	28216264	Lynch et al. (2017)	vomiting	ATP1B1	UBERON_0001008	""
cardiovascular	inhibition_acute	GO_0045823	ENSG00000143153	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1B1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000143153	28216264	Lynch et al. (2017)	decreased heart rate	ATP1B1	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000143153	28216264	Lynch et al. (2017)	atrioventricular block	ATP1B1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000143153	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1B1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004287	ENSG00000143153	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1B1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000143153	28216264	Lynch et al. (2017)	increased urine excretion	ATP1B1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000143153	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1B1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002017	ENSG00000143153	28216264	Lynch et al. (2017)	vomiting	ATP1B1	UBERON_0004535	""
cardiovascular system	inhibition_general	""	ENSG00000180210	""	Urban et al. (2012)	thrombin-deficient mice were found to be prone to fatal hemorrhagic events	F2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
central nervous system	activation_acute	HP_0100738	ENSG00000113327	28216264	Lynch et al. (2017)	increased eating	GABRG2	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000113327	28216264	Lynch et al. (2017)	convulsions	GABRG2	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000113327	28216264	Lynch et al. (2017)	decreased sleep	GABRG2	UBERON_0001017	""
cardiovascular	activation_acute	""	ENSG00000113327	28216264	Lynch et al. (2017)	muscle relaxation	GABRG2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000113327	28216264	Lynch et al. (2017)	convulsions	GABRG2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000113327	28216264	Lynch et al. (2017)	decreased sleep	GABRG2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0100738	ENSG00000113327	28216264	Lynch et al. (2017)	increased eating	GABRG2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009874	ENSG00000113327	28216264	Lynch et al. (2017)	decreased anxiety	GABRG2	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009840	ENSG00000113327	28216264	Lynch et al. (2017)	increased respiratory rate	GABRG2	UBERON_0001017	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000113327	28216264	Lynch et al. (2017)	ataxia	GABRG2	UBERON_0001017	""
central nervous system	activation_acute	""	ENSG00000113327	28216264	Lynch et al. (2017)	muscle relaxation	GABRG2	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009872	ENSG00000113327	28216264	Lynch et al. (2017)	increased cardiac output	GABRG2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0001072	ENSG00000113327	28216264	Lynch et al. (2017)	decreased memory	GABRG2	UBERON_0001017	""
cardiovascular	activation_acute	GO_0045822	ENSG00000113327	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRG2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009872	ENSG00000113327	28216264	Lynch et al. (2017)	increased cardiac output	GABRG2	UBERON_0001017	""
cardiovascular	activation_acute	GO_1904057	ENSG00000113327	28216264	Lynch et al. (2017)	decreased pain	GABRG2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0008568	ENSG00000113327	28216264	Lynch et al. (2017)	increased sleep	GABRG2	UBERON_0001017	""
central nervous system	activation_acute	EFO_0003890	ENSG00000113327	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRG2	UBERON_0001017	""
central nervous system	activation_acute	EFO_0005251	ENSG00000113327	28216264	Lynch et al. (2017)	decreased blood pressure	GABRG2	UBERON_0001017	""
central nervous system	activation_acute	HP_0002045	ENSG00000113327	28216264	Lynch et al. (2017)	decreased body temperature	GABRG2	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000113327	28216264	Lynch et al. (2017)	decreased convulsions	GABRG2	UBERON_0004535	""
central nervous system	activation_acute	GO_1904057	ENSG00000113327	28216264	Lynch et al. (2017)	decreased pain	GABRG2	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000113327	28216264	Lynch et al. (2017)	increased respiratory rate	GABRG2	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0008568	ENSG00000113327	28216264	Lynch et al. (2017)	increased sleep	GABRG2	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000113327	28216264	Lynch et al. (2017)	decreased blood pressure	GABRG2	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000113327	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRG2	UBERON_0004535	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000113327	28216264	Lynch et al. (2017)	ataxia	GABRG2	UBERON_0004535	""
central nervous system	activation_acute	GO_0045822	ENSG00000113327	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRG2	UBERON_0001017	""
cardiovascular	activation_acute	HP_0002045	ENSG00000113327	28216264	Lynch et al. (2017)	decreased body temperature	GABRG2	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000113327	28216264	Lynch et al. (2017)	decreased anxiety	GABRG2	UBERON_0004535	""
central nervous system	activation_acute	GO_0040013	ENSG00000113327	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRG2	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000113327	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRG2	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000113327	28216264	Lynch et al. (2017)	decreased memory	GABRG2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000113327	28216264	Lynch et al. (2017)	decreased convulsions	GABRG2	UBERON_0001017	""
cardiovascular	activation_acute	""	ENSG00000121361	28216264	Lynch et al. (2017)	cardiac lesions	KCNJ8	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000121361	28216264	Lynch et al. (2017)	decreased heart rate	KCNJ8	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000121361	28216264	Lynch et al. (2017)	atrioventricular block	KCNJ8	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000842	ENSG00000121361	28216264	Lynch et al. (2017)	increased blood insulin	KCNJ8	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001943	ENSG00000121361	28216264	Lynch et al. (2017)	decreased blood glucose	KCNJ8	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000121361	28216264	Lynch et al. (2017)	increased urine excretion	KCNJ8	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000121361	28216264	Lynch et al. (2017)	increased urinary sodium excretion	KCNJ8	UBERON_0004535	""
pancreas	activation_acute	HP_0040216	ENSG00000121361	28216264	Lynch et al. (2017)	decreased blood insulin	KCNJ8	UBERON_0001264	""
pancreas	inhibition_acute	HP_0001662	ENSG00000121361	28216264	Lynch et al. (2017)	decreased heart rate	KCNJ8	UBERON_0001264	""
pancreas	inhibition_acute	MONDO_0000465	ENSG00000121361	28216264	Lynch et al. (2017)	atrioventricular block	KCNJ8	UBERON_0001264	""
pancreas	inhibition_acute	HP_0000842	ENSG00000121361	28216264	Lynch et al. (2017)	increased blood insulin	KCNJ8	UBERON_0001264	""
pancreas	inhibition_acute	HP_0001943	ENSG00000121361	28216264	Lynch et al. (2017)	decreased blood glucose	KCNJ8	UBERON_0001264	""
pancreas	inhibition_acute	HP_0000103	ENSG00000121361	28216264	Lynch et al. (2017)	increased urine excretion	KCNJ8	UBERON_0001264	""
pancreas	inhibition_acute	GO_0035815	ENSG00000121361	28216264	Lynch et al. (2017)	increased urinary sodium excretion	KCNJ8	UBERON_0001264	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000121361	28216264	Lynch et al. (2017)	decreased blood pressure	KCNJ8	UBERON_0004535	""
pancreas	activation_acute	HP_0031860	ENSG00000121361	28216264	Lynch et al. (2017)	abnormal pulse	KCNJ8	UBERON_0001264	""
renal	activation_acute	HP_0040216	ENSG00000121361	28216264	Lynch et al. (2017)	decreased blood insulin	KCNJ8	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000121361	28216264	Lynch et al. (2017)	decreased heart rate	KCNJ8	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000121361	28216264	Lynch et al. (2017)	atrioventricular block	KCNJ8	UBERON_0001008	""
renal	inhibition_acute	HP_0000842	ENSG00000121361	28216264	Lynch et al. (2017)	increased blood insulin	KCNJ8	UBERON_0001008	""
renal	inhibition_acute	HP_0001943	ENSG00000121361	28216264	Lynch et al. (2017)	decreased blood glucose	KCNJ8	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000121361	28216264	Lynch et al. (2017)	increased urine excretion	KCNJ8	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000121361	28216264	Lynch et al. (2017)	increased urinary sodium excretion	KCNJ8	UBERON_0001008	""
renal	activation_acute	EFO_0004269	ENSG00000121361	28216264	Lynch et al. (2017)	cardiac arrhythmia	KCNJ8	UBERON_0001008	""
renal	activation_acute	""	ENSG00000121361	28216264	Lynch et al. (2017)	cardiac lesions	KCNJ8	UBERON_0001008	""
renal	activation_acute	EFO_0005251	ENSG00000121361	28216264	Lynch et al. (2017)	decreased blood pressure	KCNJ8	UBERON_0001008	""
renal	activation_acute	HP_0011015	ENSG00000121361	28216264	Lynch et al. (2017)	increased/decreased blood glucose	KCNJ8	UBERON_0001008	""
cardiovascular	activation_acute	HP_0040216	ENSG00000121361	28216264	Lynch et al. (2017)	decreased blood insulin	KCNJ8	UBERON_0004535	""
cardiovascular	activation_acute	HP_0031860	ENSG00000121361	28216264	Lynch et al. (2017)	abnormal pulse	KCNJ8	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001649	ENSG00000121361	28216264	Lynch et al. (2017)	increased heart rate	KCNJ8	UBERON_0004535	""
pancreas	activation_acute	EFO_0005251	ENSG00000121361	28216264	Lynch et al. (2017)	decreased blood pressure	KCNJ8	UBERON_0001264	""
renal	activation_acute	HP_0031860	ENSG00000121361	28216264	Lynch et al. (2017)	abnormal pulse	KCNJ8	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0004269	ENSG00000121361	28216264	Lynch et al. (2017)	cardiac arrhythmia	KCNJ8	UBERON_0004535	""
pancreas	activation_acute	EFO_0004269	ENSG00000121361	28216264	Lynch et al. (2017)	cardiac arrhythmia	KCNJ8	UBERON_0001264	""
pancreas	activation_acute	HP_0001649	ENSG00000121361	28216264	Lynch et al. (2017)	increased heart rate	KCNJ8	UBERON_0001264	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000121361	28216264	Lynch et al. (2017)	decreased convulsions	KCNJ8	UBERON_0004535	""
pancreas	activation_acute	HP_0011015	ENSG00000121361	28216264	Lynch et al. (2017)	increased/decreased blood glucose	KCNJ8	UBERON_0001264	""
cardiovascular	activation_acute	HP_0011015	ENSG00000121361	28216264	Lynch et al. (2017)	increased/decreased blood glucose	KCNJ8	UBERON_0004535	""
pancreas	activation_acute	""	ENSG00000121361	28216264	Lynch et al. (2017)	cardiac lesions	KCNJ8	UBERON_0001264	""
renal	activation_acute	EFO_0009853	ENSG00000121361	28216264	Lynch et al. (2017)	decreased convulsions	KCNJ8	UBERON_0001008	""
renal	activation_acute	HP_0001649	ENSG00000121361	28216264	Lynch et al. (2017)	increased heart rate	KCNJ8	UBERON_0001008	""
pancreas	activation_acute	EFO_0009853	ENSG00000121361	28216264	Lynch et al. (2017)	decreased convulsions	KCNJ8	UBERON_0001264	""
central nervous system	activation_acute	EFO_0009853	ENSG00000105642	28216264	Lynch et al. (2017)	decreased convulsions	KCNN1	UBERON_0001017	""
central nervous system	inhibition_acute	""	ENSG00000105642	28216264	Lynch et al. (2017)	increased atrial refractory period	KCNN1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000105642	28216264	Lynch et al. (2017)	convulsions	KCNN1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000105642	28216264	Lynch et al. (2017)	neurotoxicity	KCNN1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000105642	28216264	Lynch et al. (2017)	decreased convulsions	KCNN1	UBERON_0004535	""
cardiovascular	inhibition_acute	""	ENSG00000105642	28216264	Lynch et al. (2017)	increased atrial refractory period	KCNN1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000105642	28216264	Lynch et al. (2017)	convulsions	KCNN1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000105642	28216264	Lynch et al. (2017)	neurotoxicity	KCNN1	UBERON_0004535	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000105642	28216264	Lynch et al. (2017)	ataxia	KCNN1	UBERON_0004535	""
central nervous system	activation_acute	GO_0040013	ENSG00000105642	28216264	Lynch et al. (2017)	decreased locomotor activity	KCNN1	UBERON_0001017	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000105642	28216264	Lynch et al. (2017)	ataxia	KCNN1	UBERON_0001017	""
cardiovascular	activation_acute	GO_0040013	ENSG00000105642	28216264	Lynch et al. (2017)	decreased locomotor activity	KCNN1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0004269	ENSG00000105711	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000105711	28216264	Lynch et al. (2017)	decreased pain	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	NCIT_C74532	ENSG00000105711	28216264	Lynch et al. (2017)	agitation	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_1000712	ENSG00000105711	28216264	Lynch et al. (2017)	decreased sweating	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011499	ENSG00000105711	28216264	Lynch et al. (2017)	increased pupil diameter	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000105711	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0031860	ENSG00000105711	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000105711	28216264	Lynch et al. (2017)	decreased blood pressure	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0045822	ENSG00000105711	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_1001497	ENSG00000105711	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0006677	ENSG00000105711	28216264	Lynch et al. (2017)	increased QRS complex	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000105711	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009839	ENSG00000105711	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000105711	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011037	ENSG00000105711	28216264	Lynch et al. (2017)	decreased urine excretion	SCN1B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001259	ENSG00000105711	28216264	Lynch et al. (2017)	coma	SCN1B	UBERON_0004535	""
respiratory	activation_acute	HP_0002094	ENSG00000105711	28216264	Lynch et al. (2017)	dyspnea	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	GO_1904057	ENSG00000105711	28216264	Lynch et al. (2017)	decreased pain	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	NCIT_C74532	ENSG00000105711	28216264	Lynch et al. (2017)	agitation	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_1000712	ENSG00000105711	28216264	Lynch et al. (2017)	decreased sweating	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0011499	ENSG00000105711	28216264	Lynch et al. (2017)	increased pupil diameter	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009853	ENSG00000105711	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0031860	ENSG00000105711	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0005251	ENSG00000105711	28216264	Lynch et al. (2017)	decreased blood pressure	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	GO_0045822	ENSG00000105711	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_1001497	ENSG00000105711	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0006677	ENSG00000105711	28216264	Lynch et al. (2017)	increased QRS complex	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0004269	ENSG00000105711	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009839	ENSG00000105711	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0030897	ENSG00000105711	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0011037	ENSG00000105711	28216264	Lynch et al. (2017)	decreased urine excretion	SCN1B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0001259	ENSG00000105711	28216264	Lynch et al. (2017)	coma	SCN1B	UBERON_0001004	""
respiratory	activation_acute	GO_0040013	ENSG00000105711	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN1B	UBERON_0001004	""
cardiovascular	activation_acute	HP_0001649	ENSG00000105711	28216264	Lynch et al. (2017)	increased heart rate	SCN1B	UBERON_0004535	""
respiratory	activation_acute	HP_0001649	ENSG00000105711	28216264	Lynch et al. (2017)	increased heart rate	SCN1B	UBERON_0001004	""
cardiovascular	activation_acute	HP_0002094	ENSG00000105711	28216264	Lynch et al. (2017)	dyspnea	SCN1B	UBERON_0004535	""
respiratory	activation_acute	EFO_0004269	ENSG00000105711	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN1B	UBERON_0001004	""
respiratory	activation_acute	EFO_0009853	ENSG00000105711	28216264	Lynch et al. (2017)	convulsions	SCN1B	UBERON_0001004	""
cardiovascular	activation_acute	GO_0040013	ENSG00000105711	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN1B	UBERON_0004535	""
nervous system	activation_acute	EFO_0009853	ENSG00000105711	28216264	Lynch et al. (2017)	convulsions	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000105711	28216264	Lynch et al. (2017)	decreased pain	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	NCIT_C74532	ENSG00000105711	28216264	Lynch et al. (2017)	agitation	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_1000712	ENSG00000105711	28216264	Lynch et al. (2017)	decreased sweating	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0011499	ENSG00000105711	28216264	Lynch et al. (2017)	increased pupil diameter	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000105711	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0031860	ENSG00000105711	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0005251	ENSG00000105711	28216264	Lynch et al. (2017)	decreased blood pressure	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	GO_0045822	ENSG00000105711	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_1001497	ENSG00000105711	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0006677	ENSG00000105711	28216264	Lynch et al. (2017)	increased QRS complex	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004269	ENSG00000105711	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009839	ENSG00000105711	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030897	ENSG00000105711	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0011037	ENSG00000105711	28216264	Lynch et al. (2017)	decreased urine excretion	SCN1B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001259	ENSG00000105711	28216264	Lynch et al. (2017)	coma	SCN1B	UBERON_0001016	""
nervous system	activation_acute	GO_0040013	ENSG00000105711	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN1B	UBERON_0001016	""
nervous system	activation_acute	HP_0001649	ENSG00000105711	28216264	Lynch et al. (2017)	increased heart rate	SCN1B	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000105711	28216264	Lynch et al. (2017)	convulsions	SCN1B	UBERON_0004535	""
nervous system	activation_acute	HP_0002094	ENSG00000105711	28216264	Lynch et al. (2017)	dyspnea	SCN1B	UBERON_0001016	""
nervous system	activation_acute	EFO_0004269	ENSG00000105711	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN1B	UBERON_0001016	""
immune	activation_general	EFO_0005251	ENSG00000196639	23197038	Bowes et al. (2012)	decreased blood pressure	HRH1	UBERON_0002405	""
immune	inhibition_general	EFO_0009868	ENSG00000196639	23197038	Bowes et al. (2012)	sedation	HRH1	UBERON_0002405	""
immune	inhibition_general	""	ENSG00000196639	23197038	Bowes et al. (2012)	decreased allergic responses	HRH1	UBERON_0002405	""
immune	inhibition_general	EFO_0004566	ENSG00000196639	23197038	Bowes et al. (2012)	increased body weight	HRH1	UBERON_0002405	""
immune	activation_general	EFO_1000669	ENSG00000196639	23197038	Bowes et al. (2012)	allergic responses of flare, flush and wheal	HRH1	UBERON_0002405	""
immune	activation_general	EFO_0009836	ENSG00000196639	23197038	Bowes et al. (2012)	bronchoconstriction	HRH1	UBERON_0002405	""
cardiovascular system	activation_general	EFO_0005251	ENSG00000196639	23197038	Bowes et al. (2012)	decreased blood pressure	HRH1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009868	ENSG00000196639	23197038	Bowes et al. (2012)	sedation	HRH1	UBERON_0004535	""
cardiovascular system	inhibition_general	""	ENSG00000196639	23197038	Bowes et al. (2012)	decreased allergic responses	HRH1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0004566	ENSG00000196639	23197038	Bowes et al. (2012)	increased body weight	HRH1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_1000669	ENSG00000196639	23197038	Bowes et al. (2012)	allergic responses of flare, flush and wheal	HRH1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009836	ENSG00000196639	23197038	Bowes et al. (2012)	bronchoconstriction	HRH1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0032263	ENSG00000189221	23197038	Bowes et al. (2012)	increased blood pressure when combined with amines such as tyramine	MAOA	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009878	ENSG00000189221	23197038	Bowes et al. (2012)	drug-drug interaction potential	MAOA	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009847	ENSG00000189221	23197038	Bowes et al. (2012)	dizziness	MAOA	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0008568	ENSG00000189221	23197038	Bowes et al. (2012)	sleep disturbances	MAOA	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0002018	ENSG00000189221	23197038	Bowes et al. (2012)	nausea	MAOA	UBERON_0004535	""
central nervous system	inhibition_general	HP_0032263	ENSG00000189221	23197038	Bowes et al. (2012)	increased blood pressure when combined with amines such as tyramine	MAOA	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0009878	ENSG00000189221	23197038	Bowes et al. (2012)	drug-drug interaction potential	MAOA	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0009847	ENSG00000189221	23197038	Bowes et al. (2012)	dizziness	MAOA	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0008568	ENSG00000189221	23197038	Bowes et al. (2012)	sleep disturbances	MAOA	UBERON_0001017	""
central nervous system	inhibition_general	HP_0002018	ENSG00000189221	23197038	Bowes et al. (2012)	nausea	MAOA	UBERON_0001017	""
cardiovascular system	inhibition_general	EFO_0000373	ENSG00000103546	""	Urban et al. (2012)	congestive heart failure	SLC6A2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000537	ENSG00000103546	""	Urban et al. (2012)	hypertension (supine)	SLC6A2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0001649	ENSG00000103546	""	Urban et al. (2012)	tachycardia	SLC6A2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000103546	""	Urban et al. (2012)	may be useful for treatment of ADHD (atomoxetine) and depression	SLC6A2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular	activation_acute	EFO_0004287	ENSG00000043591	28216264	Lynch et al. (2017)	ventricular fibrillation	ADRB1	UBERON_0004535	""
cardiovascular	activation_chronic	EFO_0002503	ENSG00000043591	28216264	Lynch et al. (2017)	cardiac hypertrophy	ADRB1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000043591	28216264	Lynch et al. (2017)	decreased blood pressure	ADRB1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000043591	28216264	Lynch et al. (2017)	decreased heart rate	ADRB1	UBERON_0004535	""
cardiovascular	activation_chronic	HP_0001685	ENSG00000043591	28216264	Lynch et al. (2017)	myocardial fibrosis	ADRB1	UBERON_0004535	""
cardiovascular	activation_chronic	EFO_0003144	ENSG00000043591	28216264	Lynch et al. (2017)	heart failure	ADRB1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0025428	ENSG00000043591	28216264	Lynch et al. (2017)	bronchospasm	ADRB1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001649	ENSG00000043591	28216264	Lynch et al. (2017)	increased heart rate	ADRB1	UBERON_0004535	""
cardiovascular	activation_acute	GO_0045823	ENSG00000043591	28216264	Lynch et al. (2017)	increased cardiac contractility	ADRB1	UBERON_0004535	""
cardiovascular system	activation_general	""	ENSG00000144891	""	Urban et al. (2012)	vasocontriction	AGTR1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000144891	""	Urban et al. (2012)	antihypertensive and cardioprotective agent	AGTR1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000144891	""	Urban et al. (2012)	hypotension	AGTR1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0009869	ENSG00000144891	""	Urban et al. (2012)	dry mouth	AGTR1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0001959	ENSG00000144891	""	Urban et al. (2012)	excessive thirst	AGTR1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0009847	ENSG00000144891	""	Urban et al. (2012)	dizziness	AGTR1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0031860	ENSG00000144891	""	Urban et al. (2012)	slow or irregular heartbeat	AGTR1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0045823	ENSG00000144891	""	Urban et al. (2012)	positive inotropy	AGTR1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0008283	ENSG00000144891	""	Urban et al. (2012)	cell proliferation and migration	AGTR1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000163485	""	Urban et al. (2012)	cardioprotection	ADORA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	""	ENSG00000163485	""	Urban et al. (2012)	vasodilation	ADORA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0000103	ENSG00000163485	""	Urban et al. (2012)	diuresis	ADORA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	GO_0035812	ENSG00000163485	""	Urban et al. (2012)	natriuresis	ADORA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0001662	ENSG00000163485	""	Urban et al. (2012)	bradycardia	ADORA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000163485	""	Urban et al. (2012)	vasoconstriction	ADORA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009836	ENSG00000163485	""	Urban et al. (2012)	bronchoconstriction	ADORA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009843	ENSG00000163485	""	Urban et al. (2012)	induction of sleep	ADORA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
renal	activation_general	""	ENSG00000163485	""	Urban et al. (2012)	cardioprotection	ADORA1	UBERON_0001008	https://doi.org/10.1002/9781118098141.ch2
renal	inhibition_general	""	ENSG00000163485	""	Urban et al. (2012)	vasodilation	ADORA1	UBERON_0001008	https://doi.org/10.1002/9781118098141.ch2
renal	inhibition_general	HP_0000103	ENSG00000163485	""	Urban et al. (2012)	diuresis	ADORA1	UBERON_0001008	https://doi.org/10.1002/9781118098141.ch2
renal	inhibition_general	GO_0035812	ENSG00000163485	""	Urban et al. (2012)	natriuresis	ADORA1	UBERON_0001008	https://doi.org/10.1002/9781118098141.ch2
renal	activation_general	HP_0001662	ENSG00000163485	""	Urban et al. (2012)	bradycardia	ADORA1	UBERON_0001008	https://doi.org/10.1002/9781118098141.ch2
renal	activation_general	""	ENSG00000163485	""	Urban et al. (2012)	vasoconstriction	ADORA1	UBERON_0001008	https://doi.org/10.1002/9781118098141.ch2
renal	activation_general	EFO_0009836	ENSG00000163485	""	Urban et al. (2012)	bronchoconstriction	ADORA1	UBERON_0001008	https://doi.org/10.1002/9781118098141.ch2
renal	activation_general	EFO_0009843	ENSG00000163485	""	Urban et al. (2012)	induction of sleep	ADORA1	UBERON_0001008	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000163485	""	Urban et al. (2012)	cardioprotection	ADORA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000163485	""	Urban et al. (2012)	vasodilation	ADORA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0000103	ENSG00000163485	""	Urban et al. (2012)	diuresis	ADORA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	GO_0035812	ENSG00000163485	""	Urban et al. (2012)	natriuresis	ADORA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0001662	ENSG00000163485	""	Urban et al. (2012)	bradycardia	ADORA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000163485	""	Urban et al. (2012)	vasoconstriction	ADORA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009836	ENSG00000163485	""	Urban et al. (2012)	bronchoconstriction	ADORA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009843	ENSG00000163485	""	Urban et al. (2012)	induction of sleep	ADORA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000151067	""	Urban et al. (2012)	increased mortality of heart failure patients	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0005251	ENSG00000151067	""	Urban et al. (2012)	hypotension	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	""	ENSG00000151067	""	Urban et al. (2012)	reflex tachycardia	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0004269	ENSG00000151067	""	Urban et al. (2012)	arrhythmia	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0009847	ENSG00000151067	""	Urban et al. (2012)	dizziness	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0002315	ENSG00000151067	""	Urban et al. (2012)	headache	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0031284	ENSG00000151067	""	Urban et al. (2012)	redness in the face	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	""	ENSG00000151067	""	Urban et al. (2012)	fluid buildup in the legs	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0031860	ENSG00000151067	""	Urban et al. (2012)	effect on heart rate	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0002019	ENSG00000151067	""	Urban et al. (2012)	constipation	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0001250	ENSG00000151067	""	Urban et al. (2012)	induction of seizures	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000151067	""	Urban et al. (2012)	increases in peripheral vascular resistance	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0032263	ENSG00000151067	""	Urban et al. (2012)	increased systolic blood pressure	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0004269	ENSG00000151067	""	Urban et al. (2012)	arrhythmia	CACNA1C	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000151067	""	Urban et al. (2012)	increased mortality of heart failure patients	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000151067	""	Urban et al. (2012)	hypotension	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000151067	""	Urban et al. (2012)	reflex tachycardia	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0004269	ENSG00000151067	""	Urban et al. (2012)	arrhythmia	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0009847	ENSG00000151067	""	Urban et al. (2012)	dizziness	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0002315	ENSG00000151067	""	Urban et al. (2012)	headache	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0031284	ENSG00000151067	""	Urban et al. (2012)	redness in the face	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000151067	""	Urban et al. (2012)	fluid buildup in the legs	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0031860	ENSG00000151067	""	Urban et al. (2012)	effect on heart rate	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0002019	ENSG00000151067	""	Urban et al. (2012)	constipation	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0001250	ENSG00000151067	""	Urban et al. (2012)	induction of seizures	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000151067	""	Urban et al. (2012)	increases in peripheral vascular resistance	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0032263	ENSG00000151067	""	Urban et al. (2012)	increased systolic blood pressure	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0004269	ENSG00000151067	""	Urban et al. (2012)	arrhythmia	CACNA1C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	""	ENSG00000151067	""	Urban et al. (2012)	increased mortality of heart failure patients	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	EFO_0005251	ENSG00000151067	""	Urban et al. (2012)	hypotension	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	""	ENSG00000151067	""	Urban et al. (2012)	reflex tachycardia	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	EFO_0004269	ENSG00000151067	""	Urban et al. (2012)	arrhythmia	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	EFO_0009847	ENSG00000151067	""	Urban et al. (2012)	dizziness	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	HP_0002315	ENSG00000151067	""	Urban et al. (2012)	headache	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	HP_0031284	ENSG00000151067	""	Urban et al. (2012)	redness in the face	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	""	ENSG00000151067	""	Urban et al. (2012)	fluid buildup in the legs	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	HP_0031860	ENSG00000151067	""	Urban et al. (2012)	effect on heart rate	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	HP_0002019	ENSG00000151067	""	Urban et al. (2012)	constipation	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	HP_0001250	ENSG00000151067	""	Urban et al. (2012)	induction of seizures	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	""	ENSG00000151067	""	Urban et al. (2012)	increases in peripheral vascular resistance	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	HP_0032263	ENSG00000151067	""	Urban et al. (2012)	increased systolic blood pressure	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	EFO_0004269	ENSG00000151067	""	Urban et al. (2012)	arrhythmia	CACNA1C	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
renal	activation_acute	EFO_0009833	ENSG00000151617	28216264	Lynch et al. (2017)	glomerular and tubulointerstitial structural injury	EDNRA	UBERON_0001008	""
renal	inhibition_acute	HP_0001649	ENSG00000151617	28216264	Lynch et al. (2017)	increased heart rate	EDNRA	UBERON_0001008	""
renal	inhibition_developmental toxicity	Orphanet_271853	ENSG00000151617	28216264	Lynch et al. (2017)	cardiac anomaly	EDNRA	UBERON_0001008	""
renal	inhibition_developmental toxicity	HP_0000271	ENSG00000151617	28216264	Lynch et al. (2017)	abnormal face	EDNRA	UBERON_0001008	""
renal	inhibition_developmental toxicity	HP_0000175	ENSG00000151617	28216264	Lynch et al. (2017)	cleft palate	EDNRA	UBERON_0001008	""
renal	inhibition_developmental toxicity	HP_0010515	ENSG00000151617	28216264	Lynch et al. (2017)	thymic hypoplasia	EDNRA	UBERON_0001008	""
renal	inhibition_developmental toxicity	Orphanet_68335	ENSG00000151617	28216264	Lynch et al. (2017)	chromosome 22 deletions	EDNRA	UBERON_0001008	""
renal	inhibition_acute	EFO_0005251	ENSG00000151617	28216264	Lynch et al. (2017)	decreased blood pressure	EDNRA	UBERON_0001008	""
renal	inhibition_acute	HP_0011037	ENSG00000151617	28216264	Lynch et al. (2017)	decreased urine excretion	EDNRA	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000151617	28216264	Lynch et al. (2017)	decreased pain	EDNRA	UBERON_0001008	""
renal	inhibition_acute	GO_0120061	ENSG00000151617	28216264	Lynch et al. (2017)	decreased gastric emptying	EDNRA	UBERON_0001008	""
renal	inhibition_acute	HP_0030897	ENSG00000151617	28216264	Lynch et al. (2017)	decreased intestinal transit	EDNRA	UBERON_0001008	""
gastrointestinal	activation_acute	HP_0032263	ENSG00000151617	28216264	Lynch et al. (2017)	increased blood pressure	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0001649	ENSG00000151617	28216264	Lynch et al. (2017)	increased heart rate	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_developmental toxicity	Orphanet_271853	ENSG00000151617	28216264	Lynch et al. (2017)	cardiac anomaly	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_developmental toxicity	HP_0000271	ENSG00000151617	28216264	Lynch et al. (2017)	abnormal face	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_developmental toxicity	HP_0000175	ENSG00000151617	28216264	Lynch et al. (2017)	cleft palate	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_developmental toxicity	HP_0010515	ENSG00000151617	28216264	Lynch et al. (2017)	thymic hypoplasia	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_developmental toxicity	Orphanet_68335	ENSG00000151617	28216264	Lynch et al. (2017)	chromosome 22 deletions	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0005251	ENSG00000151617	28216264	Lynch et al. (2017)	decreased blood pressure	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0011037	ENSG00000151617	28216264	Lynch et al. (2017)	decreased urine excretion	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1904057	ENSG00000151617	28216264	Lynch et al. (2017)	decreased pain	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0120061	ENSG00000151617	28216264	Lynch et al. (2017)	decreased gastric emptying	EDNRA	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0030897	ENSG00000151617	28216264	Lynch et al. (2017)	decreased intestinal transit	EDNRA	UBERON_0005409	""
renal	activation_acute	GO_0008283	ENSG00000151617	28216264	Lynch et al. (2017)	increased cell proliferation	EDNRA	UBERON_0001008	""
cardiovascular	activation_acute	GO_0008283	ENSG00000151617	28216264	Lynch et al. (2017)	increased cell proliferation	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000151617	28216264	Lynch et al. (2017)	increased heart rate	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	Orphanet_271853	ENSG00000151617	28216264	Lynch et al. (2017)	cardiac anomaly	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	HP_0000271	ENSG00000151617	28216264	Lynch et al. (2017)	abnormal face	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	HP_0000175	ENSG00000151617	28216264	Lynch et al. (2017)	cleft palate	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	HP_0010515	ENSG00000151617	28216264	Lynch et al. (2017)	thymic hypoplasia	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	Orphanet_68335	ENSG00000151617	28216264	Lynch et al. (2017)	chromosome 22 deletions	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000151617	28216264	Lynch et al. (2017)	decreased blood pressure	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011037	ENSG00000151617	28216264	Lynch et al. (2017)	decreased urine excretion	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000151617	28216264	Lynch et al. (2017)	decreased pain	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0120061	ENSG00000151617	28216264	Lynch et al. (2017)	decreased gastric emptying	EDNRA	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000151617	28216264	Lynch et al. (2017)	decreased intestinal transit	EDNRA	UBERON_0004535	""
nervous system	activation_acute	EFO_0009833	ENSG00000151617	28216264	Lynch et al. (2017)	glomerular and tubulointerstitial structural injury	EDNRA	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001649	ENSG00000151617	28216264	Lynch et al. (2017)	increased heart rate	EDNRA	UBERON_0001016	""
nervous system	inhibition_developmental toxicity	Orphanet_271853	ENSG00000151617	28216264	Lynch et al. (2017)	cardiac anomaly	EDNRA	UBERON_0001016	""
nervous system	inhibition_developmental toxicity	HP_0000271	ENSG00000151617	28216264	Lynch et al. (2017)	abnormal face	EDNRA	UBERON_0001016	""
nervous system	inhibition_developmental toxicity	HP_0000175	ENSG00000151617	28216264	Lynch et al. (2017)	cleft palate	EDNRA	UBERON_0001016	""
nervous system	inhibition_developmental toxicity	HP_0010515	ENSG00000151617	28216264	Lynch et al. (2017)	thymic hypoplasia	EDNRA	UBERON_0001016	""
nervous system	inhibition_developmental toxicity	Orphanet_68335	ENSG00000151617	28216264	Lynch et al. (2017)	chromosome 22 deletions	EDNRA	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0005251	ENSG00000151617	28216264	Lynch et al. (2017)	decreased blood pressure	EDNRA	UBERON_0001016	""
nervous system	inhibition_acute	HP_0011037	ENSG00000151617	28216264	Lynch et al. (2017)	decreased urine excretion	EDNRA	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000151617	28216264	Lynch et al. (2017)	decreased pain	EDNRA	UBERON_0001016	""
nervous system	inhibition_acute	GO_0120061	ENSG00000151617	28216264	Lynch et al. (2017)	decreased gastric emptying	EDNRA	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030897	ENSG00000151617	28216264	Lynch et al. (2017)	decreased intestinal transit	EDNRA	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0003896	ENSG00000151617	28216264	Lynch et al. (2017)	pulmonary left ventricular hypertrophy	EDNRA	UBERON_0004535	""
nervous system	activation_acute	EFO_0009836	ENSG00000151617	28216264	Lynch et al. (2017)	bronchoconstriction	EDNRA	UBERON_0001016	""
renal	activation_acute	EFO_0003896	ENSG00000151617	28216264	Lynch et al. (2017)	pulmonary left ventricular hypertrophy	EDNRA	UBERON_0001008	""
nervous system	activation_acute	HP_0001662	ENSG00000151617	28216264	Lynch et al. (2017)	decreased heart rate	EDNRA	UBERON_0001016	""
gastrointestinal	activation_acute	GO_0045823	ENSG00000151617	28216264	Lynch et al. (2017)	increased cardiac contractility	EDNRA	UBERON_0005409	""
nervous system	activation_acute	EFO_0003896	ENSG00000151617	28216264	Lynch et al. (2017)	pulmonary left ventricular hypertrophy	EDNRA	UBERON_0001016	""
gastrointestinal	activation_acute	GO_0008283	ENSG00000151617	28216264	Lynch et al. (2017)	increased cell proliferation	EDNRA	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0009833	ENSG00000151617	28216264	Lynch et al. (2017)	glomerular and tubulointerstitial structural injury	EDNRA	UBERON_0004535	""
renal	activation_acute	GO_0045823	ENSG00000151617	28216264	Lynch et al. (2017)	increased cardiac contractility	EDNRA	UBERON_0001008	""
nervous system	activation_acute	GO_1904058	ENSG00000151617	28216264	Lynch et al. (2017)	increased pain	EDNRA	UBERON_0001016	""
gastrointestinal	activation_acute	GO_1904058	ENSG00000151617	28216264	Lynch et al. (2017)	increased pain	EDNRA	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0009836	ENSG00000151617	28216264	Lynch et al. (2017)	bronchoconstriction	EDNRA	UBERON_0004535	""
cardiovascular	activation_acute	GO_1904058	ENSG00000151617	28216264	Lynch et al. (2017)	increased pain	EDNRA	UBERON_0004535	""
renal	activation_acute	EFO_0009452	ENSG00000151617	28216264	Lynch et al. (2017)	increased aldosterone secretion	EDNRA	UBERON_0001008	""
renal	activation_acute	HP_0001662	ENSG00000151617	28216264	Lynch et al. (2017)	decreased heart rate	EDNRA	UBERON_0001008	""
renal	activation_acute	HP_0032263	ENSG00000151617	28216264	Lynch et al. (2017)	increased blood pressure	EDNRA	UBERON_0001008	""
cardiovascular	activation_acute	HP_0032263	ENSG00000151617	28216264	Lynch et al. (2017)	increased blood pressure	EDNRA	UBERON_0004535	""
nervous system	activation_acute	GO_0045823	ENSG00000151617	28216264	Lynch et al. (2017)	increased cardiac contractility	EDNRA	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_0009833	ENSG00000151617	28216264	Lynch et al. (2017)	glomerular and tubulointerstitial structural injury	EDNRA	UBERON_0005409	""
nervous system	activation_acute	HP_0032263	ENSG00000151617	28216264	Lynch et al. (2017)	increased blood pressure	EDNRA	UBERON_0001016	""
nervous system	activation_acute	GO_0008283	ENSG00000151617	28216264	Lynch et al. (2017)	increased cell proliferation	EDNRA	UBERON_0001016	""
nervous system	activation_acute	EFO_0009452	ENSG00000151617	28216264	Lynch et al. (2017)	increased aldosterone secretion	EDNRA	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_0003896	ENSG00000151617	28216264	Lynch et al. (2017)	pulmonary left ventricular hypertrophy	EDNRA	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009452	ENSG00000151617	28216264	Lynch et al. (2017)	increased aldosterone secretion	EDNRA	UBERON_0005409	""
cardiovascular	activation_acute	HP_0001662	ENSG00000151617	28216264	Lynch et al. (2017)	decreased heart rate	EDNRA	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009452	ENSG00000151617	28216264	Lynch et al. (2017)	increased aldosterone secretion	EDNRA	UBERON_0004535	""
renal	activation_acute	EFO_0009836	ENSG00000151617	28216264	Lynch et al. (2017)	bronchoconstriction	EDNRA	UBERON_0001008	""
cardiovascular	activation_acute	GO_0045823	ENSG00000151617	28216264	Lynch et al. (2017)	increased cardiac contractility	EDNRA	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0001662	ENSG00000151617	28216264	Lynch et al. (2017)	decreased heart rate	EDNRA	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009836	ENSG00000151617	28216264	Lynch et al. (2017)	bronchoconstriction	EDNRA	UBERON_0005409	""
renal	activation_acute	GO_1904058	ENSG00000151617	28216264	Lynch et al. (2017)	increased pain	EDNRA	UBERON_0001008	""
nervous system	activation_acute	GO_0040013	ENSG00000282608	28216264	Lynch et al. (2017)	decreased locomotor activity	ADORA3	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000282608	28216264	Lynch et al. (2017)	increased convulsions	ADORA3	UBERON_0001016	""
respiratory	activation_acute	GO_1904057	ENSG00000282608	28216264	Lynch et al. (2017)	decreased pain	ADORA3	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009853	ENSG00000282608	28216264	Lynch et al. (2017)	increased convulsions	ADORA3	UBERON_0001004	""
nervous system	activation_acute	GO_1904057	ENSG00000282608	28216264	Lynch et al. (2017)	decreased pain	ADORA3	UBERON_0001016	""
respiratory	activation_acute	EFO_0009836	ENSG00000282608	28216264	Lynch et al. (2017)	increased bronchoconstriction	ADORA3	UBERON_0001004	""
nervous system	activation_acute	EFO_0009853	ENSG00000282608	28216264	Lynch et al. (2017)	decreased convulsions	ADORA3	UBERON_0001016	""
nervous system	activation_acute	EFO_0009836	ENSG00000282608	28216264	Lynch et al. (2017)	increased bronchoconstriction	ADORA3	UBERON_0001016	""
respiratory	activation_acute	EFO_0009853	ENSG00000282608	28216264	Lynch et al. (2017)	decreased convulsions	ADORA3	UBERON_0001004	""
respiratory	activation_acute	GO_0040013	ENSG00000282608	28216264	Lynch et al. (2017)	decreased locomotor activity	ADORA3	UBERON_0001004	""
cardiovascular system	activation_general	""	ENSG00000138435	""	Urban et al. (2012)	modulation of neurotransmitters (e.g. dopaminergic, serotoninergic, glutamatergic) with effects on cognitive and motor function. They exhibit analgesic activity (epibatidine) and may stimulate autonomic cardiovascular, respiratory, and gastrointestinal function (palpitation/nausea)	CHRNA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000138435	""	Urban et al. (2012)	muscle relaxant	CHRNA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000138435	""	Urban et al. (2012)	antihypertensive agent	CHRNA1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
respiratory	activation_general	""	ENSG00000138435	""	Urban et al. (2012)	modulation of neurotransmitters (e.g. dopaminergic, serotoninergic, glutamatergic) with effects on cognitive and motor function. They exhibit analgesic activity (epibatidine) and may stimulate autonomic cardiovascular, respiratory, and gastrointestinal function (palpitation/nausea)	CHRNA1	UBERON_0001004	https://doi.org/10.1002/9781118098141.ch2
respiratory	inhibition_general	""	ENSG00000138435	""	Urban et al. (2012)	muscle relaxant	CHRNA1	UBERON_0001004	https://doi.org/10.1002/9781118098141.ch2
respiratory	inhibition_general	""	ENSG00000138435	""	Urban et al. (2012)	antihypertensive agent	CHRNA1	UBERON_0001004	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000138435	""	Urban et al. (2012)	modulation of neurotransmitters (e.g. dopaminergic, serotoninergic, glutamatergic) with effects on cognitive and motor function. They exhibit analgesic activity (epibatidine) and may stimulate autonomic cardiovascular, respiratory, and gastrointestinal function (palpitation/nausea)	CHRNA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	""	ENSG00000138435	""	Urban et al. (2012)	muscle relaxant	CHRNA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	""	ENSG00000138435	""	Urban et al. (2012)	antihypertensive agent	CHRNA1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	""	ENSG00000138435	""	Urban et al. (2012)	modulation of neurotransmitters (e.g. dopaminergic, serotoninergic, glutamatergic) with effects on cognitive and motor function. They exhibit analgesic activity (epibatidine) and may stimulate autonomic cardiovascular, respiratory, and gastrointestinal function (palpitation/nausea)	CHRNA1	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	""	ENSG00000138435	""	Urban et al. (2012)	muscle relaxant	CHRNA1	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	""	ENSG00000138435	""	Urban et al. (2012)	antihypertensive agent	CHRNA1	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_acute	""	ENSG00000196639	28216264	Lynch et al. (2017)	scratching	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0050728	ENSG00000196639	28216264	Lynch et al. (2017)	decreased inflammation	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1904057	ENSG00000196639	28216264	Lynch et al. (2017)	decreased pain	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0008568	ENSG00000196639	28216264	Lynch et al. (2017)	increased sleep	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009868	ENSG00000196639	28216264	Lynch et al. (2017)	sedation	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0040017	ENSG00000196639	28216264	Lynch et al. (2017)	increased locomotor activity	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009853	ENSG00000196639	28216264	Lynch et al. (2017)	increased convulsions	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0030972	ENSG00000196639	28216264	Lynch et al. (2017)	decreased/increased blood pressure	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0001649	ENSG00000196639	28216264	Lynch et al. (2017)	increased heart rate	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0005184	ENSG00000196639	28216264	Lynch et al. (2017)	increased QTc interval	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0004269	ENSG00000196639	28216264	Lynch et al. (2017)	cardiac arrhythmia	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0030897	ENSG00000196639	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HRH1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0004566	ENSG00000196639	28216264	Lynch et al. (2017)	increased body weight	HRH1	UBERON_0005409	""
immune	activation_acute	""	ENSG00000196639	28216264	Lynch et al. (2017)	scratching	HRH1	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000196639	28216264	Lynch et al. (2017)	decreased inflammation	HRH1	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000196639	28216264	Lynch et al. (2017)	decreased pain	HRH1	UBERON_0002405	""
immune	inhibition_acute	EFO_0008568	ENSG00000196639	28216264	Lynch et al. (2017)	increased sleep	HRH1	UBERON_0002405	""
immune	inhibition_acute	EFO_0009868	ENSG00000196639	28216264	Lynch et al. (2017)	sedation	HRH1	UBERON_0002405	""
immune	inhibition_acute	GO_0040017	ENSG00000196639	28216264	Lynch et al. (2017)	increased locomotor activity	HRH1	UBERON_0002405	""
immune	inhibition_acute	EFO_0009853	ENSG00000196639	28216264	Lynch et al. (2017)	increased convulsions	HRH1	UBERON_0002405	""
immune	inhibition_acute	HP_0030972	ENSG00000196639	28216264	Lynch et al. (2017)	decreased/increased blood pressure	HRH1	UBERON_0002405	""
immune	inhibition_acute	HP_0001649	ENSG00000196639	28216264	Lynch et al. (2017)	increased heart rate	HRH1	UBERON_0002405	""
immune	inhibition_acute	HP_0005184	ENSG00000196639	28216264	Lynch et al. (2017)	increased QTc interval	HRH1	UBERON_0002405	""
immune	inhibition_acute	EFO_0004269	ENSG00000196639	28216264	Lynch et al. (2017)	cardiac arrhythmia	HRH1	UBERON_0002405	""
immune	inhibition_acute	HP_0030897	ENSG00000196639	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HRH1	UBERON_0002405	""
immune	inhibition_acute	EFO_0004566	ENSG00000196639	28216264	Lynch et al. (2017)	increased body weight	HRH1	UBERON_0002405	""
nervous system	activation_acute	GO_1904058	ENSG00000196639	28216264	Lynch et al. (2017)	increased pain	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050728	ENSG00000196639	28216264	Lynch et al. (2017)	decreased inflammation	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000196639	28216264	Lynch et al. (2017)	decreased pain	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0008568	ENSG00000196639	28216264	Lynch et al. (2017)	increased sleep	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009868	ENSG00000196639	28216264	Lynch et al. (2017)	sedation	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0040017	ENSG00000196639	28216264	Lynch et al. (2017)	increased locomotor activity	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000196639	28216264	Lynch et al. (2017)	increased convulsions	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030972	ENSG00000196639	28216264	Lynch et al. (2017)	decreased/increased blood pressure	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001649	ENSG00000196639	28216264	Lynch et al. (2017)	increased heart rate	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0005184	ENSG00000196639	28216264	Lynch et al. (2017)	increased QTc interval	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004269	ENSG00000196639	28216264	Lynch et al. (2017)	cardiac arrhythmia	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030897	ENSG00000196639	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HRH1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004566	ENSG00000196639	28216264	Lynch et al. (2017)	increased body weight	HRH1	UBERON_0001016	""
cardiovascular	activation_acute	EFO_1000951	ENSG00000196639	28216264	Lynch et al. (2017)	tongue swelling	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0050728	ENSG00000196639	28216264	Lynch et al. (2017)	decreased inflammation	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000196639	28216264	Lynch et al. (2017)	decreased pain	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000196639	28216264	Lynch et al. (2017)	increased sleep	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009868	ENSG00000196639	28216264	Lynch et al. (2017)	sedation	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040017	ENSG00000196639	28216264	Lynch et al. (2017)	increased locomotor activity	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000196639	28216264	Lynch et al. (2017)	increased convulsions	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030972	ENSG00000196639	28216264	Lynch et al. (2017)	decreased/increased blood pressure	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000196639	28216264	Lynch et al. (2017)	increased heart rate	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0005184	ENSG00000196639	28216264	Lynch et al. (2017)	increased QTc interval	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000196639	28216264	Lynch et al. (2017)	cardiac arrhythmia	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000196639	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HRH1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004566	ENSG00000196639	28216264	Lynch et al. (2017)	increased body weight	HRH1	UBERON_0004535	""
immune	activation_acute	HP_0000975	ENSG00000196639	28216264	Lynch et al. (2017)	sweating	HRH1	UBERON_0002405	""
gastrointestinal	activation_acute	EFO_0009836	ENSG00000196639	28216264	Lynch et al. (2017)	bronchoconstriction	HRH1	UBERON_0005409	""
immune	activation_acute	HP_0000282	ENSG00000196639	28216264	Lynch et al. (2017)	facial swelling	HRH1	UBERON_0002405	""
immune	activation_acute	GO_1904058	ENSG00000196639	28216264	Lynch et al. (2017)	increased pain	HRH1	UBERON_0002405	""
immune	activation_acute	EFO_0005251	ENSG00000196639	28216264	Lynch et al. (2017)	decreased blood pressure	HRH1	UBERON_0002405	""
nervous system	activation_acute	HP_0032155	ENSG00000196639	28216264	Lynch et al. (2017)	abdominal cramps	HRH1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0001959	ENSG00000196639	28216264	Lynch et al. (2017)	increased drinking	HRH1	UBERON_0004535	""
immune	activation_acute	GO_0006954	ENSG00000196639	28216264	Lynch et al. (2017)	inflammation	HRH1	UBERON_0002405	""
gastrointestinal	activation_acute	HP_0032155	ENSG00000196639	28216264	Lynch et al. (2017)	abdominal cramps	HRH1	UBERON_0005409	""
nervous system	activation_acute	EFO_0005251	ENSG00000196639	28216264	Lynch et al. (2017)	decreased blood pressure	HRH1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000282	ENSG00000196639	28216264	Lynch et al. (2017)	facial swelling	HRH1	UBERON_0004535	""
immune	activation_acute	EFO_1000951	ENSG00000196639	28216264	Lynch et al. (2017)	tongue swelling	HRH1	UBERON_0002405	""
immune	activation_acute	HP_0002014	ENSG00000196639	28216264	Lynch et al. (2017)	diarrhea	HRH1	UBERON_0002405	""
cardiovascular	activation_acute	HP_0031284	ENSG00000196639	28216264	Lynch et al. (2017)	flushing	HRH1	UBERON_0004535	""
cardiovascular	activation_acute	GO_0006954	ENSG00000196639	28216264	Lynch et al. (2017)	inflammation	HRH1	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0031284	ENSG00000196639	28216264	Lynch et al. (2017)	flushing	HRH1	UBERON_0005409	""
cardiovascular	activation_acute	EFO_1000697	ENSG00000196639	28216264	Lynch et al. (2017)	skin rash	HRH1	UBERON_0004535	""
nervous system	activation_acute	HP_0000282	ENSG00000196639	28216264	Lynch et al. (2017)	facial swelling	HRH1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000975	ENSG00000196639	28216264	Lynch et al. (2017)	sweating	HRH1	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0001959	ENSG00000196639	28216264	Lynch et al. (2017)	increased drinking	HRH1	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000196639	28216264	Lynch et al. (2017)	decreased blood pressure	HRH1	UBERON_0004535	""
gastrointestinal	activation_acute	GO_1904058	ENSG00000196639	28216264	Lynch et al. (2017)	increased pain	HRH1	UBERON_0005409	""
nervous system	activation_acute	HP_0002014	ENSG00000196639	28216264	Lynch et al. (2017)	diarrhea	HRH1	UBERON_0001016	""
nervous system	activation_acute	HP_0001959	ENSG00000196639	28216264	Lynch et al. (2017)	increased drinking	HRH1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0000975	ENSG00000196639	28216264	Lynch et al. (2017)	sweating	HRH1	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0002014	ENSG00000196639	28216264	Lynch et al. (2017)	diarrhea	HRH1	UBERON_0005409	""
immune	activation_acute	HP_0031284	ENSG00000196639	28216264	Lynch et al. (2017)	flushing	HRH1	UBERON_0002405	""
immune	activation_acute	EFO_1000697	ENSG00000196639	28216264	Lynch et al. (2017)	skin rash	HRH1	UBERON_0002405	""
cardiovascular	activation_acute	HP_0032155	ENSG00000196639	28216264	Lynch et al. (2017)	abdominal cramps	HRH1	UBERON_0004535	""
immune	activation_acute	HP_0001959	ENSG00000196639	28216264	Lynch et al. (2017)	increased drinking	HRH1	UBERON_0002405	""
gastrointestinal	activation_acute	GO_0006954	ENSG00000196639	28216264	Lynch et al. (2017)	inflammation	HRH1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_1000697	ENSG00000196639	28216264	Lynch et al. (2017)	skin rash	HRH1	UBERON_0005409	""
cardiovascular	activation_acute	HP_0002014	ENSG00000196639	28216264	Lynch et al. (2017)	diarrhea	HRH1	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_1000951	ENSG00000196639	28216264	Lynch et al. (2017)	tongue swelling	HRH1	UBERON_0005409	""
cardiovascular	activation_acute	GO_1904058	ENSG00000196639	28216264	Lynch et al. (2017)	increased pain	HRH1	UBERON_0004535	""
nervous system	activation_acute	GO_0006954	ENSG00000196639	28216264	Lynch et al. (2017)	inflammation	HRH1	UBERON_0001016	""
nervous system	activation_acute	""	ENSG00000196639	28216264	Lynch et al. (2017)	scratching	HRH1	UBERON_0001016	""
nervous system	activation_acute	HP_0031284	ENSG00000196639	28216264	Lynch et al. (2017)	flushing	HRH1	UBERON_0001016	""
immune	activation_acute	HP_0032155	ENSG00000196639	28216264	Lynch et al. (2017)	abdominal cramps	HRH1	UBERON_0002405	""
cardiovascular	activation_acute	EFO_0009836	ENSG00000196639	28216264	Lynch et al. (2017)	bronchoconstriction	HRH1	UBERON_0004535	""
nervous system	activation_acute	EFO_1000951	ENSG00000196639	28216264	Lynch et al. (2017)	tongue swelling	HRH1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009836	ENSG00000196639	28216264	Lynch et al. (2017)	bronchoconstriction	HRH1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009853	ENSG00000196639	28216264	Lynch et al. (2017)	decreased convulsions	HRH1	UBERON_0001016	""
cardiovascular	activation_acute	""	ENSG00000196639	28216264	Lynch et al. (2017)	scratching	HRH1	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0000282	ENSG00000196639	28216264	Lynch et al. (2017)	facial swelling	HRH1	UBERON_0005409	""
nervous system	activation_acute	EFO_1000697	ENSG00000196639	28216264	Lynch et al. (2017)	skin rash	HRH1	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000196639	28216264	Lynch et al. (2017)	decreased convulsions	HRH1	UBERON_0004535	""
nervous system	activation_acute	HP_0000975	ENSG00000196639	28216264	Lynch et al. (2017)	sweating	HRH1	UBERON_0001016	""
immune	activation_acute	EFO_0009836	ENSG00000196639	28216264	Lynch et al. (2017)	bronchoconstriction	HRH1	UBERON_0002405	""
gastrointestinal	activation_acute	EFO_0005251	ENSG00000196639	28216264	Lynch et al. (2017)	decreased blood pressure	HRH1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009853	ENSG00000196639	28216264	Lynch et al. (2017)	decreased convulsions	HRH1	UBERON_0005409	""
immune	activation_acute	EFO_0009853	ENSG00000196639	28216264	Lynch et al. (2017)	decreased convulsions	HRH1	UBERON_0002405	""
renal	activation_acute	HP_0002045	ENSG00000149295	28216264	Lynch et al. (2017)	decreased body temperature	DRD2	UBERON_0001008	""
renal	activation_chronic	EFO_0009551	ENSG00000149295	28216264	Lynch et al. (2017)	fibrotic valvular heart disease	DRD2	UBERON_0001008	""
renal	inhibition_acute	GO_0040013	ENSG00000149295	28216264	Lynch et al. (2017)	decreased locomotor activity	DRD2	UBERON_0001008	""
renal	inhibition_acute	EFO_0009845	ENSG00000149295	28216264	Lynch et al. (2017)	catalepsy	DRD2	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000149295	28216264	Lynch et al. (2017)	increased convulsions	DRD2	UBERON_0001008	""
renal	inhibition_acute	HP_0410204	ENSG00000149295	28216264	Lynch et al. (2017)	increased gastrointestinal transit	DRD2	UBERON_0001008	""
renal	inhibition_acute	HP_0032263	ENSG00000149295	28216264	Lynch et al. (2017)	increased blood pressure	DRD2	UBERON_0001008	""
renal	inhibition_acute	EFO_0005252	ENSG00000149295	28216264	Lynch et al. (2017)	orthostatic hypotension	DRD2	UBERON_0001008	""
renal	inhibition_acute	NCIT_C95746	ENSG00000149295	28216264	Lynch et al. (2017)	drowsiness	DRD2	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000149295	28216264	Lynch et al. (2017)	increased urine excretion	DRD2	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000149295	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD2	UBERON_0001008	""
renal	activation_chronic	EFO_0003144	ENSG00000149295	28216264	Lynch et al. (2017)	heart failure	DRD2	UBERON_0001008	""
gastrointestinal	activation_acute	HP_0000733	ENSG00000149295	28216264	Lynch et al. (2017)	stereotypy	DRD2	UBERON_0005409	""
gastrointestinal	activation_chronic	EFO_0009551	ENSG00000149295	28216264	Lynch et al. (2017)	fibrotic valvular heart disease	DRD2	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0040013	ENSG00000149295	28216264	Lynch et al. (2017)	decreased locomotor activity	DRD2	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009845	ENSG00000149295	28216264	Lynch et al. (2017)	catalepsy	DRD2	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009853	ENSG00000149295	28216264	Lynch et al. (2017)	increased convulsions	DRD2	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0410204	ENSG00000149295	28216264	Lynch et al. (2017)	increased gastrointestinal transit	DRD2	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0032263	ENSG00000149295	28216264	Lynch et al. (2017)	increased blood pressure	DRD2	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0005252	ENSG00000149295	28216264	Lynch et al. (2017)	orthostatic hypotension	DRD2	UBERON_0005409	""
gastrointestinal	inhibition_acute	NCIT_C95746	ENSG00000149295	28216264	Lynch et al. (2017)	drowsiness	DRD2	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000103	ENSG00000149295	28216264	Lynch et al. (2017)	increased urine excretion	DRD2	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0035815	ENSG00000149295	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD2	UBERON_0005409	""
gastrointestinal	activation_chronic	EFO_0003144	ENSG00000149295	28216264	Lynch et al. (2017)	heart failure	DRD2	UBERON_0005409	""
central nervous system	activation_acute	EFO_0005251	ENSG00000149295	28216264	Lynch et al. (2017)	decreased blood pressure	DRD2	UBERON_0001017	""
central nervous system	activation_chronic	EFO_0009551	ENSG00000149295	28216264	Lynch et al. (2017)	fibrotic valvular heart disease	DRD2	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0040013	ENSG00000149295	28216264	Lynch et al. (2017)	decreased locomotor activity	DRD2	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009845	ENSG00000149295	28216264	Lynch et al. (2017)	catalepsy	DRD2	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000149295	28216264	Lynch et al. (2017)	increased convulsions	DRD2	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0410204	ENSG00000149295	28216264	Lynch et al. (2017)	increased gastrointestinal transit	DRD2	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0032263	ENSG00000149295	28216264	Lynch et al. (2017)	increased blood pressure	DRD2	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005252	ENSG00000149295	28216264	Lynch et al. (2017)	orthostatic hypotension	DRD2	UBERON_0001017	""
central nervous system	inhibition_acute	NCIT_C95746	ENSG00000149295	28216264	Lynch et al. (2017)	drowsiness	DRD2	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0000103	ENSG00000149295	28216264	Lynch et al. (2017)	increased urine excretion	DRD2	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0035815	ENSG00000149295	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD2	UBERON_0001017	""
central nervous system	activation_chronic	EFO_0003144	ENSG00000149295	28216264	Lynch et al. (2017)	heart failure	DRD2	UBERON_0001017	""
cardiovascular	activation_acute	HP_0000733	ENSG00000149295	28216264	Lynch et al. (2017)	stereotypy	DRD2	UBERON_0004535	""
cardiovascular	activation_chronic	EFO_0009551	ENSG00000149295	28216264	Lynch et al. (2017)	fibrotic valvular heart disease	DRD2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040013	ENSG00000149295	28216264	Lynch et al. (2017)	decreased locomotor activity	DRD2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009845	ENSG00000149295	28216264	Lynch et al. (2017)	catalepsy	DRD2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000149295	28216264	Lynch et al. (2017)	increased convulsions	DRD2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0410204	ENSG00000149295	28216264	Lynch et al. (2017)	increased gastrointestinal transit	DRD2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000149295	28216264	Lynch et al. (2017)	increased blood pressure	DRD2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005252	ENSG00000149295	28216264	Lynch et al. (2017)	orthostatic hypotension	DRD2	UBERON_0004535	""
cardiovascular	inhibition_acute	NCIT_C95746	ENSG00000149295	28216264	Lynch et al. (2017)	drowsiness	DRD2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000149295	28216264	Lynch et al. (2017)	increased urine excretion	DRD2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000149295	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD2	UBERON_0004535	""
cardiovascular	activation_chronic	EFO_0003144	ENSG00000149295	28216264	Lynch et al. (2017)	heart failure	DRD2	UBERON_0004535	""
cardiovascular	activation_acute	GO_0035815	ENSG00000149295	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD2	UBERON_0004535	""
central nervous system	activation_acute	HP_0001662	ENSG00000149295	28216264	Lynch et al. (2017)	decreased heart rate	DRD2	UBERON_0001017	""
gastrointestinal	activation_acute	EFO_0003890	ENSG00000149295	28216264	Lynch et al. (2017)	drug abuse/dependence	DRD2	UBERON_0005409	""
central nervous system	activation_acute	EFO_0009853	ENSG00000149295	28216264	Lynch et al. (2017)	decreased convulsions	DRD2	UBERON_0001017	""
cardiovascular	activation_acute	HP_0001662	ENSG00000149295	28216264	Lynch et al. (2017)	decreased heart rate	DRD2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0004372	ENSG00000149295	28216264	Lynch et al. (2017)	confusion	DRD2	UBERON_0004535	""
renal	activation_acute	GO_1904057	ENSG00000149295	28216264	Lynch et al. (2017)	decreased pain	DRD2	UBERON_0001008	""
central nervous system	activation_acute	HP_0002017	ENSG00000149295	28216264	Lynch et al. (2017)	vomiting	DRD2	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000149295	28216264	Lynch et al. (2017)	drug abuse/dependence	DRD2	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0009853	ENSG00000149295	28216264	Lynch et al. (2017)	decreased convulsions	DRD2	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0001662	ENSG00000149295	28216264	Lynch et al. (2017)	decreased heart rate	DRD2	UBERON_0005409	""
renal	activation_acute	HP_0004372	ENSG00000149295	28216264	Lynch et al. (2017)	confusion	DRD2	UBERON_0001008	""
gastrointestinal	activation_acute	HP_0001279	ENSG00000149295	28216264	Lynch et al. (2017)	fainting	DRD2	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0004372	ENSG00000149295	28216264	Lynch et al. (2017)	confusion	DRD2	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0001380	ENSG00000149295	28216264	Lynch et al. (2017)	decreased pituitary hormone secretion	DRD2	UBERON_0004535	""
renal	activation_acute	HP_0000738	ENSG00000149295	28216264	Lynch et al. (2017)	hallucinations	DRD2	UBERON_0001008	""
renal	activation_acute	EFO_0001380	ENSG00000149295	28216264	Lynch et al. (2017)	decreased pituitary hormone secretion	DRD2	UBERON_0001008	""
cardiovascular	activation_acute	GO_1904057	ENSG00000149295	28216264	Lynch et al. (2017)	decreased pain	DRD2	UBERON_0004535	""
renal	activation_acute	EFO_0009853	ENSG00000149295	28216264	Lynch et al. (2017)	decreased convulsions	DRD2	UBERON_0001008	""
renal	activation_acute	EFO_0003890	ENSG00000149295	28216264	Lynch et al. (2017)	drug abuse/dependence	DRD2	UBERON_0001008	""
cardiovascular	activation_acute	HP_0000738	ENSG00000149295	28216264	Lynch et al. (2017)	hallucinations	DRD2	UBERON_0004535	""
central nervous system	activation_acute	HP_0001279	ENSG00000149295	28216264	Lynch et al. (2017)	fainting	DRD2	UBERON_0001017	""
cardiovascular	activation_acute	HP_0002045	ENSG00000149295	28216264	Lynch et al. (2017)	decreased body temperature	DRD2	UBERON_0004535	""
central nervous system	activation_acute	GO_0035815	ENSG00000149295	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD2	UBERON_0001017	""
renal	activation_acute	HP_0001279	ENSG00000149295	28216264	Lynch et al. (2017)	fainting	DRD2	UBERON_0001008	""
renal	activation_acute	EFO_0005251	ENSG00000149295	28216264	Lynch et al. (2017)	decreased blood pressure	DRD2	UBERON_0001008	""
central nervous system	activation_acute	HP_0030897	ENSG00000149295	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	DRD2	UBERON_0001017	""
central nervous system	activation_acute	HP_0004372	ENSG00000149295	28216264	Lynch et al. (2017)	confusion	DRD2	UBERON_0001017	""
renal	activation_acute	HP_0002017	ENSG00000149295	28216264	Lynch et al. (2017)	vomiting	DRD2	UBERON_0001008	""
gastrointestinal	activation_acute	EFO_0001380	ENSG00000149295	28216264	Lynch et al. (2017)	decreased pituitary hormone secretion	DRD2	UBERON_0005409	""
cardiovascular	activation_acute	HP_0002017	ENSG00000149295	28216264	Lynch et al. (2017)	vomiting	DRD2	UBERON_0004535	""
renal	activation_acute	GO_0035815	ENSG00000149295	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD2	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000149295	28216264	Lynch et al. (2017)	decreased blood pressure	DRD2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0030897	ENSG00000149295	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	DRD2	UBERON_0004535	""
gastrointestinal	activation_acute	GO_0035815	ENSG00000149295	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD2	UBERON_0005409	""
renal	activation_acute	HP_0030897	ENSG00000149295	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	DRD2	UBERON_0001008	""
renal	activation_acute	NCIT_C95746	ENSG00000149295	28216264	Lynch et al. (2017)	drowsiness	DRD2	UBERON_0001008	""
central nervous system	activation_acute	HP_0002045	ENSG00000149295	28216264	Lynch et al. (2017)	decreased body temperature	DRD2	UBERON_0001017	""
gastrointestinal	activation_acute	NCIT_C95746	ENSG00000149295	28216264	Lynch et al. (2017)	drowsiness	DRD2	UBERON_0005409	""
cardiovascular	activation_acute	HP_0001279	ENSG00000149295	28216264	Lynch et al. (2017)	fainting	DRD2	UBERON_0004535	""
renal	activation_acute	HP_0001662	ENSG00000149295	28216264	Lynch et al. (2017)	decreased heart rate	DRD2	UBERON_0001008	""
gastrointestinal	activation_acute	GO_1904057	ENSG00000149295	28216264	Lynch et al. (2017)	decreased pain	DRD2	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0030897	ENSG00000149295	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	DRD2	UBERON_0005409	""
renal	activation_acute	""	ENSG00000149295	28216264	Lynch et al. (2017)	decreased/increased Locomotor activity	DRD2	UBERON_0001008	""
central nervous system	activation_acute	EFO_0003890	ENSG00000149295	28216264	Lynch et al. (2017)	drug abuse/dependence	DRD2	UBERON_0001017	""
renal	activation_acute	HP_0000733	ENSG00000149295	28216264	Lynch et al. (2017)	stereotypy	DRD2	UBERON_0001008	""
gastrointestinal	activation_acute	HP_0000738	ENSG00000149295	28216264	Lynch et al. (2017)	hallucinations	DRD2	UBERON_0005409	""
central nervous system	activation_acute	EFO_0001380	ENSG00000149295	28216264	Lynch et al. (2017)	decreased pituitary hormone secretion	DRD2	UBERON_0001017	""
cardiovascular	activation_acute	""	ENSG00000149295	28216264	Lynch et al. (2017)	decreased/increased Locomotor activity	DRD2	UBERON_0004535	""
central nervous system	activation_acute	NCIT_C95746	ENSG00000149295	28216264	Lynch et al. (2017)	drowsiness	DRD2	UBERON_0001017	""
cardiovascular	activation_acute	NCIT_C95746	ENSG00000149295	28216264	Lynch et al. (2017)	drowsiness	DRD2	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0005251	ENSG00000149295	28216264	Lynch et al. (2017)	decreased blood pressure	DRD2	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0002017	ENSG00000149295	28216264	Lynch et al. (2017)	vomiting	DRD2	UBERON_0005409	""
gastrointestinal	activation_acute	""	ENSG00000149295	28216264	Lynch et al. (2017)	decreased/increased Locomotor activity	DRD2	UBERON_0005409	""
central nervous system	activation_acute	HP_0000733	ENSG00000149295	28216264	Lynch et al. (2017)	stereotypy	DRD2	UBERON_0001017	""
gastrointestinal	activation_acute	HP_0002045	ENSG00000149295	28216264	Lynch et al. (2017)	decreased body temperature	DRD2	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000149295	28216264	Lynch et al. (2017)	decreased convulsions	DRD2	UBERON_0004535	""
central nervous system	activation_acute	""	ENSG00000149295	28216264	Lynch et al. (2017)	decreased/increased Locomotor activity	DRD2	UBERON_0001017	""
central nervous system	activation_acute	GO_1904057	ENSG00000149295	28216264	Lynch et al. (2017)	decreased pain	DRD2	UBERON_0001017	""
central nervous system	activation_acute	HP_0000738	ENSG00000149295	28216264	Lynch et al. (2017)	hallucinations	DRD2	UBERON_0001017	""
renal	activation_acute	GO_0040012	ENSG00000184845	28216264	Lynch et al. (2017)	increased/decreased locomotor activity	DRD1	UBERON_0001008	""
renal	activation_chronic	EFO_0009551	ENSG00000184845	28216264	Lynch et al. (2017)	fibrotic valvular heart disease	DRD1	UBERON_0001008	""
renal	inhibition_acute	GO_0040013	ENSG00000184845	28216264	Lynch et al. (2017)	decreased locomotor activity	DRD1	UBERON_0001008	""
renal	inhibition_acute	EFO_1000904	ENSG00000184845	28216264	Lynch et al. (2017)	dyskinesia	DRD1	UBERON_0001008	""
renal	inhibition_acute	HP_0001300	ENSG00000184845	28216264	Lynch et al. (2017)	parkinsonism	DRD1	UBERON_0001008	""
renal	inhibition_acute	MONDO_0002050	ENSG00000184845	28216264	Lynch et al. (2017)	depression	DRD1	UBERON_0001008	""
renal	inhibition_acute	EFO_0005230	ENSG00000184845	28216264	Lynch et al. (2017)	anxiety	DRD1	UBERON_0001008	""
renal	inhibition_acute	EFO_0004320	ENSG00000184845	28216264	Lynch et al. (2017)	suicidal intent	DRD1	UBERON_0001008	""
renal	inhibition_acute	EFO_0009845	ENSG00000184845	28216264	Lynch et al. (2017)	catalepsy	DRD1	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000184845	28216264	Lynch et al. (2017)	decreased convulsions	DRD1	UBERON_0001008	""
renal	inhibition_acute	HP_0032263	ENSG00000184845	28216264	Lynch et al. (2017)	increased blood pressure	DRD1	UBERON_0001008	""
renal	activation_chronic	EFO_0003144	ENSG00000184845	28216264	Lynch et al. (2017)	heart failure	DRD1	UBERON_0001008	""
central nervous system	activation_acute	EFO_1000904	ENSG00000184845	28216264	Lynch et al. (2017)	dyskinesia	DRD1	UBERON_0001017	""
central nervous system	activation_chronic	EFO_0009551	ENSG00000184845	28216264	Lynch et al. (2017)	fibrotic valvular heart disease	DRD1	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0040013	ENSG00000184845	28216264	Lynch et al. (2017)	decreased locomotor activity	DRD1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_1000904	ENSG00000184845	28216264	Lynch et al. (2017)	dyskinesia	DRD1	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001300	ENSG00000184845	28216264	Lynch et al. (2017)	parkinsonism	DRD1	UBERON_0001017	""
central nervous system	inhibition_acute	MONDO_0002050	ENSG00000184845	28216264	Lynch et al. (2017)	depression	DRD1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005230	ENSG00000184845	28216264	Lynch et al. (2017)	anxiety	DRD1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0004320	ENSG00000184845	28216264	Lynch et al. (2017)	suicidal intent	DRD1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009845	ENSG00000184845	28216264	Lynch et al. (2017)	catalepsy	DRD1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000184845	28216264	Lynch et al. (2017)	decreased convulsions	DRD1	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0032263	ENSG00000184845	28216264	Lynch et al. (2017)	increased blood pressure	DRD1	UBERON_0001017	""
central nervous system	activation_chronic	EFO_0003144	ENSG00000184845	28216264	Lynch et al. (2017)	heart failure	DRD1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009853	ENSG00000184845	28216264	Lynch et al. (2017)	convulsions	DRD1	UBERON_0001017	""
renal	activation_acute	EFO_0009853	ENSG00000184845	28216264	Lynch et al. (2017)	convulsions	DRD1	UBERON_0001008	""
renal	activation_acute	EFO_0005251	ENSG00000184845	28216264	Lynch et al. (2017)	decreased blood pressure	DRD1	UBERON_0001008	""
cardiovascular	activation_acute	HP_0002315	ENSG00000184845	28216264	Lynch et al. (2017)	headache	DRD1	UBERON_0004535	""
cardiovascular	activation_chronic	EFO_0009551	ENSG00000184845	28216264	Lynch et al. (2017)	fibrotic valvular heart disease	DRD1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040013	ENSG00000184845	28216264	Lynch et al. (2017)	decreased locomotor activity	DRD1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_1000904	ENSG00000184845	28216264	Lynch et al. (2017)	dyskinesia	DRD1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001300	ENSG00000184845	28216264	Lynch et al. (2017)	parkinsonism	DRD1	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0002050	ENSG00000184845	28216264	Lynch et al. (2017)	depression	DRD1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005230	ENSG00000184845	28216264	Lynch et al. (2017)	anxiety	DRD1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004320	ENSG00000184845	28216264	Lynch et al. (2017)	suicidal intent	DRD1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009845	ENSG00000184845	28216264	Lynch et al. (2017)	catalepsy	DRD1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000184845	28216264	Lynch et al. (2017)	decreased convulsions	DRD1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000184845	28216264	Lynch et al. (2017)	increased blood pressure	DRD1	UBERON_0004535	""
cardiovascular	activation_chronic	EFO_0003144	ENSG00000184845	28216264	Lynch et al. (2017)	heart failure	DRD1	UBERON_0004535	""
cardiovascular	activation_acute	GO_0035815	ENSG00000184845	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD1	UBERON_0004535	""
renal	activation_acute	EFO_0009849	ENSG00000184845	28216264	Lynch et al. (2017)	increased arousal	DRD1	UBERON_0001008	""
cardiovascular	activation_acute	HP_0002180	ENSG00000184845	28216264	Lynch et al. (2017)	neurodegeneration	DRD1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000184845	28216264	Lynch et al. (2017)	drug abuse/dependence	DRD1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0005251	ENSG00000184845	28216264	Lynch et al. (2017)	decreased blood pressure	DRD1	UBERON_0001017	""
renal	activation_acute	HP_0002018	ENSG00000184845	28216264	Lynch et al. (2017)	nausea	DRD1	UBERON_0001008	""
central nervous system	activation_acute	HP_0002018	ENSG00000184845	28216264	Lynch et al. (2017)	nausea	DRD1	UBERON_0001017	""
central nervous system	activation_acute	HP_0002180	ENSG00000184845	28216264	Lynch et al. (2017)	neurodegeneration	DRD1	UBERON_0001017	""
renal	activation_acute	HP_0002180	ENSG00000184845	28216264	Lynch et al. (2017)	neurodegeneration	DRD1	UBERON_0001008	""
renal	activation_acute	EFO_0005407	ENSG00000184845	28216264	Lynch et al. (2017)	psychosis	DRD1	UBERON_0001008	""
central nervous system	activation_acute	HP_0002315	ENSG00000184845	28216264	Lynch et al. (2017)	headache	DRD1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009849	ENSG00000184845	28216264	Lynch et al. (2017)	increased arousal	DRD1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009847	ENSG00000184845	28216264	Lynch et al. (2017)	dizziness	DRD1	UBERON_0001017	""
renal	activation_acute	EFO_0009847	ENSG00000184845	28216264	Lynch et al. (2017)	dizziness	DRD1	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0005407	ENSG00000184845	28216264	Lynch et al. (2017)	psychosis	DRD1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_1000904	ENSG00000184845	28216264	Lynch et al. (2017)	dyskinesia	DRD1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002018	ENSG00000184845	28216264	Lynch et al. (2017)	nausea	DRD1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0003890	ENSG00000184845	28216264	Lynch et al. (2017)	drug abuse/dependence	DRD1	UBERON_0001017	""
cardiovascular	activation_acute	GO_0040012	ENSG00000184845	28216264	Lynch et al. (2017)	increased/decreased locomotor activity	DRD1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009849	ENSG00000184845	28216264	Lynch et al. (2017)	increased arousal	DRD1	UBERON_0001017	""
central nervous system	activation_acute	GO_0040012	ENSG00000184845	28216264	Lynch et al. (2017)	increased/decreased locomotor activity	DRD1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000184845	28216264	Lynch et al. (2017)	decreased blood pressure	DRD1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000184845	28216264	Lynch et al. (2017)	convulsions	DRD1	UBERON_0004535	""
central nervous system	activation_acute	GO_0035815	ENSG00000184845	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD1	UBERON_0001017	""
cardiovascular	activation_acute	HP_0000103	ENSG00000184845	28216264	Lynch et al. (2017)	increased urine excretion	DRD1	UBERON_0004535	""
renal	activation_acute	HP_0000103	ENSG00000184845	28216264	Lynch et al. (2017)	increased urine excretion	DRD1	UBERON_0001008	""
central nervous system	activation_acute	EFO_0005407	ENSG00000184845	28216264	Lynch et al. (2017)	psychosis	DRD1	UBERON_0001017	""
renal	activation_acute	HP_0002315	ENSG00000184845	28216264	Lynch et al. (2017)	headache	DRD1	UBERON_0001008	""
renal	activation_acute	GO_0035815	ENSG00000184845	28216264	Lynch et al. (2017)	increased urinary sodium excretion	DRD1	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0009847	ENSG00000184845	28216264	Lynch et al. (2017)	dizziness	DRD1	UBERON_0004535	""
central nervous system	activation_acute	HP_0000103	ENSG00000184845	28216264	Lynch et al. (2017)	increased urine excretion	DRD1	UBERON_0001017	""
renal	activation_acute	EFO_0003890	ENSG00000184845	28216264	Lynch et al. (2017)	drug abuse/dependence	DRD1	UBERON_0001008	""
renal	activation_acute	EFO_1000904	ENSG00000184845	28216264	Lynch et al. (2017)	dyskinesia	DRD1	UBERON_0001008	""
immune	activation_acute	HP_0000103	ENSG00000135124	28216264	Lynch et al. (2017)	increased urine excretion	P2RX4	UBERON_0002405	""
immune	activation_chronic	HP_0002180	ENSG00000135124	28216264	Lynch et al. (2017)	neurodegeneration	P2RX4	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000135124	28216264	Lynch et al. (2017)	decreased pain	P2RX4	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000135124	28216264	Lynch et al. (2017)	decreased inflammation	P2RX4	UBERON_0002405	""
immune	inhibition_acute	EFO_0009853	ENSG00000135124	28216264	Lynch et al. (2017)	decreased convulsions	P2RX4	UBERON_0002405	""
immune	activation_acute	EFO_0009473	ENSG00000135124	28216264	Lynch et al. (2017)	hemolysis	P2RX4	UBERON_0002405	""
nervous system	activation_acute	HP_0000103	ENSG00000135124	28216264	Lynch et al. (2017)	increased urine excretion	P2RX4	UBERON_0001016	""
nervous system	activation_chronic	HP_0002180	ENSG00000135124	28216264	Lynch et al. (2017)	neurodegeneration	P2RX4	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000135124	28216264	Lynch et al. (2017)	decreased pain	P2RX4	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050728	ENSG00000135124	28216264	Lynch et al. (2017)	decreased inflammation	P2RX4	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000135124	28216264	Lynch et al. (2017)	decreased convulsions	P2RX4	UBERON_0001016	""
renal	activation_acute	HP_0000103	ENSG00000135124	28216264	Lynch et al. (2017)	increased urine excretion	P2RX4	UBERON_0001008	""
renal	activation_chronic	HP_0002180	ENSG00000135124	28216264	Lynch et al. (2017)	neurodegeneration	P2RX4	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000135124	28216264	Lynch et al. (2017)	decreased pain	P2RX4	UBERON_0001008	""
renal	inhibition_acute	GO_0050728	ENSG00000135124	28216264	Lynch et al. (2017)	decreased inflammation	P2RX4	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000135124	28216264	Lynch et al. (2017)	decreased convulsions	P2RX4	UBERON_0001008	""
immune	activation_acute	GO_0035815	ENSG00000135124	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX4	UBERON_0002405	""
nervous system	activation_acute	EFO_0009473	ENSG00000135124	28216264	Lynch et al. (2017)	hemolysis	P2RX4	UBERON_0001016	""
renal	activation_acute	GO_0035815	ENSG00000135124	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX4	UBERON_0001008	""
nervous system	activation_acute	GO_1904058	ENSG00000135124	28216264	Lynch et al. (2017)	increased pain	P2RX4	UBERON_0001016	""
renal	activation_acute	GO_1904058	ENSG00000135124	28216264	Lynch et al. (2017)	increased pain	P2RX4	UBERON_0001008	""
nervous system	activation_acute	GO_0035815	ENSG00000135124	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX4	UBERON_0001016	""
renal	activation_acute	EFO_0009473	ENSG00000135124	28216264	Lynch et al. (2017)	hemolysis	P2RX4	UBERON_0001008	""
immune	activation_acute	GO_1904058	ENSG00000135124	28216264	Lynch et al. (2017)	increased pain	P2RX4	UBERON_0002405	""
renal	inhibition_acute	EFO_0005251	ENSG00000159640	28216264	Lynch et al. (2017)	decreased blood pressure	ACE	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_1001255	ENSG00000159640	28216264	Lynch et al. (2017)	increased risk spontaneous abortion	ACE	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000159640	28216264	Lynch et al. (2017)	increased urine excretion	ACE	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000159640	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ACE	UBERON_0001008	""
renal	inhibition_acute	Orphanet_47159	ENSG00000159640	28216264	Lynch et al. (2017)	proximal tubular degeneration	ACE	UBERON_0001008	""
renal	inhibition_acute	HP_0000111	ENSG00000159640	28216264	Lynch et al. (2017)	juxtaglomerular cell hyperplasia	ACE	UBERON_0001008	""
renal	inhibition_acute	EFO_0009832	ENSG00000159640	28216264	Lynch et al. (2017)	interstitial cell infiltration	ACE	UBERON_0001008	""
renal	inhibition_acute	HP_0004398	ENSG00000159640	28216264	Lynch et al. (2017)	gastrointestinal hemorrhagic erosion/ulcer	ACE	UBERON_0001008	""
renal	inhibition_acute	HP_0010972	ENSG00000159640	28216264	Lynch et al. (2017)	decreased bone marrow erythropoiesis	ACE	UBERON_0001008	""
renal	inhibition_acute	""	ENSG00000159640	28216264	Lynch et al. (2017)	hepatocytic vacuolar degeneration	ACE	UBERON_0001008	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000159640	28216264	Lynch et al. (2017)	decreased blood pressure	ACE	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	EFO_1001255	ENSG00000159640	28216264	Lynch et al. (2017)	increased risk spontaneous abortion	ACE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000159640	28216264	Lynch et al. (2017)	increased urine excretion	ACE	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000159640	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ACE	UBERON_0004535	""
cardiovascular	inhibition_acute	Orphanet_47159	ENSG00000159640	28216264	Lynch et al. (2017)	proximal tubular degeneration	ACE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000111	ENSG00000159640	28216264	Lynch et al. (2017)	juxtaglomerular cell hyperplasia	ACE	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009832	ENSG00000159640	28216264	Lynch et al. (2017)	interstitial cell infiltration	ACE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0004398	ENSG00000159640	28216264	Lynch et al. (2017)	gastrointestinal hemorrhagic erosion/ulcer	ACE	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0010972	ENSG00000159640	28216264	Lynch et al. (2017)	decreased bone marrow erythropoiesis	ACE	UBERON_0004535	""
cardiovascular	inhibition_acute	""	ENSG00000159640	28216264	Lynch et al. (2017)	hepatocytic vacuolar degeneration	ACE	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000151834	28216264	Lynch et al. (2017)	muscle relaxation	GABRA2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000151834	28216264	Lynch et al. (2017)	convulsions	GABRA2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000151834	28216264	Lynch et al. (2017)	decreased sleep	GABRA2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0008568	ENSG00000151834	28216264	Lynch et al. (2017)	increased sleep	GABRA2	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000151834	28216264	Lynch et al. (2017)	convulsions	GABRA2	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000151834	28216264	Lynch et al. (2017)	decreased sleep	GABRA2	UBERON_0001017	""
central nervous system	activation_acute	GO_0045822	ENSG00000151834	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA2	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009853	ENSG00000151834	28216264	Lynch et al. (2017)	decreased convulsions	GABRA2	UBERON_0001017	""
cardiovascular	activation_acute	HP_0002045	ENSG00000151834	28216264	Lynch et al. (2017)	decreased body temperature	GABRA2	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000151834	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA2	UBERON_0004535	""
cardiovascular	activation_acute	GO_1904057	ENSG00000151834	28216264	Lynch et al. (2017)	decreased pain	GABRA2	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000151834	28216264	Lynch et al. (2017)	decreased convulsions	GABRA2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009874	ENSG00000151834	28216264	Lynch et al. (2017)	decreased anxiety	GABRA2	UBERON_0001017	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000151834	28216264	Lynch et al. (2017)	ataxia	GABRA2	UBERON_0001017	""
central nervous system	activation_acute	GO_0040013	ENSG00000151834	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA2	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000151834	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0003890	ENSG00000151834	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA2	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009840	ENSG00000151834	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA2	UBERON_0001017	""
central nervous system	activation_acute	EFO_0001072	ENSG00000151834	28216264	Lynch et al. (2017)	decreased memory	GABRA2	UBERON_0001017	""
cardiovascular	activation_acute	GO_0040013	ENSG00000151834	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA2	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000151834	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009872	ENSG00000151834	28216264	Lynch et al. (2017)	increased cardiac output	GABRA2	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000151834	28216264	Lynch et al. (2017)	decreased memory	GABRA2	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0008568	ENSG00000151834	28216264	Lynch et al. (2017)	increased sleep	GABRA2	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009872	ENSG00000151834	28216264	Lynch et al. (2017)	increased cardiac output	GABRA2	UBERON_0004535	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000151834	28216264	Lynch et al. (2017)	ataxia	GABRA2	UBERON_0004535	""
cardiovascular	activation_acute	HP_0100738	ENSG00000151834	28216264	Lynch et al. (2017)	increased eating	GABRA2	UBERON_0004535	""
cardiovascular	activation_acute	GO_0045822	ENSG00000151834	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0005251	ENSG00000151834	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA2	UBERON_0001017	""
central nervous system	activation_acute	HP_0002045	ENSG00000151834	28216264	Lynch et al. (2017)	decreased body temperature	GABRA2	UBERON_0001017	""
central nervous system	activation_acute	""	ENSG00000151834	28216264	Lynch et al. (2017)	muscle relaxation	GABRA2	UBERON_0001017	""
central nervous system	activation_acute	GO_1904057	ENSG00000151834	28216264	Lynch et al. (2017)	decreased pain	GABRA2	UBERON_0001017	""
central nervous system	activation_acute	HP_0100738	ENSG00000151834	28216264	Lynch et al. (2017)	increased eating	GABRA2	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000151834	28216264	Lynch et al. (2017)	decreased anxiety	GABRA2	UBERON_0004535	""
gastrointestinal	activation_general	HP_0003470	ENSG00000101204	23197038	Bowes et al. (2012)	paralysis	CHRNA4	UBERON_0005409	""
gastrointestinal	inhibition_general	""	ENSG00000101204	23197038	Bowes et al. (2012)	muscle relaxation	CHRNA4	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0002019	ENSG00000101204	23197038	Bowes et al. (2012)	constipation	CHRNA4	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0002104	ENSG00000101204	23197038	Bowes et al. (2012)	apnoea	CHRNA4	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0005251	ENSG00000101204	23197038	Bowes et al. (2012)	decreased blood pressure	CHRNA4	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0001662	ENSG00000101204	23197038	Bowes et al. (2012)	decreased heart rate	CHRNA4	UBERON_0005409	""
gastrointestinal	activation_general	EFO_1001484	ENSG00000101204	23197038	Bowes et al. (2012)	analgesia	CHRNA4	UBERON_0005409	""
gastrointestinal	activation_general	HP_0001649	ENSG00000101204	23197038	Bowes et al. (2012)	increased heart rate	CHRNA4	UBERON_0005409	""
gastrointestinal	activation_general	HP_0001962	ENSG00000101204	23197038	Bowes et al. (2012)	palpitations	CHRNA4	UBERON_0005409	""
gastrointestinal	activation_general	HP_0002018	ENSG00000101204	23197038	Bowes et al. (2012)	nausea	CHRNA4	UBERON_0005409	""
gastrointestinal	activation_general	EFO_0003890	ENSG00000101204	23197038	Bowes et al. (2012)	abuse potential	CHRNA4	UBERON_0005409	""
cardiovascular system	activation_general	HP_0003470	ENSG00000101204	23197038	Bowes et al. (2012)	paralysis	CHRNA4	UBERON_0004535	""
cardiovascular system	inhibition_general	""	ENSG00000101204	23197038	Bowes et al. (2012)	muscle relaxation	CHRNA4	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0002019	ENSG00000101204	23197038	Bowes et al. (2012)	constipation	CHRNA4	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0002104	ENSG00000101204	23197038	Bowes et al. (2012)	apnoea	CHRNA4	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000101204	23197038	Bowes et al. (2012)	decreased blood pressure	CHRNA4	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001662	ENSG00000101204	23197038	Bowes et al. (2012)	decreased heart rate	CHRNA4	UBERON_0004535	""
cardiovascular system	activation_general	EFO_1001484	ENSG00000101204	23197038	Bowes et al. (2012)	analgesia	CHRNA4	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001649	ENSG00000101204	23197038	Bowes et al. (2012)	increased heart rate	CHRNA4	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001962	ENSG00000101204	23197038	Bowes et al. (2012)	palpitations	CHRNA4	UBERON_0004535	""
cardiovascular system	activation_general	HP_0002018	ENSG00000101204	23197038	Bowes et al. (2012)	nausea	CHRNA4	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0003890	ENSG00000101204	23197038	Bowes et al. (2012)	abuse potential	CHRNA4	UBERON_0004535	""
central nervous system	activation_general	HP_0003470	ENSG00000101204	23197038	Bowes et al. (2012)	paralysis	CHRNA4	UBERON_0001017	""
central nervous system	inhibition_general	""	ENSG00000101204	23197038	Bowes et al. (2012)	muscle relaxation	CHRNA4	UBERON_0001017	""
central nervous system	inhibition_general	HP_0002019	ENSG00000101204	23197038	Bowes et al. (2012)	constipation	CHRNA4	UBERON_0001017	""
central nervous system	inhibition_general	HP_0002104	ENSG00000101204	23197038	Bowes et al. (2012)	apnoea	CHRNA4	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0005251	ENSG00000101204	23197038	Bowes et al. (2012)	decreased blood pressure	CHRNA4	UBERON_0001017	""
central nervous system	inhibition_general	HP_0001662	ENSG00000101204	23197038	Bowes et al. (2012)	decreased heart rate	CHRNA4	UBERON_0001017	""
central nervous system	activation_general	EFO_1001484	ENSG00000101204	23197038	Bowes et al. (2012)	analgesia	CHRNA4	UBERON_0001017	""
central nervous system	activation_general	HP_0001649	ENSG00000101204	23197038	Bowes et al. (2012)	increased heart rate	CHRNA4	UBERON_0001017	""
central nervous system	activation_general	HP_0001962	ENSG00000101204	23197038	Bowes et al. (2012)	palpitations	CHRNA4	UBERON_0001017	""
central nervous system	activation_general	HP_0002018	ENSG00000101204	23197038	Bowes et al. (2012)	nausea	CHRNA4	UBERON_0001017	""
central nervous system	activation_general	EFO_0003890	ENSG00000101204	23197038	Bowes et al. (2012)	abuse potential	CHRNA4	UBERON_0001017	""
pulmonary	activation_general	HP_0003470	ENSG00000101204	23197038	Bowes et al. (2012)	paralysis	CHRNA4	UBERON_0002048	""
pulmonary	inhibition_general	""	ENSG00000101204	23197038	Bowes et al. (2012)	muscle relaxation	CHRNA4	UBERON_0002048	""
pulmonary	inhibition_general	HP_0002019	ENSG00000101204	23197038	Bowes et al. (2012)	constipation	CHRNA4	UBERON_0002048	""
pulmonary	inhibition_general	HP_0002104	ENSG00000101204	23197038	Bowes et al. (2012)	apnoea	CHRNA4	UBERON_0002048	""
pulmonary	inhibition_general	EFO_0005251	ENSG00000101204	23197038	Bowes et al. (2012)	decreased blood pressure	CHRNA4	UBERON_0002048	""
pulmonary	inhibition_general	HP_0001662	ENSG00000101204	23197038	Bowes et al. (2012)	decreased heart rate	CHRNA4	UBERON_0002048	""
pulmonary	activation_general	EFO_1001484	ENSG00000101204	23197038	Bowes et al. (2012)	analgesia	CHRNA4	UBERON_0002048	""
pulmonary	activation_general	HP_0001649	ENSG00000101204	23197038	Bowes et al. (2012)	increased heart rate	CHRNA4	UBERON_0002048	""
pulmonary	activation_general	HP_0001962	ENSG00000101204	23197038	Bowes et al. (2012)	palpitations	CHRNA4	UBERON_0002048	""
pulmonary	activation_general	HP_0002018	ENSG00000101204	23197038	Bowes et al. (2012)	nausea	CHRNA4	UBERON_0002048	""
pulmonary	activation_general	EFO_0003890	ENSG00000101204	23197038	Bowes et al. (2012)	abuse potential	CHRNA4	UBERON_0002048	""
cardiovascular system	activation_general	""	ENSG00000151617	""	Urban et al. (2012)	vasoconstriction	EDNRA	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_developmental toxicity	EFO_0009880	ENSG00000151617	""	Urban et al. (2012)	teratogenicity	EDNRA	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009836	ENSG00000151617	""	Urban et al. (2012)	bronchoconstriction	EDNRA	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0035932	ENSG00000151617	""	Urban et al. (2012)	aldosterone secretion	EDNRA	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0033687	ENSG00000151617	""	Urban et al. (2012)	osteoblast proliferation	EDNRA	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000142208	""	Urban et al. (2012)	may be cardioprotective	AKT1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0003074	ENSG00000142208	""	Urban et al. (2012)	hyperglycemia	AKT1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000142208	""	Urban et al. (2012)	apoptototic cell death in cancer cells	AKT1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
gonad	activation_acute	EFO_0009836	ENSG00000075073	28216264	Lynch et al. (2017)	bronchoconstriction	TACR2	UBERON_0000991	""
gonad	inhibition_acute	HP_0030897	ENSG00000075073	28216264	Lynch et al. (2017)	decreased intestinal transit	TACR2	UBERON_0000991	""
gonad	inhibition_acute	GO_1904057	ENSG00000075073	28216264	Lynch et al. (2017)	decreased pain	TACR2	UBERON_0000991	""
gonad	inhibition_acute	GO_0050728	ENSG00000075073	28216264	Lynch et al. (2017)	decreased inflammation	TACR2	UBERON_0000991	""
gonad	inhibition_acute	EFO_0009874	ENSG00000075073	28216264	Lynch et al. (2017)	decreased anxiety	TACR2	UBERON_0000991	""
gonad	inhibition_acute	HP_0000029	ENSG00000075073	28216264	Lynch et al. (2017)	testicular degeneration	TACR2	UBERON_0000991	""
gonad	inhibition_acute	HP_0000823	ENSG00000075073	28216264	Lynch et al. (2017)	delayed/absent sexual maturity	TACR2	UBERON_0000991	""
gastrointestinal	activation_acute	EFO_0009836	ENSG00000075073	28216264	Lynch et al. (2017)	bronchoconstriction	TACR2	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0030897	ENSG00000075073	28216264	Lynch et al. (2017)	decreased intestinal transit	TACR2	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1904057	ENSG00000075073	28216264	Lynch et al. (2017)	decreased pain	TACR2	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0050728	ENSG00000075073	28216264	Lynch et al. (2017)	decreased inflammation	TACR2	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009874	ENSG00000075073	28216264	Lynch et al. (2017)	decreased anxiety	TACR2	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000029	ENSG00000075073	28216264	Lynch et al. (2017)	testicular degeneration	TACR2	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0000823	ENSG00000075073	28216264	Lynch et al. (2017)	delayed/absent sexual maturity	TACR2	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0410204	ENSG00000075073	28216264	Lynch et al. (2017)	increased intestinal transit	TACR2	UBERON_0005409	""
immune	activation_acute	EFO_1000781	ENSG00000075073	28216264	Lynch et al. (2017)	increased urinary bladder contractions	TACR2	UBERON_0002405	""
immune	inhibition_acute	HP_0030897	ENSG00000075073	28216264	Lynch et al. (2017)	decreased intestinal transit	TACR2	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000075073	28216264	Lynch et al. (2017)	decreased pain	TACR2	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000075073	28216264	Lynch et al. (2017)	decreased inflammation	TACR2	UBERON_0002405	""
immune	inhibition_acute	EFO_0009874	ENSG00000075073	28216264	Lynch et al. (2017)	decreased anxiety	TACR2	UBERON_0002405	""
immune	inhibition_acute	HP_0000029	ENSG00000075073	28216264	Lynch et al. (2017)	testicular degeneration	TACR2	UBERON_0002405	""
immune	inhibition_acute	HP_0000823	ENSG00000075073	28216264	Lynch et al. (2017)	delayed/absent sexual maturity	TACR2	UBERON_0002405	""
immune	activation_acute	HP_0410204	ENSG00000075073	28216264	Lynch et al. (2017)	increased intestinal transit	TACR2	UBERON_0002405	""
gonad	activation_acute	HP_0410204	ENSG00000075073	28216264	Lynch et al. (2017)	increased intestinal transit	TACR2	UBERON_0000991	""
immune	activation_acute	EFO_0009836	ENSG00000075073	28216264	Lynch et al. (2017)	bronchoconstriction	TACR2	UBERON_0002405	""
gonad	activation_acute	EFO_1000781	ENSG00000075073	28216264	Lynch et al. (2017)	increased urinary bladder contractions	TACR2	UBERON_0000991	""
gastrointestinal	activation_acute	EFO_1000781	ENSG00000075073	28216264	Lynch et al. (2017)	increased urinary bladder contractions	TACR2	UBERON_0005409	""
cardiovascular system	inhibition_general	GO_0050728	ENSG00000073756	""	Urban et al. (2012)	antiinflammatory	PTGS2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	GO_0045839	ENSG00000073756	""	Urban et al. (2012)	inhibits some mitogenic actions	PTGS2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000319	ENSG00000073756	""	Urban et al. (2012)	increased risk of adverse cardiovascular events (heart failure, clotting)	PTGS2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000073756	""	Urban et al. (2012)	increased risk of wound infections	PTGS2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0004755	ENSG00000073756	""	Urban et al. (2012)	supraventricular tachycardia	PTGS2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000073756	""	Urban et al. (2012)	hypotension	PTGS2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000612	ENSG00000073756	""	Urban et al. (2012)	myocardial infarction	PTGS2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000073756	""	Urban et al. (2012)	cerebrovascular events have been reported	PTGS2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0032263	ENSG00000168539	""	Urban et al. (2012)	increased blood pressure	CHRM1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0100543	ENSG00000168539	""	Urban et al. (2012)	disruption of cognitive functions such as learning and memory	CHRM1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0001649	ENSG00000168539	""	Urban et al. (2012)	increased heart rate	CHRM1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000168539	""	Urban et al. (2012)	increased sympathetic outflow	CHRM1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0012719	ENSG00000168539	""	Urban et al. (2012)	gastrointestinal side effects	CHRM1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	GO_0042752	ENSG00000168539	""	Urban et al. (2012)	may be involved in the regulation of circadian rhythm	CHRM1	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	HP_0032263	ENSG00000168539	""	Urban et al. (2012)	increased blood pressure	CHRM1	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	HP_0100543	ENSG00000168539	""	Urban et al. (2012)	disruption of cognitive functions such as learning and memory	CHRM1	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	HP_0001649	ENSG00000168539	""	Urban et al. (2012)	increased heart rate	CHRM1	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	""	ENSG00000168539	""	Urban et al. (2012)	increased sympathetic outflow	CHRM1	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	HP_0012719	ENSG00000168539	""	Urban et al. (2012)	gastrointestinal side effects	CHRM1	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	GO_0042752	ENSG00000168539	""	Urban et al. (2012)	may be involved in the regulation of circadian rhythm	CHRM1	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0032263	ENSG00000168539	""	Urban et al. (2012)	increased blood pressure	CHRM1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0100543	ENSG00000168539	""	Urban et al. (2012)	disruption of cognitive functions such as learning and memory	CHRM1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0001649	ENSG00000168539	""	Urban et al. (2012)	increased heart rate	CHRM1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000168539	""	Urban et al. (2012)	increased sympathetic outflow	CHRM1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0012719	ENSG00000168539	""	Urban et al. (2012)	gastrointestinal side effects	CHRM1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0042752	ENSG00000168539	""	Urban et al. (2012)	may be involved in the regulation of circadian rhythm	CHRM1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000184160	""	Urban et al. (2012)	involved in many processes such as the startle reflex, stress response, and locomotion	ADRA2C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000184160	""	Urban et al. (2012)	venous contraction (contraction of human saphenous vein)	ADRA2C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0000537	ENSG00000184160	""	Urban et al. (2012)	hypertension	ADRA2C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_1001375	ENSG00000184160	""	Urban et al. (2012)	cardiac ischemia	ADRA2C	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
central nervous system	activation_general	""	ENSG00000184160	""	Urban et al. (2012)	involved in many processes such as the startle reflex, stress response, and locomotion	ADRA2C	UBERON_0001017	https://doi.org/10.1002/9781118098141.ch2
central nervous system	activation_general	""	ENSG00000184160	""	Urban et al. (2012)	venous contraction (contraction of human saphenous vein)	ADRA2C	UBERON_0001017	https://doi.org/10.1002/9781118098141.ch2
central nervous system	activation_general	EFO_0000537	ENSG00000184160	""	Urban et al. (2012)	hypertension	ADRA2C	UBERON_0001017	https://doi.org/10.1002/9781118098141.ch2
central nervous system	activation_general	EFO_1001375	ENSG00000184160	""	Urban et al. (2012)	cardiac ischemia	ADRA2C	UBERON_0001017	https://doi.org/10.1002/9781118098141.ch2
renal	inhibition_acute	GO_0045823	ENSG00000132681	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1A4	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000132681	28216264	Lynch et al. (2017)	decreased heart rate	ATP1A4	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000132681	28216264	Lynch et al. (2017)	atrioventricular block	ATP1A4	UBERON_0001008	""
renal	inhibition_acute	EFO_0004269	ENSG00000132681	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1A4	UBERON_0001008	""
renal	inhibition_acute	EFO_0004287	ENSG00000132681	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1A4	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000132681	28216264	Lynch et al. (2017)	increased urine excretion	ATP1A4	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000132681	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1A4	UBERON_0001008	""
renal	inhibition_acute	HP_0002017	ENSG00000132681	28216264	Lynch et al. (2017)	vomiting	ATP1A4	UBERON_0001008	""
cardiovascular	inhibition_acute	GO_0045823	ENSG00000132681	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1A4	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000132681	28216264	Lynch et al. (2017)	decreased heart rate	ATP1A4	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000132681	28216264	Lynch et al. (2017)	atrioventricular block	ATP1A4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000132681	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1A4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004287	ENSG00000132681	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1A4	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000132681	28216264	Lynch et al. (2017)	increased urine excretion	ATP1A4	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000132681	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1A4	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002017	ENSG00000132681	28216264	Lynch et al. (2017)	vomiting	ATP1A4	UBERON_0004535	""
immune	activation_general	GO_0050777	ENSG00000282608	""	Urban et al. (2012)	immunosuppression	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
immune	inhibition_general	EFO_1001375	ENSG00000282608	""	Urban et al. (2012)	myocardial ischemia (inferred by author)	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
immune	inhibition_general	GO_0050729	ENSG00000282608	""	Urban et al. (2012)	proinflammatory effects (inferred by author)	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
immune	inhibition_general	EFO_0000537	ENSG00000282608	""	Urban et al. (2012)	hypertension (inferred by author)	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
immune	inhibition_general	""	ENSG00000282608	""	Urban et al. (2012)	interference with the regulation of cell growth (inferred by author)	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
immune	activation_general	EFO_0005251	ENSG00000282608	""	Urban et al. (2012)	hypotension	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
immune	activation_general	""	ENSG00000282608	""	Urban et al. (2012)	antiischaemic (cardioprotective)	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
immune	activation_general	""	ENSG00000282608	""	Urban et al. (2012)	proischemic (cerebral)	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
immune	activation_general	EFO_0009426	ENSG00000282608	""	Urban et al. (2012)	cell necrosis	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
immune	activation_general	GO_0008283	ENSG00000282608	""	Urban et al. (2012)	cell proliferation	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
immune	activation_general	""	ENSG00000282608	""	Urban et al. (2012)	angiogenesis	ADORA3	UBERON_0002405	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0050777	ENSG00000282608	""	Urban et al. (2012)	immunosuppression	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_1001375	ENSG00000282608	""	Urban et al. (2012)	myocardial ischemia (inferred by author)	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	GO_0050729	ENSG00000282608	""	Urban et al. (2012)	proinflammatory effects (inferred by author)	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000537	ENSG00000282608	""	Urban et al. (2012)	hypertension (inferred by author)	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000282608	""	Urban et al. (2012)	interference with the regulation of cell growth (inferred by author)	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0005251	ENSG00000282608	""	Urban et al. (2012)	hypotension	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000282608	""	Urban et al. (2012)	antiischaemic (cardioprotective)	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000282608	""	Urban et al. (2012)	proischemic (cerebral)	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009426	ENSG00000282608	""	Urban et al. (2012)	cell necrosis	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0008283	ENSG00000282608	""	Urban et al. (2012)	cell proliferation	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000282608	""	Urban et al. (2012)	angiogenesis	ADORA3	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000123374	""	HeCaToS	cardiomyocyte hyperproliferation	CDK2	UBERON_0004535	https://www.hecatos.eu/IManager/Download/687/66208/16240/1534958/EN/16240_1534958_NCDS_D1.5_Package_of_predictive_models_of_target-pathway-ADME_activities__M21.pdf
cardiovascular system	activation_general	HP_0001662	ENSG00000181072	""	Urban et al. (2012)	bradycardia	CHRM2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0001962	ENSG00000181072	""	Urban et al. (2012)	palpitations	CHRM2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0004269	ENSG00000181072	""	Urban et al. (2012)	dysrhythmia	CHRM2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000181072	""	Urban et al. (2012)	peripheral edema	CHRM2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0001649	ENSG00000181072	""	Urban et al. (2012)	tachycardia	CHRM2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000181072	""	Urban et al. (2012)	vagal effects (key role in control of heart rate and smooth muscle activity)	CHRM2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	GO_0045823	ENSG00000172572	23197038	Bowes et al. (2012)	increased cardiac contractility	PDE3A	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001649	ENSG00000172572	23197038	Bowes et al. (2012)	increased heart rate	PDE3A	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000172572	23197038	Bowes et al. (2012)	decreased blood pressure	PDE3A	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001873	ENSG00000172572	23197038	Bowes et al. (2012)	thrombocytopaenia	PDE3A	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0004308	ENSG00000172572	23197038	Bowes et al. (2012)	ventricular arrhythmia	PDE3A	UBERON_0004535	""
pulmonary	inhibition_acute	HP_0002579	ENSG00000087085	23197038	Bowes et al. (2012)	decreased gastrointestinal motility	ACHE	UBERON_0002048	""
pulmonary	inhibition_general	EFO_0005251	ENSG00000087085	23197038	Bowes et al. (2012)	decreased blood pressure	ACHE	UBERON_0002048	""
pulmonary	inhibition_general	HP_0001662	ENSG00000087085	23197038	Bowes et al. (2012)	decreased heart rate	ACHE	UBERON_0002048	""
pulmonary	inhibition_general	HP_0030895	ENSG00000087085	23197038	Bowes et al. (2012)	increased gastrointestinal motility	ACHE	UBERON_0002048	""
pulmonary	inhibition_general	EFO_0009836	ENSG00000087085	23197038	Bowes et al. (2012)	bronchoconstriction	ACHE	UBERON_0002048	""
pulmonary	inhibition_general	EFO_0009835	ENSG00000087085	23197038	Bowes et al. (2012)	increased respiratory secretions	ACHE	UBERON_0002048	""
gastrointestinal	inhibition_acute	HP_0002579	ENSG00000087085	23197038	Bowes et al. (2012)	decreased gastrointestinal motility	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0005251	ENSG00000087085	23197038	Bowes et al. (2012)	decreased blood pressure	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0001662	ENSG00000087085	23197038	Bowes et al. (2012)	decreased heart rate	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0030895	ENSG00000087085	23197038	Bowes et al. (2012)	increased gastrointestinal motility	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0009836	ENSG00000087085	23197038	Bowes et al. (2012)	bronchoconstriction	ACHE	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0009835	ENSG00000087085	23197038	Bowes et al. (2012)	increased respiratory secretions	ACHE	UBERON_0005409	""
cardiovascular system	inhibition_acute	HP_0002579	ENSG00000087085	23197038	Bowes et al. (2012)	decreased gastrointestinal motility	ACHE	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000087085	23197038	Bowes et al. (2012)	decreased blood pressure	ACHE	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001662	ENSG00000087085	23197038	Bowes et al. (2012)	decreased heart rate	ACHE	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0030895	ENSG00000087085	23197038	Bowes et al. (2012)	increased gastrointestinal motility	ACHE	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009836	ENSG00000087085	23197038	Bowes et al. (2012)	bronchoconstriction	ACHE	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009835	ENSG00000087085	23197038	Bowes et al. (2012)	increased respiratory secretions	ACHE	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002148	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood phosphate	CALCRL	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000064989	28216264	Lynch et al. (2017)	decreased pain	CALCRL	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000064989	28216264	Lynch et al. (2017)	increased blood pressure	CALCRL	UBERON_0004535	""
nervous system	activation_acute	HP_0003074	ENSG00000064989	28216264	Lynch et al. (2017)	increased blood glucose	CALCRL	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000064989	28216264	Lynch et al. (2017)	decreased pain	CALCRL	UBERON_0001016	""
nervous system	inhibition_acute	HP_0032263	ENSG00000064989	28216264	Lynch et al. (2017)	increased blood pressure	CALCRL	UBERON_0001016	""
gastrointestinal	activation_acute	GO_1904058	ENSG00000064989	28216264	Lynch et al. (2017)	increased pain	CALCRL	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1904057	ENSG00000064989	28216264	Lynch et al. (2017)	decreased pain	CALCRL	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0032263	ENSG00000064989	28216264	Lynch et al. (2017)	increased blood pressure	CALCRL	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0031284	ENSG00000064989	28216264	Lynch et al. (2017)	facial flushing	CALCRL	UBERON_0005409	""
cardiovascular	activation_acute	HP_0001649	ENSG00000064989	28216264	Lynch et al. (2017)	increased heart rate	CALCRL	UBERON_0004535	""
nervous system	activation_acute	HP_0002901	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood calcium	CALCRL	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0001649	ENSG00000064989	28216264	Lynch et al. (2017)	increased heart rate	CALCRL	UBERON_0005409	""
blood	activation_acute	HP_0031284	ENSG00000064989	28216264	Lynch et al. (2017)	facial flushing	CALCRL	UBERON_0000178	""
blood	inhibition_acute	GO_1904057	ENSG00000064989	28216264	Lynch et al. (2017)	decreased pain	CALCRL	UBERON_0000178	""
blood	inhibition_acute	HP_0032263	ENSG00000064989	28216264	Lynch et al. (2017)	increased blood pressure	CALCRL	UBERON_0000178	""
nervous system	activation_acute	GO_0120061	ENSG00000064989	28216264	Lynch et al. (2017)	decreased gastric emptying	CALCRL	UBERON_0001016	""
cardiovascular	activation_acute	HP_0003074	ENSG00000064989	28216264	Lynch et al. (2017)	increased blood glucose	CALCRL	UBERON_0004535	""
blood	activation_acute	HP_0002148	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood phosphate	CALCRL	UBERON_0000178	""
blood	activation_acute	EFO_0005251	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood pressure	CALCRL	UBERON_0000178	""
cardiovascular	activation_acute	HP_0031284	ENSG00000064989	28216264	Lynch et al. (2017)	facial flushing	CALCRL	UBERON_0004535	""
blood	activation_acute	GO_1904058	ENSG00000064989	28216264	Lynch et al. (2017)	increased pain	CALCRL	UBERON_0000178	""
blood	activation_acute	HP_0002901	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood calcium	CALCRL	UBERON_0000178	""
cardiovascular	activation_acute	GO_0045823	ENSG00000064989	28216264	Lynch et al. (2017)	increased cardiac contractility	CALCRL	UBERON_0004535	""
blood	activation_acute	GO_0120061	ENSG00000064989	28216264	Lynch et al. (2017)	decreased gastric emptying	CALCRL	UBERON_0000178	""
nervous system	activation_acute	GO_0045823	ENSG00000064989	28216264	Lynch et al. (2017)	increased cardiac contractility	CALCRL	UBERON_0001016	""
gastrointestinal	activation_acute	GO_0120061	ENSG00000064989	28216264	Lynch et al. (2017)	decreased gastric emptying	CALCRL	UBERON_0005409	""
cardiovascular	activation_acute	GO_0120061	ENSG00000064989	28216264	Lynch et al. (2017)	decreased gastric emptying	CALCRL	UBERON_0004535	""
blood	activation_acute	HP_0003074	ENSG00000064989	28216264	Lynch et al. (2017)	increased blood glucose	CALCRL	UBERON_0000178	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood pressure	CALCRL	UBERON_0004535	""
blood	activation_acute	HP_0001649	ENSG00000064989	28216264	Lynch et al. (2017)	increased heart rate	CALCRL	UBERON_0000178	""
gastrointestinal	activation_acute	HP_0002901	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood calcium	CALCRL	UBERON_0005409	""
nervous system	activation_acute	HP_0031284	ENSG00000064989	28216264	Lynch et al. (2017)	facial flushing	CALCRL	UBERON_0001016	""
blood	activation_acute	GO_0045823	ENSG00000064989	28216264	Lynch et al. (2017)	increased cardiac contractility	CALCRL	UBERON_0000178	""
nervous system	activation_acute	HP_0001649	ENSG00000064989	28216264	Lynch et al. (2017)	increased heart rate	CALCRL	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_0005251	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood pressure	CALCRL	UBERON_0005409	""
cardiovascular	activation_acute	GO_1904058	ENSG00000064989	28216264	Lynch et al. (2017)	increased pain	CALCRL	UBERON_0004535	""
gastrointestinal	activation_acute	GO_0045823	ENSG00000064989	28216264	Lynch et al. (2017)	increased cardiac contractility	CALCRL	UBERON_0005409	""
nervous system	activation_acute	HP_0002148	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood phosphate	CALCRL	UBERON_0001016	""
nervous system	activation_acute	EFO_0005251	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood pressure	CALCRL	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0002148	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood phosphate	CALCRL	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0003074	ENSG00000064989	28216264	Lynch et al. (2017)	increased blood glucose	CALCRL	UBERON_0005409	""
nervous system	activation_acute	GO_1904058	ENSG00000064989	28216264	Lynch et al. (2017)	increased pain	CALCRL	UBERON_0001016	""
cardiovascular	activation_acute	HP_0002901	ENSG00000064989	28216264	Lynch et al. (2017)	decreased blood calcium	CALCRL	UBERON_0004535	""
immune	activation_acute	GO_0035815	ENSG00000099957	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX6	UBERON_0002405	""
immune	activation_chronic	HP_0002180	ENSG00000099957	28216264	Lynch et al. (2017)	neurodegeneration	P2RX6	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000099957	28216264	Lynch et al. (2017)	decreased pain	P2RX6	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000099957	28216264	Lynch et al. (2017)	decreased inflammation	P2RX6	UBERON_0002405	""
immune	inhibition_acute	EFO_0009853	ENSG00000099957	28216264	Lynch et al. (2017)	decreased convulsions	P2RX6	UBERON_0002405	""
renal	activation_acute	GO_0035815	ENSG00000099957	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX6	UBERON_0001008	""
renal	activation_chronic	HP_0002180	ENSG00000099957	28216264	Lynch et al. (2017)	neurodegeneration	P2RX6	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000099957	28216264	Lynch et al. (2017)	decreased pain	P2RX6	UBERON_0001008	""
renal	inhibition_acute	GO_0050728	ENSG00000099957	28216264	Lynch et al. (2017)	decreased inflammation	P2RX6	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000099957	28216264	Lynch et al. (2017)	decreased convulsions	P2RX6	UBERON_0001008	""
renal	activation_acute	HP_0000103	ENSG00000099957	28216264	Lynch et al. (2017)	increased urine excretion	P2RX6	UBERON_0001008	""
nervous system	activation_acute	GO_0035815	ENSG00000099957	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX6	UBERON_0001016	""
nervous system	activation_chronic	HP_0002180	ENSG00000099957	28216264	Lynch et al. (2017)	neurodegeneration	P2RX6	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000099957	28216264	Lynch et al. (2017)	decreased pain	P2RX6	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050728	ENSG00000099957	28216264	Lynch et al. (2017)	decreased inflammation	P2RX6	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000099957	28216264	Lynch et al. (2017)	decreased convulsions	P2RX6	UBERON_0001016	""
nervous system	activation_acute	EFO_0009473	ENSG00000099957	28216264	Lynch et al. (2017)	hemolysis	P2RX6	UBERON_0001016	""
immune	activation_acute	HP_0000103	ENSG00000099957	28216264	Lynch et al. (2017)	increased urine excretion	P2RX6	UBERON_0002405	""
renal	activation_acute	GO_1904058	ENSG00000099957	28216264	Lynch et al. (2017)	increased pain	P2RX6	UBERON_0001008	""
nervous system	activation_acute	HP_0000103	ENSG00000099957	28216264	Lynch et al. (2017)	increased urine excretion	P2RX6	UBERON_0001016	""
nervous system	activation_acute	GO_1904058	ENSG00000099957	28216264	Lynch et al. (2017)	increased pain	P2RX6	UBERON_0001016	""
renal	activation_acute	EFO_0009473	ENSG00000099957	28216264	Lynch et al. (2017)	hemolysis	P2RX6	UBERON_0001008	""
immune	activation_acute	GO_1904058	ENSG00000099957	28216264	Lynch et al. (2017)	increased pain	P2RX6	UBERON_0002405	""
immune	activation_acute	EFO_0009473	ENSG00000099957	28216264	Lynch et al. (2017)	hemolysis	P2RX6	UBERON_0002405	""
cardiovascular system	activation_general	""	ENSG00000169252	""	Urban et al. (2012)	may relax smooth muscle	ADRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0001662	ENSG00000169252	""	Urban et al. (2012)	bradycardia	ADRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000319	ENSG00000169252	""	Urban et al. (2012)	may stress cardiovascular performance (b blockers)	ADRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0045823	ENSG00000169252	""	Urban et al. (2012)	may contribute to cardiac contractility (bronchodilatation, cardiac arrest)	ADRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0001252	ENSG00000169252	""	Urban et al. (2012)	hypotonia	ADRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000169252	""	Urban et al. (2012)	vasodilatation of the vascular beds of skeletal muscle	ADRB2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_acute	EFO_0005251	ENSG00000082556	28216264	Lynch et al. (2017)	decreased blood pressure	OPRK1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1904058	ENSG00000082556	28216264	Lynch et al. (2017)	increased pain	OPRK1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009853	ENSG00000082556	28216264	Lynch et al. (2017)	increased convulsions	OPRK1	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009874	ENSG00000082556	28216264	Lynch et al. (2017)	decreased anxiety	OPRK1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0025382	ENSG00000082556	28216264	Lynch et al. (2017)	decreased drinking	OPRK1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0100738	ENSG00000082556	28216264	Lynch et al. (2017)	decreased eating	OPRK1	UBERON_0005409	""
nervous system	activation_acute	EFO_0005230	ENSG00000082556	28216264	Lynch et al. (2017)	increased anxiety	OPRK1	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904058	ENSG00000082556	28216264	Lynch et al. (2017)	increased pain	OPRK1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000082556	28216264	Lynch et al. (2017)	increased convulsions	OPRK1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009874	ENSG00000082556	28216264	Lynch et al. (2017)	decreased anxiety	OPRK1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0025382	ENSG00000082556	28216264	Lynch et al. (2017)	decreased drinking	OPRK1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0100738	ENSG00000082556	28216264	Lynch et al. (2017)	decreased eating	OPRK1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0000738	ENSG00000082556	28216264	Lynch et al. (2017)	hallucinations	OPRK1	UBERON_0005409	""
nervous system	activation_acute	HP_0030082	ENSG00000082556	28216264	Lynch et al. (2017)	decreased then increased drinking	OPRK1	UBERON_0001016	""
nervous system	activation_acute	EFO_0005251	ENSG00000082556	28216264	Lynch et al. (2017)	decreased blood pressure	OPRK1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0030082	ENSG00000082556	28216264	Lynch et al. (2017)	decreased then increased drinking	OPRK1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904058	ENSG00000082556	28216264	Lynch et al. (2017)	increased pain	OPRK1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000082556	28216264	Lynch et al. (2017)	increased convulsions	OPRK1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009874	ENSG00000082556	28216264	Lynch et al. (2017)	decreased anxiety	OPRK1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0025382	ENSG00000082556	28216264	Lynch et al. (2017)	decreased drinking	OPRK1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0100738	ENSG00000082556	28216264	Lynch et al. (2017)	decreased eating	OPRK1	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0003890	ENSG00000082556	28216264	Lynch et al. (2017)	drug abuse/dependence	OPRK1	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0031860	ENSG00000082556	28216264	Lynch et al. (2017)	decreased/increased heart rate	OPRK1	UBERON_0005409	""
nervous system	activation_acute	HP_0000738	ENSG00000082556	28216264	Lynch et al. (2017)	hallucinations	OPRK1	UBERON_0001016	""
nervous system	activation_acute	HP_0002045	ENSG00000082556	28216264	Lynch et al. (2017)	decreased body temperature	OPRK1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0000103	ENSG00000082556	28216264	Lynch et al. (2017)	increased urine excretion	OPRK1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009867	ENSG00000082556	28216264	Lynch et al. (2017)	dysphoria	OPRK1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002045	ENSG00000082556	28216264	Lynch et al. (2017)	decreased body temperature	OPRK1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009847	ENSG00000082556	28216264	Lynch et al. (2017)	dizziness	OPRK1	UBERON_0004535	""
nervous system	activation_acute	EFO_0009853	ENSG00000082556	28216264	Lynch et al. (2017)	decreased convulsions	OPRK1	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_0009853	ENSG00000082556	28216264	Lynch et al. (2017)	decreased convulsions	OPRK1	UBERON_0005409	""
cardiovascular	activation_acute	GO_0040013	ENSG00000082556	28216264	Lynch et al. (2017)	decreased locomotor activity	OPRK1	UBERON_0004535	""
gastrointestinal	activation_acute	GO_0040013	ENSG00000082556	28216264	Lynch et al. (2017)	decreased locomotor activity	OPRK1	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0030082	ENSG00000082556	28216264	Lynch et al. (2017)	decreased then increased drinking	OPRK1	UBERON_0005409	""
gastrointestinal	activation_acute	GO_0045822	ENSG00000082556	28216264	Lynch et al. (2017)	decreased cardiac contractility	OPRK1	UBERON_0005409	""
nervous system	activation_acute	HP_0031860	ENSG00000082556	28216264	Lynch et al. (2017)	decreased/increased heart rate	OPRK1	UBERON_0001016	""
cardiovascular	activation_acute	GO_0050728	ENSG00000082556	28216264	Lynch et al. (2017)	decreased inflammation	OPRK1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000082556	28216264	Lynch et al. (2017)	drug abuse/dependence	OPRK1	UBERON_0004535	""
nervous system	activation_acute	GO_0040013	ENSG00000082556	28216264	Lynch et al. (2017)	decreased locomotor activity	OPRK1	UBERON_0001016	""
nervous system	activation_acute	GO_0045822	ENSG00000082556	28216264	Lynch et al. (2017)	decreased cardiac contractility	OPRK1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0030897	ENSG00000082556	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	OPRK1	UBERON_0004535	""
nervous system	activation_acute	HP_0000103	ENSG00000082556	28216264	Lynch et al. (2017)	increased urine excretion	OPRK1	UBERON_0001016	""
nervous system	activation_acute	EFO_0003890	ENSG00000082556	28216264	Lynch et al. (2017)	drug abuse/dependence	OPRK1	UBERON_0001016	""
cardiovascular	activation_acute	GO_0045822	ENSG00000082556	28216264	Lynch et al. (2017)	decreased cardiac contractility	OPRK1	UBERON_0004535	""
nervous system	activation_acute	GO_1904057	ENSG00000082556	28216264	Lynch et al. (2017)	decreased pain	OPRK1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0002045	ENSG00000082556	28216264	Lynch et al. (2017)	decreased body temperature	OPRK1	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000082556	28216264	Lynch et al. (2017)	decreased blood pressure	OPRK1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0000738	ENSG00000082556	28216264	Lynch et al. (2017)	hallucinations	OPRK1	UBERON_0004535	""
gastrointestinal	activation_acute	GO_0050728	ENSG00000082556	28216264	Lynch et al. (2017)	decreased inflammation	OPRK1	UBERON_0005409	""
cardiovascular	activation_acute	HP_0031860	ENSG00000082556	28216264	Lynch et al. (2017)	decreased/increased heart rate	OPRK1	UBERON_0004535	""
gastrointestinal	activation_acute	GO_1904057	ENSG00000082556	28216264	Lynch et al. (2017)	decreased pain	OPRK1	UBERON_0005409	""
cardiovascular	activation_acute	HP_0100738	ENSG00000082556	28216264	Lynch et al. (2017)	increased/decreased eating	OPRK1	UBERON_0004535	""
cardiovascular	activation_acute	GO_1904057	ENSG00000082556	28216264	Lynch et al. (2017)	decreased pain	OPRK1	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0009847	ENSG00000082556	28216264	Lynch et al. (2017)	dizziness	OPRK1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0005230	ENSG00000082556	28216264	Lynch et al. (2017)	increased anxiety	OPRK1	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009867	ENSG00000082556	28216264	Lynch et al. (2017)	dysphoria	OPRK1	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0005230	ENSG00000082556	28216264	Lynch et al. (2017)	increased anxiety	OPRK1	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0030897	ENSG00000082556	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	OPRK1	UBERON_0005409	""
cardiovascular	activation_acute	HP_0004372	ENSG00000082556	28216264	Lynch et al. (2017)	confusion	OPRK1	UBERON_0004535	""
nervous system	activation_acute	HP_0004372	ENSG00000082556	28216264	Lynch et al. (2017)	confusion	OPRK1	UBERON_0001016	""
nervous system	activation_acute	HP_0030897	ENSG00000082556	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	OPRK1	UBERON_0001016	""
nervous system	activation_acute	HP_0100738	ENSG00000082556	28216264	Lynch et al. (2017)	increased/decreased eating	OPRK1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009867	ENSG00000082556	28216264	Lynch et al. (2017)	dysphoria	OPRK1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0004372	ENSG00000082556	28216264	Lynch et al. (2017)	confusion	OPRK1	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000082556	28216264	Lynch et al. (2017)	decreased convulsions	OPRK1	UBERON_0004535	""
nervous system	activation_acute	EFO_0009847	ENSG00000082556	28216264	Lynch et al. (2017)	dizziness	OPRK1	UBERON_0001016	""
nervous system	activation_acute	GO_0050728	ENSG00000082556	28216264	Lynch et al. (2017)	decreased inflammation	OPRK1	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0100738	ENSG00000082556	28216264	Lynch et al. (2017)	increased/decreased eating	OPRK1	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0000103	ENSG00000082556	28216264	Lynch et al. (2017)	increased urine excretion	OPRK1	UBERON_0005409	""
central nervous system	activation_acute	EFO_0009853	ENSG00000022355	28216264	Lynch et al. (2017)	decreased convulsions	GABRA1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000022355	28216264	Lynch et al. (2017)	convulsions	GABRA1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000022355	28216264	Lynch et al. (2017)	decreased sleep	GABRA1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000022355	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000022355	28216264	Lynch et al. (2017)	convulsions	GABRA1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000022355	28216264	Lynch et al. (2017)	decreased sleep	GABRA1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0100738	ENSG00000022355	28216264	Lynch et al. (2017)	increased eating	GABRA1	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000022355	28216264	Lynch et al. (2017)	muscle relaxation	GABRA1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0008568	ENSG00000022355	28216264	Lynch et al. (2017)	increased sleep	GABRA1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0005251	ENSG00000022355	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA1	UBERON_0001017	""
central nervous system	activation_acute	GO_0040013	ENSG00000022355	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000022355	28216264	Lynch et al. (2017)	decreased memory	GABRA1	UBERON_0004535	""
central nervous system	activation_acute	HP_0100738	ENSG00000022355	28216264	Lynch et al. (2017)	increased eating	GABRA1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009874	ENSG00000022355	28216264	Lynch et al. (2017)	decreased anxiety	GABRA1	UBERON_0001017	""
central nervous system	activation_acute	""	ENSG00000022355	28216264	Lynch et al. (2017)	muscle relaxation	GABRA1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000022355	28216264	Lynch et al. (2017)	decreased anxiety	GABRA1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000022355	28216264	Lynch et al. (2017)	decreased convulsions	GABRA1	UBERON_0004535	""
central nervous system	activation_acute	GO_1904057	ENSG00000022355	28216264	Lynch et al. (2017)	decreased pain	GABRA1	UBERON_0001017	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000022355	28216264	Lynch et al. (2017)	ataxia	GABRA1	UBERON_0001017	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000022355	28216264	Lynch et al. (2017)	ataxia	GABRA1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0008568	ENSG00000022355	28216264	Lynch et al. (2017)	increased sleep	GABRA1	UBERON_0001017	""
central nervous system	activation_acute	HP_0002045	ENSG00000022355	28216264	Lynch et al. (2017)	decreased body temperature	GABRA1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009840	ENSG00000022355	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0003890	ENSG00000022355	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA1	UBERON_0001017	""
central nervous system	activation_acute	GO_0045822	ENSG00000022355	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA1	UBERON_0001017	""
cardiovascular	activation_acute	GO_1904057	ENSG00000022355	28216264	Lynch et al. (2017)	decreased pain	GABRA1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0001072	ENSG00000022355	28216264	Lynch et al. (2017)	decreased memory	GABRA1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000022355	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA1	UBERON_0004535	""
cardiovascular	activation_acute	GO_0045822	ENSG00000022355	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009872	ENSG00000022355	28216264	Lynch et al. (2017)	increased cardiac output	GABRA1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009872	ENSG00000022355	28216264	Lynch et al. (2017)	increased cardiac output	GABRA1	UBERON_0001017	""
cardiovascular	activation_acute	GO_0040013	ENSG00000022355	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002045	ENSG00000022355	28216264	Lynch et al. (2017)	decreased body temperature	GABRA1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000022355	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000183454	28216264	Lynch et al. (2017)	convulsions	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000183454	28216264	Lynch et al. (2017)	decreased pain	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000735	ENSG00000183454	28216264	Lynch et al. (2017)	impaired social interactions	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000733	ENSG00000183454	28216264	Lynch et al. (2017)	stereotypy	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_chronic	EFO_0005407	ENSG00000183454	28216264	Lynch et al. (2017)	psychosis	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0002180	ENSG00000183454	28216264	Lynch et al. (2017)	neurodegeneration	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040017	ENSG00000183454	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000437	ENSG00000183454	28216264	Lynch et al. (2017)	ataxia	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000183454	28216264	Lynch et al. (2017)	dizziness	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0001072	ENSG00000183454	28216264	Lynch et al. (2017)	decreased memory	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005407	ENSG00000183454	28216264	Lynch et al. (2017)	psychosis	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000183454	28216264	Lynch et al. (2017)	decreased convulsions	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003890	ENSG00000183454	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000183454	28216264	Lynch et al. (2017)	neurotoxicity	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000183454	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000183454	28216264	Lynch et al. (2017)	increased heart rate	GRIN2A	UBERON_0004535	""
central nervous system	activation_acute	EFO_0003843	ENSG00000183454	28216264	Lynch et al. (2017)	pain	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1904057	ENSG00000183454	28216264	Lynch et al. (2017)	decreased pain	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000735	ENSG00000183454	28216264	Lynch et al. (2017)	impaired social interactions	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000733	ENSG00000183454	28216264	Lynch et al. (2017)	stereotypy	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_chronic	EFO_0005407	ENSG00000183454	28216264	Lynch et al. (2017)	psychosis	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0002180	ENSG00000183454	28216264	Lynch et al. (2017)	neurodegeneration	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0040017	ENSG00000183454	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	MONDO_0000437	ENSG00000183454	28216264	Lynch et al. (2017)	ataxia	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009847	ENSG00000183454	28216264	Lynch et al. (2017)	dizziness	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0001072	ENSG00000183454	28216264	Lynch et al. (2017)	decreased memory	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005407	ENSG00000183454	28216264	Lynch et al. (2017)	psychosis	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000183454	28216264	Lynch et al. (2017)	decreased convulsions	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003890	ENSG00000183454	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000183454	28216264	Lynch et al. (2017)	neurotoxicity	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0032263	ENSG00000183454	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2A	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001649	ENSG00000183454	28216264	Lynch et al. (2017)	increased heart rate	GRIN2A	UBERON_0001017	""
cardiovascular	activation_acute	HP_0032263	ENSG00000183454	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2A	UBERON_0004535	""
cardiovascular	activation_acute	HP_0031860	ENSG00000183454	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN2A	UBERON_0004535	""
central nervous system	activation_acute	HP_0031860	ENSG00000183454	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN2A	UBERON_0001017	""
central nervous system	activation_acute	HP_0032263	ENSG00000183454	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2A	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0003843	ENSG00000183454	28216264	Lynch et al. (2017)	pain	GRIN2A	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000183454	28216264	Lynch et al. (2017)	convulsions	GRIN2A	UBERON_0001017	""
gastrointestinal	inhibition_general	EFO_0004698	ENSG00000108576	""	Urban et al. (2012)	insomnia	SLC6A4	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	EFO_0005230	ENSG00000108576	""	Urban et al. (2012)	anxiety	SLC6A4	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	HP_0002017	ENSG00000108576	""	Urban et al. (2012)	nausea and vomiting	SLC6A4	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	EFO_0004714	ENSG00000108576	""	Urban et al. (2012)	sexual dysfunction	SLC6A4	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	HP_0032155	ENSG00000108576	""	Urban et al. (2012)	gastrointestinal cramps	SLC6A4	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	HP_0002014	ENSG00000108576	""	Urban et al. (2012)	diarrhea	SLC6A4	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	HP_0002315	ENSG00000108576	""	Urban et al. (2012)	headache	SLC6A4	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	EFO_0009551	ENSG00000108576	""	Urban et al. (2012)	valvular heart disease	SLC6A4	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	MONDO_0001999	ENSG00000108576	""	Urban et al. (2012)	primary pulmonary hypertension	SLC6A4	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0004698	ENSG00000108576	""	Urban et al. (2012)	insomnia	SLC6A4	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0005230	ENSG00000108576	""	Urban et al. (2012)	anxiety	SLC6A4	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0002017	ENSG00000108576	""	Urban et al. (2012)	nausea and vomiting	SLC6A4	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0004714	ENSG00000108576	""	Urban et al. (2012)	sexual dysfunction	SLC6A4	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0032155	ENSG00000108576	""	Urban et al. (2012)	gastrointestinal cramps	SLC6A4	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0002014	ENSG00000108576	""	Urban et al. (2012)	diarrhea	SLC6A4	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0002315	ENSG00000108576	""	Urban et al. (2012)	headache	SLC6A4	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0009551	ENSG00000108576	""	Urban et al. (2012)	valvular heart disease	SLC6A4	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	MONDO_0001999	ENSG00000108576	""	Urban et al. (2012)	primary pulmonary hypertension	SLC6A4	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0004698	ENSG00000108576	""	Urban et al. (2012)	insomnia	SLC6A4	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0005230	ENSG00000108576	""	Urban et al. (2012)	anxiety	SLC6A4	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0002017	ENSG00000108576	""	Urban et al. (2012)	nausea and vomiting	SLC6A4	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0004714	ENSG00000108576	""	Urban et al. (2012)	sexual dysfunction	SLC6A4	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0032155	ENSG00000108576	""	Urban et al. (2012)	gastrointestinal cramps	SLC6A4	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0002014	ENSG00000108576	""	Urban et al. (2012)	diarrhea	SLC6A4	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	HP_0002315	ENSG00000108576	""	Urban et al. (2012)	headache	SLC6A4	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0009551	ENSG00000108576	""	Urban et al. (2012)	valvular heart disease	SLC6A4	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	MONDO_0001999	ENSG00000108576	""	Urban et al. (2012)	primary pulmonary hypertension	SLC6A4	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000135914	""	Urban et al. (2012)	cardiac valvulopathy	HTR2B	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_developmental toxicity	EFO_0000318	ENSG00000135914	""	Urban et al. (2012)	possible effect on cardiac development leading to cardiomyopathy (based on knockout mouse data)	HTR2B	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0000537	ENSG00000135914	""	Urban et al. (2012)	hypertension	HTR2B	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000135914	""	Urban et al. (2012)	withdrawal of pergolide products	HTR2B	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
immune	activation_acute	EFO_0009874	ENSG00000100300	28216264	Lynch et al. (2017)	decreased anxiety	TSPO	UBERON_0002405	""
immune	inhibition_acute	EFO_0009853	ENSG00000100300	28216264	Lynch et al. (2017)	decreased convulsions	TSPO	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000100300	28216264	Lynch et al. (2017)	decreased inflammation	TSPO	UBERON_0002405	""
immune	activation_acute	GO_0050728	ENSG00000100300	28216264	Lynch et al. (2017)	decreased inflammation	TSPO	UBERON_0002405	""
central nervous system	activation_acute	GO_0050728	ENSG00000100300	28216264	Lynch et al. (2017)	decreased inflammation	TSPO	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000100300	28216264	Lynch et al. (2017)	decreased convulsions	TSPO	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0050728	ENSG00000100300	28216264	Lynch et al. (2017)	decreased inflammation	TSPO	UBERON_0001017	""
immune	activation_acute	EFO_0009853	ENSG00000100300	28216264	Lynch et al. (2017)	convulsions	TSPO	UBERON_0002405	""
central nervous system	activation_acute	EFO_0009874	ENSG00000100300	28216264	Lynch et al. (2017)	decreased anxiety	TSPO	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009853	ENSG00000100300	28216264	Lynch et al. (2017)	convulsions	TSPO	UBERON_0001017	""
blood	activation_acute	EFO_0001361	ENSG00000108576	28216264	Lynch et al. (2017)	pulmonary hypertension	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	EFO_0005230	ENSG00000108576	28216264	Lynch et al. (2017)	decreased/increased anxiety	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	GO_0040012	ENSG00000108576	28216264	Lynch et al. (2017)	decreased/increased locomotor activity	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	GO_0090331	ENSG00000108576	28216264	Lynch et al. (2017)	decreased platelet aggregation	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	HP_0002018	ENSG00000108576	28216264	Lynch et al. (2017)	nausea	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	""	ENSG00000108576	28216264	Lynch et al. (2017)	decreased appetite	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	HP_0100738	ENSG00000108576	28216264	Lynch et al. (2017)	decreased eating	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	EFO_0005245	ENSG00000108576	28216264	Lynch et al. (2017)	decreased body weight	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	HP_0002014	ENSG00000108576	28216264	Lynch et al. (2017)	diarrhea	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	HP_0002019	ENSG00000108576	28216264	Lynch et al. (2017)	constipation	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	EFO_0009869	ENSG00000108576	28216264	Lynch et al. (2017)	dry mouth	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	HP_0002315	ENSG00000108576	28216264	Lynch et al. (2017)	headache	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	EFO_0009847	ENSG00000108576	28216264	Lynch et al. (2017)	dizziness	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	EFO_0008568	ENSG00000108576	28216264	Lynch et al. (2017)	decreased sleep	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	NCIT_C74532	ENSG00000108576	28216264	Lynch et al. (2017)	agitation	SLC6A4	UBERON_0000178	""
blood	inhibition_acute	HP_0001337	ENSG00000108576	28216264	Lynch et al. (2017)	tremor	SLC6A4	UBERON_0000178	""
gastrointestinal	activation_acute	EFO_0001361	ENSG00000108576	28216264	Lynch et al. (2017)	pulmonary hypertension	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0005230	ENSG00000108576	28216264	Lynch et al. (2017)	decreased/increased anxiety	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0040012	ENSG00000108576	28216264	Lynch et al. (2017)	decreased/increased locomotor activity	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0090331	ENSG00000108576	28216264	Lynch et al. (2017)	decreased platelet aggregation	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0002018	ENSG00000108576	28216264	Lynch et al. (2017)	nausea	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	""	ENSG00000108576	28216264	Lynch et al. (2017)	decreased appetite	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0100738	ENSG00000108576	28216264	Lynch et al. (2017)	decreased eating	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0005245	ENSG00000108576	28216264	Lynch et al. (2017)	decreased body weight	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0002014	ENSG00000108576	28216264	Lynch et al. (2017)	diarrhea	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0002019	ENSG00000108576	28216264	Lynch et al. (2017)	constipation	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009869	ENSG00000108576	28216264	Lynch et al. (2017)	dry mouth	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0002315	ENSG00000108576	28216264	Lynch et al. (2017)	headache	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009847	ENSG00000108576	28216264	Lynch et al. (2017)	dizziness	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0008568	ENSG00000108576	28216264	Lynch et al. (2017)	decreased sleep	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	NCIT_C74532	ENSG00000108576	28216264	Lynch et al. (2017)	agitation	SLC6A4	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0001337	ENSG00000108576	28216264	Lynch et al. (2017)	tremor	SLC6A4	UBERON_0005409	""
central nervous system	activation_acute	EFO_0001361	ENSG00000108576	28216264	Lynch et al. (2017)	pulmonary hypertension	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005230	ENSG00000108576	28216264	Lynch et al. (2017)	decreased/increased anxiety	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0040012	ENSG00000108576	28216264	Lynch et al. (2017)	decreased/increased locomotor activity	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0090331	ENSG00000108576	28216264	Lynch et al. (2017)	decreased platelet aggregation	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0002018	ENSG00000108576	28216264	Lynch et al. (2017)	nausea	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	""	ENSG00000108576	28216264	Lynch et al. (2017)	decreased appetite	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0100738	ENSG00000108576	28216264	Lynch et al. (2017)	decreased eating	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005245	ENSG00000108576	28216264	Lynch et al. (2017)	decreased body weight	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0002014	ENSG00000108576	28216264	Lynch et al. (2017)	diarrhea	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0002019	ENSG00000108576	28216264	Lynch et al. (2017)	constipation	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009869	ENSG00000108576	28216264	Lynch et al. (2017)	dry mouth	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0002315	ENSG00000108576	28216264	Lynch et al. (2017)	headache	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009847	ENSG00000108576	28216264	Lynch et al. (2017)	dizziness	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000108576	28216264	Lynch et al. (2017)	decreased sleep	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	NCIT_C74532	ENSG00000108576	28216264	Lynch et al. (2017)	agitation	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001337	ENSG00000108576	28216264	Lynch et al. (2017)	tremor	SLC6A4	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0001361	ENSG00000108576	28216264	Lynch et al. (2017)	pulmonary hypertension	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005230	ENSG00000108576	28216264	Lynch et al. (2017)	decreased/increased anxiety	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040012	ENSG00000108576	28216264	Lynch et al. (2017)	decreased/increased locomotor activity	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0090331	ENSG00000108576	28216264	Lynch et al. (2017)	decreased platelet aggregation	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002018	ENSG00000108576	28216264	Lynch et al. (2017)	nausea	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	""	ENSG00000108576	28216264	Lynch et al. (2017)	decreased appetite	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0100738	ENSG00000108576	28216264	Lynch et al. (2017)	decreased eating	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005245	ENSG00000108576	28216264	Lynch et al. (2017)	decreased body weight	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002014	ENSG00000108576	28216264	Lynch et al. (2017)	diarrhea	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002019	ENSG00000108576	28216264	Lynch et al. (2017)	constipation	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009869	ENSG00000108576	28216264	Lynch et al. (2017)	dry mouth	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002315	ENSG00000108576	28216264	Lynch et al. (2017)	headache	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000108576	28216264	Lynch et al. (2017)	dizziness	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000108576	28216264	Lynch et al. (2017)	decreased sleep	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	NCIT_C74532	ENSG00000108576	28216264	Lynch et al. (2017)	agitation	SLC6A4	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001337	ENSG00000108576	28216264	Lynch et al. (2017)	tremor	SLC6A4	UBERON_0004535	""
cardiovascular	activation_acute	GO_0035814	ENSG00000181408	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	UTS2R	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000181408	28216264	Lynch et al. (2017)	increased urine excretion	UTS2R	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000181408	28216264	Lynch et al. (2017)	increased urinary sodium excretion	UTS2R	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001943	ENSG00000181408	28216264	Lynch et al. (2017)	decreased blood glucose	UTS2R	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0050728	ENSG00000181408	28216264	Lynch et al. (2017)	decreased inflammation	UTS2R	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000181408	28216264	Lynch et al. (2017)	decreased blood pressure	UTS2R	UBERON_0004535	""
renal	activation_acute	EFO_0005251	ENSG00000181408	28216264	Lynch et al. (2017)	decreased blood pressure	UTS2R	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000181408	28216264	Lynch et al. (2017)	increased urine excretion	UTS2R	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000181408	28216264	Lynch et al. (2017)	increased urinary sodium excretion	UTS2R	UBERON_0001008	""
renal	inhibition_acute	HP_0001943	ENSG00000181408	28216264	Lynch et al. (2017)	decreased blood glucose	UTS2R	UBERON_0001008	""
renal	inhibition_acute	GO_0050728	ENSG00000181408	28216264	Lynch et al. (2017)	decreased inflammation	UTS2R	UBERON_0001008	""
renal	inhibition_acute	EFO_0005251	ENSG00000181408	28216264	Lynch et al. (2017)	decreased blood pressure	UTS2R	UBERON_0001008	""
cardiovascular	activation_acute	GO_0045822	ENSG00000181408	28216264	Lynch et al. (2017)	decreased cardiac contractility	UTS2R	UBERON_0004535	""
renal	activation_acute	GO_0035814	ENSG00000181408	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	UTS2R	UBERON_0001008	""
renal	activation_acute	HP_0012364	ENSG00000181408	28216264	Lynch et al. (2017)	decreased urinary potassium excretion	UTS2R	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000181408	28216264	Lynch et al. (2017)	decreased blood pressure	UTS2R	UBERON_0004535	""
renal	activation_acute	HP_0011037	ENSG00000181408	28216264	Lynch et al. (2017)	decreased urine excretion	UTS2R	UBERON_0001008	""
cardiovascular	activation_acute	HP_0011037	ENSG00000181408	28216264	Lynch et al. (2017)	decreased urine excretion	UTS2R	UBERON_0004535	""
cardiovascular	activation_acute	HP_0012364	ENSG00000181408	28216264	Lynch et al. (2017)	decreased urinary potassium excretion	UTS2R	UBERON_0004535	""
renal	activation_acute	GO_0045822	ENSG00000181408	28216264	Lynch et al. (2017)	decreased cardiac contractility	UTS2R	UBERON_0001008	""
cardiovascular system	inhibition_chronic	""	ENSG00000152270	""	Urban et al. (2012)	increased mortality in heart failure patients	PDE3B	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0004308	ENSG00000152270	""	Urban et al. (2012)	could induce ventricular arrhythmias in ~10% of patients	PDE3B	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0001649	ENSG00000152270	""	Urban et al. (2012)	tachycardia	PDE3B	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000152270	""	Urban et al. (2012)	hypotension	PDE3B	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_chronic	HP_0001873	ENSG00000152270	""	Urban et al. (2012)	thrombocytopenia	PDE3B	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0045823	ENSG00000043591	""	Urban et al. (2012)	may stimulate cardiac muscle (increase heart rate and force of contraction)	ADRB1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0000319	ENSG00000043591	""	Urban et al. (2012)	may stress cardiovascular performance	ADRB1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	HP_0001662	ENSG00000043591	""	Urban et al. (2012)	bradycardia	ADRB1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0060087	ENSG00000043591	""	Urban et al. (2012)	may contribute to the relaxation of blood vessels	ADRB1	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009874	ENSG00000164128	""	Urban et al. (2012)	anxiolytic effects	NPY1R	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	""	ENSG00000164128	""	Urban et al. (2012)	vasodilation (especially venous)	NPY1R	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	inhibition_general	EFO_0005230	ENSG00000164128	""	Urban et al. (2012)	increase in anxiety-related effects	NPY1R	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	""	ENSG00000164128	""	Urban et al. (2012)	vasoconstriction (vasodilation in subcutaneous arteries)	NPY1R	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	EFO_0009829	ENSG00000164128	""	Urban et al. (2012)	smooth-muscle cell growth leading to atherosclerosis, restenosis, stroke	NPY1R	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
nervous system	activation_general	HP_0100738	ENSG00000164128	""	Urban et al. (2012)	may result in stimulation of feeding behavior	NPY1R	UBERON_0001016	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009874	ENSG00000164128	""	Urban et al. (2012)	anxiolytic effects	NPY1R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	""	ENSG00000164128	""	Urban et al. (2012)	vasodilation (especially venous)	NPY1R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	EFO_0005230	ENSG00000164128	""	Urban et al. (2012)	increase in anxiety-related effects	NPY1R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000164128	""	Urban et al. (2012)	vasoconstriction (vasodilation in subcutaneous arteries)	NPY1R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0009829	ENSG00000164128	""	Urban et al. (2012)	smooth-muscle cell growth leading to atherosclerosis, restenosis, stroke	NPY1R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0100738	ENSG00000164128	""	Urban et al. (2012)	may result in stimulation of feeding behavior	NPY1R	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular	activation_acute	HP_0000733	ENSG00000178394	28216264	Lynch et al. (2017)	stereotypy	HTR1A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040017	ENSG00000178394	28216264	Lynch et al. (2017)	increased locomotor activity	HTR1A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009874	ENSG00000178394	28216264	Lynch et al. (2017)	decreased anxiety	HTR1A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004874	ENSG00000178394	28216264	Lynch et al. (2017)	increased memory	HTR1A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000178394	28216264	Lynch et al. (2017)	decreased sleep	HTR1A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0003401	ENSG00000178394	28216264	Lynch et al. (2017)	paresthesia	HTR1A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000178394	28216264	Lynch et al. (2017)	dizziness	HTR1A	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0021084	ENSG00000178394	28216264	Lynch et al. (2017)	visual disturbances	HTR1A	UBERON_0004535	""
endocrine	activation_acute	HP_0002045	ENSG00000178394	28216264	Lynch et al. (2017)	decreased body temperature	HTR1A	UBERON_0000949	""
endocrine	inhibition_acute	GO_0040017	ENSG00000178394	28216264	Lynch et al. (2017)	increased locomotor activity	HTR1A	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0009874	ENSG00000178394	28216264	Lynch et al. (2017)	decreased anxiety	HTR1A	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0004874	ENSG00000178394	28216264	Lynch et al. (2017)	increased memory	HTR1A	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0008568	ENSG00000178394	28216264	Lynch et al. (2017)	decreased sleep	HTR1A	UBERON_0000949	""
endocrine	inhibition_acute	HP_0003401	ENSG00000178394	28216264	Lynch et al. (2017)	paresthesia	HTR1A	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0009847	ENSG00000178394	28216264	Lynch et al. (2017)	dizziness	HTR1A	UBERON_0000949	""
endocrine	inhibition_acute	MONDO_0021084	ENSG00000178394	28216264	Lynch et al. (2017)	visual disturbances	HTR1A	UBERON_0000949	""
cardiovascular	activation_acute	EFO_0008568	ENSG00000178394	28216264	Lynch et al. (2017)	increased/decreased sleep	HTR1A	UBERON_0004535	""
endocrine	activation_acute	EFO_0005251	ENSG00000178394	28216264	Lynch et al. (2017)	decreased blood pressure	HTR1A	UBERON_0000949	""
nervous system	activation_acute	HP_0001649	ENSG00000178394	28216264	Lynch et al. (2017)	increased heart rate	HTR1A	UBERON_0001016	""
nervous system	inhibition_acute	GO_0040017	ENSG00000178394	28216264	Lynch et al. (2017)	increased locomotor activity	HTR1A	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009874	ENSG00000178394	28216264	Lynch et al. (2017)	decreased anxiety	HTR1A	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004874	ENSG00000178394	28216264	Lynch et al. (2017)	increased memory	HTR1A	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0008568	ENSG00000178394	28216264	Lynch et al. (2017)	decreased sleep	HTR1A	UBERON_0001016	""
nervous system	inhibition_acute	HP_0003401	ENSG00000178394	28216264	Lynch et al. (2017)	paresthesia	HTR1A	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009847	ENSG00000178394	28216264	Lynch et al. (2017)	dizziness	HTR1A	UBERON_0001016	""
nervous system	inhibition_acute	MONDO_0021084	ENSG00000178394	28216264	Lynch et al. (2017)	visual disturbances	HTR1A	UBERON_0001016	""
endocrine	activation_acute	HP_0001649	ENSG00000178394	28216264	Lynch et al. (2017)	increased heart rate	HTR1A	UBERON_0000949	""
cardiovascular	activation_acute	GO_0030252	ENSG00000178394	28216264	Lynch et al. (2017)	growth hormone secretion	HTR1A	UBERON_0004535	""
endocrine	activation_acute	GO_0030252	ENSG00000178394	28216264	Lynch et al. (2017)	growth hormone secretion	HTR1A	UBERON_0000949	""
endocrine	activation_acute	HP_0000733	ENSG00000178394	28216264	Lynch et al. (2017)	stereotypy	HTR1A	UBERON_0000949	""
endocrine	activation_acute	EFO_0008568	ENSG00000178394	28216264	Lynch et al. (2017)	increased/decreased sleep	HTR1A	UBERON_0000949	""
nervous system	activation_acute	HP_0000733	ENSG00000178394	28216264	Lynch et al. (2017)	stereotypy	HTR1A	UBERON_0001016	""
endocrine	activation_acute	EFO_0003015	ENSG00000178394	28216264	Lynch et al. (2017)	decreased aggression	HTR1A	UBERON_0000949	""
cardiovascular	activation_acute	GO_0040012	ENSG00000178394	28216264	Lynch et al. (2017)	decreased/increased locomotor activity	HTR1A	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002045	ENSG00000178394	28216264	Lynch et al. (2017)	decreased body temperature	HTR1A	UBERON_0004535	""
nervous system	activation_acute	GO_0043400	ENSG00000178394	28216264	Lynch et al. (2017)	cortisol secretion	HTR1A	UBERON_0001016	""
cardiovascular	activation_acute	HP_0007686	ENSG00000178394	28216264	Lynch et al. (2017)	increased/decreased pupil diameter	HTR1A	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000178394	28216264	Lynch et al. (2017)	decreased memory	HTR1A	UBERON_0004535	""
nervous system	activation_acute	GO_0030252	ENSG00000178394	28216264	Lynch et al. (2017)	growth hormone secretion	HTR1A	UBERON_0001016	""
nervous system	activation_acute	HP_0002045	ENSG00000178394	28216264	Lynch et al. (2017)	decreased body temperature	HTR1A	UBERON_0001016	""
cardiovascular	activation_acute	GO_0043400	ENSG00000178394	28216264	Lynch et al. (2017)	cortisol secretion	HTR1A	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001649	ENSG00000178394	28216264	Lynch et al. (2017)	increased heart rate	HTR1A	UBERON_0004535	""
endocrine	activation_acute	EFO_0009874	ENSG00000178394	28216264	Lynch et al. (2017)	decreased anxiety	HTR1A	UBERON_0000949	""
endocrine	activation_acute	GO_1904057	ENSG00000178394	28216264	Lynch et al. (2017)	decreased pain	HTR1A	UBERON_0000949	""
endocrine	activation_acute	GO_0040012	ENSG00000178394	28216264	Lynch et al. (2017)	decreased/increased locomotor activity	HTR1A	UBERON_0000949	""
nervous system	activation_acute	EFO_0008568	ENSG00000178394	28216264	Lynch et al. (2017)	increased/decreased sleep	HTR1A	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000178394	28216264	Lynch et al. (2017)	decreased anxiety	HTR1A	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000178394	28216264	Lynch et al. (2017)	decreased blood pressure	HTR1A	UBERON_0004535	""
cardiovascular	activation_acute	GO_1904057	ENSG00000178394	28216264	Lynch et al. (2017)	decreased pain	HTR1A	UBERON_0004535	""
nervous system	activation_acute	EFO_0001072	ENSG00000178394	28216264	Lynch et al. (2017)	decreased memory	HTR1A	UBERON_0001016	""
endocrine	activation_acute	HP_0003154	ENSG00000178394	28216264	Lynch et al. (2017)	increased adrenocorticotropic hormone	HTR1A	UBERON_0000949	""
endocrine	activation_acute	HP_0007686	ENSG00000178394	28216264	Lynch et al. (2017)	increased/decreased pupil diameter	HTR1A	UBERON_0000949	""
nervous system	activation_acute	GO_0040012	ENSG00000178394	28216264	Lynch et al. (2017)	decreased/increased locomotor activity	HTR1A	UBERON_0001016	""
cardiovascular	activation_acute	HP_0003154	ENSG00000178394	28216264	Lynch et al. (2017)	increased adrenocorticotropic hormone	HTR1A	UBERON_0004535	""
nervous system	activation_acute	GO_1904057	ENSG00000178394	28216264	Lynch et al. (2017)	decreased pain	HTR1A	UBERON_0001016	""
endocrine	activation_acute	GO_0043400	ENSG00000178394	28216264	Lynch et al. (2017)	cortisol secretion	HTR1A	UBERON_0000949	""
cardiovascular	activation_acute	EFO_0003015	ENSG00000178394	28216264	Lynch et al. (2017)	decreased aggression	HTR1A	UBERON_0004535	""
endocrine	activation_acute	EFO_0001072	ENSG00000178394	28216264	Lynch et al. (2017)	decreased memory	HTR1A	UBERON_0000949	""
nervous system	activation_acute	EFO_0003015	ENSG00000178394	28216264	Lynch et al. (2017)	decreased aggression	HTR1A	UBERON_0001016	""
nervous system	activation_acute	HP_0007686	ENSG00000178394	28216264	Lynch et al. (2017)	increased/decreased pupil diameter	HTR1A	UBERON_0001016	""
nervous system	activation_acute	HP_0003154	ENSG00000178394	28216264	Lynch et al. (2017)	increased adrenocorticotropic hormone	HTR1A	UBERON_0001016	""
nervous system	activation_acute	EFO_0009874	ENSG00000178394	28216264	Lynch et al. (2017)	decreased anxiety	HTR1A	UBERON_0001016	""
nervous system	activation_acute	EFO_0005251	ENSG00000178394	28216264	Lynch et al. (2017)	decreased blood pressure	HTR1A	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0030897	ENSG00000163394	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	CCKAR	UBERON_0005409	""
gastrointestinal	activation_chronic	HP_0032263	ENSG00000163394	28216264	Lynch et al. (2017)	increased blood pressure	CCKAR	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0100738	ENSG00000163394	28216264	Lynch et al. (2017)	increased eating	CCKAR	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0120062	ENSG00000163394	28216264	Lynch et al. (2017)	increased gastric emptying	CCKAR	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0410204	ENSG00000163394	28216264	Lynch et al. (2017)	increased intestinal transit	CCKAR	UBERON_0005409	""
gastrointestinal	inhibition_acute	MONDO_0001751	ENSG00000163394	28216264	Lynch et al. (2017)	cholestasis	CCKAR	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0004799	ENSG00000163394	28216264	Lynch et al. (2017)	cholelethiasis	CCKAR	UBERON_0005409	""
gastrointestinal	activation_chronic	HP_0001649	ENSG00000163394	28216264	Lynch et al. (2017)	increased heart rate	CCKAR	UBERON_0005409	""
gastrointestinal	activation_chronic	EFO_0005230	ENSG00000163394	28216264	Lynch et al. (2017)	anxiety	CCKAR	UBERON_0005409	""
gastrointestinal	activation_chronic	HP_0012378	ENSG00000163394	28216264	Lynch et al. (2017)	fatigue	CCKAR	UBERON_0005409	""
gastrointestinal	activation_chronic	EFO_0008568	ENSG00000163394	28216264	Lynch et al. (2017)	decreased sleep	CCKAR	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0002018	ENSG00000163394	28216264	Lynch et al. (2017)	nausea	CCKAR	UBERON_0005409	""
nervous system	activation_acute	EFO_0009669	ENSG00000163394	28216264	Lynch et al. (2017)	gas	CCKAR	UBERON_0001016	""
nervous system	activation_chronic	HP_0032263	ENSG00000163394	28216264	Lynch et al. (2017)	increased blood pressure	CCKAR	UBERON_0001016	""
nervous system	inhibition_acute	HP_0100738	ENSG00000163394	28216264	Lynch et al. (2017)	increased eating	CCKAR	UBERON_0001016	""
nervous system	inhibition_acute	GO_0120062	ENSG00000163394	28216264	Lynch et al. (2017)	increased gastric emptying	CCKAR	UBERON_0001016	""
nervous system	inhibition_acute	HP_0410204	ENSG00000163394	28216264	Lynch et al. (2017)	increased intestinal transit	CCKAR	UBERON_0001016	""
nervous system	inhibition_acute	MONDO_0001751	ENSG00000163394	28216264	Lynch et al. (2017)	cholestasis	CCKAR	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004799	ENSG00000163394	28216264	Lynch et al. (2017)	cholelethiasis	CCKAR	UBERON_0001016	""
nervous system	activation_chronic	HP_0001649	ENSG00000163394	28216264	Lynch et al. (2017)	increased heart rate	CCKAR	UBERON_0001016	""
nervous system	activation_chronic	EFO_0005230	ENSG00000163394	28216264	Lynch et al. (2017)	anxiety	CCKAR	UBERON_0001016	""
nervous system	activation_chronic	HP_0012378	ENSG00000163394	28216264	Lynch et al. (2017)	fatigue	CCKAR	UBERON_0001016	""
nervous system	activation_chronic	EFO_0008568	ENSG00000163394	28216264	Lynch et al. (2017)	decreased sleep	CCKAR	UBERON_0001016	""
gastrointestinal	activation_acute	GO_0120061	ENSG00000163394	28216264	Lynch et al. (2017)	decreased gastric emptying	CCKAR	UBERON_0005409	""
nervous system	activation_acute	HP_0100738	ENSG00000163394	28216264	Lynch et al. (2017)	decreased eating	CCKAR	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0002045	ENSG00000163394	28216264	Lynch et al. (2017)	decreased body temperature	CCKAR	UBERON_0005409	""
gallbladder	activation_acute	HP_0100738	ENSG00000163394	28216264	Lynch et al. (2017)	decreased eating	CCKAR	UBERON_0002110	""
gallbladder	activation_chronic	HP_0032263	ENSG00000163394	28216264	Lynch et al. (2017)	increased blood pressure	CCKAR	UBERON_0002110	""
gallbladder	inhibition_acute	HP_0100738	ENSG00000163394	28216264	Lynch et al. (2017)	increased eating	CCKAR	UBERON_0002110	""
gallbladder	inhibition_acute	GO_0120062	ENSG00000163394	28216264	Lynch et al. (2017)	increased gastric emptying	CCKAR	UBERON_0002110	""
gallbladder	inhibition_acute	HP_0410204	ENSG00000163394	28216264	Lynch et al. (2017)	increased intestinal transit	CCKAR	UBERON_0002110	""
gallbladder	inhibition_acute	MONDO_0001751	ENSG00000163394	28216264	Lynch et al. (2017)	cholestasis	CCKAR	UBERON_0002110	""
gallbladder	inhibition_acute	EFO_0004799	ENSG00000163394	28216264	Lynch et al. (2017)	cholelethiasis	CCKAR	UBERON_0002110	""
gallbladder	activation_chronic	HP_0001649	ENSG00000163394	28216264	Lynch et al. (2017)	increased heart rate	CCKAR	UBERON_0002110	""
gallbladder	activation_chronic	EFO_0005230	ENSG00000163394	28216264	Lynch et al. (2017)	anxiety	CCKAR	UBERON_0002110	""
gallbladder	activation_chronic	HP_0012378	ENSG00000163394	28216264	Lynch et al. (2017)	fatigue	CCKAR	UBERON_0002110	""
gallbladder	activation_chronic	EFO_0008568	ENSG00000163394	28216264	Lynch et al. (2017)	decreased sleep	CCKAR	UBERON_0002110	""
gastrointestinal	activation_acute	GO_0040013	ENSG00000163394	28216264	Lynch et al. (2017)	decreased locomotor activity	CCKAR	UBERON_0005409	""
nervous system	activation_acute	HP_0002045	ENSG00000163394	28216264	Lynch et al. (2017)	decreased body temperature	CCKAR	UBERON_0001016	""
nervous system	activation_acute	HP_0030897	ENSG00000163394	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	CCKAR	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0002027	ENSG00000163394	28216264	Lynch et al. (2017)	abdominal pain hypersenstivity	CCKAR	UBERON_0005409	""
gallbladder	activation_acute	GO_0120061	ENSG00000163394	28216264	Lynch et al. (2017)	decreased gastric emptying	CCKAR	UBERON_0002110	""
nervous system	activation_acute	HP_0002018	ENSG00000163394	28216264	Lynch et al. (2017)	nausea	CCKAR	UBERON_0001016	""
gallbladder	activation_acute	GO_0040013	ENSG00000163394	28216264	Lynch et al. (2017)	decreased locomotor activity	CCKAR	UBERON_0002110	""
gastrointestinal	activation_acute	HP_0005609	ENSG00000163394	28216264	Lynch et al. (2017)	gallbladder contraction	CCKAR	UBERON_0005409	""
gallbladder	activation_acute	HP_0003270	ENSG00000163394	28216264	Lynch et al. (2017)	bloating	CCKAR	UBERON_0002110	""
nervous system	activation_acute	HP_0002027	ENSG00000163394	28216264	Lynch et al. (2017)	abdominal pain hypersenstivity	CCKAR	UBERON_0001016	""
gallbladder	activation_acute	HP_0002045	ENSG00000163394	28216264	Lynch et al. (2017)	decreased body temperature	CCKAR	UBERON_0002110	""
gastrointestinal	activation_acute	HP_0003270	ENSG00000163394	28216264	Lynch et al. (2017)	bloating	CCKAR	UBERON_0005409	""
gallbladder	activation_acute	HP_0002018	ENSG00000163394	28216264	Lynch et al. (2017)	nausea	CCKAR	UBERON_0002110	""
nervous system	activation_acute	GO_0120061	ENSG00000163394	28216264	Lynch et al. (2017)	decreased gastric emptying	CCKAR	UBERON_0001016	""
gastrointestinal	activation_acute	HP_0100738	ENSG00000163394	28216264	Lynch et al. (2017)	decreased eating	CCKAR	UBERON_0005409	""
gallbladder	activation_acute	HP_0002027	ENSG00000163394	28216264	Lynch et al. (2017)	abdominal pain hypersenstivity	CCKAR	UBERON_0002110	""
gallbladder	activation_acute	EFO_0009669	ENSG00000163394	28216264	Lynch et al. (2017)	gas	CCKAR	UBERON_0002110	""
nervous system	activation_acute	HP_0005609	ENSG00000163394	28216264	Lynch et al. (2017)	gallbladder contraction	CCKAR	UBERON_0001016	""
gallbladder	activation_acute	HP_0030897	ENSG00000163394	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	CCKAR	UBERON_0002110	""
nervous system	activation_acute	HP_0003270	ENSG00000163394	28216264	Lynch et al. (2017)	bloating	CCKAR	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_0009669	ENSG00000163394	28216264	Lynch et al. (2017)	gas	CCKAR	UBERON_0005409	""
nervous system	activation_acute	GO_0040013	ENSG00000163394	28216264	Lynch et al. (2017)	decreased locomotor activity	CCKAR	UBERON_0001016	""
gallbladder	activation_acute	HP_0005609	ENSG00000163394	28216264	Lynch et al. (2017)	gallbladder contraction	CCKAR	UBERON_0002110	""
cardiovascular system	activation_general	HP_0001685	ENSG00000166148	""	Urban et al. (2012)	myocardial fibrosis	AVPR1A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0002503	ENSG00000166148	""	Urban et al. (2012)	hypertrophy	AVPR1A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	""	ENSG00000166148	""	Urban et al. (2012)	vasoconstriction	AVPR1A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	EFO_0003144	ENSG00000166148	""	Urban et al. (2012)	heart failure	AVPR1A	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
immune	activation_acute	HP_0030897	ENSG00000114812	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	VIPR1	UBERON_0002405	""
immune	inhibition_acute	GO_0006954	ENSG00000114812	28216264	Lynch et al. (2017)	inflammation	VIPR1	UBERON_0002405	""
immune	inhibition_acute	HP_0410204	ENSG00000114812	28216264	Lynch et al. (2017)	increased gastrointestinal transit	VIPR1	UBERON_0002405	""
immune	activation_acute	GO_0050777	ENSG00000114812	28216264	Lynch et al. (2017)	immunosuppression	VIPR1	UBERON_0002405	""
gastrointestinal	activation_acute	HP_0030897	ENSG00000114812	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	VIPR1	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0006954	ENSG00000114812	28216264	Lynch et al. (2017)	inflammation	VIPR1	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0410204	ENSG00000114812	28216264	Lynch et al. (2017)	increased gastrointestinal transit	VIPR1	UBERON_0005409	""
gastrointestinal	activation_acute	GO_0050728	ENSG00000114812	28216264	Lynch et al. (2017)	decreased inflammation	VIPR1	UBERON_0005409	""
immune	activation_acute	GO_0050728	ENSG00000114812	28216264	Lynch et al. (2017)	decreased inflammation	VIPR1	UBERON_0002405	""
gastrointestinal	activation_acute	GO_0050777	ENSG00000114812	28216264	Lynch et al. (2017)	immunosuppression	VIPR1	UBERON_0005409	""
renal	activation_acute	HP_0032263	ENSG00000144891	28216264	Lynch et al. (2017)	increased blood pressure	AGTR1	UBERON_0001008	""
renal	inhibition_acute	EFO_0005251	ENSG00000144891	28216264	Lynch et al. (2017)	decreased blood pressure	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_0000480	ENSG00000144891	28216264	Lynch et al. (2017)	death	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_0007401	ENSG00000144891	28216264	Lynch et al. (2017)	oligoamnios	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_1002048	ENSG00000144891	28216264	Lynch et al. (2017)	renal failure	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_0005251	ENSG00000144891	28216264	Lynch et al. (2017)	decreased blood pressure	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	HP_0002089	ENSG00000144891	28216264	Lynch et al. (2017)	pulmonary hypoplasia	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_1000644	ENSG00000144891	28216264	Lynch et al. (2017)	respiratory distress syndrome	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	HP_0001643	ENSG00000144891	28216264	Lynch et al. (2017)	persistent patent ductus arteriosus	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	HP_0010539	ENSG00000144891	28216264	Lynch et al. (2017)	hypocalvaria	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	MONDO_0019054	ENSG00000144891	28216264	Lynch et al. (2017)	limb defects	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	EFO_0000495	ENSG00000144891	28216264	Lynch et al. (2017)	intrauterine growth retardation	AGTR1	UBERON_0001008	""
renal	inhibition_developmental toxicity	MONDO_0016054	ENSG00000144891	28216264	Lynch et al. (2017)	cerebral complications	AGTR1	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000144891	28216264	Lynch et al. (2017)	decreased pain	AGTR1	UBERON_0001008	""
renal	inhibition_acute	HP_0012590	ENSG00000144891	28216264	Lynch et al. (2017)	increased/decreased urine excretion	AGTR1	UBERON_0001008	""
renal	inhibition_acute	GO_0035813	ENSG00000144891	28216264	Lynch et al. (2017)	increased/decreased urinary sodium excretion	AGTR1	UBERON_0001008	""
cardiovascular	activation_acute	GO_1904058	ENSG00000144891	28216264	Lynch et al. (2017)	increased pain	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000144891	28216264	Lynch et al. (2017)	decreased blood pressure	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	EFO_0000480	ENSG00000144891	28216264	Lynch et al. (2017)	death	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	EFO_0007401	ENSG00000144891	28216264	Lynch et al. (2017)	oligoamnios	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	EFO_1002048	ENSG00000144891	28216264	Lynch et al. (2017)	renal failure	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	EFO_0005251	ENSG00000144891	28216264	Lynch et al. (2017)	decreased blood pressure	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	HP_0002089	ENSG00000144891	28216264	Lynch et al. (2017)	pulmonary hypoplasia	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	EFO_1000644	ENSG00000144891	28216264	Lynch et al. (2017)	respiratory distress syndrome	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	HP_0001643	ENSG00000144891	28216264	Lynch et al. (2017)	persistent patent ductus arteriosus	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	HP_0010539	ENSG00000144891	28216264	Lynch et al. (2017)	hypocalvaria	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	MONDO_0019054	ENSG00000144891	28216264	Lynch et al. (2017)	limb defects	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	EFO_0000495	ENSG00000144891	28216264	Lynch et al. (2017)	intrauterine growth retardation	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	MONDO_0016054	ENSG00000144891	28216264	Lynch et al. (2017)	cerebral complications	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000144891	28216264	Lynch et al. (2017)	decreased pain	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0012590	ENSG00000144891	28216264	Lynch et al. (2017)	increased/decreased urine excretion	AGTR1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035813	ENSG00000144891	28216264	Lynch et al. (2017)	increased/decreased urinary sodium excretion	AGTR1	UBERON_0004535	""
renal	activation_acute	GO_1904058	ENSG00000144891	28216264	Lynch et al. (2017)	increased pain	AGTR1	UBERON_0001008	""
cardiovascular	activation_acute	GO_0035814	ENSG00000144891	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	AGTR1	UBERON_0004535	""
renal	activation_acute	GO_0035814	ENSG00000144891	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	AGTR1	UBERON_0001008	""
cardiovascular	activation_acute	HP_0032263	ENSG00000144891	28216264	Lynch et al. (2017)	increased blood pressure	AGTR1	UBERON_0004535	""
cardiovascular	activation_acute	GO_1904057	ENSG00000135312	28216264	Lynch et al. (2017)	decreased pain	HTR1B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003015	ENSG00000135312	28216264	Lynch et al. (2017)	increased aggression	HTR1B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009874	ENSG00000135312	28216264	Lynch et al. (2017)	decreased anxiety	HTR1B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004874	ENSG00000135312	28216264	Lynch et al. (2017)	increased memory	HTR1B	UBERON_0004535	""
nervous system	activation_acute	EFO_0001072	ENSG00000135312	28216264	Lynch et al. (2017)	decreased memory	HTR1B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0003015	ENSG00000135312	28216264	Lynch et al. (2017)	increased aggression	HTR1B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009874	ENSG00000135312	28216264	Lynch et al. (2017)	decreased anxiety	HTR1B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004874	ENSG00000135312	28216264	Lynch et al. (2017)	increased memory	HTR1B	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0003015	ENSG00000135312	28216264	Lynch et al. (2017)	decreased aggression	HTR1B	UBERON_0004535	""
cardiovascular	activation_acute	HP_0032263	ENSG00000135312	28216264	Lynch et al. (2017)	increased blood pressure	HTR1B	UBERON_0004535	""
nervous system	activation_acute	HP_0100738	ENSG00000135312	28216264	Lynch et al. (2017)	decreased eating	HTR1B	UBERON_0001016	""
nervous system	activation_acute	EFO_0009874	ENSG00000135312	28216264	Lynch et al. (2017)	decreased anxiety	HTR1B	UBERON_0001016	""
nervous system	activation_acute	HP_0032263	ENSG00000135312	28216264	Lynch et al. (2017)	increased blood pressure	HTR1B	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000135312	28216264	Lynch et al. (2017)	decreased memory	HTR1B	UBERON_0004535	""
cardiovascular	activation_acute	HP_0100738	ENSG00000135312	28216264	Lynch et al. (2017)	decreased eating	HTR1B	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002045	ENSG00000135312	28216264	Lynch et al. (2017)	decreased body temperature	HTR1B	UBERON_0004535	""
nervous system	activation_acute	GO_1904057	ENSG00000135312	28216264	Lynch et al. (2017)	decreased pain	HTR1B	UBERON_0001016	""
nervous system	activation_acute	HP_0002045	ENSG00000135312	28216264	Lynch et al. (2017)	decreased body temperature	HTR1B	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000135312	28216264	Lynch et al. (2017)	decreased anxiety	HTR1B	UBERON_0004535	""
nervous system	activation_acute	EFO_0003015	ENSG00000135312	28216264	Lynch et al. (2017)	decreased aggression	HTR1B	UBERON_0001016	""
immune	activation_general	GO_0050777	ENSG00000113580	23197038	Bowes et al. (2012)	immunosuppression	NR3C1	UBERON_0002405	""
immune	inhibition_general	HP_0001943	ENSG00000113580	23197038	Bowes et al. (2012)	hypoglycaemia	NR3C1	UBERON_0002405	""
immune	activation_general	HP_0003074	ENSG00000113580	23197038	Bowes et al. (2012)	hyperglycaemia	NR3C1	UBERON_0002405	""
immune	activation_general	EFO_0002614	ENSG00000113580	23197038	Bowes et al. (2012)	insulin resistance	NR3C1	UBERON_0002405	""
immune	activation_general	EFO_0009851	ENSG00000113580	23197038	Bowes et al. (2012)	muscle wasting	NR3C1	UBERON_0002405	""
immune	activation_general	EFO_0004566	ENSG00000113580	23197038	Bowes et al. (2012)	increased body weight	NR3C1	UBERON_0002405	""
immune	activation_general	EFO_0003882	ENSG00000113580	23197038	Bowes et al. (2012)	osteoporosis	NR3C1	UBERON_0002405	""
immune	activation_general	EFO_0000516	ENSG00000113580	23197038	Bowes et al. (2012)	glaucoma	NR3C1	UBERON_0002405	""
immune	activation_general	HP_0032263	ENSG00000113580	23197038	Bowes et al. (2012)	increased blood pressure	NR3C1	UBERON_0002405	""
immune	activation_general	HP_0002900	ENSG00000113580	23197038	Bowes et al. (2012)	decreased plasma potassium	NR3C1	UBERON_0002405	""
immune	activation_general	EFO_0004269	ENSG00000113580	23197038	Bowes et al. (2012)	cardiac arrhythmia	NR3C1	UBERON_0002405	""
endocrine	activation_general	GO_0050777	ENSG00000113580	23197038	Bowes et al. (2012)	immunosuppression	NR3C1	UBERON_0000949	""
endocrine	inhibition_general	HP_0001943	ENSG00000113580	23197038	Bowes et al. (2012)	hypoglycaemia	NR3C1	UBERON_0000949	""
endocrine	activation_general	HP_0003074	ENSG00000113580	23197038	Bowes et al. (2012)	hyperglycaemia	NR3C1	UBERON_0000949	""
endocrine	activation_general	EFO_0002614	ENSG00000113580	23197038	Bowes et al. (2012)	insulin resistance	NR3C1	UBERON_0000949	""
endocrine	activation_general	EFO_0009851	ENSG00000113580	23197038	Bowes et al. (2012)	muscle wasting	NR3C1	UBERON_0000949	""
endocrine	activation_general	EFO_0004566	ENSG00000113580	23197038	Bowes et al. (2012)	increased body weight	NR3C1	UBERON_0000949	""
endocrine	activation_general	EFO_0003882	ENSG00000113580	23197038	Bowes et al. (2012)	osteoporosis	NR3C1	UBERON_0000949	""
endocrine	activation_general	EFO_0000516	ENSG00000113580	23197038	Bowes et al. (2012)	glaucoma	NR3C1	UBERON_0000949	""
endocrine	activation_general	HP_0032263	ENSG00000113580	23197038	Bowes et al. (2012)	increased blood pressure	NR3C1	UBERON_0000949	""
endocrine	activation_general	HP_0002900	ENSG00000113580	23197038	Bowes et al. (2012)	decreased plasma potassium	NR3C1	UBERON_0000949	""
endocrine	activation_general	EFO_0004269	ENSG00000113580	23197038	Bowes et al. (2012)	cardiac arrhythmia	NR3C1	UBERON_0000949	""
central nervous system	inhibition_general	EFO_0003890	ENSG00000142319	23197038	Bowes et al. (2012)	addictive psychostimulation	SLC6A3	UBERON_0001017	""
central nervous system	inhibition_general	MONDO_0002050	ENSG00000142319	23197038	Bowes et al. (2012)	depression	SLC6A3	UBERON_0001017	""
central nervous system	inhibition_general	HP_0001300	ENSG00000142319	23197038	Bowes et al. (2012)	parkinsonism	SLC6A3	UBERON_0001017	""
central nervous system	inhibition_general	HP_0001250	ENSG00000142319	23197038	Bowes et al. (2012)	seizures	SLC6A3	UBERON_0001017	""
central nervous system	inhibition_general	HP_0001332	ENSG00000142319	23197038	Bowes et al. (2012)	dystonia	SLC6A3	UBERON_0001017	""
central nervous system	inhibition_general	EFO_1000904	ENSG00000142319	23197038	Bowes et al. (2012)	dyskinesia	SLC6A3	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0003894	ENSG00000142319	23197038	Bowes et al. (2012)	acne	SLC6A3	UBERON_0001017	""
cardiovascular	inhibition_acute	GO_0045823	ENSG00000163399	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1A1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000163399	28216264	Lynch et al. (2017)	decreased heart rate	ATP1A1	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000163399	28216264	Lynch et al. (2017)	atrioventricular block	ATP1A1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000163399	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1A1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004287	ENSG00000163399	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1A1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000163399	28216264	Lynch et al. (2017)	increased urine excretion	ATP1A1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000163399	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1A1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002017	ENSG00000163399	28216264	Lynch et al. (2017)	vomiting	ATP1A1	UBERON_0004535	""
renal	inhibition_acute	GO_0045823	ENSG00000163399	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1A1	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000163399	28216264	Lynch et al. (2017)	decreased heart rate	ATP1A1	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000163399	28216264	Lynch et al. (2017)	atrioventricular block	ATP1A1	UBERON_0001008	""
renal	inhibition_acute	EFO_0004269	ENSG00000163399	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1A1	UBERON_0001008	""
renal	inhibition_acute	EFO_0004287	ENSG00000163399	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1A1	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000163399	28216264	Lynch et al. (2017)	increased urine excretion	ATP1A1	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000163399	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1A1	UBERON_0001008	""
renal	inhibition_acute	HP_0002017	ENSG00000163399	28216264	Lynch et al. (2017)	vomiting	ATP1A1	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000105464	28216264	Lynch et al. (2017)	convulsions	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000105464	28216264	Lynch et al. (2017)	decreased pain	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000735	ENSG00000105464	28216264	Lynch et al. (2017)	impaired social interactions	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000733	ENSG00000105464	28216264	Lynch et al. (2017)	stereotypy	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_chronic	EFO_0005407	ENSG00000105464	28216264	Lynch et al. (2017)	psychosis	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0002180	ENSG00000105464	28216264	Lynch et al. (2017)	neurodegeneration	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040017	ENSG00000105464	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000437	ENSG00000105464	28216264	Lynch et al. (2017)	ataxia	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000105464	28216264	Lynch et al. (2017)	dizziness	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0001072	ENSG00000105464	28216264	Lynch et al. (2017)	decreased memory	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005407	ENSG00000105464	28216264	Lynch et al. (2017)	psychosis	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000105464	28216264	Lynch et al. (2017)	decreased convulsions	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003890	ENSG00000105464	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000105464	28216264	Lynch et al. (2017)	neurotoxicity	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000105464	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2D	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000105464	28216264	Lynch et al. (2017)	increased heart rate	GRIN2D	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003843	ENSG00000105464	28216264	Lynch et al. (2017)	pain	GRIN2D	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000105464	28216264	Lynch et al. (2017)	convulsions	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1904057	ENSG00000105464	28216264	Lynch et al. (2017)	decreased pain	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000735	ENSG00000105464	28216264	Lynch et al. (2017)	impaired social interactions	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000733	ENSG00000105464	28216264	Lynch et al. (2017)	stereotypy	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_chronic	EFO_0005407	ENSG00000105464	28216264	Lynch et al. (2017)	psychosis	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0002180	ENSG00000105464	28216264	Lynch et al. (2017)	neurodegeneration	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0040017	ENSG00000105464	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	MONDO_0000437	ENSG00000105464	28216264	Lynch et al. (2017)	ataxia	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009847	ENSG00000105464	28216264	Lynch et al. (2017)	dizziness	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0001072	ENSG00000105464	28216264	Lynch et al. (2017)	decreased memory	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005407	ENSG00000105464	28216264	Lynch et al. (2017)	psychosis	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000105464	28216264	Lynch et al. (2017)	decreased convulsions	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003890	ENSG00000105464	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000105464	28216264	Lynch et al. (2017)	neurotoxicity	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0032263	ENSG00000105464	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2D	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001649	ENSG00000105464	28216264	Lynch et al. (2017)	increased heart rate	GRIN2D	UBERON_0001017	""
cardiovascular	activation_acute	HP_0031860	ENSG00000105464	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN2D	UBERON_0004535	""
central nervous system	activation_acute	EFO_0003843	ENSG00000105464	28216264	Lynch et al. (2017)	pain	GRIN2D	UBERON_0001017	""
central nervous system	activation_acute	HP_0031860	ENSG00000105464	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN2D	UBERON_0001017	""
central nervous system	activation_acute	HP_0032263	ENSG00000105464	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2D	UBERON_0001017	""
cardiovascular	activation_acute	HP_0032263	ENSG00000105464	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2D	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002094	ENSG00000149575	28216264	Lynch et al. (2017)	dyspnea	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000149575	28216264	Lynch et al. (2017)	decreased pain	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	NCIT_C74532	ENSG00000149575	28216264	Lynch et al. (2017)	agitation	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_1000712	ENSG00000149575	28216264	Lynch et al. (2017)	decreased sweating	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011499	ENSG00000149575	28216264	Lynch et al. (2017)	increased pupil diameter	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000149575	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0031860	ENSG00000149575	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000149575	28216264	Lynch et al. (2017)	decreased blood pressure	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0045822	ENSG00000149575	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_1001497	ENSG00000149575	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0006677	ENSG00000149575	28216264	Lynch et al. (2017)	increased QRS complex	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000149575	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009839	ENSG00000149575	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000149575	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0011037	ENSG00000149575	28216264	Lynch et al. (2017)	decreased urine excretion	SCN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001259	ENSG00000149575	28216264	Lynch et al. (2017)	coma	SCN2B	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000149575	28216264	Lynch et al. (2017)	convulsions	SCN2B	UBERON_0004535	""
respiratory	activation_acute	EFO_0004269	ENSG00000149575	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	GO_1904057	ENSG00000149575	28216264	Lynch et al. (2017)	decreased pain	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	NCIT_C74532	ENSG00000149575	28216264	Lynch et al. (2017)	agitation	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_1000712	ENSG00000149575	28216264	Lynch et al. (2017)	decreased sweating	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0011499	ENSG00000149575	28216264	Lynch et al. (2017)	increased pupil diameter	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009853	ENSG00000149575	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0031860	ENSG00000149575	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0005251	ENSG00000149575	28216264	Lynch et al. (2017)	decreased blood pressure	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	GO_0045822	ENSG00000149575	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_1001497	ENSG00000149575	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0006677	ENSG00000149575	28216264	Lynch et al. (2017)	increased QRS complex	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0004269	ENSG00000149575	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	EFO_0009839	ENSG00000149575	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0030897	ENSG00000149575	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0011037	ENSG00000149575	28216264	Lynch et al. (2017)	decreased urine excretion	SCN2B	UBERON_0001004	""
respiratory	inhibition_acute	HP_0001259	ENSG00000149575	28216264	Lynch et al. (2017)	coma	SCN2B	UBERON_0001004	""
respiratory	activation_acute	HP_0001649	ENSG00000149575	28216264	Lynch et al. (2017)	increased heart rate	SCN2B	UBERON_0001004	""
nervous system	activation_acute	HP_0002094	ENSG00000149575	28216264	Lynch et al. (2017)	dyspnea	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000149575	28216264	Lynch et al. (2017)	decreased pain	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	NCIT_C74532	ENSG00000149575	28216264	Lynch et al. (2017)	agitation	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_1000712	ENSG00000149575	28216264	Lynch et al. (2017)	decreased sweating	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0011499	ENSG00000149575	28216264	Lynch et al. (2017)	increased pupil diameter	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000149575	28216264	Lynch et al. (2017)	decreased/increased convulsions	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0031860	ENSG00000149575	28216264	Lynch et al. (2017)	decreased/increased heart rate	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0005251	ENSG00000149575	28216264	Lynch et al. (2017)	decreased blood pressure	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	GO_0045822	ENSG00000149575	28216264	Lynch et al. (2017)	decreased cardiac contractility	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_1001497	ENSG00000149575	28216264	Lynch et al. (2017)	decreased cardiac conduction	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0006677	ENSG00000149575	28216264	Lynch et al. (2017)	increased QRS complex	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004269	ENSG00000149575	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009839	ENSG00000149575	28216264	Lynch et al. (2017)	decreased respiratory rate	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030897	ENSG00000149575	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0011037	ENSG00000149575	28216264	Lynch et al. (2017)	decreased urine excretion	SCN2B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0001259	ENSG00000149575	28216264	Lynch et al. (2017)	coma	SCN2B	UBERON_0001016	""
respiratory	activation_acute	HP_0002094	ENSG00000149575	28216264	Lynch et al. (2017)	dyspnea	SCN2B	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0004269	ENSG00000149575	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN2B	UBERON_0004535	""
nervous system	activation_acute	GO_0040013	ENSG00000149575	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN2B	UBERON_0001016	""
cardiovascular	activation_acute	HP_0001649	ENSG00000149575	28216264	Lynch et al. (2017)	increased heart rate	SCN2B	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000149575	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN2B	UBERON_0004535	""
nervous system	activation_acute	HP_0001649	ENSG00000149575	28216264	Lynch et al. (2017)	increased heart rate	SCN2B	UBERON_0001016	""
nervous system	activation_acute	EFO_0004269	ENSG00000149575	28216264	Lynch et al. (2017)	cardiac arrhythmia	SCN2B	UBERON_0001016	""
respiratory	activation_acute	EFO_0009853	ENSG00000149575	28216264	Lynch et al. (2017)	convulsions	SCN2B	UBERON_0001004	""
nervous system	activation_acute	EFO_0009853	ENSG00000149575	28216264	Lynch et al. (2017)	convulsions	SCN2B	UBERON_0001016	""
respiratory	activation_acute	GO_0040013	ENSG00000149575	28216264	Lynch et al. (2017)	decreased locomotor activity	SCN2B	UBERON_0001004	""
gastrointestinal	activation_acute	HP_0410204	ENSG00000166736	28216264	Lynch et al. (2017)	increased gastrointestinal transit	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0030897	ENSG00000166736	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0002019	ENSG00000166736	28216264	Lynch et al. (2017)	constipation	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0031685	ENSG00000166736	28216264	Lynch et al. (2017)	hard stool	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0003270	ENSG00000166736	28216264	Lynch et al. (2017)	abdominal distension	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_acute	MONDO_0000701	ENSG00000166736	28216264	Lynch et al. (2017)	ischemic colitis	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1904057	ENSG00000166736	28216264	Lynch et al. (2017)	decreased pain	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0050728	ENSG00000166736	28216264	Lynch et al. (2017)	decreased inflammation	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0004874	ENSG00000166736	28216264	Lynch et al. (2017)	increased memory	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009874	ENSG00000166736	28216264	Lynch et al. (2017)	decreased anxiety	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009847	ENSG00000166736	28216264	Lynch et al. (2017)	dizziness	HTR3A	UBERON_0005409	""
cardiovascular	activation_acute	HP_0001649	ENSG00000166736	28216264	Lynch et al. (2017)	increased heart rate	HTR3A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000166736	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HTR3A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002019	ENSG00000166736	28216264	Lynch et al. (2017)	constipation	HTR3A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0031685	ENSG00000166736	28216264	Lynch et al. (2017)	hard stool	HTR3A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0003270	ENSG00000166736	28216264	Lynch et al. (2017)	abdominal distension	HTR3A	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000701	ENSG00000166736	28216264	Lynch et al. (2017)	ischemic colitis	HTR3A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000166736	28216264	Lynch et al. (2017)	decreased pain	HTR3A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0050728	ENSG00000166736	28216264	Lynch et al. (2017)	decreased inflammation	HTR3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004874	ENSG00000166736	28216264	Lynch et al. (2017)	increased memory	HTR3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009874	ENSG00000166736	28216264	Lynch et al. (2017)	decreased anxiety	HTR3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000166736	28216264	Lynch et al. (2017)	dizziness	HTR3A	UBERON_0004535	""
central nervous system	activation_acute	HP_0410204	ENSG00000166736	28216264	Lynch et al. (2017)	increased gastrointestinal transit	HTR3A	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0030897	ENSG00000166736	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HTR3A	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0002019	ENSG00000166736	28216264	Lynch et al. (2017)	constipation	HTR3A	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0031685	ENSG00000166736	28216264	Lynch et al. (2017)	hard stool	HTR3A	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0003270	ENSG00000166736	28216264	Lynch et al. (2017)	abdominal distension	HTR3A	UBERON_0001017	""
central nervous system	inhibition_acute	MONDO_0000701	ENSG00000166736	28216264	Lynch et al. (2017)	ischemic colitis	HTR3A	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1904057	ENSG00000166736	28216264	Lynch et al. (2017)	decreased pain	HTR3A	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0050728	ENSG00000166736	28216264	Lynch et al. (2017)	decreased inflammation	HTR3A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0004874	ENSG00000166736	28216264	Lynch et al. (2017)	increased memory	HTR3A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009874	ENSG00000166736	28216264	Lynch et al. (2017)	decreased anxiety	HTR3A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009847	ENSG00000166736	28216264	Lynch et al. (2017)	dizziness	HTR3A	UBERON_0001017	""
cardiovascular	activation_acute	HP_0032263	ENSG00000166736	28216264	Lynch et al. (2017)	increased blood pressure	HTR3A	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000166736	28216264	Lynch et al. (2017)	drug abuse/dependence	HTR3A	UBERON_0004535	""
cardiovascular	activation_acute	GO_0120062	ENSG00000166736	28216264	Lynch et al. (2017)	increased gastric emptying	HTR3A	UBERON_0004535	""
gastrointestinal	activation_acute	GO_0120062	ENSG00000166736	28216264	Lynch et al. (2017)	increased gastric emptying	HTR3A	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0002017	ENSG00000166736	28216264	Lynch et al. (2017)	vomiting	HTR3A	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0002104	ENSG00000166736	28216264	Lynch et al. (2017)	apnea	HTR3A	UBERON_0005409	""
central nervous system	activation_acute	HP_0032263	ENSG00000166736	28216264	Lynch et al. (2017)	increased blood pressure	HTR3A	UBERON_0001017	""
central nervous system	activation_acute	HP_0002017	ENSG00000166736	28216264	Lynch et al. (2017)	vomiting	HTR3A	UBERON_0001017	""
gastrointestinal	activation_acute	EFO_0001072	ENSG00000166736	28216264	Lynch et al. (2017)	decreased memory	HTR3A	UBERON_0005409	""
central nervous system	activation_acute	HP_0002104	ENSG00000166736	28216264	Lynch et al. (2017)	apnea	HTR3A	UBERON_0001017	""
cardiovascular	activation_acute	HP_0002104	ENSG00000166736	28216264	Lynch et al. (2017)	apnea	HTR3A	UBERON_0004535	""
central nervous system	activation_acute	GO_0120062	ENSG00000166736	28216264	Lynch et al. (2017)	increased gastric emptying	HTR3A	UBERON_0001017	""
cardiovascular	activation_acute	HP_0410204	ENSG00000166736	28216264	Lynch et al. (2017)	increased gastrointestinal transit	HTR3A	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0003890	ENSG00000166736	28216264	Lynch et al. (2017)	drug abuse/dependence	HTR3A	UBERON_0005409	""
central nervous system	activation_acute	HP_0001649	ENSG00000166736	28216264	Lynch et al. (2017)	increased heart rate	HTR3A	UBERON_0001017	""
gastrointestinal	activation_acute	HP_0001649	ENSG00000166736	28216264	Lynch et al. (2017)	increased heart rate	HTR3A	UBERON_0005409	""
central nervous system	activation_acute	EFO_0001072	ENSG00000166736	28216264	Lynch et al. (2017)	decreased memory	HTR3A	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000166736	28216264	Lynch et al. (2017)	decreased memory	HTR3A	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0032263	ENSG00000166736	28216264	Lynch et al. (2017)	increased blood pressure	HTR3A	UBERON_0005409	""
central nervous system	activation_acute	EFO_0003890	ENSG00000166736	28216264	Lynch et al. (2017)	drug abuse/dependence	HTR3A	UBERON_0001017	""
cardiovascular	activation_acute	HP_0002017	ENSG00000166736	28216264	Lynch et al. (2017)	vomiting	HTR3A	UBERON_0004535	""
endocrine	activation_acute	GO_1904057	ENSG00000113580	28216264	Lynch et al. (2017)	decreased pain	NR3C1	UBERON_0000949	""
endocrine	inhibition_acute	GO_0050729	ENSG00000113580	28216264	Lynch et al. (2017)	increased inflammation	NR3C1	UBERON_0000949	""
endocrine	inhibition_acute	GO_0051930	ENSG00000113580	28216264	Lynch et al. (2017)	increased/decreased pain	NR3C1	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0001072	ENSG00000113580	28216264	Lynch et al. (2017)	decreased memory	NR3C1	UBERON_0000949	""
endocrine	inhibition_acute	HP_0012378	ENSG00000113580	28216264	Lynch et al. (2017)	fatigue	NR3C1	UBERON_0000949	""
endocrine	inhibition_acute	HP_0002900	ENSG00000113580	28216264	Lynch et al. (2017)	decreased blood potassium	NR3C1	UBERON_0000949	""
endocrine	inhibition_acute	EFO_0009373	ENSG00000113580	28216264	Lynch et al. (2017)	edema	NR3C1	UBERON_0000949	""
endocrine	inhibition_acute	MONDO_0041161	ENSG00000113580	28216264	Lynch et al. (2017)	endometrial thickening	NR3C1	UBERON_0000949	""
immune	activation_acute	HP_0003074	ENSG00000113580	28216264	Lynch et al. (2017)	increased blood glucose	NR3C1	UBERON_0002405	""
immune	inhibition_acute	GO_0050729	ENSG00000113580	28216264	Lynch et al. (2017)	increased inflammation	NR3C1	UBERON_0002405	""
immune	inhibition_acute	GO_0051930	ENSG00000113580	28216264	Lynch et al. (2017)	increased/decreased pain	NR3C1	UBERON_0002405	""
immune	inhibition_acute	EFO_0001072	ENSG00000113580	28216264	Lynch et al. (2017)	decreased memory	NR3C1	UBERON_0002405	""
immune	inhibition_acute	HP_0012378	ENSG00000113580	28216264	Lynch et al. (2017)	fatigue	NR3C1	UBERON_0002405	""
immune	inhibition_acute	HP_0002900	ENSG00000113580	28216264	Lynch et al. (2017)	decreased blood potassium	NR3C1	UBERON_0002405	""
immune	inhibition_acute	EFO_0009373	ENSG00000113580	28216264	Lynch et al. (2017)	edema	NR3C1	UBERON_0002405	""
immune	inhibition_acute	MONDO_0041161	ENSG00000113580	28216264	Lynch et al. (2017)	endometrial thickening	NR3C1	UBERON_0002405	""
nervous system	activation_acute	GO_0061045	ENSG00000113580	28216264	Lynch et al. (2017)	decreased wound repair	NR3C1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050729	ENSG00000113580	28216264	Lynch et al. (2017)	increased inflammation	NR3C1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0051930	ENSG00000113580	28216264	Lynch et al. (2017)	increased/decreased pain	NR3C1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0001072	ENSG00000113580	28216264	Lynch et al. (2017)	decreased memory	NR3C1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0012378	ENSG00000113580	28216264	Lynch et al. (2017)	fatigue	NR3C1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0002900	ENSG00000113580	28216264	Lynch et al. (2017)	decreased blood potassium	NR3C1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009373	ENSG00000113580	28216264	Lynch et al. (2017)	edema	NR3C1	UBERON_0001016	""
nervous system	inhibition_acute	MONDO_0041161	ENSG00000113580	28216264	Lynch et al. (2017)	endometrial thickening	NR3C1	UBERON_0001016	""
nervous system	activation_acute	EFO_0002614	ENSG00000113580	28216264	Lynch et al. (2017)	insulin resistance	NR3C1	UBERON_0001016	""
immune	activation_acute	EFO_0003882	ENSG00000113580	28216264	Lynch et al. (2017)	osteoporosis	NR3C1	UBERON_0002405	""
immune	activation_acute	GO_0010876	ENSG00000113580	28216264	Lynch et al. (2017)	lipid redistribution	NR3C1	UBERON_0002405	""
immune	activation_acute	GO_0050728	ENSG00000113580	28216264	Lynch et al. (2017)	decreased inflammation	NR3C1	UBERON_0002405	""
nervous system	activation_acute	HP_0003074	ENSG00000113580	28216264	Lynch et al. (2017)	increased blood glucose	NR3C1	UBERON_0001016	""
nervous system	activation_acute	HP_0003199	ENSG00000113580	28216264	Lynch et al. (2017)	decreased muscle mass	NR3C1	UBERON_0001016	""
nervous system	activation_acute	GO_0010876	ENSG00000113580	28216264	Lynch et al. (2017)	lipid redistribution	NR3C1	UBERON_0001016	""
endocrine	activation_acute	HP_0003074	ENSG00000113580	28216264	Lynch et al. (2017)	increased blood glucose	NR3C1	UBERON_0000949	""
endocrine	activation_acute	GO_0061045	ENSG00000113580	28216264	Lynch et al. (2017)	decreased wound repair	NR3C1	UBERON_0000949	""
nervous system	activation_acute	EFO_0003882	ENSG00000113580	28216264	Lynch et al. (2017)	osteoporosis	NR3C1	UBERON_0001016	""
endocrine	activation_acute	EFO_0002614	ENSG00000113580	28216264	Lynch et al. (2017)	insulin resistance	NR3C1	UBERON_0000949	""
immune	activation_acute	EFO_0002614	ENSG00000113580	28216264	Lynch et al. (2017)	insulin resistance	NR3C1	UBERON_0002405	""
immune	activation_acute	HP_0032263	ENSG00000113580	28216264	Lynch et al. (2017)	increased blood pressure	NR3C1	UBERON_0002405	""
endocrine	activation_acute	GO_0035815	ENSG00000113580	28216264	Lynch et al. (2017)	increased urinary sodium excretion	NR3C1	UBERON_0000949	""
immune	activation_acute	GO_0061045	ENSG00000113580	28216264	Lynch et al. (2017)	decreased wound repair	NR3C1	UBERON_0002405	""
nervous system	activation_acute	GO_0050728	ENSG00000113580	28216264	Lynch et al. (2017)	decreased inflammation	NR3C1	UBERON_0001016	""
endocrine	activation_acute	GO_0010876	ENSG00000113580	28216264	Lynch et al. (2017)	lipid redistribution	NR3C1	UBERON_0000949	""
nervous system	activation_acute	GO_1904057	ENSG00000113580	28216264	Lynch et al. (2017)	decreased pain	NR3C1	UBERON_0001016	""
immune	activation_acute	GO_0035815	ENSG00000113580	28216264	Lynch et al. (2017)	increased urinary sodium excretion	NR3C1	UBERON_0002405	""
immune	activation_acute	EFO_0004874	ENSG00000113580	28216264	Lynch et al. (2017)	increased memory	NR3C1	UBERON_0002405	""
endocrine	activation_acute	EFO_0003882	ENSG00000113580	28216264	Lynch et al. (2017)	osteoporosis	NR3C1	UBERON_0000949	""
endocrine	activation_acute	HP_0032263	ENSG00000113580	28216264	Lynch et al. (2017)	increased blood pressure	NR3C1	UBERON_0000949	""
immune	activation_acute	HP_0003199	ENSG00000113580	28216264	Lynch et al. (2017)	decreased muscle mass	NR3C1	UBERON_0002405	""
nervous system	activation_acute	EFO_0004874	ENSG00000113580	28216264	Lynch et al. (2017)	increased memory	NR3C1	UBERON_0001016	""
nervous system	activation_acute	HP_0032263	ENSG00000113580	28216264	Lynch et al. (2017)	increased blood pressure	NR3C1	UBERON_0001016	""
endocrine	activation_acute	GO_0050728	ENSG00000113580	28216264	Lynch et al. (2017)	decreased inflammation	NR3C1	UBERON_0000949	""
immune	activation_acute	GO_1904057	ENSG00000113580	28216264	Lynch et al. (2017)	decreased pain	NR3C1	UBERON_0002405	""
endocrine	activation_acute	HP_0003199	ENSG00000113580	28216264	Lynch et al. (2017)	decreased muscle mass	NR3C1	UBERON_0000949	""
nervous system	activation_acute	GO_0035815	ENSG00000113580	28216264	Lynch et al. (2017)	increased urinary sodium excretion	NR3C1	UBERON_0001016	""
endocrine	activation_acute	EFO_0004874	ENSG00000113580	28216264	Lynch et al. (2017)	increased memory	NR3C1	UBERON_0000949	""
renal	activation_acute	EFO_0004269	ENSG00000006071	28216264	Lynch et al. (2017)	cardiac arrhythmia	ABCC8	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000006071	28216264	Lynch et al. (2017)	decreased heart rate	ABCC8	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000006071	28216264	Lynch et al. (2017)	atrioventricular block	ABCC8	UBERON_0001008	""
renal	inhibition_acute	HP_0000842	ENSG00000006071	28216264	Lynch et al. (2017)	increased blood insulin	ABCC8	UBERON_0001008	""
renal	inhibition_acute	HP_0001943	ENSG00000006071	28216264	Lynch et al. (2017)	decreased blood glucose	ABCC8	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000006071	28216264	Lynch et al. (2017)	increased urine excretion	ABCC8	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000006071	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ABCC8	UBERON_0001008	""
pancreas	activation_acute	EFO_0004269	ENSG00000006071	28216264	Lynch et al. (2017)	cardiac arrhythmia	ABCC8	UBERON_0001264	""
pancreas	inhibition_acute	HP_0001662	ENSG00000006071	28216264	Lynch et al. (2017)	decreased heart rate	ABCC8	UBERON_0001264	""
pancreas	inhibition_acute	MONDO_0000465	ENSG00000006071	28216264	Lynch et al. (2017)	atrioventricular block	ABCC8	UBERON_0001264	""
pancreas	inhibition_acute	HP_0000842	ENSG00000006071	28216264	Lynch et al. (2017)	increased blood insulin	ABCC8	UBERON_0001264	""
pancreas	inhibition_acute	HP_0001943	ENSG00000006071	28216264	Lynch et al. (2017)	decreased blood glucose	ABCC8	UBERON_0001264	""
pancreas	inhibition_acute	HP_0000103	ENSG00000006071	28216264	Lynch et al. (2017)	increased urine excretion	ABCC8	UBERON_0001264	""
pancreas	inhibition_acute	GO_0035815	ENSG00000006071	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ABCC8	UBERON_0001264	""
pancreas	activation_acute	EFO_0009853	ENSG00000006071	28216264	Lynch et al. (2017)	decreased convulsions	ABCC8	UBERON_0001264	""
renal	activation_acute	EFO_0005251	ENSG00000006071	28216264	Lynch et al. (2017)	decreased blood pressure	ABCC8	UBERON_0001008	""
pancreas	activation_acute	HP_0011015	ENSG00000006071	28216264	Lynch et al. (2017)	increased/decreased blood glucose	ABCC8	UBERON_0001264	""
cardiovascular	activation_acute	""	ENSG00000006071	28216264	Lynch et al. (2017)	cardiac lesions	ABCC8	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000006071	28216264	Lynch et al. (2017)	decreased heart rate	ABCC8	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000006071	28216264	Lynch et al. (2017)	atrioventricular block	ABCC8	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000842	ENSG00000006071	28216264	Lynch et al. (2017)	increased blood insulin	ABCC8	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001943	ENSG00000006071	28216264	Lynch et al. (2017)	decreased blood glucose	ABCC8	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000006071	28216264	Lynch et al. (2017)	increased urine excretion	ABCC8	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000006071	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ABCC8	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001649	ENSG00000006071	28216264	Lynch et al. (2017)	increased heart rate	ABCC8	UBERON_0004535	""
pancreas	activation_acute	HP_0001649	ENSG00000006071	28216264	Lynch et al. (2017)	increased heart rate	ABCC8	UBERON_0001264	""
renal	activation_acute	HP_0031860	ENSG00000006071	28216264	Lynch et al. (2017)	abnormal pulse	ABCC8	UBERON_0001008	""
renal	activation_acute	HP_0001649	ENSG00000006071	28216264	Lynch et al. (2017)	increased heart rate	ABCC8	UBERON_0001008	""
renal	activation_acute	HP_0011015	ENSG00000006071	28216264	Lynch et al. (2017)	increased/decreased blood glucose	ABCC8	UBERON_0001008	""
cardiovascular	activation_acute	HP_0040216	ENSG00000006071	28216264	Lynch et al. (2017)	decreased blood insulin	ABCC8	UBERON_0004535	""
pancreas	activation_acute	HP_0040216	ENSG00000006071	28216264	Lynch et al. (2017)	decreased blood insulin	ABCC8	UBERON_0001264	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000006071	28216264	Lynch et al. (2017)	decreased convulsions	ABCC8	UBERON_0004535	""
renal	activation_acute	""	ENSG00000006071	28216264	Lynch et al. (2017)	cardiac lesions	ABCC8	UBERON_0001008	""
pancreas	activation_acute	EFO_0005251	ENSG00000006071	28216264	Lynch et al. (2017)	decreased blood pressure	ABCC8	UBERON_0001264	""
cardiovascular	activation_acute	HP_0031860	ENSG00000006071	28216264	Lynch et al. (2017)	abnormal pulse	ABCC8	UBERON_0004535	""
renal	activation_acute	HP_0040216	ENSG00000006071	28216264	Lynch et al. (2017)	decreased blood insulin	ABCC8	UBERON_0001008	""
pancreas	activation_acute	""	ENSG00000006071	28216264	Lynch et al. (2017)	cardiac lesions	ABCC8	UBERON_0001264	""
cardiovascular	activation_acute	HP_0011015	ENSG00000006071	28216264	Lynch et al. (2017)	increased/decreased blood glucose	ABCC8	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000006071	28216264	Lynch et al. (2017)	decreased blood pressure	ABCC8	UBERON_0004535	""
pancreas	activation_acute	HP_0031860	ENSG00000006071	28216264	Lynch et al. (2017)	abnormal pulse	ABCC8	UBERON_0001264	""
renal	activation_acute	EFO_0009853	ENSG00000006071	28216264	Lynch et al. (2017)	decreased convulsions	ABCC8	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0004269	ENSG00000006071	28216264	Lynch et al. (2017)	cardiac arrhythmia	ABCC8	UBERON_0004535	""
immune	activation_acute	GO_0050727	ENSG00000164128	28216264	Lynch et al. (2017)	decreased/increased inflammation	NPY1R	UBERON_0002405	""
immune	inhibition_acute	HP_0100738	ENSG00000164128	28216264	Lynch et al. (2017)	decreased eating	NPY1R	UBERON_0002405	""
immune	activation_acute	GO_1904057	ENSG00000164128	28216264	Lynch et al. (2017)	decreased pain	NPY1R	UBERON_0002405	""
nervous system	activation_acute	GO_1904057	ENSG00000164128	28216264	Lynch et al. (2017)	decreased pain	NPY1R	UBERON_0001016	""
nervous system	inhibition_acute	HP_0100738	ENSG00000164128	28216264	Lynch et al. (2017)	decreased eating	NPY1R	UBERON_0001016	""
nervous system	activation_acute	GO_0050727	ENSG00000164128	28216264	Lynch et al. (2017)	decreased/increased inflammation	NPY1R	UBERON_0001016	""
gastrointestinal	activation_acute	GO_0050727	ENSG00000164128	28216264	Lynch et al. (2017)	decreased/increased inflammation	NPY1R	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0100738	ENSG00000164128	28216264	Lynch et al. (2017)	decreased eating	NPY1R	UBERON_0005409	""
gastrointestinal	activation_acute	GO_1904057	ENSG00000164128	28216264	Lynch et al. (2017)	decreased pain	NPY1R	UBERON_0005409	""
central nervous system	activation_general	GO_0006939	ENSG00000120907	23197038	Bowes et al. (2012)	smooth muscle contraction	ADRA1A	UBERON_0001017	""
central nervous system	inhibition_general	HP_0001252	ENSG00000120907	23197038	Bowes et al. (2012)	decreased smooth muscle tone	ADRA1A	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0005252	ENSG00000120907	23197038	Bowes et al. (2012)	orthostatic hypotension	ADRA1A	UBERON_0001017	""
central nervous system	inhibition_general	HP_0001649	ENSG00000120907	23197038	Bowes et al. (2012)	increased heart rate	ADRA1A	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0009847	ENSG00000120907	23197038	Bowes et al. (2012)	dizziness	ADRA1A	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0004714	ENSG00000120907	23197038	Bowes et al. (2012)	impact on various aspects of sexual function	ADRA1A	UBERON_0001017	""
central nervous system	activation_general	HP_0032263	ENSG00000120907	23197038	Bowes et al. (2012)	increased blood pressure	ADRA1A	UBERON_0001017	""
central nervous system	activation_general	GO_0045823	ENSG00000120907	23197038	Bowes et al. (2012)	cardiac positive ionotropy	ADRA1A	UBERON_0001017	""
central nervous system	activation_general	EFO_0004269	ENSG00000120907	23197038	Bowes et al. (2012)	potential for arrhythmia	ADRA1A	UBERON_0001017	""
central nervous system	activation_general	HP_0011499	ENSG00000120907	23197038	Bowes et al. (2012)	mydriasis	ADRA1A	UBERON_0001017	""
central nervous system	activation_general	HP_0040216	ENSG00000120907	23197038	Bowes et al. (2012)	decreased insulin release	ADRA1A	UBERON_0001017	""
cardiovascular system	activation_general	GO_0006939	ENSG00000120907	23197038	Bowes et al. (2012)	smooth muscle contraction	ADRA1A	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001252	ENSG00000120907	23197038	Bowes et al. (2012)	decreased smooth muscle tone	ADRA1A	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005252	ENSG00000120907	23197038	Bowes et al. (2012)	orthostatic hypotension	ADRA1A	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001649	ENSG00000120907	23197038	Bowes et al. (2012)	increased heart rate	ADRA1A	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009847	ENSG00000120907	23197038	Bowes et al. (2012)	dizziness	ADRA1A	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0004714	ENSG00000120907	23197038	Bowes et al. (2012)	impact on various aspects of sexual function	ADRA1A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0032263	ENSG00000120907	23197038	Bowes et al. (2012)	increased blood pressure	ADRA1A	UBERON_0004535	""
cardiovascular system	activation_general	GO_0045823	ENSG00000120907	23197038	Bowes et al. (2012)	cardiac positive ionotropy	ADRA1A	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0004269	ENSG00000120907	23197038	Bowes et al. (2012)	potential for arrhythmia	ADRA1A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0011499	ENSG00000120907	23197038	Bowes et al. (2012)	mydriasis	ADRA1A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0040216	ENSG00000120907	23197038	Bowes et al. (2012)	decreased insulin release	ADRA1A	UBERON_0004535	""
gastrointestinal	activation_general	GO_0006939	ENSG00000120907	23197038	Bowes et al. (2012)	smooth muscle contraction	ADRA1A	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0001252	ENSG00000120907	23197038	Bowes et al. (2012)	decreased smooth muscle tone	ADRA1A	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0005252	ENSG00000120907	23197038	Bowes et al. (2012)	orthostatic hypotension	ADRA1A	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0001649	ENSG00000120907	23197038	Bowes et al. (2012)	increased heart rate	ADRA1A	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0009847	ENSG00000120907	23197038	Bowes et al. (2012)	dizziness	ADRA1A	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0004714	ENSG00000120907	23197038	Bowes et al. (2012)	impact on various aspects of sexual function	ADRA1A	UBERON_0005409	""
gastrointestinal	activation_general	HP_0032263	ENSG00000120907	23197038	Bowes et al. (2012)	increased blood pressure	ADRA1A	UBERON_0005409	""
gastrointestinal	activation_general	GO_0045823	ENSG00000120907	23197038	Bowes et al. (2012)	cardiac positive ionotropy	ADRA1A	UBERON_0005409	""
gastrointestinal	activation_general	EFO_0004269	ENSG00000120907	23197038	Bowes et al. (2012)	potential for arrhythmia	ADRA1A	UBERON_0005409	""
gastrointestinal	activation_general	HP_0011499	ENSG00000120907	23197038	Bowes et al. (2012)	mydriasis	ADRA1A	UBERON_0005409	""
gastrointestinal	activation_general	HP_0040216	ENSG00000120907	23197038	Bowes et al. (2012)	decreased insulin release	ADRA1A	UBERON_0005409	""
gastrointestinal	activation_general	HP_0100738	ENSG00000163394	23197038	Bowes et al. (2012)	decreased food intake	CCKAR	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0004210	ENSG00000163394	23197038	Bowes et al. (2012)	increased development of gallstones	CCKAR	UBERON_0005409	""
gastrointestinal	activation_general	HP_0005609	ENSG00000163394	23197038	Bowes et al. (2012)	gallbladder contraction	CCKAR	UBERON_0005409	""
gastrointestinal	activation_general	GO_0030157	ENSG00000163394	23197038	Bowes et al. (2012)	pancreatic enzyme secretion	CCKAR	UBERON_0005409	""
gastrointestinal	activation_general	HP_0030895	ENSG00000163394	23197038	Bowes et al. (2012)	increased gastrointestinal motility	CCKAR	UBERON_0005409	""
gastrointestinal	activation_general	""	ENSG00000163394	23197038	Bowes et al. (2012)	activation of dopamine-mediated behaviour	CCKAR	UBERON_0005409	""
central nervous system	activation_general	""	ENSG00000135312	23197038	Bowes et al. (2012)	cerebral and coronary artery vasoconstriction	HTR1B	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0003015	ENSG00000135312	23197038	Bowes et al. (2012)	increased aggression	HTR1B	UBERON_0001017	""
central nervous system	activation_general	HP_0032263	ENSG00000135312	23197038	Bowes et al. (2012)	increased blood pressure	HTR1B	UBERON_0001017	""
cardiovascular system	activation_general	""	ENSG00000135312	23197038	Bowes et al. (2012)	cerebral and coronary artery vasoconstriction	HTR1B	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0003015	ENSG00000135312	23197038	Bowes et al. (2012)	increased aggression	HTR1B	UBERON_0004535	""
cardiovascular system	activation_general	HP_0032263	ENSG00000135312	23197038	Bowes et al. (2012)	increased blood pressure	HTR1B	UBERON_0004535	""
immune	activation_acute	GO_0006954	ENSG00000067182	28216264	Lynch et al. (2017)	inflammation	TNFRSF1A	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000067182	28216264	Lynch et al. (2017)	decreased pain	TNFRSF1A	UBERON_0002405	""
immune	inhibition_acute	MONDO_0016474	ENSG00000067182	28216264	Lynch et al. (2017)	lupus-like syndrome	TNFRSF1A	UBERON_0002405	""
immune	inhibition_acute	Orphanet_797	ENSG00000067182	28216264	Lynch et al. (2017)	sarcoidosis	TNFRSF1A	UBERON_0002405	""
immune	activation_acute	EFO_0005251	ENSG00000067182	28216264	Lynch et al. (2017)	decreased blood pressure	TNFRSF1A	UBERON_0002405	""
immune	activation_acute	GO_1904058	ENSG00000067182	28216264	Lynch et al. (2017)	increased pain	TNFRSF1A	UBERON_0002405	""
cardiovascular	activation_acute	EFO_0003843	ENSG00000161509	28216264	Lynch et al. (2017)	pain	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000161509	28216264	Lynch et al. (2017)	decreased pain	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000735	ENSG00000161509	28216264	Lynch et al. (2017)	impaired social interactions	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000733	ENSG00000161509	28216264	Lynch et al. (2017)	stereotypy	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_chronic	EFO_0005407	ENSG00000161509	28216264	Lynch et al. (2017)	psychosis	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0002180	ENSG00000161509	28216264	Lynch et al. (2017)	neurodegeneration	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040017	ENSG00000161509	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000437	ENSG00000161509	28216264	Lynch et al. (2017)	ataxia	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000161509	28216264	Lynch et al. (2017)	dizziness	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0001072	ENSG00000161509	28216264	Lynch et al. (2017)	decreased memory	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005407	ENSG00000161509	28216264	Lynch et al. (2017)	psychosis	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000161509	28216264	Lynch et al. (2017)	decreased convulsions	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003890	ENSG00000161509	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000161509	28216264	Lynch et al. (2017)	neurotoxicity	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000161509	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2C	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000161509	28216264	Lynch et al. (2017)	increased heart rate	GRIN2C	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000161509	28216264	Lynch et al. (2017)	convulsions	GRIN2C	UBERON_0004535	""
cardiovascular	activation_acute	HP_0032263	ENSG00000161509	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2C	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000161509	28216264	Lynch et al. (2017)	convulsions	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1904057	ENSG00000161509	28216264	Lynch et al. (2017)	decreased pain	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000735	ENSG00000161509	28216264	Lynch et al. (2017)	impaired social interactions	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000733	ENSG00000161509	28216264	Lynch et al. (2017)	stereotypy	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_chronic	EFO_0005407	ENSG00000161509	28216264	Lynch et al. (2017)	psychosis	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0002180	ENSG00000161509	28216264	Lynch et al. (2017)	neurodegeneration	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0040017	ENSG00000161509	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	MONDO_0000437	ENSG00000161509	28216264	Lynch et al. (2017)	ataxia	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009847	ENSG00000161509	28216264	Lynch et al. (2017)	dizziness	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0001072	ENSG00000161509	28216264	Lynch et al. (2017)	decreased memory	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005407	ENSG00000161509	28216264	Lynch et al. (2017)	psychosis	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000161509	28216264	Lynch et al. (2017)	decreased convulsions	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003890	ENSG00000161509	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000161509	28216264	Lynch et al. (2017)	neurotoxicity	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0032263	ENSG00000161509	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2C	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001649	ENSG00000161509	28216264	Lynch et al. (2017)	increased heart rate	GRIN2C	UBERON_0001017	""
central nervous system	activation_acute	EFO_0003843	ENSG00000161509	28216264	Lynch et al. (2017)	pain	GRIN2C	UBERON_0001017	""
central nervous system	activation_acute	HP_0032263	ENSG00000161509	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2C	UBERON_0001017	""
central nervous system	activation_acute	HP_0031860	ENSG00000161509	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN2C	UBERON_0001017	""
cardiovascular	activation_acute	HP_0031860	ENSG00000161509	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN2C	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003843	ENSG00000198785	28216264	Lynch et al. (2017)	pain	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000198785	28216264	Lynch et al. (2017)	decreased pain	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000735	ENSG00000198785	28216264	Lynch et al. (2017)	impaired social interactions	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000733	ENSG00000198785	28216264	Lynch et al. (2017)	stereotypy	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_chronic	EFO_0005407	ENSG00000198785	28216264	Lynch et al. (2017)	psychosis	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0002180	ENSG00000198785	28216264	Lynch et al. (2017)	neurodegeneration	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040017	ENSG00000198785	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000437	ENSG00000198785	28216264	Lynch et al. (2017)	ataxia	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000198785	28216264	Lynch et al. (2017)	dizziness	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0001072	ENSG00000198785	28216264	Lynch et al. (2017)	decreased memory	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005407	ENSG00000198785	28216264	Lynch et al. (2017)	psychosis	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000198785	28216264	Lynch et al. (2017)	decreased convulsions	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003890	ENSG00000198785	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000198785	28216264	Lynch et al. (2017)	neurotoxicity	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000198785	28216264	Lynch et al. (2017)	increased blood pressure	GRIN3A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000198785	28216264	Lynch et al. (2017)	increased heart rate	GRIN3A	UBERON_0004535	""
cardiovascular	activation_acute	HP_0031860	ENSG00000198785	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN3A	UBERON_0004535	""
central nervous system	activation_acute	HP_0032263	ENSG00000198785	28216264	Lynch et al. (2017)	increased blood pressure	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1904057	ENSG00000198785	28216264	Lynch et al. (2017)	decreased pain	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000735	ENSG00000198785	28216264	Lynch et al. (2017)	impaired social interactions	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000733	ENSG00000198785	28216264	Lynch et al. (2017)	stereotypy	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_chronic	EFO_0005407	ENSG00000198785	28216264	Lynch et al. (2017)	psychosis	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0002180	ENSG00000198785	28216264	Lynch et al. (2017)	neurodegeneration	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0040017	ENSG00000198785	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	MONDO_0000437	ENSG00000198785	28216264	Lynch et al. (2017)	ataxia	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009847	ENSG00000198785	28216264	Lynch et al. (2017)	dizziness	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0001072	ENSG00000198785	28216264	Lynch et al. (2017)	decreased memory	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005407	ENSG00000198785	28216264	Lynch et al. (2017)	psychosis	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000198785	28216264	Lynch et al. (2017)	decreased convulsions	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003890	ENSG00000198785	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000198785	28216264	Lynch et al. (2017)	neurotoxicity	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0032263	ENSG00000198785	28216264	Lynch et al. (2017)	increased blood pressure	GRIN3A	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001649	ENSG00000198785	28216264	Lynch et al. (2017)	increased heart rate	GRIN3A	UBERON_0001017	""
central nervous system	activation_acute	HP_0031860	ENSG00000198785	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN3A	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009853	ENSG00000198785	28216264	Lynch et al. (2017)	convulsions	GRIN3A	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000198785	28216264	Lynch et al. (2017)	convulsions	GRIN3A	UBERON_0004535	""
central nervous system	activation_acute	EFO_0003843	ENSG00000198785	28216264	Lynch et al. (2017)	pain	GRIN3A	UBERON_0001017	""
cardiovascular	activation_acute	HP_0032263	ENSG00000198785	28216264	Lynch et al. (2017)	increased blood pressure	GRIN3A	UBERON_0004535	""
gastrointestinal	activation_general	GO_0060454	ENSG00000113749	""	Urban et al. (2012)	stimulation of gastric acid secretion	HRH2	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	inhibition_general	GO_0060455	ENSG00000113749	""	Urban et al. (2012)	reduction of gastric acid secretion	HRH2	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	GO_0045823	ENSG00000113749	""	Urban et al. (2012)	positive inotropic effect on the human ventricle	HRH2	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
gastrointestinal	activation_general	HP_0002017	ENSG00000113749	""	Urban et al. (2012)	emesis	HRH2	UBERON_0005409	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0060454	ENSG00000113749	""	Urban et al. (2012)	stimulation of gastric acid secretion	HRH2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	inhibition_general	GO_0060455	ENSG00000113749	""	Urban et al. (2012)	reduction of gastric acid secretion	HRH2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	GO_0045823	ENSG00000113749	""	Urban et al. (2012)	positive inotropic effect on the human ventricle	HRH2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
cardiovascular system	activation_general	HP_0002017	ENSG00000113749	""	Urban et al. (2012)	emesis	HRH2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
central nervous system	activation_general	HP_0001662	ENSG00000149295	23197038	Bowes et al. (2012)	decreased heart rate	DRD2	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0005252	ENSG00000149295	23197038	Bowes et al. (2012)	orthostatic hypotension	DRD2	UBERON_0001017	""
central nervous system	inhibition_general	NCIT_C95746	ENSG00000149295	23197038	Bowes et al. (2012)	drowsiness	DRD2	UBERON_0001017	""
central nervous system	inhibition_general	HP_0030895	ENSG00000149295	23197038	Bowes et al. (2012)	increased gastrointestinal motility	DRD2	UBERON_0001017	""
central nervous system	activation_general	HP_0001279	ENSG00000149295	23197038	Bowes et al. (2012)	syncope	DRD2	UBERON_0001017	""
central nervous system	activation_general	HP_0000738	ENSG00000149295	23197038	Bowes et al. (2012)	hallucinations	DRD2	UBERON_0001017	""
central nervous system	activation_general	HP_0004372	ENSG00000149295	23197038	Bowes et al. (2012)	confusion	DRD2	UBERON_0001017	""
central nervous system	activation_general	NCIT_C95746	ENSG00000149295	23197038	Bowes et al. (2012)	drowsiness	DRD2	UBERON_0001017	""
central nervous system	activation_general	GO_0035815	ENSG00000149295	23197038	Bowes et al. (2012)	increased sodium excretion	DRD2	UBERON_0001017	""
central nervous system	activation_general	HP_0002017	ENSG00000149295	23197038	Bowes et al. (2012)	emesis	DRD2	UBERON_0001017	""
central nervous system	activation_general	EFO_0001380	ENSG00000149295	23197038	Bowes et al. (2012)	decreased pituitary hormone secretions	DRD2	UBERON_0001017	""
endocrine	activation_general	HP_0001662	ENSG00000149295	23197038	Bowes et al. (2012)	decreased heart rate	DRD2	UBERON_0000949	""
endocrine	inhibition_general	EFO_0005252	ENSG00000149295	23197038	Bowes et al. (2012)	orthostatic hypotension	DRD2	UBERON_0000949	""
endocrine	inhibition_general	NCIT_C95746	ENSG00000149295	23197038	Bowes et al. (2012)	drowsiness	DRD2	UBERON_0000949	""
endocrine	inhibition_general	HP_0030895	ENSG00000149295	23197038	Bowes et al. (2012)	increased gastrointestinal motility	DRD2	UBERON_0000949	""
endocrine	activation_general	HP_0001279	ENSG00000149295	23197038	Bowes et al. (2012)	syncope	DRD2	UBERON_0000949	""
endocrine	activation_general	HP_0000738	ENSG00000149295	23197038	Bowes et al. (2012)	hallucinations	DRD2	UBERON_0000949	""
endocrine	activation_general	HP_0004372	ENSG00000149295	23197038	Bowes et al. (2012)	confusion	DRD2	UBERON_0000949	""
endocrine	activation_general	NCIT_C95746	ENSG00000149295	23197038	Bowes et al. (2012)	drowsiness	DRD2	UBERON_0000949	""
endocrine	activation_general	GO_0035815	ENSG00000149295	23197038	Bowes et al. (2012)	increased sodium excretion	DRD2	UBERON_0000949	""
endocrine	activation_general	HP_0002017	ENSG00000149295	23197038	Bowes et al. (2012)	emesis	DRD2	UBERON_0000949	""
endocrine	activation_general	EFO_0001380	ENSG00000149295	23197038	Bowes et al. (2012)	decreased pituitary hormone secretions	DRD2	UBERON_0000949	""
cardiovascular system	activation_general	HP_0001662	ENSG00000149295	23197038	Bowes et al. (2012)	decreased heart rate	DRD2	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005252	ENSG00000149295	23197038	Bowes et al. (2012)	orthostatic hypotension	DRD2	UBERON_0004535	""
cardiovascular system	inhibition_general	NCIT_C95746	ENSG00000149295	23197038	Bowes et al. (2012)	drowsiness	DRD2	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0030895	ENSG00000149295	23197038	Bowes et al. (2012)	increased gastrointestinal motility	DRD2	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001279	ENSG00000149295	23197038	Bowes et al. (2012)	syncope	DRD2	UBERON_0004535	""
cardiovascular system	activation_general	HP_0000738	ENSG00000149295	23197038	Bowes et al. (2012)	hallucinations	DRD2	UBERON_0004535	""
cardiovascular system	activation_general	HP_0004372	ENSG00000149295	23197038	Bowes et al. (2012)	confusion	DRD2	UBERON_0004535	""
cardiovascular system	activation_general	NCIT_C95746	ENSG00000149295	23197038	Bowes et al. (2012)	drowsiness	DRD2	UBERON_0004535	""
cardiovascular system	activation_general	GO_0035815	ENSG00000149295	23197038	Bowes et al. (2012)	increased sodium excretion	DRD2	UBERON_0004535	""
cardiovascular system	activation_general	HP_0002017	ENSG00000149295	23197038	Bowes et al. (2012)	emesis	DRD2	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0001380	ENSG00000149295	23197038	Bowes et al. (2012)	decreased pituitary hormone secretions	DRD2	UBERON_0004535	""
immune	activation_acute	EFO_0004874	ENSG00000148680	28216264	Lynch et al. (2017)	increased memory	HTR7	UBERON_0002405	""
immune	inhibition_acute	EFO_0004874	ENSG00000148680	28216264	Lynch et al. (2017)	increased/decreased memory	HTR7	UBERON_0002405	""
immune	inhibition_acute	EFO_0008568	ENSG00000148680	28216264	Lynch et al. (2017)	decreased sleep	HTR7	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000148680	28216264	Lynch et al. (2017)	decreased pain	HTR7	UBERON_0002405	""
immune	inhibition_acute	EFO_0009874	ENSG00000148680	28216264	Lynch et al. (2017)	decreased anxiety	HTR7	UBERON_0002405	""
immune	activation_acute	GO_0050728	ENSG00000148680	28216264	Lynch et al. (2017)	decreased inflammation	HTR7	UBERON_0002405	""
nervous system	activation_acute	GO_0051930	ENSG00000148680	28216264	Lynch et al. (2017)	decreased/increased pain	HTR7	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004874	ENSG00000148680	28216264	Lynch et al. (2017)	increased/decreased memory	HTR7	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0008568	ENSG00000148680	28216264	Lynch et al. (2017)	decreased sleep	HTR7	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000148680	28216264	Lynch et al. (2017)	decreased pain	HTR7	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009874	ENSG00000148680	28216264	Lynch et al. (2017)	decreased anxiety	HTR7	UBERON_0001016	""
nervous system	activation_acute	EFO_0004874	ENSG00000148680	28216264	Lynch et al. (2017)	increased memory	HTR7	UBERON_0001016	""
immune	activation_acute	EFO_0008568	ENSG00000148680	28216264	Lynch et al. (2017)	decreased sleep	HTR7	UBERON_0002405	""
immune	activation_acute	GO_0051930	ENSG00000148680	28216264	Lynch et al. (2017)	decreased/increased pain	HTR7	UBERON_0002405	""
nervous system	activation_acute	HP_0002045	ENSG00000148680	28216264	Lynch et al. (2017)	decreased body temperature	HTR7	UBERON_0001016	""
nervous system	activation_acute	EFO_0008568	ENSG00000148680	28216264	Lynch et al. (2017)	decreased sleep	HTR7	UBERON_0001016	""
immune	activation_acute	HP_0002045	ENSG00000148680	28216264	Lynch et al. (2017)	decreased body temperature	HTR7	UBERON_0002405	""
nervous system	activation_acute	GO_0050728	ENSG00000148680	28216264	Lynch et al. (2017)	decreased inflammation	HTR7	UBERON_0001016	""
central nervous system	activation_acute	HP_0031860	ENSG00000176884	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1904057	ENSG00000176884	28216264	Lynch et al. (2017)	decreased pain	GRIN1	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000735	ENSG00000176884	28216264	Lynch et al. (2017)	impaired social interactions	GRIN1	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000733	ENSG00000176884	28216264	Lynch et al. (2017)	stereotypy	GRIN1	UBERON_0001017	""
central nervous system	inhibition_chronic	EFO_0005407	ENSG00000176884	28216264	Lynch et al. (2017)	psychosis	GRIN1	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0002180	ENSG00000176884	28216264	Lynch et al. (2017)	neurodegeneration	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0040017	ENSG00000176884	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	MONDO_0000437	ENSG00000176884	28216264	Lynch et al. (2017)	ataxia	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009847	ENSG00000176884	28216264	Lynch et al. (2017)	dizziness	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0001072	ENSG00000176884	28216264	Lynch et al. (2017)	decreased memory	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005407	ENSG00000176884	28216264	Lynch et al. (2017)	psychosis	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000176884	28216264	Lynch et al. (2017)	decreased convulsions	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003890	ENSG00000176884	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000176884	28216264	Lynch et al. (2017)	neurotoxicity	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0032263	ENSG00000176884	28216264	Lynch et al. (2017)	increased blood pressure	GRIN1	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001649	ENSG00000176884	28216264	Lynch et al. (2017)	increased heart rate	GRIN1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009853	ENSG00000176884	28216264	Lynch et al. (2017)	convulsions	GRIN1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0003843	ENSG00000176884	28216264	Lynch et al. (2017)	pain	GRIN1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0003843	ENSG00000176884	28216264	Lynch et al. (2017)	pain	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000176884	28216264	Lynch et al. (2017)	decreased pain	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000735	ENSG00000176884	28216264	Lynch et al. (2017)	impaired social interactions	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000733	ENSG00000176884	28216264	Lynch et al. (2017)	stereotypy	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_chronic	EFO_0005407	ENSG00000176884	28216264	Lynch et al. (2017)	psychosis	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0002180	ENSG00000176884	28216264	Lynch et al. (2017)	neurodegeneration	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040017	ENSG00000176884	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000437	ENSG00000176884	28216264	Lynch et al. (2017)	ataxia	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000176884	28216264	Lynch et al. (2017)	dizziness	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0001072	ENSG00000176884	28216264	Lynch et al. (2017)	decreased memory	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005407	ENSG00000176884	28216264	Lynch et al. (2017)	psychosis	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000176884	28216264	Lynch et al. (2017)	decreased convulsions	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003890	ENSG00000176884	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000176884	28216264	Lynch et al. (2017)	neurotoxicity	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000176884	28216264	Lynch et al. (2017)	increased blood pressure	GRIN1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000176884	28216264	Lynch et al. (2017)	increased heart rate	GRIN1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0032263	ENSG00000176884	28216264	Lynch et al. (2017)	increased blood pressure	GRIN1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0031860	ENSG00000176884	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000176884	28216264	Lynch et al. (2017)	convulsions	GRIN1	UBERON_0004535	""
central nervous system	activation_acute	HP_0032263	ENSG00000176884	28216264	Lynch et al. (2017)	increased blood pressure	GRIN1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009874	ENSG00000182256	28216264	Lynch et al. (2017)	decreased anxiety	GABRG3	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000182256	28216264	Lynch et al. (2017)	convulsions	GABRG3	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000182256	28216264	Lynch et al. (2017)	decreased sleep	GABRG3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000182256	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRG3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000182256	28216264	Lynch et al. (2017)	convulsions	GABRG3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000182256	28216264	Lynch et al. (2017)	decreased sleep	GABRG3	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002045	ENSG00000182256	28216264	Lynch et al. (2017)	decreased body temperature	GABRG3	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000182256	28216264	Lynch et al. (2017)	muscle relaxation	GABRG3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000182256	28216264	Lynch et al. (2017)	decreased convulsions	GABRG3	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009872	ENSG00000182256	28216264	Lynch et al. (2017)	increased cardiac output	GABRG3	UBERON_0001017	""
central nervous system	activation_acute	GO_0045822	ENSG00000182256	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRG3	UBERON_0001017	""
cardiovascular	activation_acute	GO_1904057	ENSG00000182256	28216264	Lynch et al. (2017)	decreased pain	GABRG3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009840	ENSG00000182256	28216264	Lynch et al. (2017)	increased respiratory rate	GABRG3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009872	ENSG00000182256	28216264	Lynch et al. (2017)	increased cardiac output	GABRG3	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000182256	28216264	Lynch et al. (2017)	decreased convulsions	GABRG3	UBERON_0004535	""
central nervous system	activation_acute	GO_1904057	ENSG00000182256	28216264	Lynch et al. (2017)	decreased pain	GABRG3	UBERON_0001017	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000182256	28216264	Lynch et al. (2017)	ataxia	GABRG3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0008568	ENSG00000182256	28216264	Lynch et al. (2017)	increased sleep	GABRG3	UBERON_0004535	""
central nervous system	activation_acute	HP_0002045	ENSG00000182256	28216264	Lynch et al. (2017)	decreased body temperature	GABRG3	UBERON_0001017	""
cardiovascular	activation_acute	HP_0100738	ENSG00000182256	28216264	Lynch et al. (2017)	increased eating	GABRG3	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000182256	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRG3	UBERON_0004535	""
cardiovascular	activation_acute	GO_0045822	ENSG00000182256	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRG3	UBERON_0004535	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000182256	28216264	Lynch et al. (2017)	ataxia	GABRG3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0005251	ENSG00000182256	28216264	Lynch et al. (2017)	decreased blood pressure	GABRG3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000182256	28216264	Lynch et al. (2017)	decreased memory	GABRG3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0001072	ENSG00000182256	28216264	Lynch et al. (2017)	decreased memory	GABRG3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000182256	28216264	Lynch et al. (2017)	decreased anxiety	GABRG3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0003890	ENSG00000182256	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRG3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000182256	28216264	Lynch et al. (2017)	increased respiratory rate	GABRG3	UBERON_0004535	""
central nervous system	activation_acute	GO_0040013	ENSG00000182256	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRG3	UBERON_0001017	""
central nervous system	activation_acute	HP_0100738	ENSG00000182256	28216264	Lynch et al. (2017)	increased eating	GABRG3	UBERON_0001017	""
central nervous system	activation_acute	""	ENSG00000182256	28216264	Lynch et al. (2017)	muscle relaxation	GABRG3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000182256	28216264	Lynch et al. (2017)	decreased blood pressure	GABRG3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0008568	ENSG00000182256	28216264	Lynch et al. (2017)	increased sleep	GABRG3	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009872	ENSG00000109158	28216264	Lynch et al. (2017)	increased cardiac output	GABRA4	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000109158	28216264	Lynch et al. (2017)	convulsions	GABRA4	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000109158	28216264	Lynch et al. (2017)	decreased sleep	GABRA4	UBERON_0001017	""
central nervous system	activation_acute	GO_0040013	ENSG00000109158	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA4	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009840	ENSG00000109158	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA4	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000109158	28216264	Lynch et al. (2017)	decreased memory	GABRA4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000109158	28216264	Lynch et al. (2017)	convulsions	GABRA4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000109158	28216264	Lynch et al. (2017)	decreased sleep	GABRA4	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000109158	28216264	Lynch et al. (2017)	muscle relaxation	GABRA4	UBERON_0004535	""
central nervous system	activation_acute	EFO_0003890	ENSG00000109158	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA4	UBERON_0001017	""
central nervous system	activation_acute	GO_1904057	ENSG00000109158	28216264	Lynch et al. (2017)	decreased pain	GABRA4	UBERON_0001017	""
cardiovascular	activation_acute	HP_0002045	ENSG00000109158	28216264	Lynch et al. (2017)	decreased body temperature	GABRA4	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000109158	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA4	UBERON_0004535	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000109158	28216264	Lynch et al. (2017)	ataxia	GABRA4	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000109158	28216264	Lynch et al. (2017)	decreased convulsions	GABRA4	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000109158	28216264	Lynch et al. (2017)	decreased anxiety	GABRA4	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000109158	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA4	UBERON_0004535	""
central nervous system	activation_acute	HP_0100738	ENSG00000109158	28216264	Lynch et al. (2017)	increased eating	GABRA4	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009872	ENSG00000109158	28216264	Lynch et al. (2017)	increased cardiac output	GABRA4	UBERON_0004535	""
central nervous system	activation_acute	EFO_0008568	ENSG00000109158	28216264	Lynch et al. (2017)	increased sleep	GABRA4	UBERON_0001017	""
cardiovascular	activation_acute	GO_0045822	ENSG00000109158	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA4	UBERON_0004535	""
cardiovascular	activation_acute	HP_0100738	ENSG00000109158	28216264	Lynch et al. (2017)	increased eating	GABRA4	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009874	ENSG00000109158	28216264	Lynch et al. (2017)	decreased anxiety	GABRA4	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009853	ENSG00000109158	28216264	Lynch et al. (2017)	decreased convulsions	GABRA4	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0008568	ENSG00000109158	28216264	Lynch et al. (2017)	increased sleep	GABRA4	UBERON_0004535	""
central nervous system	activation_acute	EFO_0001072	ENSG00000109158	28216264	Lynch et al. (2017)	decreased memory	GABRA4	UBERON_0001017	""
central nervous system	activation_acute	EFO_0005251	ENSG00000109158	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA4	UBERON_0001017	""
central nervous system	activation_acute	""	ENSG00000109158	28216264	Lynch et al. (2017)	muscle relaxation	GABRA4	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000109158	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA4	UBERON_0004535	""
central nervous system	activation_acute	HP_0002045	ENSG00000109158	28216264	Lynch et al. (2017)	decreased body temperature	GABRA4	UBERON_0001017	""
central nervous system	activation_acute	GO_0045822	ENSG00000109158	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA4	UBERON_0001017	""
cardiovascular	activation_acute	GO_1904057	ENSG00000109158	28216264	Lynch et al. (2017)	decreased pain	GABRA4	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000109158	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA4	UBERON_0004535	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000109158	28216264	Lynch et al. (2017)	ataxia	GABRA4	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002045	ENSG00000011677	28216264	Lynch et al. (2017)	decreased body temperature	GABRA3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000011677	28216264	Lynch et al. (2017)	convulsions	GABRA3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000011677	28216264	Lynch et al. (2017)	decreased sleep	GABRA3	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000011677	28216264	Lynch et al. (2017)	decreased anxiety	GABRA3	UBERON_0004535	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000011677	28216264	Lynch et al. (2017)	ataxia	GABRA3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0008568	ENSG00000011677	28216264	Lynch et al. (2017)	increased sleep	GABRA3	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000011677	28216264	Lynch et al. (2017)	convulsions	GABRA3	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000011677	28216264	Lynch et al. (2017)	decreased sleep	GABRA3	UBERON_0001017	""
cardiovascular	activation_acute	GO_0045822	ENSG00000011677	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0001072	ENSG00000011677	28216264	Lynch et al. (2017)	decreased memory	GABRA3	UBERON_0001017	""
cardiovascular	activation_acute	GO_1904057	ENSG00000011677	28216264	Lynch et al. (2017)	decreased pain	GABRA3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000011677	28216264	Lynch et al. (2017)	decreased convulsions	GABRA3	UBERON_0001017	""
central nervous system	activation_acute	EFO_0003890	ENSG00000011677	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA3	UBERON_0001017	""
cardiovascular	activation_acute	HP_0100738	ENSG00000011677	28216264	Lynch et al. (2017)	increased eating	GABRA3	UBERON_0004535	""
central nervous system	activation_acute	HP_0100738	ENSG00000011677	28216264	Lynch et al. (2017)	increased eating	GABRA3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0008568	ENSG00000011677	28216264	Lynch et al. (2017)	increased sleep	GABRA3	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000011677	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA3	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000011677	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA3	UBERON_0004535	""
central nervous system	activation_acute	""	ENSG00000011677	28216264	Lynch et al. (2017)	muscle relaxation	GABRA3	UBERON_0001017	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000011677	28216264	Lynch et al. (2017)	ataxia	GABRA3	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009872	ENSG00000011677	28216264	Lynch et al. (2017)	increased cardiac output	GABRA3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000011677	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRA3	UBERON_0004535	""
cardiovascular	activation_acute	""	ENSG00000011677	28216264	Lynch et al. (2017)	muscle relaxation	GABRA3	UBERON_0004535	""
central nervous system	activation_acute	GO_0040013	ENSG00000011677	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRA3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000011677	28216264	Lynch et al. (2017)	decreased memory	GABRA3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009874	ENSG00000011677	28216264	Lynch et al. (2017)	decreased anxiety	GABRA3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009872	ENSG00000011677	28216264	Lynch et al. (2017)	increased cardiac output	GABRA3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0005251	ENSG00000011677	28216264	Lynch et al. (2017)	decreased blood pressure	GABRA3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000011677	28216264	Lynch et al. (2017)	decreased convulsions	GABRA3	UBERON_0004535	""
central nervous system	activation_acute	GO_0045822	ENSG00000011677	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRA3	UBERON_0001017	""
central nervous system	activation_acute	HP_0002045	ENSG00000011677	28216264	Lynch et al. (2017)	decreased body temperature	GABRA3	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009840	ENSG00000011677	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA3	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000011677	28216264	Lynch et al. (2017)	increased respiratory rate	GABRA3	UBERON_0004535	""
central nervous system	activation_acute	GO_1904057	ENSG00000011677	28216264	Lynch et al. (2017)	decreased pain	GABRA3	UBERON_0001017	""
cardiovascular system	activation_general	""	ENSG00000128271	23197038	Bowes et al. (2012)	coronary vasodilation	ADORA2A	UBERON_0004535	""
cardiovascular system	inhibition_general	GO_1901731	ENSG00000128271	23197038	Bowes et al. (2012)	potential for stimulation of platelet aggregation	ADORA2A	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0032263	ENSG00000128271	23197038	Bowes et al. (2012)	increased blood pressure	ADORA2A	UBERON_0004535	""
cardiovascular system	inhibition_general	NCIT_C74532	ENSG00000128271	23197038	Bowes et al. (2012)	nervousness (tremors, agitation)	ADORA2A	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009849	ENSG00000128271	23197038	Bowes et al. (2012)	arousal	ADORA2A	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0004698	ENSG00000128271	23197038	Bowes et al. (2012)	insomnia	ADORA2A	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0005251	ENSG00000128271	23197038	Bowes et al. (2012)	decreased blood pressure	ADORA2A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001265	ENSG00000128271	23197038	Bowes et al. (2012)	decreased reflex	ADORA2A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001649	ENSG00000128271	23197038	Bowes et al. (2012)	increased heart rate	ADORA2A	UBERON_0004535	""
cardiovascular system	activation_general	GO_0090331	ENSG00000128271	23197038	Bowes et al. (2012)	decreased platelet aggregation	ADORA2A	UBERON_0004535	""
cardiovascular system	activation_general	GO_0002695	ENSG00000128271	23197038	Bowes et al. (2012)	decreased leukocyte activation	ADORA2A	UBERON_0004535	""
cardiovascular system	activation_general	GO_0040013	ENSG00000128271	23197038	Bowes et al. (2012)	decreased locomotor activity	ADORA2A	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009843	ENSG00000128271	23197038	Bowes et al. (2012)	sleep induction	ADORA2A	UBERON_0004535	""
central nervous system	activation_general	""	ENSG00000128271	23197038	Bowes et al. (2012)	coronary vasodilation	ADORA2A	UBERON_0001017	""
central nervous system	inhibition_general	GO_1901731	ENSG00000128271	23197038	Bowes et al. (2012)	potential for stimulation of platelet aggregation	ADORA2A	UBERON_0001017	""
central nervous system	inhibition_general	HP_0032263	ENSG00000128271	23197038	Bowes et al. (2012)	increased blood pressure	ADORA2A	UBERON_0001017	""
central nervous system	inhibition_general	NCIT_C74532	ENSG00000128271	23197038	Bowes et al. (2012)	nervousness (tremors, agitation)	ADORA2A	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0009849	ENSG00000128271	23197038	Bowes et al. (2012)	arousal	ADORA2A	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0004698	ENSG00000128271	23197038	Bowes et al. (2012)	insomnia	ADORA2A	UBERON_0001017	""
central nervous system	activation_general	EFO_0005251	ENSG00000128271	23197038	Bowes et al. (2012)	decreased blood pressure	ADORA2A	UBERON_0001017	""
central nervous system	activation_general	HP_0001265	ENSG00000128271	23197038	Bowes et al. (2012)	decreased reflex	ADORA2A	UBERON_0001017	""
central nervous system	activation_general	HP_0001649	ENSG00000128271	23197038	Bowes et al. (2012)	increased heart rate	ADORA2A	UBERON_0001017	""
central nervous system	activation_general	GO_0090331	ENSG00000128271	23197038	Bowes et al. (2012)	decreased platelet aggregation	ADORA2A	UBERON_0001017	""
central nervous system	activation_general	GO_0002695	ENSG00000128271	23197038	Bowes et al. (2012)	decreased leukocyte activation	ADORA2A	UBERON_0001017	""
central nervous system	activation_general	GO_0040013	ENSG00000128271	23197038	Bowes et al. (2012)	decreased locomotor activity	ADORA2A	UBERON_0001017	""
central nervous system	activation_general	EFO_0009843	ENSG00000128271	23197038	Bowes et al. (2012)	sleep induction	ADORA2A	UBERON_0001017	""
nervous system	activation_acute	EFO_0005230	ENSG00000147246	28216264	Lynch et al. (2017)	increased anxiety	HTR2C	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009874	ENSG00000147246	28216264	Lynch et al. (2017)	decreased anxiety	HTR2C	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0004874	ENSG00000147246	28216264	Lynch et al. (2017)	increased memory	HTR2C	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0003890	ENSG00000147246	28216264	Lynch et al. (2017)	drug abuse/dependence	HTR2C	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000147246	28216264	Lynch et al. (2017)	decreased convulsions	HTR2C	UBERON_0001016	""
nervous system	activation_acute	""	ENSG00000147246	28216264	Lynch et al. (2017)	abnormal mouth movements	HTR2C	UBERON_0001016	""
nervous system	activation_acute	HP_0100738	ENSG00000147246	28216264	Lynch et al. (2017)	decreased eating	HTR2C	UBERON_0001016	""
nervous system	activation_acute	GO_0040013	ENSG00000147246	28216264	Lynch et al. (2017)	decreased locomotor activity	HTR2C	UBERON_0001016	""
nervous system	activation_acute	GO_0043084	ENSG00000147246	28216264	Lynch et al. (2017)	penile erection	HTR2C	UBERON_0001016	""
nervous system	activation_acute	EFO_0001072	ENSG00000147246	28216264	Lynch et al. (2017)	decreased memory	HTR2C	UBERON_0001016	""
nervous system	activation_acute	EFO_0009853	ENSG00000147246	28216264	Lynch et al. (2017)	increased convulsions	HTR2C	UBERON_0001016	""
nervous system	activation_acute	GO_0035815	ENSG00000108405	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX1	UBERON_0001016	""
nervous system	activation_chronic	HP_0002180	ENSG00000108405	28216264	Lynch et al. (2017)	neurodegeneration	P2RX1	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000108405	28216264	Lynch et al. (2017)	decreased pain	P2RX1	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050728	ENSG00000108405	28216264	Lynch et al. (2017)	decreased inflammation	P2RX1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000108405	28216264	Lynch et al. (2017)	decreased convulsions	P2RX1	UBERON_0001016	""
nervous system	activation_acute	GO_1904058	ENSG00000108405	28216264	Lynch et al. (2017)	increased pain	P2RX1	UBERON_0001016	""
renal	activation_acute	GO_1904058	ENSG00000108405	28216264	Lynch et al. (2017)	increased pain	P2RX1	UBERON_0001008	""
renal	activation_chronic	HP_0002180	ENSG00000108405	28216264	Lynch et al. (2017)	neurodegeneration	P2RX1	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000108405	28216264	Lynch et al. (2017)	decreased pain	P2RX1	UBERON_0001008	""
renal	inhibition_acute	GO_0050728	ENSG00000108405	28216264	Lynch et al. (2017)	decreased inflammation	P2RX1	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000108405	28216264	Lynch et al. (2017)	decreased convulsions	P2RX1	UBERON_0001008	""
immune	activation_acute	GO_1904058	ENSG00000108405	28216264	Lynch et al. (2017)	increased pain	P2RX1	UBERON_0002405	""
immune	activation_chronic	HP_0002180	ENSG00000108405	28216264	Lynch et al. (2017)	neurodegeneration	P2RX1	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000108405	28216264	Lynch et al. (2017)	decreased pain	P2RX1	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000108405	28216264	Lynch et al. (2017)	decreased inflammation	P2RX1	UBERON_0002405	""
immune	inhibition_acute	EFO_0009853	ENSG00000108405	28216264	Lynch et al. (2017)	decreased convulsions	P2RX1	UBERON_0002405	""
immune	activation_acute	HP_0000103	ENSG00000108405	28216264	Lynch et al. (2017)	increased urine excretion	P2RX1	UBERON_0002405	""
renal	activation_acute	EFO_0009473	ENSG00000108405	28216264	Lynch et al. (2017)	hemolysis	P2RX1	UBERON_0001008	""
immune	activation_acute	GO_0035815	ENSG00000108405	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX1	UBERON_0002405	""
renal	activation_acute	HP_0000103	ENSG00000108405	28216264	Lynch et al. (2017)	increased urine excretion	P2RX1	UBERON_0001008	""
nervous system	activation_acute	HP_0000103	ENSG00000108405	28216264	Lynch et al. (2017)	increased urine excretion	P2RX1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009473	ENSG00000108405	28216264	Lynch et al. (2017)	hemolysis	P2RX1	UBERON_0001016	""
renal	activation_acute	GO_0035815	ENSG00000108405	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX1	UBERON_0001008	""
immune	activation_acute	EFO_0009473	ENSG00000108405	28216264	Lynch et al. (2017)	hemolysis	P2RX1	UBERON_0002405	""
renal	activation_acute	GO_1904058	ENSG00000187848	28216264	Lynch et al. (2017)	increased pain	P2RX2	UBERON_0001008	""
renal	activation_chronic	HP_0002180	ENSG00000187848	28216264	Lynch et al. (2017)	neurodegeneration	P2RX2	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000187848	28216264	Lynch et al. (2017)	decreased pain	P2RX2	UBERON_0001008	""
renal	inhibition_acute	GO_0050728	ENSG00000187848	28216264	Lynch et al. (2017)	decreased inflammation	P2RX2	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000187848	28216264	Lynch et al. (2017)	decreased convulsions	P2RX2	UBERON_0001008	""
immune	activation_acute	HP_0000103	ENSG00000187848	28216264	Lynch et al. (2017)	increased urine excretion	P2RX2	UBERON_0002405	""
immune	activation_chronic	HP_0002180	ENSG00000187848	28216264	Lynch et al. (2017)	neurodegeneration	P2RX2	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000187848	28216264	Lynch et al. (2017)	decreased pain	P2RX2	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000187848	28216264	Lynch et al. (2017)	decreased inflammation	P2RX2	UBERON_0002405	""
immune	inhibition_acute	EFO_0009853	ENSG00000187848	28216264	Lynch et al. (2017)	decreased convulsions	P2RX2	UBERON_0002405	""
nervous system	activation_acute	GO_0035815	ENSG00000187848	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX2	UBERON_0001016	""
nervous system	activation_chronic	HP_0002180	ENSG00000187848	28216264	Lynch et al. (2017)	neurodegeneration	P2RX2	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000187848	28216264	Lynch et al. (2017)	decreased pain	P2RX2	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050728	ENSG00000187848	28216264	Lynch et al. (2017)	decreased inflammation	P2RX2	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000187848	28216264	Lynch et al. (2017)	decreased convulsions	P2RX2	UBERON_0001016	""
immune	activation_acute	GO_0035815	ENSG00000187848	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX2	UBERON_0002405	""
nervous system	activation_acute	HP_0000103	ENSG00000187848	28216264	Lynch et al. (2017)	increased urine excretion	P2RX2	UBERON_0001016	""
immune	activation_acute	GO_1904058	ENSG00000187848	28216264	Lynch et al. (2017)	increased pain	P2RX2	UBERON_0002405	""
renal	activation_acute	EFO_0009473	ENSG00000187848	28216264	Lynch et al. (2017)	hemolysis	P2RX2	UBERON_0001008	""
nervous system	activation_acute	EFO_0009473	ENSG00000187848	28216264	Lynch et al. (2017)	hemolysis	P2RX2	UBERON_0001016	""
nervous system	activation_acute	GO_1904058	ENSG00000187848	28216264	Lynch et al. (2017)	increased pain	P2RX2	UBERON_0001016	""
immune	activation_acute	EFO_0009473	ENSG00000187848	28216264	Lynch et al. (2017)	hemolysis	P2RX2	UBERON_0002405	""
renal	activation_acute	GO_0035815	ENSG00000187848	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX2	UBERON_0001008	""
renal	activation_acute	HP_0000103	ENSG00000187848	28216264	Lynch et al. (2017)	increased urine excretion	P2RX2	UBERON_0001008	""
central nervous system	activation_acute	EFO_0009853	ENSG00000163285	28216264	Lynch et al. (2017)	decreased convulsions	GABRG1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000163285	28216264	Lynch et al. (2017)	convulsions	GABRG1	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000163285	28216264	Lynch et al. (2017)	decreased sleep	GABRG1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000163285	28216264	Lynch et al. (2017)	decreased anxiety	GABRG1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000163285	28216264	Lynch et al. (2017)	convulsions	GABRG1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008568	ENSG00000163285	28216264	Lynch et al. (2017)	decreased sleep	GABRG1	UBERON_0004535	""
central nervous system	activation_acute	GO_1904057	ENSG00000163285	28216264	Lynch et al. (2017)	decreased pain	GABRG1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009872	ENSG00000163285	28216264	Lynch et al. (2017)	increased cardiac output	GABRG1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0008568	ENSG00000163285	28216264	Lynch et al. (2017)	increased sleep	GABRG1	UBERON_0004535	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000163285	28216264	Lynch et al. (2017)	ataxia	GABRG1	UBERON_0001017	""
central nervous system	activation_acute	HP_0002045	ENSG00000163285	28216264	Lynch et al. (2017)	decreased body temperature	GABRG1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000163285	28216264	Lynch et al. (2017)	decreased blood pressure	GABRG1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0001072	ENSG00000163285	28216264	Lynch et al. (2017)	decreased memory	GABRG1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009874	ENSG00000163285	28216264	Lynch et al. (2017)	decreased anxiety	GABRG1	UBERON_0001017	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000163285	28216264	Lynch et al. (2017)	ataxia	GABRG1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009840	ENSG00000163285	28216264	Lynch et al. (2017)	increased respiratory rate	GABRG1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000163285	28216264	Lynch et al. (2017)	decreased convulsions	GABRG1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0100738	ENSG00000163285	28216264	Lynch et al. (2017)	increased eating	GABRG1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0003890	ENSG00000163285	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRG1	UBERON_0001017	""
central nervous system	activation_acute	GO_0040013	ENSG00000163285	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRG1	UBERON_0001017	""
central nervous system	activation_acute	HP_0100738	ENSG00000163285	28216264	Lynch et al. (2017)	increased eating	GABRG1	UBERON_0001017	""
central nervous system	activation_acute	GO_0045822	ENSG00000163285	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRG1	UBERON_0001017	""
cardiovascular	activation_acute	GO_0045822	ENSG00000163285	28216264	Lynch et al. (2017)	decreased cardiac contractility	GABRG1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002045	ENSG00000163285	28216264	Lynch et al. (2017)	decreased body temperature	GABRG1	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000163285	28216264	Lynch et al. (2017)	decreased locomotor activity	GABRG1	UBERON_0004535	""
central nervous system	activation_acute	""	ENSG00000163285	28216264	Lynch et al. (2017)	muscle relaxation	GABRG1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009872	ENSG00000163285	28216264	Lynch et al. (2017)	increased cardiac output	GABRG1	UBERON_0001017	""
cardiovascular	activation_acute	""	ENSG00000163285	28216264	Lynch et al. (2017)	muscle relaxation	GABRG1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0001072	ENSG00000163285	28216264	Lynch et al. (2017)	decreased memory	GABRG1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009840	ENSG00000163285	28216264	Lynch et al. (2017)	increased respiratory rate	GABRG1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000163285	28216264	Lynch et al. (2017)	drug abuse/dependence	GABRG1	UBERON_0004535	""
central nervous system	activation_acute	EFO_0008568	ENSG00000163285	28216264	Lynch et al. (2017)	increased sleep	GABRG1	UBERON_0001017	""
central nervous system	activation_acute	EFO_0005251	ENSG00000163285	28216264	Lynch et al. (2017)	decreased blood pressure	GABRG1	UBERON_0001017	""
cardiovascular	activation_acute	GO_1904057	ENSG00000163285	28216264	Lynch et al. (2017)	decreased pain	GABRG1	UBERON_0004535	""
cardiovascular system	activation_general	""	ENSG00000123374	""	Urban et al. (2012)	cardiomyocyte hyperproliferation	CDK2	UBERON_0004535	https://doi.org/10.1002/9781118098141.ch2
renal	activation_acute	HP_0011015	ENSG00000187486	28216264	Lynch et al. (2017)	increased/decreased blood glucose	KCNJ11	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000187486	28216264	Lynch et al. (2017)	decreased heart rate	KCNJ11	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000187486	28216264	Lynch et al. (2017)	atrioventricular block	KCNJ11	UBERON_0001008	""
renal	inhibition_acute	HP_0000842	ENSG00000187486	28216264	Lynch et al. (2017)	increased blood insulin	KCNJ11	UBERON_0001008	""
renal	inhibition_acute	HP_0001943	ENSG00000187486	28216264	Lynch et al. (2017)	decreased blood glucose	KCNJ11	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000187486	28216264	Lynch et al. (2017)	increased urine excretion	KCNJ11	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000187486	28216264	Lynch et al. (2017)	increased urinary sodium excretion	KCNJ11	UBERON_0001008	""
renal	activation_acute	HP_0040216	ENSG00000187486	28216264	Lynch et al. (2017)	decreased blood insulin	KCNJ11	UBERON_0001008	""
pancreas	activation_acute	EFO_0009853	ENSG00000187486	28216264	Lynch et al. (2017)	decreased convulsions	KCNJ11	UBERON_0001264	""
pancreas	inhibition_acute	HP_0001662	ENSG00000187486	28216264	Lynch et al. (2017)	decreased heart rate	KCNJ11	UBERON_0001264	""
pancreas	inhibition_acute	MONDO_0000465	ENSG00000187486	28216264	Lynch et al. (2017)	atrioventricular block	KCNJ11	UBERON_0001264	""
pancreas	inhibition_acute	HP_0000842	ENSG00000187486	28216264	Lynch et al. (2017)	increased blood insulin	KCNJ11	UBERON_0001264	""
pancreas	inhibition_acute	HP_0001943	ENSG00000187486	28216264	Lynch et al. (2017)	decreased blood glucose	KCNJ11	UBERON_0001264	""
pancreas	inhibition_acute	HP_0000103	ENSG00000187486	28216264	Lynch et al. (2017)	increased urine excretion	KCNJ11	UBERON_0001264	""
pancreas	inhibition_acute	GO_0035815	ENSG00000187486	28216264	Lynch et al. (2017)	increased urinary sodium excretion	KCNJ11	UBERON_0001264	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000187486	28216264	Lynch et al. (2017)	decreased blood pressure	KCNJ11	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000187486	28216264	Lynch et al. (2017)	decreased heart rate	KCNJ11	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000187486	28216264	Lynch et al. (2017)	atrioventricular block	KCNJ11	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000842	ENSG00000187486	28216264	Lynch et al. (2017)	increased blood insulin	KCNJ11	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001943	ENSG00000187486	28216264	Lynch et al. (2017)	decreased blood glucose	KCNJ11	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000187486	28216264	Lynch et al. (2017)	increased urine excretion	KCNJ11	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000187486	28216264	Lynch et al. (2017)	increased urinary sodium excretion	KCNJ11	UBERON_0004535	""
pancreas	activation_acute	HP_0031860	ENSG00000187486	28216264	Lynch et al. (2017)	abnormal pulse	KCNJ11	UBERON_0001264	""
pancreas	activation_acute	HP_0001649	ENSG00000187486	28216264	Lynch et al. (2017)	increased heart rate	KCNJ11	UBERON_0001264	""
renal	activation_acute	HP_0031860	ENSG00000187486	28216264	Lynch et al. (2017)	abnormal pulse	KCNJ11	UBERON_0001008	""
cardiovascular	activation_acute	""	ENSG00000187486	28216264	Lynch et al. (2017)	cardiac lesions	KCNJ11	UBERON_0004535	""
cardiovascular	activation_acute	HP_0031860	ENSG00000187486	28216264	Lynch et al. (2017)	abnormal pulse	KCNJ11	UBERON_0004535	""
pancreas	activation_acute	HP_0040216	ENSG00000187486	28216264	Lynch et al. (2017)	decreased blood insulin	KCNJ11	UBERON_0001264	""
pancreas	activation_acute	""	ENSG00000187486	28216264	Lynch et al. (2017)	cardiac lesions	KCNJ11	UBERON_0001264	""
cardiovascular	activation_acute	HP_0011015	ENSG00000187486	28216264	Lynch et al. (2017)	increased/decreased blood glucose	KCNJ11	UBERON_0004535	""
renal	activation_acute	""	ENSG00000187486	28216264	Lynch et al. (2017)	cardiac lesions	KCNJ11	UBERON_0001008	""
cardiovascular	activation_acute	HP_0040216	ENSG00000187486	28216264	Lynch et al. (2017)	decreased blood insulin	KCNJ11	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001649	ENSG00000187486	28216264	Lynch et al. (2017)	increased heart rate	KCNJ11	UBERON_0004535	""
pancreas	activation_acute	EFO_0004269	ENSG00000187486	28216264	Lynch et al. (2017)	cardiac arrhythmia	KCNJ11	UBERON_0001264	""
renal	activation_acute	EFO_0004269	ENSG00000187486	28216264	Lynch et al. (2017)	cardiac arrhythmia	KCNJ11	UBERON_0001008	""
renal	activation_acute	EFO_0005251	ENSG00000187486	28216264	Lynch et al. (2017)	decreased blood pressure	KCNJ11	UBERON_0001008	""
pancreas	activation_acute	EFO_0005251	ENSG00000187486	28216264	Lynch et al. (2017)	decreased blood pressure	KCNJ11	UBERON_0001264	""
pancreas	activation_acute	HP_0011015	ENSG00000187486	28216264	Lynch et al. (2017)	increased/decreased blood glucose	KCNJ11	UBERON_0001264	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000187486	28216264	Lynch et al. (2017)	decreased convulsions	KCNJ11	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0004269	ENSG00000187486	28216264	Lynch et al. (2017)	cardiac arrhythmia	KCNJ11	UBERON_0004535	""
renal	activation_acute	HP_0001649	ENSG00000187486	28216264	Lynch et al. (2017)	increased heart rate	KCNJ11	UBERON_0001008	""
renal	activation_acute	EFO_0009853	ENSG00000187486	28216264	Lynch et al. (2017)	decreased convulsions	KCNJ11	UBERON_0001008	""
gastrointestinal	activation_general	HP_0002017	ENSG00000166736	23197038	Bowes et al. (2012)	emesis	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0002019	ENSG00000166736	23197038	Bowes et al. (2012)	constipation	HTR3A	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0009847	ENSG00000166736	23197038	Bowes et al. (2012)	dizziness	HTR3A	UBERON_0005409	""
gastrointestinal	activation_general	GO_0035483	ENSG00000166736	23197038	Bowes et al. (2012)	gastric emptying	HTR3A	UBERON_0005409	""
gastrointestinal	activation_general	HP_0003074	ENSG00000166736	23197038	Bowes et al. (2012)	hyperglycaemia	HTR3A	UBERON_0005409	""
gastrointestinal	activation_general	HP_0001649	ENSG00000166736	23197038	Bowes et al. (2012)	possible increased heart rate	HTR3A	UBERON_0005409	""
endocrine	activation_general	HP_0002017	ENSG00000166736	23197038	Bowes et al. (2012)	emesis	HTR3A	UBERON_0000949	""
endocrine	inhibition_general	HP_0002019	ENSG00000166736	23197038	Bowes et al. (2012)	constipation	HTR3A	UBERON_0000949	""
endocrine	inhibition_general	EFO_0009847	ENSG00000166736	23197038	Bowes et al. (2012)	dizziness	HTR3A	UBERON_0000949	""
endocrine	activation_general	GO_0035483	ENSG00000166736	23197038	Bowes et al. (2012)	gastric emptying	HTR3A	UBERON_0000949	""
endocrine	activation_general	HP_0003074	ENSG00000166736	23197038	Bowes et al. (2012)	hyperglycaemia	HTR3A	UBERON_0000949	""
endocrine	activation_general	HP_0001649	ENSG00000166736	23197038	Bowes et al. (2012)	possible increased heart rate	HTR3A	UBERON_0000949	""
renal	inhibition_acute	GO_0050728	ENSG00000073756	28216264	Lynch et al. (2017)	decreased inflammation	PTGS2	UBERON_0001008	""
renal	inhibition_chronic	HP_0032263	ENSG00000073756	28216264	Lynch et al. (2017)	increased blood pressure	PTGS2	UBERON_0001008	""
renal	inhibition_chronic	HP_0004936	ENSG00000073756	28216264	Lynch et al. (2017)	thrombosis	PTGS2	UBERON_0001008	""
renal	inhibition_chronic	EFO_0003914	ENSG00000073756	28216264	Lynch et al. (2017)	atherosclerosis	PTGS2	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000073756	28216264	Lynch et al. (2017)	decreased pain	PTGS2	UBERON_0001008	""
renal	inhibition_acute	GO_0035814	ENSG00000073756	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PTGS2	UBERON_0001008	""
renal	inhibition_acute	HP_0012364	ENSG00000073756	28216264	Lynch et al. (2017)	decreased urinary potassium excretion	PTGS2	UBERON_0001008	""
renal	inhibition_acute	GO_0045839	ENSG00000073756	28216264	Lynch et al. (2017)	decreased mitosis	PTGS2	UBERON_0001008	""
renal	inhibition_acute	EFO_1000883	ENSG00000073756	28216264	Lynch et al. (2017)	atherothrombosis	PTGS2	UBERON_0001008	""
renal	inhibition_acute	EFO_0000612	ENSG00000073756	28216264	Lynch et al. (2017)	heart attack	PTGS2	UBERON_0001008	""
renal	inhibition_acute	HP_0002140	ENSG00000073756	28216264	Lynch et al. (2017)	ischemic stroke	PTGS2	UBERON_0001008	""
cardiovascular	inhibition_acute	GO_0050728	ENSG00000073756	28216264	Lynch et al. (2017)	decreased inflammation	PTGS2	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0032263	ENSG00000073756	28216264	Lynch et al. (2017)	increased blood pressure	PTGS2	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0004936	ENSG00000073756	28216264	Lynch et al. (2017)	thrombosis	PTGS2	UBERON_0004535	""
cardiovascular	inhibition_chronic	EFO_0003914	ENSG00000073756	28216264	Lynch et al. (2017)	atherosclerosis	PTGS2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000073756	28216264	Lynch et al. (2017)	decreased pain	PTGS2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035814	ENSG00000073756	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PTGS2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0012364	ENSG00000073756	28216264	Lynch et al. (2017)	decreased urinary potassium excretion	PTGS2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0045839	ENSG00000073756	28216264	Lynch et al. (2017)	decreased mitosis	PTGS2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_1000883	ENSG00000073756	28216264	Lynch et al. (2017)	atherothrombosis	PTGS2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0000612	ENSG00000073756	28216264	Lynch et al. (2017)	heart attack	PTGS2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002140	ENSG00000073756	28216264	Lynch et al. (2017)	ischemic stroke	PTGS2	UBERON_0004535	""
immune	inhibition_acute	GO_0050728	ENSG00000073756	28216264	Lynch et al. (2017)	decreased inflammation	PTGS2	UBERON_0002405	""
immune	inhibition_chronic	HP_0032263	ENSG00000073756	28216264	Lynch et al. (2017)	increased blood pressure	PTGS2	UBERON_0002405	""
immune	inhibition_chronic	HP_0004936	ENSG00000073756	28216264	Lynch et al. (2017)	thrombosis	PTGS2	UBERON_0002405	""
immune	inhibition_chronic	EFO_0003914	ENSG00000073756	28216264	Lynch et al. (2017)	atherosclerosis	PTGS2	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000073756	28216264	Lynch et al. (2017)	decreased pain	PTGS2	UBERON_0002405	""
immune	inhibition_acute	GO_0035814	ENSG00000073756	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	PTGS2	UBERON_0002405	""
immune	inhibition_acute	HP_0012364	ENSG00000073756	28216264	Lynch et al. (2017)	decreased urinary potassium excretion	PTGS2	UBERON_0002405	""
immune	inhibition_acute	GO_0045839	ENSG00000073756	28216264	Lynch et al. (2017)	decreased mitosis	PTGS2	UBERON_0002405	""
immune	inhibition_acute	EFO_1000883	ENSG00000073756	28216264	Lynch et al. (2017)	atherothrombosis	PTGS2	UBERON_0002405	""
immune	inhibition_acute	EFO_0000612	ENSG00000073756	28216264	Lynch et al. (2017)	heart attack	PTGS2	UBERON_0002405	""
immune	inhibition_acute	HP_0002140	ENSG00000073756	28216264	Lynch et al. (2017)	ischemic stroke	PTGS2	UBERON_0002405	""
central nervous system	activation_acute	EFO_0003843	ENSG00000273079	28216264	Lynch et al. (2017)	pain	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1904057	ENSG00000273079	28216264	Lynch et al. (2017)	decreased pain	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000735	ENSG00000273079	28216264	Lynch et al. (2017)	impaired social interactions	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0000733	ENSG00000273079	28216264	Lynch et al. (2017)	stereotypy	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_chronic	EFO_0005407	ENSG00000273079	28216264	Lynch et al. (2017)	psychosis	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_chronic	HP_0002180	ENSG00000273079	28216264	Lynch et al. (2017)	neurodegeneration	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0040017	ENSG00000273079	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	MONDO_0000437	ENSG00000273079	28216264	Lynch et al. (2017)	ataxia	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009847	ENSG00000273079	28216264	Lynch et al. (2017)	dizziness	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0001072	ENSG00000273079	28216264	Lynch et al. (2017)	decreased memory	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005407	ENSG00000273079	28216264	Lynch et al. (2017)	psychosis	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000273079	28216264	Lynch et al. (2017)	decreased convulsions	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003890	ENSG00000273079	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000273079	28216264	Lynch et al. (2017)	neurotoxicity	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0032263	ENSG00000273079	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2B	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001649	ENSG00000273079	28216264	Lynch et al. (2017)	increased heart rate	GRIN2B	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0003843	ENSG00000273079	28216264	Lynch et al. (2017)	pain	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000273079	28216264	Lynch et al. (2017)	decreased pain	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000735	ENSG00000273079	28216264	Lynch et al. (2017)	impaired social interactions	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0000733	ENSG00000273079	28216264	Lynch et al. (2017)	stereotypy	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_chronic	EFO_0005407	ENSG00000273079	28216264	Lynch et al. (2017)	psychosis	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_chronic	HP_0002180	ENSG00000273079	28216264	Lynch et al. (2017)	neurodegeneration	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0040017	ENSG00000273079	28216264	Lynch et al. (2017)	increased locomotor activity	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000437	ENSG00000273079	28216264	Lynch et al. (2017)	ataxia	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000273079	28216264	Lynch et al. (2017)	dizziness	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0001072	ENSG00000273079	28216264	Lynch et al. (2017)	decreased memory	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005407	ENSG00000273079	28216264	Lynch et al. (2017)	psychosis	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000273079	28216264	Lynch et al. (2017)	decreased convulsions	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003890	ENSG00000273079	28216264	Lynch et al. (2017)	drug abuse/dependence	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000273079	28216264	Lynch et al. (2017)	neurotoxicity	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000273079	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000273079	28216264	Lynch et al. (2017)	increased heart rate	GRIN2B	UBERON_0004535	""
cardiovascular	activation_acute	HP_0032263	ENSG00000273079	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2B	UBERON_0004535	""
cardiovascular	activation_acute	HP_0031860	ENSG00000273079	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN2B	UBERON_0004535	""
central nervous system	activation_acute	HP_0031860	ENSG00000273079	28216264	Lynch et al. (2017)	increased then decreased heart rate	GRIN2B	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000273079	28216264	Lynch et al. (2017)	convulsions	GRIN2B	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000273079	28216264	Lynch et al. (2017)	convulsions	GRIN2B	UBERON_0001017	""
central nervous system	activation_acute	HP_0032263	ENSG00000273079	28216264	Lynch et al. (2017)	increased blood pressure	GRIN2B	UBERON_0001017	""
cardiovascular system	inhibition_general	EFO_1001497	ENSG00000183873	23197038	Bowes et al. (2012)	slowed cardiac conduction	SCN5A	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0006677	ENSG00000183873	23197038	Bowes et al. (2012)	prolonged QRS interval of ECG	SCN5A	UBERON_0004535	""
nervous system	activation_acute	EFO_0009867	ENSG00000118432	28216264	Lynch et al. (2017)	dysphoria	CNR1	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000118432	28216264	Lynch et al. (2017)	increased convulsions	CNR1	UBERON_0001016	""
nervous system	inhibition_acute	HP_0100738	ENSG00000118432	28216264	Lynch et al. (2017)	decreased eating	CNR1	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009847	ENSG00000118432	28216264	Lynch et al. (2017)	dizziness	CNR1	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000118432	28216264	Lynch et al. (2017)	increased convulsions	CNR1	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0100738	ENSG00000118432	28216264	Lynch et al. (2017)	decreased eating	CNR1	UBERON_0004535	""
cardiovascular	activation_acute	NCIT_C95746	ENSG00000118432	28216264	Lynch et al. (2017)	drowsiness	CNR1	UBERON_0004535	""
nervous system	activation_acute	NCIT_C95746	ENSG00000118432	28216264	Lynch et al. (2017)	drowsiness	CNR1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009853	ENSG00000118432	28216264	Lynch et al. (2017)	decreased convulsions	CNR1	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000118432	28216264	Lynch et al. (2017)	decreased convulsions	CNR1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002315	ENSG00000118432	28216264	Lynch et al. (2017)	headache	CNR1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0002045	ENSG00000118432	28216264	Lynch et al. (2017)	decreased body temperature	CNR1	UBERON_0004535	""
nervous system	activation_acute	GO_1904057	ENSG00000118432	28216264	Lynch et al. (2017)	decreased pain	CNR1	UBERON_0001016	""
nervous system	activation_acute	HP_0002045	ENSG00000118432	28216264	Lynch et al. (2017)	decreased body temperature	CNR1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009845	ENSG00000118432	28216264	Lynch et al. (2017)	catalepsy	CNR1	UBERON_0001016	""
cardiovascular	activation_acute	GO_1904057	ENSG00000118432	28216264	Lynch et al. (2017)	decreased pain	CNR1	UBERON_0004535	""
cardiovascular	activation_acute	NCIT_C74532	ENSG00000118432	28216264	Lynch et al. (2017)	nervousness	CNR1	UBERON_0004535	""
nervous system	activation_acute	HP_0002315	ENSG00000118432	28216264	Lynch et al. (2017)	headache	CNR1	UBERON_0001016	""
nervous system	activation_acute	EFO_0003890	ENSG00000118432	28216264	Lynch et al. (2017)	drug abuse/dependence	CNR1	UBERON_0001016	""
nervous system	activation_acute	HP_0000738	ENSG00000118432	28216264	Lynch et al. (2017)	hallucinations	CNR1	UBERON_0001016	""
nervous system	activation_acute	NCIT_C74532	ENSG00000118432	28216264	Lynch et al. (2017)	nervousness	CNR1	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000118432	28216264	Lynch et al. (2017)	decreased blood pressure	CNR1	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000118432	28216264	Lynch et al. (2017)	decreased locomotor activity	CNR1	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003890	ENSG00000118432	28216264	Lynch et al. (2017)	drug abuse/dependence	CNR1	UBERON_0004535	""
nervous system	activation_acute	EFO_0005251	ENSG00000118432	28216264	Lynch et al. (2017)	decreased blood pressure	CNR1	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009845	ENSG00000118432	28216264	Lynch et al. (2017)	catalepsy	CNR1	UBERON_0004535	""
nervous system	activation_acute	GO_0040013	ENSG00000118432	28216264	Lynch et al. (2017)	decreased locomotor activity	CNR1	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0009867	ENSG00000118432	28216264	Lynch et al. (2017)	dysphoria	CNR1	UBERON_0004535	""
nervous system	activation_acute	HP_0100738	ENSG00000118432	28216264	Lynch et al. (2017)	increased eating	CNR1	UBERON_0001016	""
nervous system	activation_acute	HP_0001662	ENSG00000118432	28216264	Lynch et al. (2017)	decreased heart rate	CNR1	UBERON_0001016	""
nervous system	activation_acute	EFO_0009847	ENSG00000118432	28216264	Lynch et al. (2017)	dizziness	CNR1	UBERON_0001016	""
cardiovascular	activation_acute	HP_0100738	ENSG00000118432	28216264	Lynch et al. (2017)	increased eating	CNR1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001662	ENSG00000118432	28216264	Lynch et al. (2017)	decreased heart rate	CNR1	UBERON_0004535	""
cardiovascular	activation_acute	HP_0000738	ENSG00000118432	28216264	Lynch et al. (2017)	hallucinations	CNR1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001662	ENSG00000181072	23197038	Bowes et al. (2012)	decreased heart rate	CHRM2	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001649	ENSG00000181072	23197038	Bowes et al. (2012)	tachycardia	CHRM2	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009836	ENSG00000181072	23197038	Bowes et al. (2012)	bronchoconstriction	CHRM2	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001337	ENSG00000181072	23197038	Bowes et al. (2012)	tremors	CHRM2	UBERON_0004535	""
cardiovascular system	activation_general	GO_0060004	ENSG00000181072	23197038	Bowes et al. (2012)	reflex	CHRM2	UBERON_0004535	""
cardiovascular system	activation_general	HP_0032263	ENSG00000181072	23197038	Bowes et al. (2012)	increased blood pressure	CHRM2	UBERON_0004535	""
cardiovascular system	activation_general	GO_0045822	ENSG00000181072	23197038	Bowes et al. (2012)	negative chronotropy and inotropy	CHRM2	UBERON_0004535	""
cardiovascular system	activation_general	EFO_1001497	ENSG00000181072	23197038	Bowes et al. (2012)	decreased cardiac conduction (PR interval)	CHRM2	UBERON_0004535	""
cardiovascular system	activation_general	GO_0098901	ENSG00000181072	23197038	Bowes et al. (2012)	decreased cardiac action potential duration	CHRM2	UBERON_0004535	""
pulmonary	activation_general	HP_0003470	ENSG00000138435	23197038	Bowes et al. (2012)	paralysis	CHRNA1	UBERON_0002048	""
pulmonary	inhibition_general	""	ENSG00000138435	23197038	Bowes et al. (2012)	muscle relaxation	CHRNA1	UBERON_0002048	""
pulmonary	inhibition_general	HP_0002019	ENSG00000138435	23197038	Bowes et al. (2012)	constipation	CHRNA1	UBERON_0002048	""
pulmonary	inhibition_general	HP_0002104	ENSG00000138435	23197038	Bowes et al. (2012)	apnoea	CHRNA1	UBERON_0002048	""
pulmonary	inhibition_general	EFO_0005251	ENSG00000138435	23197038	Bowes et al. (2012)	decreased blood pressure	CHRNA1	UBERON_0002048	""
pulmonary	inhibition_general	HP_0001662	ENSG00000138435	23197038	Bowes et al. (2012)	decreased heart rate	CHRNA1	UBERON_0002048	""
pulmonary	activation_general	EFO_1001484	ENSG00000138435	23197038	Bowes et al. (2012)	analgesia	CHRNA1	UBERON_0002048	""
pulmonary	activation_general	HP_0001649	ENSG00000138435	23197038	Bowes et al. (2012)	increased heart rate	CHRNA1	UBERON_0002048	""
pulmonary	activation_general	HP_0001962	ENSG00000138435	23197038	Bowes et al. (2012)	palpitations	CHRNA1	UBERON_0002048	""
pulmonary	activation_general	HP_0002018	ENSG00000138435	23197038	Bowes et al. (2012)	nausea	CHRNA1	UBERON_0002048	""
pulmonary	activation_general	EFO_0003890	ENSG00000138435	23197038	Bowes et al. (2012)	abuse potential	CHRNA1	UBERON_0002048	""
gastrointestinal	activation_general	HP_0003470	ENSG00000138435	23197038	Bowes et al. (2012)	paralysis	CHRNA1	UBERON_0005409	""
gastrointestinal	inhibition_general	""	ENSG00000138435	23197038	Bowes et al. (2012)	muscle relaxation	CHRNA1	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0002019	ENSG00000138435	23197038	Bowes et al. (2012)	constipation	CHRNA1	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0002104	ENSG00000138435	23197038	Bowes et al. (2012)	apnoea	CHRNA1	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0005251	ENSG00000138435	23197038	Bowes et al. (2012)	decreased blood pressure	CHRNA1	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0001662	ENSG00000138435	23197038	Bowes et al. (2012)	decreased heart rate	CHRNA1	UBERON_0005409	""
gastrointestinal	activation_general	EFO_1001484	ENSG00000138435	23197038	Bowes et al. (2012)	analgesia	CHRNA1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0001649	ENSG00000138435	23197038	Bowes et al. (2012)	increased heart rate	CHRNA1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0001962	ENSG00000138435	23197038	Bowes et al. (2012)	palpitations	CHRNA1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0002018	ENSG00000138435	23197038	Bowes et al. (2012)	nausea	CHRNA1	UBERON_0005409	""
gastrointestinal	activation_general	EFO_0003890	ENSG00000138435	23197038	Bowes et al. (2012)	abuse potential	CHRNA1	UBERON_0005409	""
cardiovascular system	activation_general	HP_0003470	ENSG00000138435	23197038	Bowes et al. (2012)	paralysis	CHRNA1	UBERON_0004535	""
cardiovascular system	inhibition_general	""	ENSG00000138435	23197038	Bowes et al. (2012)	muscle relaxation	CHRNA1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0002019	ENSG00000138435	23197038	Bowes et al. (2012)	constipation	CHRNA1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0002104	ENSG00000138435	23197038	Bowes et al. (2012)	apnoea	CHRNA1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000138435	23197038	Bowes et al. (2012)	decreased blood pressure	CHRNA1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001662	ENSG00000138435	23197038	Bowes et al. (2012)	decreased heart rate	CHRNA1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_1001484	ENSG00000138435	23197038	Bowes et al. (2012)	analgesia	CHRNA1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001649	ENSG00000138435	23197038	Bowes et al. (2012)	increased heart rate	CHRNA1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001962	ENSG00000138435	23197038	Bowes et al. (2012)	palpitations	CHRNA1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0002018	ENSG00000138435	23197038	Bowes et al. (2012)	nausea	CHRNA1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0003890	ENSG00000138435	23197038	Bowes et al. (2012)	abuse potential	CHRNA1	UBERON_0004535	""
central nervous system	activation_general	HP_0003470	ENSG00000138435	23197038	Bowes et al. (2012)	paralysis	CHRNA1	UBERON_0001017	""
central nervous system	inhibition_general	""	ENSG00000138435	23197038	Bowes et al. (2012)	muscle relaxation	CHRNA1	UBERON_0001017	""
central nervous system	inhibition_general	HP_0002019	ENSG00000138435	23197038	Bowes et al. (2012)	constipation	CHRNA1	UBERON_0001017	""
central nervous system	inhibition_general	HP_0002104	ENSG00000138435	23197038	Bowes et al. (2012)	apnoea	CHRNA1	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0005251	ENSG00000138435	23197038	Bowes et al. (2012)	decreased blood pressure	CHRNA1	UBERON_0001017	""
central nervous system	inhibition_general	HP_0001662	ENSG00000138435	23197038	Bowes et al. (2012)	decreased heart rate	CHRNA1	UBERON_0001017	""
central nervous system	activation_general	EFO_1001484	ENSG00000138435	23197038	Bowes et al. (2012)	analgesia	CHRNA1	UBERON_0001017	""
central nervous system	activation_general	HP_0001649	ENSG00000138435	23197038	Bowes et al. (2012)	increased heart rate	CHRNA1	UBERON_0001017	""
central nervous system	activation_general	HP_0001962	ENSG00000138435	23197038	Bowes et al. (2012)	palpitations	CHRNA1	UBERON_0001017	""
central nervous system	activation_general	HP_0002018	ENSG00000138435	23197038	Bowes et al. (2012)	nausea	CHRNA1	UBERON_0001017	""
central nervous system	activation_general	EFO_0003890	ENSG00000138435	23197038	Bowes et al. (2012)	abuse potential	CHRNA1	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009829	ENSG00000120907	28216264	Lynch et al. (2017)	vascular hypertrophy	ADRA1A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000120907	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA1A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000120907	28216264	Lynch et al. (2017)	increased heart rate	ADRA1A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005252	ENSG00000120907	28216264	Lynch et al. (2017)	orthostatic hypotension	ADRA1A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0000373	ENSG00000120907	28216264	Lynch et al. (2017)	chronic heart failure	ADRA1A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009847	ENSG00000120907	28216264	Lynch et al. (2017)	dizziness	ADRA1A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0012877	ENSG00000120907	28216264	Lynch et al. (2017)	retrograde ejaculation	ADRA1A	UBERON_0004535	""
cardiovascular	activation_acute	HP_0032263	ENSG00000120907	28216264	Lynch et al. (2017)	increased blood pressure	ADRA1A	UBERON_0004535	""
cardiovascular	activation_acute	HP_0011499	ENSG00000120907	28216264	Lynch et al. (2017)	increased pupil diameter	ADRA1A	UBERON_0004535	""
cardiovascular	activation_acute	GO_0045823	ENSG00000120907	28216264	Lynch et al. (2017)	increased cardiac contractility	ADRA1A	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0004269	ENSG00000120907	28216264	Lynch et al. (2017)	cardiac arrhythmia	ADRA1A	UBERON_0004535	""
gastrointestinal	activation_general	HP_0001649	ENSG00000043591	23197038	Bowes et al. (2012)	increased heart rate	ADRB1	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0005251	ENSG00000043591	23197038	Bowes et al. (2012)	decreased blood pressure	ADRB1	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0001662	ENSG00000043591	23197038	Bowes et al. (2012)	decreased heart rate	ADRB1	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0009872	ENSG00000043591	23197038	Bowes et al. (2012)	decreased cardiac output	ADRB1	UBERON_0005409	""
gastrointestinal	activation_general	GO_0045823	ENSG00000043591	23197038	Bowes et al. (2012)	increased cardiac contractility	ADRB1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0003111	ENSG00000043591	23197038	Bowes et al. (2012)	electrolyte disturbances	ADRB1	UBERON_0005409	""
gastrointestinal	activation_general	GO_1900135	ENSG00000043591	23197038	Bowes et al. (2012)	increased renin release	ADRB1	UBERON_0005409	""
gastrointestinal	activation_general	""	ENSG00000043591	23197038	Bowes et al. (2012)	relaxation of colon and oesophagus	ADRB1	UBERON_0005409	""
gastrointestinal	activation_general	EFO_0009876	ENSG00000043591	23197038	Bowes et al. (2012)	lipolysis	ADRB1	UBERON_0005409	""
cardiovascular system	activation_general	HP_0001649	ENSG00000043591	23197038	Bowes et al. (2012)	increased heart rate	ADRB1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000043591	23197038	Bowes et al. (2012)	decreased blood pressure	ADRB1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001662	ENSG00000043591	23197038	Bowes et al. (2012)	decreased heart rate	ADRB1	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0009872	ENSG00000043591	23197038	Bowes et al. (2012)	decreased cardiac output	ADRB1	UBERON_0004535	""
cardiovascular system	activation_general	GO_0045823	ENSG00000043591	23197038	Bowes et al. (2012)	increased cardiac contractility	ADRB1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0003111	ENSG00000043591	23197038	Bowes et al. (2012)	electrolyte disturbances	ADRB1	UBERON_0004535	""
cardiovascular system	activation_general	GO_1900135	ENSG00000043591	23197038	Bowes et al. (2012)	increased renin release	ADRB1	UBERON_0004535	""
cardiovascular system	activation_general	""	ENSG00000043591	23197038	Bowes et al. (2012)	relaxation of colon and oesophagus	ADRB1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009876	ENSG00000043591	23197038	Bowes et al. (2012)	lipolysis	ADRB1	UBERON_0004535	""
cardiovascular system	inhibition_general	GO_0060087	ENSG00000151067	23197038	Bowes et al. (2012)	vascular relaxation	CACNA1C	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005251	ENSG00000151067	23197038	Bowes et al. (2012)	decreased blood pressure	CACNA1C	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0005165	ENSG00000151067	23197038	Bowes et al. (2012)	decreased PR interval	CACNA1C	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0012232	ENSG00000151067	23197038	Bowes et al. (2012)	possible shortening of QT interval of ECG	CACNA1C	UBERON_0004535	""
Immune	inhibition_general	GO_0050728	ENSG00000073756	23197038	Bowes et al. (2012)	anti-inflammatory activity	PTGS2	""	""
Immune	inhibition_general	GO_0045839	ENSG00000073756	23197038	Bowes et al. (2012)	anti-mitogenic effects	PTGS2	""	""
Immune	inhibition_general	EFO_0000612	ENSG00000073756	23197038	Bowes et al. (2012)	myocardial infarction	PTGS2	""	""
Immune	inhibition_general	HP_0032263	ENSG00000073756	23197038	Bowes et al. (2012)	increased blood pressure	PTGS2	""	""
Immune	inhibition_general	HP_0002140	ENSG00000073756	23197038	Bowes et al. (2012)	ischaemic stroke	PTGS2	""	""
Immune	inhibition_general	EFO_1000883	ENSG00000073756	23197038	Bowes et al. (2012)	atherothrombosis	PTGS2	""	""
cardiovascular system	inhibition_general	GO_0050728	ENSG00000073756	23197038	Bowes et al. (2012)	anti-inflammatory activity	PTGS2	UBERON_0004535	""
cardiovascular system	inhibition_general	GO_0045839	ENSG00000073756	23197038	Bowes et al. (2012)	anti-mitogenic effects	PTGS2	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0000612	ENSG00000073756	23197038	Bowes et al. (2012)	myocardial infarction	PTGS2	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0032263	ENSG00000073756	23197038	Bowes et al. (2012)	increased blood pressure	PTGS2	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0002140	ENSG00000073756	23197038	Bowes et al. (2012)	ischaemic stroke	PTGS2	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_1000883	ENSG00000073756	23197038	Bowes et al. (2012)	atherothrombosis	PTGS2	UBERON_0004535	""
central nervous system	activation_general	HP_0031844	ENSG00000118432	23197038	Bowes et al. (2012)	euphoria	CNR1	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0005245	ENSG00000118432	23197038	Bowes et al. (2012)	increased weight loss	CNR1	UBERON_0001017	""
central nervous system	inhibition_general	HP_0002017	ENSG00000118432	23197038	Bowes et al. (2012)	emesis	CNR1	UBERON_0001017	""
central nervous system	inhibition_general	MONDO_0002050	ENSG00000118432	23197038	Bowes et al. (2012)	depression	CNR1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009867	ENSG00000118432	23197038	Bowes et al. (2012)	dysphoria	CNR1	UBERON_0001017	""
central nervous system	activation_general	EFO_0005230	ENSG00000118432	23197038	Bowes et al. (2012)	anxiety	CNR1	UBERON_0001017	""
central nervous system	activation_general	EFO_0001072	ENSG00000118432	23197038	Bowes et al. (2012)	memory impairment	CNR1	UBERON_0001017	""
central nervous system	activation_general	HP_0031987	ENSG00000118432	23197038	Bowes et al. (2012)	poor concentration	CNR1	UBERON_0001017	""
central nervous system	activation_general	EFO_1001484	ENSG00000118432	23197038	Bowes et al. (2012)	analgesia	CNR1	UBERON_0001017	""
central nervous system	activation_general	HP_0002045	ENSG00000118432	23197038	Bowes et al. (2012)	hypothermia	CNR1	UBERON_0001017	""
cardiovascular	activation_acute	HP_0410204	ENSG00000164270	28216264	Lynch et al. (2017)	increased gastrointestinal transit	HTR4	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000164270	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HTR4	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009874	ENSG00000164270	28216264	Lynch et al. (2017)	decreased anxiety	HTR4	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0410204	ENSG00000164270	28216264	Lynch et al. (2017)	increased gastrointestinal transit	HTR4	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0030897	ENSG00000164270	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HTR4	UBERON_0005409	""
gastrointestinal	inhibition_acute	EFO_0009874	ENSG00000164270	28216264	Lynch et al. (2017)	decreased anxiety	HTR4	UBERON_0005409	""
cardiovascular	activation_acute	GO_0120062	ENSG00000164270	28216264	Lynch et al. (2017)	increased gastric emptying	HTR4	UBERON_0004535	""
cardiovascular	activation_acute	HP_0005184	ENSG00000164270	28216264	Lynch et al. (2017)	increased QTc interval	HTR4	UBERON_0004535	""
central nervous system	activation_acute	EFO_0004874	ENSG00000164270	28216264	Lynch et al. (2017)	increased memory	HTR4	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0030897	ENSG00000164270	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HTR4	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009874	ENSG00000164270	28216264	Lynch et al. (2017)	decreased anxiety	HTR4	UBERON_0001017	""
gastrointestinal	activation_acute	HP_0002014	ENSG00000164270	28216264	Lynch et al. (2017)	diarrhea	HTR4	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0001279	ENSG00000164270	28216264	Lynch et al. (2017)	fainting	HTR4	UBERON_0005409	""
central nervous system	activation_acute	HP_0001279	ENSG00000164270	28216264	Lynch et al. (2017)	fainting	HTR4	UBERON_0001017	""
central nervous system	activation_acute	HP_0410204	ENSG00000164270	28216264	Lynch et al. (2017)	increased gastrointestinal transit	HTR4	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0004874	ENSG00000164270	28216264	Lynch et al. (2017)	increased memory	HTR4	UBERON_0004535	""
central nervous system	activation_acute	HP_0005184	ENSG00000164270	28216264	Lynch et al. (2017)	increased QTc interval	HTR4	UBERON_0001017	""
cardiovascular	activation_acute	HP_0002014	ENSG00000164270	28216264	Lynch et al. (2017)	diarrhea	HTR4	UBERON_0004535	""
central nervous system	activation_acute	EFO_0005251	ENSG00000164270	28216264	Lynch et al. (2017)	decreased blood pressure	HTR4	UBERON_0001017	""
cardiovascular	activation_acute	HP_0011106	ENSG00000164270	28216264	Lynch et al. (2017)	decreased blood volume	HTR4	UBERON_0004535	""
central nervous system	activation_acute	HP_0002014	ENSG00000164270	28216264	Lynch et al. (2017)	diarrhea	HTR4	UBERON_0001017	""
gastrointestinal	activation_acute	EFO_0004874	ENSG00000164270	28216264	Lynch et al. (2017)	increased memory	HTR4	UBERON_0005409	""
cardiovascular	activation_acute	HP_0001279	ENSG00000164270	28216264	Lynch et al. (2017)	fainting	HTR4	UBERON_0004535	""
central nervous system	activation_acute	HP_0001649	ENSG00000164270	28216264	Lynch et al. (2017)	increased heart rate	HTR4	UBERON_0001017	""
gastrointestinal	activation_acute	GO_0120062	ENSG00000164270	28216264	Lynch et al. (2017)	increased gastric emptying	HTR4	UBERON_0005409	""
central nervous system	activation_acute	HP_0011106	ENSG00000164270	28216264	Lynch et al. (2017)	decreased blood volume	HTR4	UBERON_0001017	""
gastrointestinal	activation_acute	HP_0005184	ENSG00000164270	28216264	Lynch et al. (2017)	increased QTc interval	HTR4	UBERON_0005409	""
central nervous system	activation_acute	GO_0120062	ENSG00000164270	28216264	Lynch et al. (2017)	increased gastric emptying	HTR4	UBERON_0001017	""
cardiovascular	activation_acute	HP_0001649	ENSG00000164270	28216264	Lynch et al. (2017)	increased heart rate	HTR4	UBERON_0004535	""
gastrointestinal	activation_acute	EFO_0005251	ENSG00000164270	28216264	Lynch et al. (2017)	decreased blood pressure	HTR4	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0011106	ENSG00000164270	28216264	Lynch et al. (2017)	decreased blood volume	HTR4	UBERON_0005409	""
gastrointestinal	activation_acute	HP_0001649	ENSG00000164270	28216264	Lynch et al. (2017)	increased heart rate	HTR4	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000164270	28216264	Lynch et al. (2017)	decreased blood pressure	HTR4	UBERON_0004535	""
central nervous system	activation_acute	GO_0090331	ENSG00000128271	28216264	Lynch et al. (2017)	decreased platelet aggregation	ADORA2A	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0032263	ENSG00000128271	28216264	Lynch et al. (2017)	increased blood pressure	ADORA2A	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0001649	ENSG00000128271	28216264	Lynch et al. (2017)	increased heart rate	ADORA2A	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1901731	ENSG00000128271	28216264	Lynch et al. (2017)	increased platelet aggregation	ADORA2A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003015	ENSG00000128271	28216264	Lynch et al. (2017)	increased aggression	ADORA2A	UBERON_0001017	""
blood	activation_acute	EFO_0005251	ENSG00000128271	28216264	Lynch et al. (2017)	decreased blood pressure	ADORA2A	UBERON_0000178	""
blood	inhibition_acute	HP_0032263	ENSG00000128271	28216264	Lynch et al. (2017)	increased blood pressure	ADORA2A	UBERON_0000178	""
blood	inhibition_acute	HP_0001649	ENSG00000128271	28216264	Lynch et al. (2017)	increased heart rate	ADORA2A	UBERON_0000178	""
blood	inhibition_acute	GO_1901731	ENSG00000128271	28216264	Lynch et al. (2017)	increased platelet aggregation	ADORA2A	UBERON_0000178	""
blood	inhibition_acute	EFO_0003015	ENSG00000128271	28216264	Lynch et al. (2017)	increased aggression	ADORA2A	UBERON_0000178	""
central nervous system	activation_acute	EFO_0005251	ENSG00000128271	28216264	Lynch et al. (2017)	decreased blood pressure	ADORA2A	UBERON_0001017	""
blood	activation_acute	GO_0090331	ENSG00000128271	28216264	Lynch et al. (2017)	decreased platelet aggregation	ADORA2A	UBERON_0000178	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000128271	28216264	Lynch et al. (2017)	decreased blood pressure	ADORA2A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0032263	ENSG00000128271	28216264	Lynch et al. (2017)	increased blood pressure	ADORA2A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000128271	28216264	Lynch et al. (2017)	increased heart rate	ADORA2A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1901731	ENSG00000128271	28216264	Lynch et al. (2017)	increased platelet aggregation	ADORA2A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003015	ENSG00000128271	28216264	Lynch et al. (2017)	increased aggression	ADORA2A	UBERON_0004535	""
cardiovascular	activation_acute	GO_0090331	ENSG00000128271	28216264	Lynch et al. (2017)	decreased platelet aggregation	ADORA2A	UBERON_0004535	""
blood	activation_acute	HP_0001649	ENSG00000128271	28216264	Lynch et al. (2017)	increased heart rate	ADORA2A	UBERON_0000178	""
central nervous system	activation_acute	HP_0001649	ENSG00000128271	28216264	Lynch et al. (2017)	increased heart rate	ADORA2A	UBERON_0001017	""
cardiovascular	activation_acute	HP_0001649	ENSG00000128271	28216264	Lynch et al. (2017)	increased heart rate	ADORA2A	UBERON_0004535	""
central nervous system	activation_general	EFO_0009853	ENSG00000168539	23197038	Bowes et al. (2012)	proconvulsant	CHRM1	UBERON_0001017	""
central nervous system	inhibition_general	HP_0100543	ENSG00000168539	23197038	Bowes et al. (2012)	decreased cognitive function	CHRM1	UBERON_0001017	""
central nervous system	inhibition_general	GO_0060455	ENSG00000168539	23197038	Bowes et al. (2012)	decreased gastric acid secretion	CHRM1	UBERON_0001017	""
central nervous system	inhibition_general	HP_0000622	ENSG00000168539	23197038	Bowes et al. (2012)	blurred vision	CHRM1	UBERON_0001017	""
central nervous system	activation_general	GO_0060454	ENSG00000168539	23197038	Bowes et al. (2012)	increased gastric acid secretion	CHRM1	UBERON_0001017	""
central nervous system	activation_general	EFO_0000537	ENSG00000168539	23197038	Bowes et al. (2012)	hypertension	CHRM1	UBERON_0001017	""
central nervous system	activation_general	HP_0001649	ENSG00000168539	23197038	Bowes et al. (2012)	tachycardia	CHRM1	UBERON_0001017	""
central nervous system	activation_general	HP_0001945	ENSG00000168539	23197038	Bowes et al. (2012)	hyperthermia	CHRM1	UBERON_0001017	""
gastrointestinal	activation_general	EFO_0009853	ENSG00000168539	23197038	Bowes et al. (2012)	proconvulsant	CHRM1	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0100543	ENSG00000168539	23197038	Bowes et al. (2012)	decreased cognitive function	CHRM1	UBERON_0005409	""
gastrointestinal	inhibition_general	GO_0060455	ENSG00000168539	23197038	Bowes et al. (2012)	decreased gastric acid secretion	CHRM1	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0000622	ENSG00000168539	23197038	Bowes et al. (2012)	blurred vision	CHRM1	UBERON_0005409	""
gastrointestinal	activation_general	GO_0060454	ENSG00000168539	23197038	Bowes et al. (2012)	increased gastric acid secretion	CHRM1	UBERON_0005409	""
gastrointestinal	activation_general	EFO_0000537	ENSG00000168539	23197038	Bowes et al. (2012)	hypertension	CHRM1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0001649	ENSG00000168539	23197038	Bowes et al. (2012)	tachycardia	CHRM1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0001945	ENSG00000168539	23197038	Bowes et al. (2012)	hyperthermia	CHRM1	UBERON_0005409	""
cardiovascular system	activation_general	EFO_0009853	ENSG00000168539	23197038	Bowes et al. (2012)	proconvulsant	CHRM1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0100543	ENSG00000168539	23197038	Bowes et al. (2012)	decreased cognitive function	CHRM1	UBERON_0004535	""
cardiovascular system	inhibition_general	GO_0060455	ENSG00000168539	23197038	Bowes et al. (2012)	decreased gastric acid secretion	CHRM1	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0000622	ENSG00000168539	23197038	Bowes et al. (2012)	blurred vision	CHRM1	UBERON_0004535	""
cardiovascular system	activation_general	GO_0060454	ENSG00000168539	23197038	Bowes et al. (2012)	increased gastric acid secretion	CHRM1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0000537	ENSG00000168539	23197038	Bowes et al. (2012)	hypertension	CHRM1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001649	ENSG00000168539	23197038	Bowes et al. (2012)	tachycardia	CHRM1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001945	ENSG00000168539	23197038	Bowes et al. (2012)	hyperthermia	CHRM1	UBERON_0004535	""
central nervous system	activation_acute	HP_0002027	ENSG00000134640	28216264	Lynch et al. (2017)	abdominal pain	MTNR1B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0008568	ENSG00000134640	28216264	Lynch et al. (2017)	decreased sleep	MTNR1B	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0001072	ENSG00000134640	28216264	Lynch et al. (2017)	decreased memory	MTNR1B	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009844	ENSG00000134640	28216264	Lynch et al. (2017)	nightmares	MTNR1B	UBERON_0001017	""
central nervous system	activation_acute	GO_1904057	ENSG00000134640	28216264	Lynch et al. (2017)	decreased pain	MTNR1B	UBERON_0001017	""
central nervous system	activation_acute	EFO_0004874	ENSG00000134640	28216264	Lynch et al. (2017)	increased memory	MTNR1B	UBERON_0001017	""
central nervous system	activation_acute	EFO_0005251	ENSG00000134640	28216264	Lynch et al. (2017)	decreased blood pressure	MTNR1B	UBERON_0001017	""
central nervous system	activation_acute	EFO_0008568	ENSG00000134640	28216264	Lynch et al. (2017)	increased sleep	MTNR1B	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009874	ENSG00000134640	28216264	Lynch et al. (2017)	decreased anxiety	MTNR1B	UBERON_0001017	""
cardiovascular system	inhibition_general	HP_0030895	ENSG00000108576	23197038	Bowes et al. (2012)	increased gastrointestinal motility	SLC6A4	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0030897	ENSG00000108576	23197038	Bowes et al. (2012)	decreased upper gastrointestinal transit	SLC6A4	UBERON_0004535	""
cardiovascular system	inhibition_general	GO_1900134	ENSG00000108576	23197038	Bowes et al. (2012)	decreased plasma renin	SLC6A4	UBERON_0004535	""
cardiovascular system	inhibition_general	GO_1904014	ENSG00000108576	23197038	Bowes et al. (2012)	increased other serotonin-mediated effects	SLC6A4	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0004698	ENSG00000108576	23197038	Bowes et al. (2012)	insomnia	SLC6A4	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0005230	ENSG00000108576	23197038	Bowes et al. (2012)	anxiety	SLC6A4	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0002018	ENSG00000108576	23197038	Bowes et al. (2012)	nausea	SLC6A4	UBERON_0004535	""
cardiovascular system	inhibition_general	EFO_0004714	ENSG00000108576	23197038	Bowes et al. (2012)	sexual dysfunction	SLC6A4	UBERON_0004535	""
central nervous system	inhibition_general	HP_0030895	ENSG00000108576	23197038	Bowes et al. (2012)	increased gastrointestinal motility	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_general	HP_0030897	ENSG00000108576	23197038	Bowes et al. (2012)	decreased upper gastrointestinal transit	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_general	GO_1900134	ENSG00000108576	23197038	Bowes et al. (2012)	decreased plasma renin	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_general	GO_1904014	ENSG00000108576	23197038	Bowes et al. (2012)	increased other serotonin-mediated effects	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0004698	ENSG00000108576	23197038	Bowes et al. (2012)	insomnia	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0005230	ENSG00000108576	23197038	Bowes et al. (2012)	anxiety	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_general	HP_0002018	ENSG00000108576	23197038	Bowes et al. (2012)	nausea	SLC6A4	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0004714	ENSG00000108576	23197038	Bowes et al. (2012)	sexual dysfunction	SLC6A4	UBERON_0001017	""
gastrointestinal	activation_acute	""	ENSG00000135914	28216264	Lynch et al. (2017)	cardiac valvulopathy	HTR2B	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0030897	ENSG00000135914	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HTR2B	UBERON_0005409	""
gastrointestinal	inhibition_developmental toxicity	EFO_0005269	ENSG00000135914	28216264	Lynch et al. (2017)	cardiovascular malformations	HTR2B	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1904057	ENSG00000135914	28216264	Lynch et al. (2017)	decreased pain	HTR2B	UBERON_0005409	""
nervous system	activation_acute	EFO_0001361	ENSG00000135914	28216264	Lynch et al. (2017)	pulmonary hypertension	HTR2B	UBERON_0001016	""
nervous system	inhibition_acute	HP_0030897	ENSG00000135914	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HTR2B	UBERON_0001016	""
nervous system	inhibition_developmental toxicity	EFO_0005269	ENSG00000135914	28216264	Lynch et al. (2017)	cardiovascular malformations	HTR2B	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000135914	28216264	Lynch et al. (2017)	decreased pain	HTR2B	UBERON_0001016	""
nervous system	activation_acute	""	ENSG00000135914	28216264	Lynch et al. (2017)	cardiac valvulopathy	HTR2B	UBERON_0001016	""
cardiovascular	activation_acute	""	ENSG00000135914	28216264	Lynch et al. (2017)	cardiac valvulopathy	HTR2B	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0030897	ENSG00000135914	28216264	Lynch et al. (2017)	decreased gastrointestinal transit	HTR2B	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	EFO_0005269	ENSG00000135914	28216264	Lynch et al. (2017)	cardiovascular malformations	HTR2B	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000135914	28216264	Lynch et al. (2017)	decreased pain	HTR2B	UBERON_0004535	""
nervous system	activation_acute	GO_1904058	ENSG00000135914	28216264	Lynch et al. (2017)	increased pain	HTR2B	UBERON_0001016	""
cardiovascular	activation_acute	GO_1904058	ENSG00000135914	28216264	Lynch et al. (2017)	increased pain	HTR2B	UBERON_0004535	""
gastrointestinal	activation_acute	GO_1904058	ENSG00000135914	28216264	Lynch et al. (2017)	increased pain	HTR2B	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0009874	ENSG00000135914	28216264	Lynch et al. (2017)	decreased anxiety	HTR2B	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0009874	ENSG00000135914	28216264	Lynch et al. (2017)	decreased anxiety	HTR2B	UBERON_0004535	""
nervous system	activation_acute	EFO_0009874	ENSG00000135914	28216264	Lynch et al. (2017)	decreased anxiety	HTR2B	UBERON_0001016	""
gastrointestinal	activation_acute	EFO_0001361	ENSG00000135914	28216264	Lynch et al. (2017)	pulmonary hypertension	HTR2B	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0001361	ENSG00000135914	28216264	Lynch et al. (2017)	pulmonary hypertension	HTR2B	UBERON_0004535	""
respiratory	activation_acute	EFO_0009836	ENSG00000168398	28216264	Lynch et al. (2017)	bronchoconstriction	BDKRB2	UBERON_0001004	""
respiratory	inhibition_acute	GO_1904057	ENSG00000168398	28216264	Lynch et al. (2017)	decreased pain	BDKRB2	UBERON_0001004	""
respiratory	inhibition_acute	GO_0035814	ENSG00000168398	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	BDKRB2	UBERON_0001004	""
renal	activation_acute	EFO_0005251	ENSG00000168398	28216264	Lynch et al. (2017)	decreased blood pressure	BDKRB2	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000168398	28216264	Lynch et al. (2017)	decreased pain	BDKRB2	UBERON_0001008	""
renal	inhibition_acute	GO_0035814	ENSG00000168398	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	BDKRB2	UBERON_0001008	""
renal	activation_acute	HP_0000103	ENSG00000168398	28216264	Lynch et al. (2017)	increased urine excretion	BDKRB2	UBERON_0001008	""
central nervous system	activation_acute	GO_0006954	ENSG00000168398	28216264	Lynch et al. (2017)	inflammation	BDKRB2	UBERON_0001017	""
central nervous system	inhibition_acute	GO_1904057	ENSG00000168398	28216264	Lynch et al. (2017)	decreased pain	BDKRB2	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0035814	ENSG00000168398	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	BDKRB2	UBERON_0001017	""
central nervous system	activation_acute	GO_0035815	ENSG00000168398	28216264	Lynch et al. (2017)	increased urinary sodium excretion	BDKRB2	UBERON_0001017	""
cardiovascular	activation_acute	HP_0000103	ENSG00000168398	28216264	Lynch et al. (2017)	increased urine excretion	BDKRB2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000168398	28216264	Lynch et al. (2017)	decreased pain	BDKRB2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035814	ENSG00000168398	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	BDKRB2	UBERON_0004535	""
renal	activation_acute	GO_0035815	ENSG00000168398	28216264	Lynch et al. (2017)	increased urinary sodium excretion	BDKRB2	UBERON_0001008	""
renal	activation_acute	EFO_0009836	ENSG00000168398	28216264	Lynch et al. (2017)	bronchoconstriction	BDKRB2	UBERON_0001008	""
central nervous system	activation_acute	EFO_0005251	ENSG00000168398	28216264	Lynch et al. (2017)	decreased blood pressure	BDKRB2	UBERON_0001017	""
respiratory	activation_acute	EFO_0005251	ENSG00000168398	28216264	Lynch et al. (2017)	decreased blood pressure	BDKRB2	UBERON_0001004	""
central nervous system	activation_acute	EFO_0009836	ENSG00000168398	28216264	Lynch et al. (2017)	bronchoconstriction	BDKRB2	UBERON_0001017	""
central nervous system	activation_acute	HP_0000103	ENSG00000168398	28216264	Lynch et al. (2017)	increased urine excretion	BDKRB2	UBERON_0001017	""
respiratory	activation_acute	GO_0035815	ENSG00000168398	28216264	Lynch et al. (2017)	increased urinary sodium excretion	BDKRB2	UBERON_0001004	""
respiratory	activation_acute	GO_0006954	ENSG00000168398	28216264	Lynch et al. (2017)	inflammation	BDKRB2	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009836	ENSG00000168398	28216264	Lynch et al. (2017)	bronchoconstriction	BDKRB2	UBERON_0004535	""
cardiovascular	activation_acute	GO_0006954	ENSG00000168398	28216264	Lynch et al. (2017)	inflammation	BDKRB2	UBERON_0004535	""
renal	activation_acute	GO_0006954	ENSG00000168398	28216264	Lynch et al. (2017)	inflammation	BDKRB2	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000168398	28216264	Lynch et al. (2017)	decreased blood pressure	BDKRB2	UBERON_0004535	""
cardiovascular	activation_acute	GO_0035815	ENSG00000168398	28216264	Lynch et al. (2017)	increased urinary sodium excretion	BDKRB2	UBERON_0004535	""
respiratory	activation_acute	HP_0000103	ENSG00000168398	28216264	Lynch et al. (2017)	increased urine excretion	BDKRB2	UBERON_0001004	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000143603	28216264	Lynch et al. (2017)	decreased convulsions	KCNN3	UBERON_0004535	""
cardiovascular	inhibition_acute	""	ENSG00000143603	28216264	Lynch et al. (2017)	increased atrial refractory period	KCNN3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000143603	28216264	Lynch et al. (2017)	convulsions	KCNN3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000143603	28216264	Lynch et al. (2017)	neurotoxicity	KCNN3	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000143603	28216264	Lynch et al. (2017)	decreased convulsions	KCNN3	UBERON_0001017	""
central nervous system	inhibition_acute	""	ENSG00000143603	28216264	Lynch et al. (2017)	increased atrial refractory period	KCNN3	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000143603	28216264	Lynch et al. (2017)	convulsions	KCNN3	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000143603	28216264	Lynch et al. (2017)	neurotoxicity	KCNN3	UBERON_0001017	""
central nervous system	activation_acute	GO_0040013	ENSG00000143603	28216264	Lynch et al. (2017)	decreased locomotor activity	KCNN3	UBERON_0001017	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000143603	28216264	Lynch et al. (2017)	ataxia	KCNN3	UBERON_0001017	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000143603	28216264	Lynch et al. (2017)	ataxia	KCNN3	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000143603	28216264	Lynch et al. (2017)	decreased locomotor activity	KCNN3	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0003144	ENSG00000274286	28216264	Lynch et al. (2017)	increased heart failure	ADRA2B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000274286	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA2B	UBERON_0004535	""
cardiovascular	inhibition_developmental toxicity	EFO_0000480	ENSG00000274286	28216264	Lynch et al. (2017)	decreased survival	ADRA2B	UBERON_0004535	""
cardiovascular	activation_acute	GO_1904057	ENSG00000274286	28216264	Lynch et al. (2017)	decreased pain	ADRA2B	UBERON_0004535	""
nervous system	activation_acute	HP_0001337	ENSG00000274286	28216264	Lynch et al. (2017)	skeletal muscle tremor	ADRA2B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0005251	ENSG00000274286	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA2B	UBERON_0001016	""
nervous system	inhibition_developmental toxicity	EFO_0000480	ENSG00000274286	28216264	Lynch et al. (2017)	decreased survival	ADRA2B	UBERON_0001016	""
cardiovascular	activation_acute	HP_0032263	ENSG00000274286	28216264	Lynch et al. (2017)	increased blood pressure	ADRA2B	UBERON_0004535	""
cardiovascular	activation_acute	HP_0001649	ENSG00000274286	28216264	Lynch et al. (2017)	increased heart rate	ADRA2B	UBERON_0004535	""
nervous system	activation_acute	EFO_0003144	ENSG00000274286	28216264	Lynch et al. (2017)	increased heart failure	ADRA2B	UBERON_0001016	""
nervous system	activation_acute	EFO_1001375	ENSG00000274286	28216264	Lynch et al. (2017)	cardiac ischemia	ADRA2B	UBERON_0001016	""
cardiovascular	activation_acute	HP_0001337	ENSG00000274286	28216264	Lynch et al. (2017)	skeletal muscle tremor	ADRA2B	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009868	ENSG00000274286	28216264	Lynch et al. (2017)	sedation	ADRA2B	UBERON_0004535	""
nervous system	activation_acute	HP_0032263	ENSG00000274286	28216264	Lynch et al. (2017)	increased blood pressure	ADRA2B	UBERON_0001016	""
nervous system	activation_acute	EFO_0009868	ENSG00000274286	28216264	Lynch et al. (2017)	sedation	ADRA2B	UBERON_0001016	""
nervous system	activation_acute	GO_1904057	ENSG00000274286	28216264	Lynch et al. (2017)	decreased pain	ADRA2B	UBERON_0001016	""
cardiovascular	activation_acute	EFO_1001375	ENSG00000274286	28216264	Lynch et al. (2017)	cardiac ischemia	ADRA2B	UBERON_0004535	""
nervous system	activation_acute	HP_0001649	ENSG00000274286	28216264	Lynch et al. (2017)	increased heart rate	ADRA2B	UBERON_0001016	""
central nervous system	activation_general	HP_0002579	ENSG00000082556	23197038	Bowes et al. (2012)	decreased gastrointestinal motility	OPRK1	UBERON_0001017	""
central nervous system	activation_general	HP_0000103	ENSG00000082556	23197038	Bowes et al. (2012)	increased urinary output	OPRK1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009868	ENSG00000082556	23197038	Bowes et al. (2012)	sedation	OPRK1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009867	ENSG00000082556	23197038	Bowes et al. (2012)	dysphoria	OPRK1	UBERON_0001017	""
central nervous system	activation_general	HP_0004372	ENSG00000082556	23197038	Bowes et al. (2012)	confusion	OPRK1	UBERON_0001017	""
central nervous system	activation_general	EFO_0009847	ENSG00000082556	23197038	Bowes et al. (2012)	dizziness	OPRK1	UBERON_0001017	""
central nervous system	activation_general	GO_0040013	ENSG00000082556	23197038	Bowes et al. (2012)	decreased locomotion	OPRK1	UBERON_0001017	""
central nervous system	activation_general	HP_0001649	ENSG00000082556	23197038	Bowes et al. (2012)	tachycardia	OPRK1	UBERON_0001017	""
cardiovascular system	activation_general	HP_0002579	ENSG00000082556	23197038	Bowes et al. (2012)	decreased gastrointestinal motility	OPRK1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0000103	ENSG00000082556	23197038	Bowes et al. (2012)	increased urinary output	OPRK1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009868	ENSG00000082556	23197038	Bowes et al. (2012)	sedation	OPRK1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009867	ENSG00000082556	23197038	Bowes et al. (2012)	dysphoria	OPRK1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0004372	ENSG00000082556	23197038	Bowes et al. (2012)	confusion	OPRK1	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009847	ENSG00000082556	23197038	Bowes et al. (2012)	dizziness	OPRK1	UBERON_0004535	""
cardiovascular system	activation_general	GO_0040013	ENSG00000082556	23197038	Bowes et al. (2012)	decreased locomotion	OPRK1	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001649	ENSG00000082556	23197038	Bowes et al. (2012)	tachycardia	OPRK1	UBERON_0004535	""
gastrointestinal	activation_general	HP_0002579	ENSG00000082556	23197038	Bowes et al. (2012)	decreased gastrointestinal motility	OPRK1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0000103	ENSG00000082556	23197038	Bowes et al. (2012)	increased urinary output	OPRK1	UBERON_0005409	""
gastrointestinal	activation_general	EFO_0009868	ENSG00000082556	23197038	Bowes et al. (2012)	sedation	OPRK1	UBERON_0005409	""
gastrointestinal	activation_general	EFO_0009867	ENSG00000082556	23197038	Bowes et al. (2012)	dysphoria	OPRK1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0004372	ENSG00000082556	23197038	Bowes et al. (2012)	confusion	OPRK1	UBERON_0005409	""
gastrointestinal	activation_general	EFO_0009847	ENSG00000082556	23197038	Bowes et al. (2012)	dizziness	OPRK1	UBERON_0005409	""
gastrointestinal	activation_general	GO_0040013	ENSG00000082556	23197038	Bowes et al. (2012)	decreased locomotion	OPRK1	UBERON_0005409	""
gastrointestinal	activation_general	HP_0001649	ENSG00000082556	23197038	Bowes et al. (2012)	tachycardia	OPRK1	UBERON_0005409	""
central nervous system	activation_general	GO_0061533	ENSG00000150594	23197038	Bowes et al. (2012)	decreased noradrenaline release and sympathetic neurotransmission	ADRA2A	UBERON_0001017	""
central nervous system	inhibition_general	HP_0030895	ENSG00000150594	23197038	Bowes et al. (2012)	increased gastrointestinal motility	ADRA2A	UBERON_0001017	""
central nervous system	inhibition_general	HP_0000842	ENSG00000150594	23197038	Bowes et al. (2012)	increased insulin secretion	ADRA2A	UBERON_0001017	""
central nervous system	activation_general	EFO_0005251	ENSG00000150594	23197038	Bowes et al. (2012)	decreased blood pressure	ADRA2A	UBERON_0001017	""
central nervous system	activation_general	HP_0001662	ENSG00000150594	23197038	Bowes et al. (2012)	decreased heart rate	ADRA2A	UBERON_0001017	""
central nervous system	activation_general	HP_0011499	ENSG00000150594	23197038	Bowes et al. (2012)	mydriasis	ADRA2A	UBERON_0001017	""
central nervous system	activation_general	EFO_0009868	ENSG00000150594	23197038	Bowes et al. (2012)	sedation	ADRA2A	UBERON_0001017	""
cardiovascular system	activation_general	GO_0061533	ENSG00000150594	23197038	Bowes et al. (2012)	decreased noradrenaline release and sympathetic neurotransmission	ADRA2A	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0030895	ENSG00000150594	23197038	Bowes et al. (2012)	increased gastrointestinal motility	ADRA2A	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0000842	ENSG00000150594	23197038	Bowes et al. (2012)	increased insulin secretion	ADRA2A	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0005251	ENSG00000150594	23197038	Bowes et al. (2012)	decreased blood pressure	ADRA2A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001662	ENSG00000150594	23197038	Bowes et al. (2012)	decreased heart rate	ADRA2A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0011499	ENSG00000150594	23197038	Bowes et al. (2012)	mydriasis	ADRA2A	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0009868	ENSG00000150594	23197038	Bowes et al. (2012)	sedation	ADRA2A	UBERON_0004535	""
immune	activation_acute	GO_0006954	ENSG00000113749	28216264	Lynch et al. (2017)	inflammation	HRH2	UBERON_0002405	""
immune	inhibition_acute	GO_0060455	ENSG00000113749	28216264	Lynch et al. (2017)	decreased gastric acid secretion	HRH2	UBERON_0002405	""
immune	inhibition_acute	GO_0120061	ENSG00000113749	28216264	Lynch et al. (2017)	decreased gastric emptying	HRH2	UBERON_0002405	""
immune	inhibition_acute	HP_0100738	ENSG00000113749	28216264	Lynch et al. (2017)	decreased eating	HRH2	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000113749	28216264	Lynch et al. (2017)	decreased inflammation	HRH2	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000113749	28216264	Lynch et al. (2017)	decreased pain	HRH2	UBERON_0002405	""
cardiovascular	activation_acute	GO_0120062	ENSG00000113749	28216264	Lynch et al. (2017)	increased gastric emptying	HRH2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0060455	ENSG00000113749	28216264	Lynch et al. (2017)	decreased gastric acid secretion	HRH2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0120061	ENSG00000113749	28216264	Lynch et al. (2017)	decreased gastric emptying	HRH2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0100738	ENSG00000113749	28216264	Lynch et al. (2017)	decreased eating	HRH2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0050728	ENSG00000113749	28216264	Lynch et al. (2017)	decreased inflammation	HRH2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_1904057	ENSG00000113749	28216264	Lynch et al. (2017)	decreased pain	HRH2	UBERON_0004535	""
immune	activation_acute	GO_0120062	ENSG00000113749	28216264	Lynch et al. (2017)	increased gastric emptying	HRH2	UBERON_0002405	""
cardiovascular	activation_acute	GO_0060454	ENSG00000113749	28216264	Lynch et al. (2017)	increased gastric acid secretion	HRH2	UBERON_0004535	""
immune	activation_acute	HP_0001649	ENSG00000113749	28216264	Lynch et al. (2017)	increased heart rate	HRH2	UBERON_0002405	""
immune	activation_acute	GO_0060454	ENSG00000113749	28216264	Lynch et al. (2017)	increased gastric acid secretion	HRH2	UBERON_0002405	""
gastrointestinal	activation_acute	GO_0120062	ENSG00000113749	28216264	Lynch et al. (2017)	increased gastric emptying	HRH2	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0060455	ENSG00000113749	28216264	Lynch et al. (2017)	decreased gastric acid secretion	HRH2	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0120061	ENSG00000113749	28216264	Lynch et al. (2017)	decreased gastric emptying	HRH2	UBERON_0005409	""
gastrointestinal	inhibition_acute	HP_0100738	ENSG00000113749	28216264	Lynch et al. (2017)	decreased eating	HRH2	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_0050728	ENSG00000113749	28216264	Lynch et al. (2017)	decreased inflammation	HRH2	UBERON_0005409	""
gastrointestinal	inhibition_acute	GO_1904057	ENSG00000113749	28216264	Lynch et al. (2017)	decreased pain	HRH2	UBERON_0005409	""
gastrointestinal	activation_acute	EFO_0005251	ENSG00000113749	28216264	Lynch et al. (2017)	decreased blood pressure	HRH2	UBERON_0005409	""
cardiovascular	activation_acute	HP_0001959	ENSG00000113749	28216264	Lynch et al. (2017)	increased drinking	HRH2	UBERON_0004535	""
gastrointestinal	activation_acute	HP_0001649	ENSG00000113749	28216264	Lynch et al. (2017)	increased heart rate	HRH2	UBERON_0005409	""
immune	activation_acute	EFO_0005251	ENSG00000113749	28216264	Lynch et al. (2017)	decreased blood pressure	HRH2	UBERON_0002405	""
gastrointestinal	activation_acute	HP_0001959	ENSG00000113749	28216264	Lynch et al. (2017)	increased drinking	HRH2	UBERON_0005409	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000113749	28216264	Lynch et al. (2017)	decreased blood pressure	HRH2	UBERON_0004535	""
gastrointestinal	activation_acute	GO_0006954	ENSG00000113749	28216264	Lynch et al. (2017)	inflammation	HRH2	UBERON_0005409	""
gastrointestinal	activation_acute	GO_0060454	ENSG00000113749	28216264	Lynch et al. (2017)	increased gastric acid secretion	HRH2	UBERON_0005409	""
cardiovascular	activation_acute	GO_0006954	ENSG00000113749	28216264	Lynch et al. (2017)	inflammation	HRH2	UBERON_0004535	""
immune	activation_acute	HP_0001959	ENSG00000113749	28216264	Lynch et al. (2017)	increased drinking	HRH2	UBERON_0002405	""
cardiovascular	activation_acute	HP_0001649	ENSG00000113749	28216264	Lynch et al. (2017)	increased heart rate	HRH2	UBERON_0004535	""
cardiovascular system	inhibition_general	HP_0001657	ENSG00000055118	23197038	Bowes et al. (2012)	prolongation of QT interval of ECG	KCNH2	UBERON_0004535	""
central nervous system	activation_acute	HP_0002045	ENSG00000166148	28216264	Lynch et al. (2017)	decreased body temperature	AVPR1A	UBERON_0001017	""
central nervous system	activation_chronic	EFO_0002503	ENSG00000166148	28216264	Lynch et al. (2017)	myocardial hypertrophy	AVPR1A	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0035814	ENSG00000166148	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	AVPR1A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009874	ENSG00000166148	28216264	Lynch et al. (2017)	decreased anxiety	AVPR1A	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0003015	ENSG00000166148	28216264	Lynch et al. (2017)	decreased aggression	AVPR1A	UBERON_0001017	""
cardiovascular	activation_acute	HP_0002045	ENSG00000166148	28216264	Lynch et al. (2017)	decreased body temperature	AVPR1A	UBERON_0004535	""
cardiovascular	activation_chronic	EFO_0002503	ENSG00000166148	28216264	Lynch et al. (2017)	myocardial hypertrophy	AVPR1A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035814	ENSG00000166148	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	AVPR1A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009874	ENSG00000166148	28216264	Lynch et al. (2017)	decreased anxiety	AVPR1A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0003015	ENSG00000166148	28216264	Lynch et al. (2017)	decreased aggression	AVPR1A	UBERON_0004535	""
renal	activation_acute	HP_0002045	ENSG00000166148	28216264	Lynch et al. (2017)	decreased body temperature	AVPR1A	UBERON_0001008	""
renal	activation_chronic	EFO_0002503	ENSG00000166148	28216264	Lynch et al. (2017)	myocardial hypertrophy	AVPR1A	UBERON_0001008	""
renal	inhibition_acute	GO_0035814	ENSG00000166148	28216264	Lynch et al. (2017)	decreased urinary sodium excretion	AVPR1A	UBERON_0001008	""
renal	inhibition_acute	EFO_0009874	ENSG00000166148	28216264	Lynch et al. (2017)	decreased anxiety	AVPR1A	UBERON_0001008	""
renal	inhibition_acute	EFO_0003015	ENSG00000166148	28216264	Lynch et al. (2017)	decreased aggression	AVPR1A	UBERON_0001008	""
renal	activation_acute	GO_0035815	ENSG00000166148	28216264	Lynch et al. (2017)	increased urinary sodium excretion	AVPR1A	UBERON_0001008	""
cardiovascular	activation_acute	GO_0035815	ENSG00000166148	28216264	Lynch et al. (2017)	increased urinary sodium excretion	AVPR1A	UBERON_0004535	""
renal	activation_acute	HP_0032263	ENSG00000166148	28216264	Lynch et al. (2017)	increased blood pressure	AVPR1A	UBERON_0001008	""
central nervous system	activation_acute	GO_0035815	ENSG00000166148	28216264	Lynch et al. (2017)	increased urinary sodium excretion	AVPR1A	UBERON_0001017	""
cardiovascular	activation_acute	HP_0032263	ENSG00000166148	28216264	Lynch et al. (2017)	increased blood pressure	AVPR1A	UBERON_0004535	""
central nervous system	activation_acute	HP_0032263	ENSG00000166148	28216264	Lynch et al. (2017)	increased blood pressure	AVPR1A	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0004874	ENSG00000166148	28216264	Lynch et al. (2017)	increased memory	AVPR1A	UBERON_0004535	""
central nervous system	activation_acute	EFO_0004874	ENSG00000166148	28216264	Lynch et al. (2017)	increased memory	AVPR1A	UBERON_0001017	""
renal	activation_acute	EFO_0004874	ENSG00000166148	28216264	Lynch et al. (2017)	increased memory	AVPR1A	UBERON_0001008	""
cardiovascular	inhibition_acute	GO_0045823	ENSG00000018625	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000018625	28216264	Lynch et al. (2017)	decreased heart rate	ATP1A2	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000018625	28216264	Lynch et al. (2017)	atrioventricular block	ATP1A2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000018625	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1A2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004287	ENSG00000018625	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000018625	28216264	Lynch et al. (2017)	increased urine excretion	ATP1A2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000018625	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1A2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002017	ENSG00000018625	28216264	Lynch et al. (2017)	vomiting	ATP1A2	UBERON_0004535	""
renal	inhibition_acute	GO_0045823	ENSG00000018625	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1A2	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000018625	28216264	Lynch et al. (2017)	decreased heart rate	ATP1A2	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000018625	28216264	Lynch et al. (2017)	atrioventricular block	ATP1A2	UBERON_0001008	""
renal	inhibition_acute	EFO_0004269	ENSG00000018625	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1A2	UBERON_0001008	""
renal	inhibition_acute	EFO_0004287	ENSG00000018625	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1A2	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000018625	28216264	Lynch et al. (2017)	increased urine excretion	ATP1A2	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000018625	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1A2	UBERON_0001008	""
renal	inhibition_acute	HP_0002017	ENSG00000018625	28216264	Lynch et al. (2017)	vomiting	ATP1A2	UBERON_0001008	""
renal	inhibition_acute	GO_0045823	ENSG00000129244	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1B2	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000129244	28216264	Lynch et al. (2017)	decreased heart rate	ATP1B2	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000129244	28216264	Lynch et al. (2017)	atrioventricular block	ATP1B2	UBERON_0001008	""
renal	inhibition_acute	EFO_0004269	ENSG00000129244	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1B2	UBERON_0001008	""
renal	inhibition_acute	EFO_0004287	ENSG00000129244	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1B2	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000129244	28216264	Lynch et al. (2017)	increased urine excretion	ATP1B2	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000129244	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1B2	UBERON_0001008	""
renal	inhibition_acute	HP_0002017	ENSG00000129244	28216264	Lynch et al. (2017)	vomiting	ATP1B2	UBERON_0001008	""
cardiovascular	inhibition_acute	GO_0045823	ENSG00000129244	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1B2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000129244	28216264	Lynch et al. (2017)	decreased heart rate	ATP1B2	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000129244	28216264	Lynch et al. (2017)	atrioventricular block	ATP1B2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000129244	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1B2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004287	ENSG00000129244	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1B2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000129244	28216264	Lynch et al. (2017)	increased urine excretion	ATP1B2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000129244	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1B2	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002017	ENSG00000129244	28216264	Lynch et al. (2017)	vomiting	ATP1B2	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0045823	ENSG00000069849	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1B3	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001662	ENSG00000069849	28216264	Lynch et al. (2017)	decreased heart rate	ATP1B3	UBERON_0004535	""
cardiovascular	inhibition_acute	MONDO_0000465	ENSG00000069849	28216264	Lynch et al. (2017)	atrioventricular block	ATP1B3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004269	ENSG00000069849	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1B3	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0004287	ENSG00000069849	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1B3	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0000103	ENSG00000069849	28216264	Lynch et al. (2017)	increased urine excretion	ATP1B3	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0035815	ENSG00000069849	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1B3	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0002017	ENSG00000069849	28216264	Lynch et al. (2017)	vomiting	ATP1B3	UBERON_0004535	""
renal	inhibition_acute	GO_0045823	ENSG00000069849	28216264	Lynch et al. (2017)	increased cardiac contractility	ATP1B3	UBERON_0001008	""
renal	inhibition_acute	HP_0001662	ENSG00000069849	28216264	Lynch et al. (2017)	decreased heart rate	ATP1B3	UBERON_0001008	""
renal	inhibition_acute	MONDO_0000465	ENSG00000069849	28216264	Lynch et al. (2017)	atrioventricular block	ATP1B3	UBERON_0001008	""
renal	inhibition_acute	EFO_0004269	ENSG00000069849	28216264	Lynch et al. (2017)	cardiac arrhythmia	ATP1B3	UBERON_0001008	""
renal	inhibition_acute	EFO_0004287	ENSG00000069849	28216264	Lynch et al. (2017)	ventricular fibrillation	ATP1B3	UBERON_0001008	""
renal	inhibition_acute	HP_0000103	ENSG00000069849	28216264	Lynch et al. (2017)	increased urine excretion	ATP1B3	UBERON_0001008	""
renal	inhibition_acute	GO_0035815	ENSG00000069849	28216264	Lynch et al. (2017)	increased urinary sodium excretion	ATP1B3	UBERON_0001008	""
renal	inhibition_acute	HP_0002017	ENSG00000069849	28216264	Lynch et al. (2017)	vomiting	ATP1B3	UBERON_0001008	""
cardiovascular system	activation_general	GO_0003092	ENSG00000166148	23197038	Bowes et al. (2012)	water retention in body	AVPR1A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0032263	ENSG00000166148	23197038	Bowes et al. (2012)	increased blood pressure	AVPR1A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001662	ENSG00000166148	23197038	Bowes et al. (2012)	decreased heart rate	AVPR1A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0001685	ENSG00000166148	23197038	Bowes et al. (2012)	myocardial fibrosis	AVPR1A	UBERON_0004535	""
cardiovascular system	activation_general	EFO_0002503	ENSG00000166148	23197038	Bowes et al. (2012)	cardiac hypertrophy	AVPR1A	UBERON_0004535	""
cardiovascular system	activation_general	HP_0002902	ENSG00000166148	23197038	Bowes et al. (2012)	hyponatraemia	AVPR1A	UBERON_0004535	""
renal	activation_general	GO_0003092	ENSG00000166148	23197038	Bowes et al. (2012)	water retention in body	AVPR1A	UBERON_0001008	""
renal	activation_general	HP_0032263	ENSG00000166148	23197038	Bowes et al. (2012)	increased blood pressure	AVPR1A	UBERON_0001008	""
renal	activation_general	HP_0001662	ENSG00000166148	23197038	Bowes et al. (2012)	decreased heart rate	AVPR1A	UBERON_0001008	""
renal	activation_general	HP_0001685	ENSG00000166148	23197038	Bowes et al. (2012)	myocardial fibrosis	AVPR1A	UBERON_0001008	""
renal	activation_general	EFO_0002503	ENSG00000166148	23197038	Bowes et al. (2012)	cardiac hypertrophy	AVPR1A	UBERON_0001008	""
renal	activation_general	HP_0002902	ENSG00000166148	23197038	Bowes et al. (2012)	hyponatraemia	AVPR1A	UBERON_0001008	""
cardiovascular	inhibition_acute	GO_0045823	ENSG00000172572	28216264	Lynch et al. (2017)	increased cardiac contractility	PDE3A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001649	ENSG00000172572	28216264	Lynch et al. (2017)	increased heart rate	PDE3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000172572	28216264	Lynch et al. (2017)	decreased blood pressure	PDE3A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0004308	ENSG00000172572	28216264	Lynch et al. (2017)	ventricular arrhythmia	PDE3A	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0001873	ENSG00000172572	28216264	Lynch et al. (2017)	decreased platelets	PDE3A	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0090331	ENSG00000172572	28216264	Lynch et al. (2017)	decreased platelet aggregation	PDE3A	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0008560	ENSG00000172572	28216264	Lynch et al. (2017)	decreased female fertility	PDE3A	UBERON_0004535	""
blood	inhibition_acute	GO_0045823	ENSG00000172572	28216264	Lynch et al. (2017)	increased cardiac contractility	PDE3A	UBERON_0000178	""
blood	inhibition_acute	HP_0001649	ENSG00000172572	28216264	Lynch et al. (2017)	increased heart rate	PDE3A	UBERON_0000178	""
blood	inhibition_acute	EFO_0005251	ENSG00000172572	28216264	Lynch et al. (2017)	decreased blood pressure	PDE3A	UBERON_0000178	""
blood	inhibition_acute	HP_0004308	ENSG00000172572	28216264	Lynch et al. (2017)	ventricular arrhythmia	PDE3A	UBERON_0000178	""
blood	inhibition_acute	HP_0001873	ENSG00000172572	28216264	Lynch et al. (2017)	decreased platelets	PDE3A	UBERON_0000178	""
blood	inhibition_acute	GO_0090331	ENSG00000172572	28216264	Lynch et al. (2017)	decreased platelet aggregation	PDE3A	UBERON_0000178	""
blood	inhibition_acute	EFO_0008560	ENSG00000172572	28216264	Lynch et al. (2017)	decreased female fertility	PDE3A	UBERON_0000178	""
cardiovascular	activation_acute	HP_0032263	ENSG00000151067	28216264	Lynch et al. (2017)	increased blood pressure	CACNA1C	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000151067	28216264	Lynch et al. (2017)	decreased blood pressure	CACNA1C	UBERON_0004535	""
cardiovascular	inhibition_acute	GO_0045822	ENSG00000151067	28216264	Lynch et al. (2017)	decreased cardiac contractility	CACNA1C	UBERON_0004535	""
cardiovascular	inhibition_acute	HP_0012248	ENSG00000151067	28216264	Lynch et al. (2017)	increased PR interval	CACNA1C	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000151067	28216264	Lynch et al. (2017)	decreased/increased convulsions	CACNA1C	UBERON_0004535	""
central nervous system	activation_acute	HP_0032263	ENSG00000151067	28216264	Lynch et al. (2017)	increased blood pressure	CACNA1C	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005251	ENSG00000151067	28216264	Lynch et al. (2017)	decreased blood pressure	CACNA1C	UBERON_0001017	""
central nervous system	inhibition_acute	GO_0045822	ENSG00000151067	28216264	Lynch et al. (2017)	decreased cardiac contractility	CACNA1C	UBERON_0001017	""
central nervous system	inhibition_acute	HP_0012248	ENSG00000151067	28216264	Lynch et al. (2017)	increased PR interval	CACNA1C	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000151067	28216264	Lynch et al. (2017)	decreased/increased convulsions	CACNA1C	UBERON_0001017	""
central nervous system	activation_acute	EFO_0009853	ENSG00000151067	28216264	Lynch et al. (2017)	increased convulsions	CACNA1C	UBERON_0001017	""
central nervous system	activation_acute	GO_0045823	ENSG00000151067	28216264	Lynch et al. (2017)	increased cardiac contractility	CACNA1C	UBERON_0001017	""
cardiovascular	activation_acute	GO_0045823	ENSG00000151067	28216264	Lynch et al. (2017)	increased cardiac contractility	CACNA1C	UBERON_0004535	""
central nervous system	activation_acute	GO_0040013	ENSG00000151067	28216264	Lynch et al. (2017)	decreased locomotor activity	CACNA1C	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000151067	28216264	Lynch et al. (2017)	increased convulsions	CACNA1C	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000151067	28216264	Lynch et al. (2017)	decreased locomotor activity	CACNA1C	UBERON_0004535	""
endocrine	activation_general	HP_0002045	ENSG00000178394	23197038	Bowes et al. (2012)	decreased body temperature	HTR1A	UBERON_0000949	""
endocrine	inhibition_general	EFO_0005230	ENSG00000178394	23197038	Bowes et al. (2012)	potentially anxiogenic	HTR1A	UBERON_0000949	""
endocrine	activation_general	GO_0042322	ENSG00000178394	23197038	Bowes et al. (2012)	reduced REM sleep	HTR1A	UBERON_0000949	""
endocrine	activation_general	HP_0003154	ENSG00000178394	23197038	Bowes et al. (2012)	increased adrenocorticotropic hormone	HTR1A	UBERON_0000949	""
endocrine	activation_general	GO_0043400	ENSG00000178394	23197038	Bowes et al. (2012)	cortisol secretion	HTR1A	UBERON_0000949	""
endocrine	activation_general	GO_0030252	ENSG00000178394	23197038	Bowes et al. (2012)	growth hormone secretion	HTR1A	UBERON_0000949	""
central nervous system	activation_general	HP_0002045	ENSG00000178394	23197038	Bowes et al. (2012)	decreased body temperature	HTR1A	UBERON_0001017	""
central nervous system	inhibition_general	EFO_0005230	ENSG00000178394	23197038	Bowes et al. (2012)	potentially anxiogenic	HTR1A	UBERON_0001017	""
central nervous system	activation_general	GO_0042322	ENSG00000178394	23197038	Bowes et al. (2012)	reduced REM sleep	HTR1A	UBERON_0001017	""
central nervous system	activation_general	HP_0003154	ENSG00000178394	23197038	Bowes et al. (2012)	increased adrenocorticotropic hormone	HTR1A	UBERON_0001017	""
central nervous system	activation_general	GO_0043400	ENSG00000178394	23197038	Bowes et al. (2012)	cortisol secretion	HTR1A	UBERON_0001017	""
central nervous system	activation_general	GO_0030252	ENSG00000178394	23197038	Bowes et al. (2012)	growth hormone secretion	HTR1A	UBERON_0001017	""
renal	activation_acute	GO_0035815	ENSG00000083454	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX5	UBERON_0001008	""
renal	activation_chronic	HP_0002180	ENSG00000083454	28216264	Lynch et al. (2017)	neurodegeneration	P2RX5	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000083454	28216264	Lynch et al. (2017)	decreased pain	P2RX5	UBERON_0001008	""
renal	inhibition_acute	GO_0050728	ENSG00000083454	28216264	Lynch et al. (2017)	decreased inflammation	P2RX5	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000083454	28216264	Lynch et al. (2017)	decreased convulsions	P2RX5	UBERON_0001008	""
renal	activation_acute	GO_1904058	ENSG00000083454	28216264	Lynch et al. (2017)	increased pain	P2RX5	UBERON_0001008	""
immune	activation_acute	GO_1904058	ENSG00000083454	28216264	Lynch et al. (2017)	increased pain	P2RX5	UBERON_0002405	""
immune	activation_chronic	HP_0002180	ENSG00000083454	28216264	Lynch et al. (2017)	neurodegeneration	P2RX5	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000083454	28216264	Lynch et al. (2017)	decreased pain	P2RX5	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000083454	28216264	Lynch et al. (2017)	decreased inflammation	P2RX5	UBERON_0002405	""
immune	inhibition_acute	EFO_0009853	ENSG00000083454	28216264	Lynch et al. (2017)	decreased convulsions	P2RX5	UBERON_0002405	""
nervous system	activation_acute	GO_1904058	ENSG00000083454	28216264	Lynch et al. (2017)	increased pain	P2RX5	UBERON_0001016	""
nervous system	activation_chronic	HP_0002180	ENSG00000083454	28216264	Lynch et al. (2017)	neurodegeneration	P2RX5	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000083454	28216264	Lynch et al. (2017)	decreased pain	P2RX5	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050728	ENSG00000083454	28216264	Lynch et al. (2017)	decreased inflammation	P2RX5	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000083454	28216264	Lynch et al. (2017)	decreased convulsions	P2RX5	UBERON_0001016	""
immune	activation_acute	EFO_0009473	ENSG00000083454	28216264	Lynch et al. (2017)	hemolysis	P2RX5	UBERON_0002405	""
nervous system	activation_acute	HP_0000103	ENSG00000083454	28216264	Lynch et al. (2017)	increased urine excretion	P2RX5	UBERON_0001016	""
renal	activation_acute	EFO_0009473	ENSG00000083454	28216264	Lynch et al. (2017)	hemolysis	P2RX5	UBERON_0001008	""
immune	activation_acute	GO_0035815	ENSG00000083454	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX5	UBERON_0002405	""
renal	activation_acute	HP_0000103	ENSG00000083454	28216264	Lynch et al. (2017)	increased urine excretion	P2RX5	UBERON_0001008	""
nervous system	activation_acute	GO_0035815	ENSG00000083454	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX5	UBERON_0001016	""
nervous system	activation_acute	EFO_0009473	ENSG00000083454	28216264	Lynch et al. (2017)	hemolysis	P2RX5	UBERON_0001016	""
immune	activation_acute	HP_0000103	ENSG00000083454	28216264	Lynch et al. (2017)	increased urine excretion	P2RX5	UBERON_0002405	""
renal	activation_acute	GO_1904058	ENSG00000089041	28216264	Lynch et al. (2017)	increased pain	P2RX7	UBERON_0001008	""
renal	activation_chronic	HP_0002180	ENSG00000089041	28216264	Lynch et al. (2017)	neurodegeneration	P2RX7	UBERON_0001008	""
renal	inhibition_acute	GO_1904057	ENSG00000089041	28216264	Lynch et al. (2017)	decreased pain	P2RX7	UBERON_0001008	""
renal	inhibition_acute	GO_0050728	ENSG00000089041	28216264	Lynch et al. (2017)	decreased inflammation	P2RX7	UBERON_0001008	""
renal	inhibition_acute	EFO_0009853	ENSG00000089041	28216264	Lynch et al. (2017)	decreased convulsions	P2RX7	UBERON_0001008	""
renal	activation_acute	HP_0000103	ENSG00000089041	28216264	Lynch et al. (2017)	increased urine excretion	P2RX7	UBERON_0001008	""
immune	activation_acute	GO_0035815	ENSG00000089041	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX7	UBERON_0002405	""
immune	activation_chronic	HP_0002180	ENSG00000089041	28216264	Lynch et al. (2017)	neurodegeneration	P2RX7	UBERON_0002405	""
immune	inhibition_acute	GO_1904057	ENSG00000089041	28216264	Lynch et al. (2017)	decreased pain	P2RX7	UBERON_0002405	""
immune	inhibition_acute	GO_0050728	ENSG00000089041	28216264	Lynch et al. (2017)	decreased inflammation	P2RX7	UBERON_0002405	""
immune	inhibition_acute	EFO_0009853	ENSG00000089041	28216264	Lynch et al. (2017)	decreased convulsions	P2RX7	UBERON_0002405	""
immune	activation_acute	HP_0000103	ENSG00000089041	28216264	Lynch et al. (2017)	increased urine excretion	P2RX7	UBERON_0002405	""
renal	activation_acute	GO_0035815	ENSG00000089041	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX7	UBERON_0001008	""
renal	activation_acute	EFO_0009473	ENSG00000089041	28216264	Lynch et al. (2017)	hemolysis	P2RX7	UBERON_0001008	""
nervous system	activation_acute	GO_0035815	ENSG00000089041	28216264	Lynch et al. (2017)	increased urinary sodium excretion	P2RX7	UBERON_0001016	""
nervous system	activation_chronic	HP_0002180	ENSG00000089041	28216264	Lynch et al. (2017)	neurodegeneration	P2RX7	UBERON_0001016	""
nervous system	inhibition_acute	GO_1904057	ENSG00000089041	28216264	Lynch et al. (2017)	decreased pain	P2RX7	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050728	ENSG00000089041	28216264	Lynch et al. (2017)	decreased inflammation	P2RX7	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0009853	ENSG00000089041	28216264	Lynch et al. (2017)	decreased convulsions	P2RX7	UBERON_0001016	""
immune	activation_acute	EFO_0009473	ENSG00000089041	28216264	Lynch et al. (2017)	hemolysis	P2RX7	UBERON_0002405	""
nervous system	activation_acute	GO_1904058	ENSG00000089041	28216264	Lynch et al. (2017)	increased pain	P2RX7	UBERON_0001016	""
nervous system	activation_acute	HP_0000103	ENSG00000089041	28216264	Lynch et al. (2017)	increased urine excretion	P2RX7	UBERON_0001016	""
immune	activation_acute	GO_1904058	ENSG00000089041	28216264	Lynch et al. (2017)	increased pain	P2RX7	UBERON_0002405	""
nervous system	activation_acute	EFO_0009473	ENSG00000089041	28216264	Lynch et al. (2017)	hemolysis	P2RX7	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0002503	ENSG00000170214	28216264	Lynch et al. (2017)	cardiac hypertrophy	ADRA1B	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005251	ENSG00000170214	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA1B	UBERON_0004535	""
renal	activation_acute	EFO_0005251	ENSG00000170214	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA1B	UBERON_0001008	""
renal	inhibition_acute	EFO_0005251	ENSG00000170214	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA1B	UBERON_0001008	""
nervous system	activation_acute	HP_0002180	ENSG00000170214	28216264	Lynch et al. (2017)	neurodegeneration	ADRA1B	UBERON_0001016	""
nervous system	inhibition_acute	EFO_0005251	ENSG00000170214	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA1B	UBERON_0001016	""
renal	activation_acute	EFO_0002503	ENSG00000170214	28216264	Lynch et al. (2017)	cardiac hypertrophy	ADRA1B	UBERON_0001008	""
nervous system	activation_acute	EFO_0005251	ENSG00000170214	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA1B	UBERON_0001016	""
cardiovascular	activation_acute	EFO_0005252	ENSG00000170214	28216264	Lynch et al. (2017)	orthostatic hypotension	ADRA1B	UBERON_0004535	""
renal	activation_acute	HP_0002180	ENSG00000170214	28216264	Lynch et al. (2017)	neurodegeneration	ADRA1B	UBERON_0001008	""
renal	activation_acute	EFO_0009853	ENSG00000170214	28216264	Lynch et al. (2017)	convulsions	ADRA1B	UBERON_0001008	""
nervous system	activation_acute	GO_0040013	ENSG00000170214	28216264	Lynch et al. (2017)	decreased locomotor activity	ADRA1B	UBERON_0001016	""
renal	activation_acute	EFO_0005252	ENSG00000170214	28216264	Lynch et al. (2017)	orthostatic hypotension	ADRA1B	UBERON_0001008	""
cardiovascular	activation_acute	EFO_0005251	ENSG00000170214	28216264	Lynch et al. (2017)	decreased blood pressure	ADRA1B	UBERON_0004535	""
nervous system	activation_acute	EFO_0002503	ENSG00000170214	28216264	Lynch et al. (2017)	cardiac hypertrophy	ADRA1B	UBERON_0001016	""
nervous system	activation_acute	EFO_0009853	ENSG00000170214	28216264	Lynch et al. (2017)	convulsions	ADRA1B	UBERON_0001016	""
nervous system	activation_acute	EFO_0005252	ENSG00000170214	28216264	Lynch et al. (2017)	orthostatic hypotension	ADRA1B	UBERON_0001016	""
renal	activation_acute	GO_0040013	ENSG00000170214	28216264	Lynch et al. (2017)	decreased locomotor activity	ADRA1B	UBERON_0001008	""
cardiovascular	activation_acute	HP_0002180	ENSG00000170214	28216264	Lynch et al. (2017)	neurodegeneration	ADRA1B	UBERON_0004535	""
cardiovascular	activation_acute	GO_0040013	ENSG00000170214	28216264	Lynch et al. (2017)	decreased locomotor activity	ADRA1B	UBERON_0004535	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000170214	28216264	Lynch et al. (2017)	convulsions	ADRA1B	UBERON_0004535	""
gastrointestinal	inhibition_general	EFO_0009879	ENSG00000095303	23197038	Bowes et al. (2012)	gastric bleeding	PTGS1	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0040223	ENSG00000095303	23197038	Bowes et al. (2012)	pulmonary bleeding	PTGS1	UBERON_0005409	""
gastrointestinal	inhibition_general	EFO_0008533	ENSG00000095303	23197038	Bowes et al. (2012)	dyspepsia	PTGS1	UBERON_0005409	""
gastrointestinal	inhibition_general	HP_0012211	ENSG00000095303	23197038	Bowes et al. (2012)	renal dysfunction	PTGS1	UBERON_0005409	""
pulmonary	inhibition_general	EFO_0009879	ENSG00000095303	23197038	Bowes et al. (2012)	gastric bleeding	PTGS1	UBERON_0002048	""
pulmonary	inhibition_general	HP_0040223	ENSG00000095303	23197038	Bowes et al. (2012)	pulmonary bleeding	PTGS1	UBERON_0002048	""
pulmonary	inhibition_general	EFO_0008533	ENSG00000095303	23197038	Bowes et al. (2012)	dyspepsia	PTGS1	UBERON_0002048	""
pulmonary	inhibition_general	HP_0012211	ENSG00000095303	23197038	Bowes et al. (2012)	renal dysfunction	PTGS1	UBERON_0002048	""
renal	inhibition_general	EFO_0009879	ENSG00000095303	23197038	Bowes et al. (2012)	gastric bleeding	PTGS1	UBERON_0001008	""
renal	inhibition_general	HP_0040223	ENSG00000095303	23197038	Bowes et al. (2012)	pulmonary bleeding	PTGS1	UBERON_0001008	""
renal	inhibition_general	EFO_0008533	ENSG00000095303	23197038	Bowes et al. (2012)	dyspepsia	PTGS1	UBERON_0001008	""
renal	inhibition_general	HP_0012211	ENSG00000095303	23197038	Bowes et al. (2012)	renal dysfunction	PTGS1	UBERON_0001008	""
cardiovascular	activation_acute	MONDO_0000437	ENSG00000080709	28216264	Lynch et al. (2017)	ataxia	KCNN2	UBERON_0004535	""
cardiovascular	inhibition_acute	""	ENSG00000080709	28216264	Lynch et al. (2017)	increased atrial refractory period	KCNN2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0009853	ENSG00000080709	28216264	Lynch et al. (2017)	convulsions	KCNN2	UBERON_0004535	""
cardiovascular	inhibition_acute	EFO_0005595	ENSG00000080709	28216264	Lynch et al. (2017)	neurotoxicity	KCNN2	UBERON_0004535	""
central nervous system	activation_acute	EFO_0009853	ENSG00000080709	28216264	Lynch et al. (2017)	decreased convulsions	KCNN2	UBERON_0001017	""
central nervous system	inhibition_acute	""	ENSG00000080709	28216264	Lynch et al. (2017)	increased atrial refractory period	KCNN2	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0009853	ENSG00000080709	28216264	Lynch et al. (2017)	convulsions	KCNN2	UBERON_0001017	""
central nervous system	inhibition_acute	EFO_0005595	ENSG00000080709	28216264	Lynch et al. (2017)	neurotoxicity	KCNN2	UBERON_0001017	""
cardiovascular	activation_acute	GO_0040013	ENSG00000080709	28216264	Lynch et al. (2017)	decreased locomotor activity	KCNN2	UBERON_0004535	""
central nervous system	activation_acute	GO_0040013	ENSG00000080709	28216264	Lynch et al. (2017)	decreased locomotor activity	KCNN2	UBERON_0001017	""
cardiovascular	activation_acute	EFO_0009853	ENSG00000080709	28216264	Lynch et al. (2017)	decreased convulsions	KCNN2	UBERON_0004535	""
central nervous system	activation_acute	MONDO_0000437	ENSG00000080709	28216264	Lynch et al. (2017)	ataxia	KCNN2	UBERON_0001017	""
nervous system	activation_acute	GO_1904057	ENSG00000188822	28216264	Lynch et al. (2017)	decreased pain	CNR2	UBERON_0001016	""
nervous system	inhibition_acute	GO_0050729	ENSG00000188822	28216264	Lynch et al. (2017)	increased inflammation	CNR2	UBERON_0001016	""
Immune	activation_acute	GO_0050728	ENSG00000188822	28216264	Lynch et al. (2017)	decreased inflammation	CNR2	""	""
Immune	inhibition_acute	GO_0050729	ENSG00000188822	28216264	Lynch et al. (2017)	increased inflammation	CNR2	""	""
nervous system	activation_acute	GO_0050728	ENSG00000188822	28216264	Lynch et al. (2017)	decreased inflammation	CNR2	UBERON_0001016	""
Immune	activation_acute	GO_1904057	ENSG00000188822	28216264	Lynch et al. (2017)	decreased pain	CNR2	""	""
nervous system	activation_acute	GO_0046878	ENSG00000184984	28216264	Lynch et al. (2017)	increased salivation	CHRM5	UBERON_0001016	""
